<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006971" GROUP_ID="PREG" ID="294305042013070964" MERGED_FROM="" MODIFIED="2008-02-04 17:45:38 +0100" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Notes for reviewers:&lt;br&gt;1. Please ensure that you are familiar with the generic protocol before starting on your review.&lt;br&gt;2. Please complete the background and modify the rest of the text to be relevant to this review.&lt;br&gt;3. Data extraction from the original trial reports will be done centrally, and you will be supplied with copies of the trials and the completed data extraction forms between the end of March and mid-April.&lt;br&gt;4. Please check that you are happy with the data extraction, and contact authors of trial reports for any clarification needed.&lt;br&gt;5. Please enter the data into the tables, which have already been constructed in this template. &lt;br&gt;6. Please note that you should only include those outcomes with data in the analysis tables as described in the generic protocol.&lt;br&gt;7. After completing the analysis, complete the text of the review and the abstract.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 16:40:52 +0000" NOTES_MODIFIED_BY="Sonja Henderson" REVIEW_NO="0307" REVMAN_SUB_VERSION="5.0.0 release candidate 2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.0">
<COVER_SHEET MODIFIED="2008-02-04 17:45:38 +0100" MODIFIED_BY="Sonja Henderson">
<TITLE>Intracervical prostaglandins for induction of labour</TITLE>
<CONTACT MODIFIED="2008-02-04 17:45:38 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="5699" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michel</FIRST_NAME><LAST_NAME>Boulvain</LAST_NAME><POSITION>Médecin adjoint agrégé</POSITION><EMAIL_1>michel.boulvain@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Département de Gynécologie et d'Obstétrique, Unité de Développement en Obstétrique</DEPARTMENT><ORGANISATION>Maternité Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse, 32</ADDRESS_1><CITY>Genève 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="">Switzerland</COUNTRY><PHONE_1>+ 41 22 3824317</PHONE_1><FAX_1>+41 22 3824424</FAX_1><FAX_2>+41 22 3824165</FAX_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-02-04 17:45:38 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="5699" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michel</FIRST_NAME><LAST_NAME>Boulvain</LAST_NAME><POSITION>Médecin adjoint agrégé</POSITION><EMAIL_1>michel.boulvain@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Département de Gynécologie et d'Obstétrique, Unité de Développement en Obstétrique</DEPARTMENT><ORGANISATION>Maternité Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse, 32</ADDRESS_1><CITY>Genève 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="">Switzerland</COUNTRY><PHONE_1>+ 41 22 3824317</PHONE_1><FAX_1>+41 22 3824424</FAX_1><FAX_2>+41 22 3824165</FAX_2></ADDRESS></PERSON><PERSON ID="15928" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Kelly</LAST_NAME><POSITION>Consultant Obstetrician and Gynaecologist</POSITION><EMAIL_1>tony.kelly@bsuh.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Brighton and Sussex University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Royal Sussex County Hospital</ADDRESS_1><ADDRESS_2>Eastern Road</ADDRESS_2><CITY>Brighton</CITY><ZIP>BN2 5BE</ZIP><COUNTRY CODE="">UK</COUNTRY><PHONE_1>+44 1273 696955</PHONE_1></ADDRESS></PERSON><PERSON ID="5761" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Olivier</FIRST_NAME><LAST_NAME>Irion</LAST_NAME><POSITION>Professor/Chair Obstetrics</POSITION><EMAIL_1>olivier.irion@hcuge.ch</EMAIL_1><URL>http://matweb.hcuge.ch/matweb/</URL><ADDRESS><DEPARTMENT>Département de Gynécologie et d'Obstétrique, Unité de Développement en Obstétrique</DEPARTMENT><ORGANISATION>Maternité Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse, 32</ADDRESS_1><CITY>Genève 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="">Switzerland</COUNTRY><PHONE_1>+41 22 3824398</PHONE_1><PHONE_2>+41 22 3824203</PHONE_2><FAX_1>+41 22 3824424</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-02-04 10:09:00 +0000" MODIFIED_BY="Lixia Dou" NOTES="&lt;p&gt;New studies found and included or excluded: 8/31/07&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 10:09:00 +0000" NOTES_MODIFIED_BY="Lixia Dou">
<UP_TO_DATE>
<DATE DAY="14" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="8" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Health Cochrane Review Incentive Scheme 2006</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-02-04 12:40:50 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-02-04 10:52:58 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-02-04 10:52:58 +0000" MODIFIED_BY="[Empty name]">Intracervical prostaglandins for induction of labour</TITLE>
<SUMMARY_BODY MODIFIED="2008-02-04 10:10:59 +0000" MODIFIED_BY="[Empty name]">
<P>Prostaglandins inserted into the cervix are effective in starting labour, but are inferior to vaginal administration.</P>
<P>Prostaglandins are produced naturally by the body during the process of labour. Their role is to prepare the cervix and to help open the cervix in response to contractions. When it is decided to induce labour and the cervix is not yet open, synthetic prostaglandins are used to ripen it before drugs that produce contractions (usually oxytocin) are given. One way to give prostaglandin is to insert it into the cervix, using a cannula during a vaginal examination. The review of fifty-six trials (7738 women) found that although this route of administration is effective, it offers no advantages when compared to other methods of administration, namely the vaginal route.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Prostaglandins have been used for cervical ripening and induction of labour since the 1970s. The goal of the administration of prostaglandins in the process of induction of labour is to achieve cervical ripening before the onset of contractions. One of the routes of administration that was proposed is intracervical. Using this route, prostaglandins are less easy to administer and the need for exposing the cervix may cause discomfort to the woman. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of intracervical prostaglandins for third trimester cervical ripening or induction of labour compared with placebo/no treatment and with vaginal prostaglandins (except misoprostol).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (August 2007) and bibliographies of relevant papers. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Clinical trials comparing intracervical prostaglandins used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods (vaginal prostaglandins, except misoprostol).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>A strategy was developed to deal with the large volume and complexity of trial data relating to labour induction. This involved a two-stage method of data extraction. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Fifty-six trials (7738 women) are included.</P>
<P>
<B>
<I>Intracervical PGE2 with placebo/no treatment: 28 trials, 3764 women </I>
</B>
<BR/>Four studies reported the number of women who did not achieve vaginal delivery within 24 hours, showing a decreased risk with PGE2 (relative risk (RR) 0.61; 95% confidence interval (CI) 0.47 to 0.79). There was a small, and statistically non-significant, reduction of the risk of caesarean section when PGE2 was used (RR 0.88; 95% CI 0.77 to 1.00). The finding was statistically significant in a subgroup of women with intact membranes and unfavourable cervix only (RR 0.82; 95% CI 0.68 to 0.98). The risk of hyperstimulation with fetal heart rate (FHR) changes was not significantly increased (RR 1.21; 95% CI 0.72 to 2.05). However, the risk of hyperstimulation without FHR changes was significantly increased (RR 1.59; 95% CI 1.09 to 2.33. </P>
<P>
<B>
<I>Intracervical PGE2 with intravaginal PGE2: 29 trials, 3881 women</I>
</B>
<BR/>The risk of not achieving vaginal delivery within 24 hours was increased with intracervical PGE2 (RR 1.26; 95% CI 1.12 to 1.41). There was no change in the risk of caesarean section (RR 1.07; 95% CI 0.93 to 1.22). The risks of hyperstimulation with FHR changes (RR 0.76; 95% CI 0.39 to 1.49) and without FHR changes (RR 0.80; 95% CI 0.56 to 1.15) were non-significantly different with the two methods of PGE2 administration. Only one trial with small sample size reported on women's views, with no difference between groups.</P>
<P>
<B>
<I>Intracervical PGE2 low dose with intracervical PGE2 high dose: two trials, 102 women</I>
</B>
<BR/>The trials are too small to provide any useful information.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Intracervical prostaglandins are effective compared to placebo, but appear inferior when compared to intravaginal prostaglandins.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-02-04 12:40:50 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Induction of labour is frequently practised to end pregnancy, both for medical reasons and for convenience. There is a debate about the possible benefits and harms of the intervention in specific indications (<I>see</I> reviews: <LINK REF="REF-G_x00fc_lmezoglu-2006" TYPE="REFERENCE">Gülmezoglu 2006</LINK>; <LINK REF="REF-Flenady-2002" TYPE="REFERENCE">Flenady 2002</LINK>; <LINK REF="REF-Boulvain-2001b" TYPE="REFERENCE">Boulvain 2001b</LINK>; <LINK REF="REF-Irion-1998a" TYPE="REFERENCE">Irion 1998a</LINK>) or with no medical indication. Many trials comparing regimens and route of administration of various drugs to achieve ripening of the cervix and induction of labour have been conducted, compared with very few evaluating the indications for labour induction. Given the frequency of this intervention, it seems important to evaluate the benefit of inducing labour in specific situations. However, when induction of labour is decided, the goal is to achieve a vaginal delivery within a limited period of time, minimising the side-effects for both the mother and the newborn. The main side-effects are dysfunctional labour and excessive uterine activity, eventually with fetal distress, both leading to caesarean section. Induction with oxytocin is associated with a high failure rate when the cervix is unripe. Artificial rupture of membranes, in the presence of unfavourable cervical status, equally has low effectiveness and may be impossible to perform. Prostaglandin preparations have been shown to promote cervical ripening and initiation of labour in women with unfavourable cervix (<LINK REF="REF-Keirse-1993" TYPE="REFERENCE">Keirse 1993</LINK>). Prostaglandin F2a was initially used, then prostaglandin E2 and its analogues were developed. More recently, prostaglandin E1 analogues (misoprostol) were evaluated and are increasingly used. Cervical ripening is achieved by the modification of cervical collagen and alteration of the relative cervical glycosaminoglycans concentration (<LINK REF="REF-Huszar-1984" TYPE="REFERENCE">Huszar 1984</LINK>; <LINK REF="REF-Rath-1993" TYPE="REFERENCE">Rath 1993</LINK>). Prostaglandins are presently widely used in clinical practice, but side-effects are reported. These include gastrointestinal symptoms (nausea, vomiting, diarrhea), fever, and uterine hyperstimulation, with or without fetal distress (<LINK REF="REF-Keirse-1993" TYPE="REFERENCE">Keirse 1993</LINK>). Cases of uterine rupture, especially in women with previous caesarean section, have been reported (<LINK REF="REF-Raskin-1999" TYPE="REFERENCE">Raskin 1999</LINK>; <LINK REF="REF-Vause-1999" TYPE="REFERENCE">Vause 1999</LINK>). Some cohort studies with large sample sizes suggest that the risk of uterine rupture remains unchanged with the use of prostaglandin (<LINK REF="REF-Chez-1995" TYPE="REFERENCE">Chez 1995</LINK>), while others suggest an increased risk associated with prostaglandin use (<LINK REF="REF-RCOG-2007" TYPE="REFERENCE">RCOG 2007</LINK>). Numerous prostaglandin preparations are, or were, available, including PGF2 alpha, PGE2, sulprostone (a synthetic analogue of PGE2), PGE1 and misoprostol (a synthetic analogue of PGE1). These have been used by various routes, including local (extra-amniotic, intracervical, intravaginal) and general administration (oral, intramuscular and intravenous). Prostaglandin preparations for local administration include: gel in either a stable triacetin gel or in a starch based gel; lactose based vaginal tablets, suppositories, pessaries or inserts. Dosages of PGE2 sulprostone are in general 0.5 mg for intracervical use, 2 to 3 mg for intravaginal use and 10 mg with the sustained-release pessary. Other preparations and dosages up to 5 mg PGE2 were however used (<LINK REF="REF-Mastrogiannis-1995" TYPE="REFERENCE">Mastrogiannis 1995</LINK>). Oral tablets and sterile preparations for parenteral use are also available. In many centres, the PGE1 analogue misoprostol has replaced the use of PGE2 analogues for cervical ripening and induction of labour. However, misoprostol is not marketed in many countries and, thus, may not be available. On the other hand, commercially prepared PGE2 analogues are expensive and need refrigeration. This also limits the availability in many centres.</P>
<P>Prostaglandin may be applied intracervically during a vaginal examination. The procedure involves the exposure of the cervix and the insertion of a cannula in the cervix. In our opinion, this procedure may cause some discomfort to the woman and is less easy, compared with the vaginal route of administration. Another potential problem is a leakage of the drug from the cervix back to the vagina. Thus, part of the drug may be absorbed vaginally, at a lower dosage than intended (<LINK REF="REF-Irion-1998a" TYPE="REFERENCE">Irion 1998a</LINK>). </P>
<P>This review is one of a series of reviews of methods of labour induction using a standardised protocol (<LINK REF="REF-Hofmeyr-2000" TYPE="REFERENCE">Hofmeyr 2000</LINK>). Readers may wish to refer to the following Cochrane systematic reviews for further information about induction of labour using prostaglandins: 'Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term' (<LINK REF="REF-Kelly-2003" TYPE="REFERENCE">Kelly 2003</LINK>); 'Extra-amniotic prostaglandin for induction of labour' (<LINK REF="REF-Hutton-2001" TYPE="REFERENCE">Hutton 2001</LINK>); 'Intravenous prostaglandin for induction of labour' (<LINK REF="REF-Luckas-2000" TYPE="REFERENCE">Luckas 2000</LINK>); 'Oral misoprostol for induction of labour' (<LINK REF="REF-Alfirevic-2006" TYPE="REFERENCE">Alfirevic 2006</LINK>); and 'Vaginal misoprostol for induction of labour' (<LINK REF="REF-Hofmeyer-2003" TYPE="REFERENCE">Hofmeyer 2003</LINK>). This review includes only the comparison of intracervical prostaglandin with placebo and with vaginal prostaglandin, excluding misoprostol (i.e. the methods above it in a hierarchical list of methods for induction of labour, <I>see</I> 'Methods of the review' section). </P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine, from the best available evidence, the effectiveness and safety of intracervical prostaglandins for third trimester cervical ripening and induction of labour compared with placebo or no treatment and with vaginal prostaglandins (except misoprostol). An additional objective was to compare dosages.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Clinical trials comparing intracervical prostaglandins for cervical ripening or labour induction with placebo or no treatment or other methods listed above it on a predefined list of methods of labour induction (for this review, vaginal prostaglandins, except misoprostol, <I>see</I> 'Methods of the review'); the trials included some form of random allocation to either group; and they reported one or more of the prestated outcomes. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Pregnant women due for third trimester induction of labour, carrying a viable fetus.</P>
<P>Predefined subgroup analyses are: previous caesarean section or not; nulliparity or multiparity; membranes intact or ruptured, and cervix unfavourable, favourable or undefined. Only those outcomes with data will appear in the analysis tables.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-02-04 10:17:28 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Intracervical prostaglandins compared with placebo or no treatment</LI>
<LI>Intracervical prostaglandins compared with vaginal prostaglandins (except misoprostol)</LI>
<LI>Low dosage intracervical prostaglandins compared with higher dosage. The division between high- and low-dose regimens was made as follows: low dose was any regimen where the dose of intracervical PGE2 was less or equal to 0.5 mg and less or equal to two doses.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-02-04 12:40:50 +0000" MODIFIED_BY="[Empty name]">
<P>Clinically relevant outcomes for trials of methods of cervical ripening/labour induction have been prespecified by two authors of labour induction reviews (Justus Hofmeyr and Zarko Alfirevic). Differences were settled by discussion.</P>
<P>Five primary outcomes were chosen as being most representative of the clinically important measures of effectiveness and complications.<BR/>(1) Vaginal delivery not achieved within 24 hours;<BR/>(2) uterine hyperstimulation with fetal heart rate (FHR) changes;<BR/>(3) caesarean section;<BR/>(4) serious neonatal morbidity or perinatal death (e.g., seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood);<BR/>(5) serious maternal morbidity or death (e.g., uterine rupture, admission to intensive care unit, septicemia).</P>
<P>Perinatal and maternal morbidity and mortality are composite outcomes. This is not an ideal solution because some components are clearly less severe than others. It is possible for one intervention to cause more deaths but less severe morbidity. However, in the context of labour induction at term this is unlikely. All these events will be rare, and a modest change in their incidence will be easier to detect if composite outcomes are presented. The incidence of individual components will be explored as secondary outcomes (<I>see</I> below).</P>
<P>Secondary outcomes relate to measures of effectiveness, complications and satisfaction.</P>
<SUBSECTION>
<HEADING LEVEL="4">Measures of effectiveness</HEADING>
<P>(6) Cervix unfavourable/unchanged after 12 to 24 hours;<BR/>(7) oxytocin augmentation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complications</HEADING>
<P>(8) Uterine hyperstimulation without FHR changes;<BR/>(9) uterine rupture;<BR/>(10) epidural analgesia;<BR/>(11) instrumental vaginal delivery;<BR/>(12) meconium-stained liquor;<BR/>(13) Apgar score less than seven at five minutes;<BR/>(14) neonatal intensive care unit admission;<BR/>(15) neonatal encephalopathy;<BR/>(16) perinatal death;<BR/>(17) disability in childhood;<BR/>(18) maternal side-effects (e.g., nausea, vomiting, diarrhoea, pyrexia);<BR/>(19) maternal nausea;<BR/>(20) maternal vomiting;<BR/>(21) maternal diarrhoea;<BR/>(22) other maternal side-effects;<BR/>(23) postpartum haemorrhage (as defined by the trial authors);<BR/>(24) serious maternal complications (e.g., intensive care unit admission, septicaemia but excluding uterine rupture);<BR/>(25) maternal death.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Measures of satisfaction</HEADING>
<P>(26) Woman not satisfied;<BR/>(27) caregiver not satisfied.</P>
<P>'Uterine rupture' will include all clinically significant ruptures of unscarred or scarred uteri. Trivial scar dehiscence noted incidentally at the time of surgery will be excluded.</P>
<P>While all the above outcomes were sought, only those with data appear in the analysis tables.</P>
<P>The terminology of uterine hyperstimulation is problematic (<LINK REF="REF-Curtis-1987" TYPE="REFERENCE">Curtis 1987</LINK>). In the reviews we will use the term 'uterine hyperstimulation without FHR changes 'to include uterine tachysystole (more than five contractions per 10 minutes for at least 20 minutes) and uterine hypersystole/hypertonus (a contraction lasting at least two minutes) and 'uterine hyperstimulation with FHR changes' to denote uterine hyperstimulation syndrome (tachysystole or hypersystole with FHR changes such as persistent decelerations, tachycardia or decreased short-term variability).</P>
<P>We included outcomes in the analysis if reasonable measures were taken to minimise observer bias; and data were available for analysis according to the original allocation.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-02-04 11:02:45 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-02-04 11:00:06 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (August 2007).</P>
<P>The Cochrane Pregnancy and Childbirth Group's Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>monthly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness search of a further 36 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Search strategies for identification of studies' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.</P>
<P>Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.</P>
<P>We did not apply any language restrictions.</P>
<P>The initial search was performed simultaneously for all reviews of methods of inducing labour, as outlined in the generic protocol for these reviews (<LINK REF="REF-Hofmeyr-2000" TYPE="REFERENCE">Hofmeyr 2000</LINK>).</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-02-04 11:13:29 +0000" MODIFIED_BY="[Empty name]">
<P>A strategy has been developed to deal with the large volume and complexity of trial data relating to labour induction. Many methods have been studied, in many different categories of women undergoing labour induction. Most trials are intervention-driven, comparing two or more methods in various categories of women. Clinicians and parents need the data arranged by category of woman to be able to choose which method is best for a particular clinical scenario. To extract these data from several hundred trial reports in a single step would be very difficult. We therefore developed a two-stage method of data extraction. The initial data extraction was done in a series of primary reviews arranged by methods of induction of labour, following a standardised methodology. The data will then be extracted from the primary reviews into a series of secondary reviews, arranged by category of woman.</P>
<P>To avoid duplication of data in the primary reviews, the labour induction methods have been listed in a specific order, from one to 27. Each primary review includes comparisons between one of the methods (from two to 27) with only those methods above it on the list. Thus, the review of intravenous oxytocin (4) will include only comparisons with intracervical prostaglandins (3), vaginal prostaglandins (2) or placebo (1). Methods identified in the future will be added to the end of the list. The current list is as follows:</P>
<OL>
<LI>placebo/no treatment;</LI>
<LI>vaginal prostaglandins (<LINK REF="REF-Kelly-2003" TYPE="REFERENCE">Kelly 2003</LINK>);</LI>
<LI>intracervical prostaglandins (this review);</LI>
<LI>intravenous oxytocin (<LINK REF="REF-Kelly-2001a" TYPE="REFERENCE">Kelly 2001a</LINK>);</LI>
<LI>amniotomy (<LINK REF="REF-Bricker-2000" TYPE="REFERENCE">Bricker 2000</LINK>);</LI>
<LI>intravenous oxytocin with amniotomy (<LINK REF="REF-Howarth-2001" TYPE="REFERENCE">Howarth 2001</LINK>);</LI>
<LI>vaginal misoprostol (<LINK REF="REF-Hofmeyr-2003" TYPE="REFERENCE">Hofmeyr 2003</LINK>);</LI>
<LI>oral misoprostol (<LINK REF="REF-Alfirevic-2006" TYPE="REFERENCE">Alfirevic 2006</LINK>);</LI>
<LI>mechanical methods including extra-amniotic Foley catheter (<LINK REF="REF-Boulvain-2001a" TYPE="REFERENCE">Boulvain 2001a</LINK>);</LI>
<LI>membrane sweeping (<LINK REF="REF-Boulvain-2005" TYPE="REFERENCE">Boulvain 2005</LINK>);</LI>
<LI>extra-amniotic prostaglandins (<LINK REF="REF-Hutton-2001" TYPE="REFERENCE">Hutton 2001</LINK>);</LI>
<LI>intravenous prostaglandins (<LINK REF="REF-Luckas-2000" TYPE="REFERENCE">Luckas 2000</LINK>);</LI>
<LI>oral prostaglandins (<LINK REF="REF-French-2001" TYPE="REFERENCE">French 2001</LINK>);</LI>
<LI>mifepristone (<LINK REF="REF-Neilson-2000" TYPE="REFERENCE">Neilson 2000</LINK>);</LI>
<LI>oestrogens with or without amniotomy (<LINK REF="REF-Thomas-2001" TYPE="REFERENCE">Thomas 2001</LINK>);</LI>
<LI>corticosteroids (<LINK REF="REF-Kavanagh-2006a" TYPE="REFERENCE">Kavanagh 2006a</LINK>);</LI>
<LI>relaxin (<LINK REF="REF-Kelly-2001c" TYPE="REFERENCE">Kelly 2001c</LINK>);</LI>
<LI>hyaluronidase (<LINK REF="REF-Kavanagh-2006b" TYPE="REFERENCE">Kavanagh 2006b</LINK>);</LI>
<LI>castor oil, bath or enema, or both (<LINK REF="REF-Kelly-2001b" TYPE="REFERENCE">Kelly 2001b</LINK>);</LI>
<LI>acupuncture (<LINK REF="REF-Smith-2003" TYPE="REFERENCE">Smith 2003</LINK>);</LI>
<LI>breast stimulation (<LINK REF="REF-Kavanagh-2005" TYPE="REFERENCE">Kavanagh 2005</LINK>);</LI>
<LI>sexual intercourse (<LINK REF="REF-Kavanagh-2001b" TYPE="REFERENCE">Kavanagh 2001b</LINK>);</LI>
<LI>homoeopathic methods (<LINK REF="REF-Smith-2003" TYPE="REFERENCE">Smith 2003</LINK>);</LI>
<LI>nitric oxide (<LINK REF="REF-Kelly-2008" TYPE="REFERENCE">Kelly 2008</LINK>);</LI>
<LI>buccal or sublingual misoprostol (<LINK REF="REF-Muzonzini-2004" TYPE="REFERENCE">Muzonzini 2004</LINK>);</LI>
<LI>hypnosis;</LI>
<LI>other methods for induction of labour.</LI>
</OL>
<P>The primary reviews are analysed by the following clinical categories of participants:</P>
<OL>
<LI>previous caesarean section or not;</LI>
<LI>nulliparity or multiparity;</LI>
<LI>membranes intact or ruptured;</LI>
<LI>cervix favourable, unfavourable or undefined.</LI>
</OL>
<P>The secondary reviews will include all methods of labour induction for each of the categories of women for which subgroup analysis has been done in the primary reviews. There will thus be six secondary reviews, of methods of labour induction in the following groups of women:</P>
<OL>
<LI>primiparous, intact membranes (unfavourable cervix, favourable cervix, cervix not defined);</LI>
<LI>primiparous, ruptured membranes (unfavourable cervix, favourable cervix, cervix not defined);</LI>
<LI>multiparous, intact membranes (unfavourable cervix, favourable cervix, cervix not defined);</LI>
<LI>multiparous, ruptured membranes (unfavourable cervix, favourable cervix, cervix not defined);</LI>
<LI>previous caesarean section, intact membranes (unfavourable cervix, favourable cervix, cervix not defined);</LI>
<LI>previous caesarean section, ruptured membranes (unfavourable cervix, favourable cervix, cervix not defined).</LI>
</OL>
<P>The original protocol intention was to include only the five primary outcome measures in the secondary reviews. However, because of the lack of data on the primary outcomes in many reviews, the protocol was changed to include secondary outcome measures in the secondary reviews.</P>
<P>Each time a primary review is updated with new data, those secondary reviews which include data which have changed will also be updated.</P>
<P>The trials included in the primary reviews were extracted from an initial set of trials covering all interventions used in induction of labour (<I>see </I>above for details of search strategy). The data extraction process was conducted centrally. This was initially co-ordinated from the Clinical Effectiveness Support Unit (CESU) at the Royal College of Obstetricians and Gynaecologists, UK, in co-operation with the Cochrane Pregnancy and Childbirth Group. However, due to the large number of trials included in this review, this process was completed by the Cochrane Pregnancy and Childbirth Group. Double-data extraction was not feasible for this final stage, and data extraction was performed by one of the members of the Pregnancy and Childbirth Group using centrally developed data forms.</P>
<P>The trials were initially reviewed on eligibility criteria, using a standardised form and the basic selection criteria specified above. Following this, data were extracted to a standardised data extraction form which was piloted for consistency and completeness. The pilot process involved the researchers at the CESU and previous review authors in the area of induction of labour.</P>
<P>Information was extracted regarding the methodological quality of trials on a number of levels. This process was completed without consideration of trial results. Assessment of selection bias examines the process involved in the generation of the random sequence and the method of allocation concealment separately. These are then judged as adequate or inadequate using the criteria described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the purpose of the reviews.</P>
<P>Performance bias was examined with regards to whom was blinded in the trials, i.e., participant, caregiver, outcome assessor or analyst. In many trials the caregiver, assessor and analyst were the same. Details of the feasibility and appropriateness of blinding at all levels were sought.</P>
<P>Predefined subgroup analyses are previous caesarean section or not; nulliparity or multiparity; membranes intact or ruptured; and cervix unfavourable, favourable or undefined. Only those outcomes with data appear in the analysis tables.</P>
<P>Individual outcome data were included in the analysis if they met the prestated criteria in 'Types of outcome measures'. Included trial data were processed as described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). Data extracted from the trials were analysed on an intention-to-treat basis (when this was not done in the original report, re-analysis was performed if possible). Where data were missing, clarification was sought from the original authors. If the attrition was such that it might significantly affect the results, these data were excluded from the analysis. This decision rests with the review authors of the primary reviews and is clearly documented. Once missing data become available, they will be included in the analyses.</P>
<P>Data were extracted from all eligible trials to examine how issues of quality influence effect size in a sensitivity analysis. In trials where reporting is poor, methodological issues are reported as unclear or clarification sought.</P>
<P>Due to the large number of trials, double data extraction was not feasible and agreement between the three data extractors was therefore assessed on a random sample of trials.</P>
<P>Once the data had been extracted, they were distributed to individual review authors for entry onto the Review Manager computer software (<LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>), checked for accuracy, and analysed as above using <LINK REF="REF-RevMan-2003" TYPE="REFERENCE">RevMan 2003</LINK>. For dichotomous data, relative risks and 95% confidence intervals are calculated, and in the absence of heterogeneity, results are pooled using a fixed-effect model.</P>
<P>The predefined criteria for sensitivity analysis include all aspects of quality assessment as mentioned above, including aspects of selection, performance and attrition bias.</P>
<P>Primary analysis is limited to the prespecified outcomes and subgroup analyses. In the event of differences in unspecified outcomes or subgroups being found, these were analysed post hoc, but clearly identified as such to avoid drawing unjustified conclusions.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>A total of 56 trials (96 publications) were included in this review. </P>
<P>A large number of studies were conducted, starting in 1978 to the present, to evaluate intracervical application of PGE2 to ripen the cervix and induce labour. These were usually of small-sample size (less than 100 women included) and therefore with limited power to show a difference in clinically important outcomes. Among the 28 included trials comparing intracervical PGE2 with placebo/no treatment (including collectively 1956 women and 1808 women, respectively), nine had a total sample size of more than 100 women and, of those, five included more than 200 women in each trial. Among the 29 included trials comparing intracervical PGE2 with intravaginal PGE2 (including collectively 1958 women and 1923 women, respectively), 13 had a total sample size of more than 100 women and, of those, seven included more than 200 women in each trial. Two trials (<LINK REF="STD-Milliez-1993" TYPE="STUDY">Milliez 1993</LINK>; <LINK REF="STD-Stiver-1991" TYPE="STUDY">Stiver 1991</LINK>) comparing different dosages of PGE2 (0.25 mg versus 0.5 mg, 0.2 mg versus 0.5 mg respectively) included 84 and 28 women respectively. </P>
<P>A number of studies conducted during the 1980s were supported by the company that marketed the PGE2 analogue (Upjohn, Kalamazoo), and some were reported by the individual authors (e.g., <I>see </I>the individual reports for <LINK REF="STD-Noah-1987" TYPE="STUDY">Noah 1987</LINK> and <LINK REF="STD-Trofatter-1993" TYPE="STUDY">Trofatter 1993</LINK>) as well as the collective reports. Despite great care to avoid including duplicate data, it might well be that some data duplication is still present, as the authors of later studies do not always refer to the previously reported ones. </P>
<P>Another difficulty in conducting this review is that some trials were only reported as abstracts with limited data available (and limited possibilities to contact the authors to ask for clarification). Also, authors have used various protocols of administration (e.g., initial dose, frequency, number of doses) of intracervical PGE2. The usual initial dose was 0.5 mg, but some authors have administered 1 mg or more. The initial dose of intracervical PGE2 was followed, or not, by repeated administration at variable intervals (from three-hourly to weekly). Oxytocin, with or without amniotomy, was usually administered after the ripening process (that is, when cervical conditions were considered suitable) or after a fixed period of time. These variable protocols of oxytocin administration may have had an influence on the overall outcome of induction of labour.<BR/>
<BR/>
<I>See</I> 'Characteristics of included studies' table for detailed information about all the included trials and 'Characteristics of excluded studies' for details of excluded studies. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-02-04 10:19:42 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy resulted in 158 references which were all assessed for inclusion. We identified 109 studies in these references. Among them, 56 trials (96 references) were included. Fifty-three studies (62 publications) were excluded.</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of intracervical PGE2 with placebo or no treatment</HEADING>
<P>All 28 included studies stated that women were randomly allocated to intracervical PGE2 or placebo or no treatment. Information regarding generation of the randomisation sequence was clearly described in 11 studies. In the majority of the studies using a placebo, preparation of the drugs was made in the pharmacy; thus decreasing the risk of a problem with the generation of the sequence. Allocation concealment and blinding of the woman and carer were considered to be achieved when placebo was used, as few details were reported by the authors. Among the six trials with a control arm with no treatment, two studies reported an adequate method of concealment of allocation (four were unclear). Outcome assessor blinding was not reported. Nine trials reported the number of exclusions or loss to follow up. All trials reporting on this issue had less than 10% exclusions or loss of participants to follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of intracervical PGE2 with intravaginal PGE2</HEADING>
<P>All 29 included studies stated that women were randomly allocated to intracervical or intravaginal PGE2. Information regarding generation of the randomisation sequence was clearly described in 12 studies. Allocation concealment was reported in 16 trials (usually the use of opaque sealed envelopes). Blinding of woman and carer was achieved only in three studies that used a double-dummy procedure (active intracervical and placebo intravaginal versus placebo intracervical and active intravaginal). Outcome assessor blinding was not reported. Twelve trials reported the number of exclusions or loss to follow up. Eleven of those had less than 10% exclusions or loss of participants to follow up (the last one excluded 15 and 12 women among 208 from the analysis).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of lower dose intracervical PGE2 with higher dose</HEADING>
<P>Both trials stated that women were randomly allocated to different dosages of PGE2. Generation of randomisation sequence was by selecting an envelope for one of the studies (<LINK REF="STD-Milliez-1993" TYPE="STUDY">Milliez 1993</LINK>). Allocation concealment, however, was unclear as the envelopes used were not described as opaque. No information was provided regarding blinding. There were no losses to follow up. The second trial, reported as abstract only, did not describe randomisation sequence, allocation concealment, blinding or follow up (<LINK REF="STD-Stiver-1991" TYPE="STUDY">Stiver 1991</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-02-04 10:20:51 +0000" MODIFIED_BY="[Empty name]">
<P>Fifty-six trials, involving 7738 women, were included in this review. Some data were available for all primary outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of intracervical PGE2 with placebo or no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>Only four studies (<LINK REF="STD-Gilson-1993" TYPE="STUDY">Gilson 1993</LINK>; <LINK REF="STD-Gr_x00fc_nberger-1986" TYPE="STUDY">Grünberger 1986</LINK>; <LINK REF="STD-Ulmsten-1982" TYPE="STUDY">Ulmsten 1982</LINK>; <LINK REF="STD-Ulmsten-1985" TYPE="STUDY">Ulmsten 1985</LINK>), including 198 women, reported the number of women who did not achieve vaginal delivery within 24 hours, showing a decreased risk with PGE2 (relative risk (RR) 0.61; 95% confidence interval (CI) 0.47 to 0.79). The outcome that was reported by the majority, 27 trials, including 3734 women, was caesarean section. There was a small, and statistically non-significant, reduction of the risk of caesarean section when PGE2 was used (RR 0.88; 95% CI 0.77 to 1.00). The finding was statistically significant in a subgroup of women with intact membranes and unfavourable cervix (10 trials; RR 0.82; 95% CI 0.68 to 0.98). The risk of hyperstimulation with fetal heart rate (FHR) changes was not significantly increased (12 trials, including 2296 women; RR 1.21; 95% CI 0.72 to 2.05). However, the risk of hyperstimulation without FHR changes was significantly increased (11 trials, including 2531 women; RR 1.59; 95% CI 1.09 to 2.33). Serious maternal morbidity or death and serious neonatal morbidity or perinatal morbidity were infrequently reported and findings were similar in the two groups (RR 0.33; 95% CI 0.01 to 7.96 and RR 0.75; 95% CI 0.19 to 2.96, respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There were no statistically significant differences found in any of the reported secondary outcomes, with the exception of vomiting, showing an increased risk with PGE2 (four trials, 1015 women; RR 2.27; 95% CI 1.11 to 4.63). No trials reported on uterine rupture, use of epidural analgesia, neonatal encephalopathy, disability in childhood, woman not satisfied or caregiver not satisfied.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of intracervical PGE2 with intravaginal PGE2</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The number of women who did not achieve vaginal delivery within 24 hours was increased with intracervical PGE2 (11 trials, involving 2200 women; RR 1.26; 95% CI 1.12 to 1.41). There was no change in the risk of caesarean section (28 trials, involving 3781 women; RR 1.07; 95% CI 0.93 to 1.22). The risks of hyperstimulation with FHR changes (13 trials, involving 1428 women; RR 0.76; 95% CI 0.39 to 1.49) and without FHR changes (13 trials, involving 1681 women; RR 0.80; 95% CI 0.56 to 1.15), were not different between the two methods of PGE2 administration. Serious maternal morbidity was infrequently reported (RR 3.07; 95% CI 0.13 to 74.71). Only one trial reported one case in the intracervical PGE2 group (<LINK REF="REF-Irion-1998a" TYPE="REFERENCE">Irion 1998a</LINK>), while two trials (<LINK REF="STD-Seeras-1995" TYPE="STUDY">Seeras 1995</LINK>; <LINK REF="STD-Zanini-1989" TYPE="STUDY">Zanini 1989</LINK>) reported there were no deaths or serious morbidity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>There were no statistically significant differences found in any of the reported secondary outcomes. No trials reported on cervix unfavourable or unchanged after 12 to 24 hours (as a proportion), neonatal encephalopathy, disability in childhood, maternal death, and woman or caregiver not satisfied. Only one trial reported on maternal views, with two women not satisfied in the intracervical group (64 women) versus three in the intravaginal group (61 women) (<LINK REF="STD-Lyndrup-1991" TYPE="STUDY">Lyndrup 1991</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison of lower dose intracervical PGE2 with higher dose </HEADING>
<P>The first study, involving 28 women, compared 0.2 mg to 0.5 mg of intracervical PGE2 gel (<LINK REF="STD-Stiver-1991" TYPE="STUDY">Stiver 1991</LINK>). Both groups received the gel at six hourly intervals until labour or spontaneous rupture of the membranes occurred, otherwise a maximum of five doses were given. The trial only reported on caesarean section rates and there was no significant difference between the groups (40% versus 30.8%; RR 1.30, 95% CI 0.47 to 3.62). The second study, involving 84 women, compared 0.25 mg intracervical PGE2 gel administered daily with 0.5 mg intracervical PGE2 gel given twice 12 hours apart (<LINK REF="STD-Milliez-1993" TYPE="STUDY">Milliez 1993</LINK>). In the first group, applications were repeated until the Bishops score greater than six or maternal or fetal condition deteriorated. The trial reported on uterine hyperstimulation with FHR changes (14.2% versus 11.9%; RR 1.2; 95% CI 0.40 to 3.63) caesarean section rates (19% versus 31%; RR 0.62; 95% CI 0.28 to 1.33) and the use of oxytocin augmentation (28.6% versus 71.4%; RR 0.40; 95% CI 0.24 to 0.67).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-02-04 10:21:22 +0000" MODIFIED_BY="[Empty name]">
<P>Intracervical route of administration is presently less used and less evaluated, replaced by either vaginal administration of PGE2 or use of misoprostol. One of the reasons might be the difficulty to achieve a true intracervical application, which may result in leaks of the products from the cervical canal in the vagina. As the pre-packaged dose is lower than with the vaginal route, this may explain the lower efficacy of intracervical prostaglandins compared to vaginal. It is surprising that little information is available concerning this issue in the included trials. Similarly, only one author has evaluated maternal views on their care and no data are available regarding caregiver's satisfaction.</P>
<SUBSECTION>
<HEADING LEVEL="2">Intracervical prostaglandin versus placebo or no treatment</HEADING>
<P>The use of intracervical prostaglandins appear to be more effective than placebo or no treatment, especially for women with unfavourable cervix and intact membranes. The only outcome, however, that was reported by the majority of the authors was caesarean section, with fewer data on the other outcomes. Many reports were only published as abstracts with limited details and data available. It was also unclear for a number of studies whether the participants were also included in a large multicenter trial (<I>see</I> 'Description of studies'). We have excluded all studies that we suspected were part of the multicenter trial to avoid as much as possible duplication of data. Results of some of the outcomes (e.g., not achieving vaginal delivery within 24 hours) show some heterogeneity, but using a random-effects model does not materially change the estimate of the effect provided by a fixed-effect model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Intracervical prostaglandin versus intravaginal prostaglandin</HEADING>
<P>Intracervical prostaglandins were shown to be less effective than intravaginal prostaglandin. This conclusion is limited by the fact that significant heterogeneity is present between trials for the comparison of the number of women 'not achieving vaginal delivery within 24 hours'. The intravaginal route should be both easier and less uncomfortable for the woman. It is surprising that no trials, except one, report on this issue. It might well be that this was, together with a perceived similar or inferior efficacy, the reason to abandon this route of administration in many centres.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Intracervical PGE2 low dose versus intracervical PGE2 high dose</HEADING>
<P>Overall there were insufficient data to make any meaningful comparisons between dosages from these trials.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Intracervical prostaglandins are effective, but do not have advantages compared to intravaginal prostaglandin. Therefore, if prostaglandin administration seems indicated, the intravaginal route should be preferred, as it is more effective and practical. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Despite the limitations of the currently available evidence, there is little scope for more research regarding intracervical use of PGE2. It would be, however, important to evaluate the safety and the benefits of the use of prostaglandin E2 (probably using the vaginal route) in women with a past history of caesarean section, as there are little data from randomised trials evaluating this issue. <BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>R Smyth (while working as an Editorial Assistant at the Cochrane Pregnancy and Childbirth Group editorial base) contributed to the following sections: Abstract, Descriptions of studies, Methodological quality of included studies and Results section. R Smyth assessed a proportion of the studies for inclusion, extracted and entered the data independently. </P>
<P>Lixia Dou, who completed the 'Characteristics of included studies' table for many of the studies.</P>
<P>Special thanks to Ingemar Ingemarsson (<LINK REF="STD-Ingemarsson-1991" TYPE="STUDY">Ingemarsson 1991</LINK>); Mike Lucas and Alex Vidaeff (<LINK REF="STD-Trofatter-1993" TYPE="STUDY">Trofatter 1993</LINK>); Charles Nager (<LINK REF="STD-Nager-1987" TYPE="STUDY">Nager 1987</LINK>); and Mike Wyldes (<LINK REF="STD-Wyldes-1992" TYPE="STUDY">Wyldes 1992</LINK>) who kindly provided unpublished information and data for this review. </P>
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team), one or more members of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Tony Kelly did the initial data collection, which was updated by Rebecca Smyth. Michel Boulvain, Tony Kelly and Olivier Irion checked the data and wrote the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-02-04 10:49:01 +0000" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernstein-1991" NAME="Bernstein 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bernstein EP, Leyland N, Gurland P, Gare D</AU>
<TI>Effect of administration of PGE2 gel and placebo gel into the cervical canal on cervical softening and induction of labour</TI>
<SO>Proceedings of the Annual Meeting of Society of Obstetricans and Gynaecologists of Canada</SO>
<YR>1986</YR>
<PG>108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bernstein EP. Prostaglandin E2 gel for cervical ripening and labour induction. A Canadian multi-centre placebo-controlled trial. Proceedings of Annual Meeting of Society of Obstetricians and Gynaecologists of Canada; 1991 June 11-15; Toronto, Ontario, Canada 1991;70&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bernstein EP</AU>
<TI>Prostaglandin E2 gel for cervical ripening and labour induction. A Canadian multi-centre placebo-controlled trial</TI>
<SO>Proceedings of the Annual Meeting of Society of Obstetricians and Gynaecologists of Canada; 1991 June 11-15; Toronto, Ontario, Canada</SO>
<YR>1991</YR>
<PG>70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bernstein P, Leyland N, Gurland P, Gare D. Cervical ripening and labor induction with prostaglandin E2 gel: a placebo-controlled study. Am J Obstet Gynecol 1987;156:336-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein P, Leyland N, Gurland P, Gare D</AU>
<TI>Cervical ripening and labor induction with prostaglandin E2 gel: a placebo-controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1987</YR>
<VL>156</VL>
<PG>336-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bernstein P. Prostaglandin E2 gel for cervical ripening and labour induction: a multicentre placebo-controlled trial [published erratum appears in Can Med Assoc J 1992 Apr 15;146(8):1290]. Cmaj 1991;145:1249-54.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein P</AU>
<TI>Prostaglandin E2 gel for cervical ripening and labour induction: a multicentre placebo-controlled trial [published erratum appears in Can Med Assoc J 1992 Apr 15;146(8):1290]</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1991</YR>
<VL>145</VL>
<PG>1249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Christilaw J, King JF</AU>
<TI>A randomised, placebo controlled trial to determine the effect of intracervical prostaglandin gel on the unripe cervix, prior to induction of labour</TI>
<SO>Proceedings of the Annual Meeting of Society of Obstetricians and Gynaecologists of Canada; 1986</SO>
<YR>1986</YR>
<PG>107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buttino-1990" NAME="Buttino 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Buttino LT Jr., Garite TJ. Intracervical prostaglandin in postdate pregnancy. A randomized trial. J Reprod Med 1990;35:155-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buttino LT, Garite TJ</AU>
<TI>Intracervical prostaglandin in postdate pregnancy. A randomized trial</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1990</YR>
<VL>35</VL>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabrol-1988" NAME="Cabrol 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Cabrol D, Bernard N, Chouraqui A, Domenichini Y, Lemaire P, Lopes P, et al. [Ripening of the cervix uteri at term by a single intracervical application of prostaglandin E2 gel]. J Gynecol Obstet Biol Reprod 1988;17:527-34.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabrol D, Bernard N, Chouraqui A, Domenichini Y, Lemaire P, Lopes P, et al</AU>
<TI>Ripening of the cervix uteri at term by a single intracervical application of prostaglandin E2 gel</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>1988</YR>
<VL>17</VL>
<PG>527-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chyu-1997" NAME="Chyu 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Chyu JK, Strassner HT. Prostaglandin E2 for cervical ripening: a randomized comparison of Cervidil versus Prepidil. Am J Obstet Gynecol 1997;177:606-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chyu JK, Strassner HT</AU>
<TI>Prostaglandin E2 for cervical ripening: a randomized comparison of Cervidil versus Prepidil</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>177</VL>
<PG>606-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corrado-2001" NAME="Corrado 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Corrado F, Cannata ML, Facciola G, Stella NC. Intravaginal vs. intracervical pge2 gel first application for labor induction. International Journal of Gynecology &amp;amp; Obstetrics 2001;75:195-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corrado F, Cannata ML, Facciola G, Stella NC</AU>
<TI>Intravaginal vs. intracervical pge2 gel first application for labor induction</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2001</YR>
<VL>75</VL>
<PG>195-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Darroca-1996" NAME="Darroca 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Darroca RJ, Buttino L, Jr., Miller J, Khamis HJ. Prostaglandin E2 gel for cervical ripening in patients with an indication for delivery. Obstet Gynecol 1996;87:228-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Darroca RJ, Buttino L, Miller J, Khamis HJ</AU>
<TI>Prostaglandin E2 gel for cervical ripening in patients with an indication for delivery</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1996</YR>
<VL>87</VL>
<PG>228-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duhl-1997" NAME="Duhl 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duhl A, Tolosa J, Leiva M, Memiroff R</AU>
<TI>Randomized trial of intravaginal gel, intravaginal time release insert and intracervical gel with prostaglandin E2 for induction of labour</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S113</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekman-1983" NAME="Ekman 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Ekman G, Forman A, Marsal K, Ulmsten U. Intravaginal versus intracervical application of prostaglandin E2 in viscous gel for cervical priming and induction of labor at term in patients with an unfavorable cervical state. Am J Obstet Gynecol 1983;147:657-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekman G, Forman A, Marsal K, Ulmsten U</AU>
<TI>Intravaginal versus intracervical application of prostaglandin E2 in viscous gel for cervical priming and induction of labor at term in patients with an unfavorable cervical state</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1983</YR>
<VL>147</VL>
<PG>657-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Din-2000" NAME="El-Din 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>El-Din NMN, El-Morghatz DAM</AU>
<TI>Cervical ripening and induction of labour with misoprostol, prostaglandin E2 or prostaglandin E2 gel: a randomized comparative clinical trial</TI>
<SO>XVI FIGO World Congress of Obstetrics and Gynecology (Book 4); 2000 Sept 3-8; Washington DC, USA</SO>
<YR>2000</YR>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilson-1993" NAME="Gilson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilson GJ, Curet LB</AU>
<TI>Intracervical dinoprostone (PGE2): does it actually lower the cesarean section rate</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gilson GJ, Izquierdo LA, Chatterjee MS, Curet LB, Qualls CR</AU>
<TI>Prevention of caesarean section. Does intracervical dinoprostone work?</TI>
<SO>Western Journal of Medicine</SO>
<YR>1993</YR>
<VL>159</VL>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gr_x00fc_nberger-1986" NAME="Grünberger 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Grunberger W, Spona J. The effect of paracervical PGE2 instillation on levels of maternal serum 13,14-dihydro-15-keto-PGF2alpha and progesterone . Archives of Gynecology 1986;239:93-9. RS tried to contact authors to confirm if all deliveries were vaginal. Contact unsucessful (April 2007), presume all deliveries were.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grünberger W, Spona J</AU>
<TI>The effect of paracervical PGE2 instillation on levels of maternal serum 13,14-dihydro-15-keto-PGF2alpha and progesterone</TI>
<SO>Archives of Gynecology</SO>
<YR>1986</YR>
<VL>239</VL>
<PG>93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hales-1994" NAME="Hales 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Hales K, Rayburn W, Turnbull G, Christensen D, Patatanian E. Double-blind comparison of intracervical and intravaginal prostaglandin E2 for cervical ripening and induction of labor . American Journal of Obstetrics and Gynecology 1994;170:365&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hales K, Rayburn W, Turnbull G, Christensen D, Patatanian E</AU>
<TI>Double-blind comparison of intracervical and intravaginal prostaglandin E2 for cervical ripening and induction of labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>365</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Hales KA, Rayburn WF, Turnbull GL, Christensen HD, Patatanian E. Double-blind comparison of intracervical and intravaginal prostaglandin E2 for cervical ripening and induction of labor. Am J Obstet Gynecol 1994;171:1087-91.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hales KA, Rayburn WF, Turnbull GL, Christensen HD, Patatanian E</AU>
<TI>Double-blind comparison of intracervical and intravaginal prostaglandin E2 for cervical ripening and induction of labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>171</VL>
<PG>1087-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heinzl-1980" NAME="Heinzl 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Heinzl S, Ramzin MS, Schneider M, Luescher KP. [Priming of cervix with prostaglandin gel during immature birth situation at term (author's transl)]. Z Geburtshilfe Perinatol 1980;184:395-400.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinzl S, Ramzin MS, Schneider M, Luescher KP</AU>
<TI>Priming of cervix with prostaglandin gel during immature birth situation at term (author's transl)</TI>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1980</YR>
<VL>184</VL>
<PG>395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hidar-2000" NAME="Hidar 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hidar S, Bibi M, Jerbi M, Bouguizene S, Nouira M, Mellouli R, et al</AU>
<TI>Contribution of intracervical PGE2 administration in premature rupture of the membranes at term. Prospective randomised clinical trial</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>2000</YR>
<VL>29</VL>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hutchon-1980" NAME="Hutchon 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Hutchon DJ, Geirsson R, Patel NB. A double-blind controlled trial of PGE2 gel in cervical ripening. Int J Gynaecol Obstet 1980;17:604-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hutchon DJ, Geirsson R, Patel NB</AU>
<TI>A double-blind controlled trial of PGE2 gel in cervical ripening</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1980</YR>
<VL>17</VL>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hutchon DJR, Geirsson RT, Patel NB</AU>
<TI>A double-blind controlled trial of intracervical prostaglandin E2 in cervical ripening [abstract]</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1980</YR>
<VL>59</VL>
<NO>Suppl 93</NO>
<PG>83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irion-1998" NAME="Irion 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Irion O, Pedrazzoli J, Mermillod B. A randomized trial comparing vaginal and cervical prostaglandin gel for cervical ripening and labor induction. Obstet Gynecol 1998;91:65-71.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Irion O, Pedrazzoli J, Mermillod B</AU>
<TI>A randomized trial comparing vaginal and cervical prostaglandin gel for cervical ripening and labor induction</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>91</VL>
<PG>65-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedrazzoli J, Irion O, Mermillod B, Beguin F</AU>
<TI>A randomised comparison of an intravaginal and an intracervical prostaglandin E2 gel for cervical ripening and induction of labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>S111</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pedrazzoli J, Irion O, Mermillod B, Beguin F</AU>
<TI>A randomised comparison of an intravaginal and an intracervical prostaglandin E2 gel for cervical ripening and induction of labour</TI>
<SO>20th Congress of the Swiss Society of Gynecology and Obstetrics; 1997 June; Lugano, Switzerland</SO>
<YR>1997</YR>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keirse-1995" NAME="Keirse 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Keirse MJ, de Koning Gans HJ. Randomized comparison of the effects of endocervical and vaginal prostaglandin E2 gel in women with various degrees of cervical ripeness. Dutch Collaborative Prostaglandin Trialists' Group. Am J Obstet Gynecol 1995;173:1859-64.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Keirse MJ, de Koning Gans HJ, the Duch Collaborative Prostaglandin Trialists' Group</AU>
<TI>Randomized comparison of the effects of endocervical and vaginal prostaglandin E2 gel in women with various degrees of cervical ripeness. Dutch Collaborative Prostaglandin Trialists' Group</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>1859-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Keirse MJNC, Schulpen MAGT, De Koning Gans HJ. A randomized controlled comparison of endocervical and vaginal PGE2 in triacetin gel for cervical ripening and induction of labour. Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands 1991;214&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keirse MJNC, Schulpen MAGT, De Koning Gans HJ</AU>
<TI>A randomized controlled comparison of endocervical and vaginal PGE2 in triacetin gel for cervical ripening and induction of labour</TI>
<SO>Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands</SO>
<YR>1991</YR>
<PG>214</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>de Koning Gans GHJ, Keirse MJNC</AU>
<TI>A comparison between intra-cervical and intra-vaginal application of prepidil gel for the induction of labour</TI>
<SO>Personal communication</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-2000" NAME="Kemp 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kemp B, Winkler M, Rath W</AU>
<TI>Induction of labor by prostaglandin E2 in relation to Bishop score</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larmon-2002" NAME="Larmon 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;[12374]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larmon JE, Magann EF, Dickerson GA, Morrison JC</AU>
<TI>Outpatient cervical ripening with prostaglandin E2 and estriol</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2002</YR>
<VL>11</VL>
<PG>113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laube-1986" NAME="Laube 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Laube DW, Zlatnik FJ, Pitkin RM. Preinduction cervical ripening with prostaglandin E2 intracervical gel. Obstet Gynecol 1986;68:54-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laube DW, Zlatnik FJ, Pitkin RM</AU>
<TI>Preinduction cervical ripening with prostaglandin E2 intracervical gel</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1986</YR>
<VL>68</VL>
<PG>54-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Legarth-1988" NAME="Legarth 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Legarth J, Guldbaek E, Scher NJ. The efficiency of prostaglandin E2 vaginal suppositories versus intracervical prostaglandin gel for induction of labor in patients with unfavorable inducibility prospects. Eur J Obstet Gynecol Reprod Biol 1988;27:93-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Legarth J, Guldbaek E, Scher NJ</AU>
<TI>The efficiency of prostaglandin E2 vaginal suppositories versus intracervical prostaglandin gel for induction of labor in patients with unfavorable inducibility prospects</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1988</YR>
<VL>27</VL>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Legarth J, Guldbaek E, Secher NJ. The efficiency of prostaglandin E2 vaginal suppository vs intracervical prostaglandin gel for induction of labor in patients with unfavorable Bishop score . Archives of Gynecology 1985;237(Suppl 1):103&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Legarth J, Guldbaek E, Secher NJ</AU>
<TI>The efficiency of prostaglandin E2 vaginal suppository vs intracervical prostaglandin gel for induction of labor in patients with unfavorable Bishop score</TI>
<SO>Archives of Gynecology</SO>
<YR>1985</YR>
<VL>237</VL>
<NO>Suppl 1</NO>
<PG>103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lien-1998" NAME="Lien 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Lien JM, Morgan MA, Garite TJ, Kennedy KA, Sassoon DA, Freeman RK. Antepartum cervical ripening: applying prostaglandin E2 gel in conjunction with scheduled nonstress tests in postdate pregnancies. Am J Obstet Gynecol 1998;179:453-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lien JM, Morgan MA, Garite TJ, Kennedy KA, Sassoon DA, Freeman RK</AU>
<TI>Antepartum cervical ripening: applying prostaglandin E2 gel in conjunction with scheduled nonstress tests in postdate pregnancies</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<PG>453-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopes-1991" NAME="Lopes 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopes P, Besse O, Sagot P, Dantal F, De Morel P, Panel N, et al</AU>
<TI>Induction of labour with vaginal prostaglandin E2 with a 'Spongel'. Results of a prospective randomised study taking into account Bishops score and the dose of PGE2 used</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>1990</YR>
<VL>19</VL>
<PG>505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[6363]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lopes P, Besse O, Sagot P, Dantal F, De Morel P, Panel N, et al</AU>
<TI>PGE2 application on a biodegradable support for cervix ripening and induction of labour</TI>
<SO>Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands</SO>
<YR>1991</YR>
<PG>147</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lopes P, Besse O, Sagot P, Dantal F, de Morel P, Panel N, et al. [The value of the administration of prostaglandin E2 on the biodegradable support of the maturation of the cervix uteri and the induction of labor]. J Gynecol Obstet Biol Reprod 1991;20:827-32.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lopes P, Besse O, Sagot P, Dantal F, de Morel P, Panel N, et al</AU>
<TI>The value of the administration of prostaglandin E2 on the biodegradable support of the maturation of the cervix uteri and the induction of labor</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>827-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyndrup-1991" NAME="Lyndrup 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Lyndrup J, Nickelsen C, Guldbaek E, Weber T. Induction of labor by prostaglandin E2: intracervical gel or vaginal pessaries? Eur J Obstet Gynecol Reprod Biol 1991;42:101-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lyndrup J, Nickelsen C, Guldbaek E, Weber T</AU>
<TI>Induction of labor by prostaglandin E2: intracervical gel or vaginal pessaries?</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1991</YR>
<VL>42</VL>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lyndrup J, Nickelsen C, Guldbaek E, Weber T. Induction of labour by prostaglandin-E2: intracervical gel or vaginal pessaries? Proceedings of 13th World Congress of Gynaecology and Obstetrics (FIGO); 1991 Sept 15-20; Singapore 1991;70&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lyndrup J, Nickelsen C, Guldbaek E, Weber T</AU>
<TI>Induction of labour by prostaglandin-E2: intracervical gel or vaginal pessaries?</TI>
<SO>Proceedings of 13th World Congress of Gynaecology and Obstetrics (FIGO); 1991 Sept 15-20; Singapore</SO>
<YR>1991</YR>
<PG>70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lyndrup J. Induction of labor by PGE2 and other local methods. Physiology, methods and guidelines for patient selection. Acta Obstetricia et Gynecologica Scandinavica 1996;75:86-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyndrup J</AU>
<TI>Induction of labor by PGE2 and other local methods. Physiology, methods and guidelines for patient selection</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1996</YR>
<VL>75</VL>
<PG>86-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKenna-1999" NAME="McKenna 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;McKenna DS, Costa SW, Samuels P. Prostaglandin E2 cervical ripening without subsequent induction of labor. Obstet Gynecol 1999;94:11-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKenna DS, Costa SW, Samuels P</AU>
<TI>Prostaglandin E2 cervical ripening without subsequent induction of labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1999</YR>
<VL>94</VL>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milliez-1993" NAME="Milliez 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Milliez JM, Jannet D, Touboul C, Khelifati Y, el Medjadji M. Two different regimens of preinduction ripening of the uterine cervix with prostaglandin E2: a randomized clinical study. Eur J Obstet Gynecol Reprod Biol 1993;50:163-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milliez JM, Jannet D, Touboul C, Khelifati Y, El Medjadji M</AU>
<TI>Two different regimens of preinduction ripening of the uterine cervix with prostaglandin E2: a randomized clinical study</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1993</YR>
<VL>50</VL>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nager-1987" NAME="Nager 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Nager CW, Key TC, Moore TR. Cervical ripening and labor outcome with preinduction intracervical prostaglandin E2 (Prepidil) gel. J Perinatol 1987;7:189-93.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nager CW, Key TC, Moore TR</AU>
<TI>Cervical ripening and labor outcome with preinduction intracervical prostaglandin E2 (Prepidil) gel</TI>
<SO>Journal of Perinatology</SO>
<YR>1987</YR>
<VL>7</VL>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NICHHD-1994" NAME="NICHHD 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Medearis AL</AU>
<TI>Postterm pregnancy: active labour induction (PGE2 gel) not associated with improved outcomes compared to expectant management. A preliminary report</TI>
<SO>Proceedings of 10th Annual Meeting of Society of Perinatal Obstetricians; 1990 Jan 23-27; Houston, Texas, USA</SO>
<YR>1990</YR>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;A clinical trial of induction of labor versus expectant management in postterm pregnancy. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1994;170:716-23.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units</AU>
<TI>A clinical trial of induction of labor versus expectant management in postterm pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1994</YR>
<VL>170</VL>
<PG>716-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nimrod-1984" NAME="Nimrod 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Nimrod C, Currie J, Yee J, Dodd G, Persaud D. Cervical ripening and labor induction with intracervical triacetin base prostaglandin E2 gel: a placebo-controlled study. Obstet Gynecol 1984;64:476-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nimrod C, Currie J, Yee J, Dodd G, Persaud D</AU>
<TI>Cervical ripening and labor induction with intracervical triacetin base prostaglandin E2 gel: a placebo-controlled study</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1984</YR>
<VL>64</VL>
<PG>476-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noah-1987" NAME="Noah 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Bung P, Baer S, Djahanschahi D, Huch R, Huch A, Huber JF, et al. [Multicenter experiences with the intracervical administration of a new PGE2 gel in labor induction]. Geburtshilfe Frauenheilkd 1986;46:93-7. RS TO WRITE TO AUTHOR TO CONFIRM PART OF NOAH TRIAL&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bung P, Baer S, Djahanschahi D, Huch R, Huch A, Huber JF, et al</AU>
<TI>Multicenter experiences with the intracervical administration of a new PGE2 gel in labor induction</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1986</YR>
<VL>46</VL>
<PG>93-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Keirse MJNC, Kanhai HHH, Verwey RA</AU>
<TI>European multi-centre trial of intracervical PGE2 in triacetin gel: report of the Leiden data</TI>
<SO>The role of prostaglandins in labour</SO>
<YR>1985</YR>
<PG>93-100</PG>
<ED>Wood C</ED>
<PB>RSM Services Limited</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Keirse MJNC, Schulpen MAGT, Corbeij RSACM, Oosterbaan HP. Vaginal PGE2 gel vs intravenous oxytocin after cervical ripening with endocervical PGE2 gel . In: Keirse MJNC, de Koning Gans HJ. Priming and induction of labour by prostaglandins &amp;quot;A state of the art&amp;quot; , Postgrad Med Ed Committee, Leiden. 1987;53-76&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Keirse MJNC, Schulpen MAGT, Corbeij RSACM, Oosterbaan HP</AU>
<TI>Vaginal PGE2 gel vs intravenous oxytocin after cervical ripening with endocervical PGE2 gel</TI>
<SO>Priming and induction of labour by prostaglandins "A state of the art"</SO>
<YR>1987</YR>
<PG>53-76</PG>
<ED>Keirse MJNC, de Koning Gans HJ</ED>
<PB>Postgrad Med Ed Committee</PB>
<CY>Leiden</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Kieback DG, Zahradnik HP, Quaas L, Kroner-Fehmel EE, Lippert TH. Clinical evaluation of endocervical prostaglandin E2-triacetin-gel for preinduction cervical softening in pregnant women at term. Prostaglandins 1986;32:81-5. RS TO WRITE TO AUTHOR TO CONFIRM PART OF NOAH TRIAL&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kieback DG, Zahradnik HP, Quaas L, Kroner-Fehmel EE, Lippert TH</AU>
<TI>Clinical evaluation of endocervical prostaglandin E2-triacetin-gel for preinduction cervical softening in pregnant women at term</TI>
<SO>Prostaglandins</SO>
<YR>1986</YR>
<VL>32</VL>
<PG>81-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Kimball FA, Ruppel PL, Noah ML, Decoster JM, De La Fuente P, Castillo JM, Hernandez JM. The effect of endocervical PGE2-gel (Prepidil) gel on plasma levels of 13,14-dihydro-15-keto-PGE2 (PGEM) in women at term . Prostaglandins 1986;32:527-37 RS TO WRITE TO AUTHOR TO CONFIRM PART OF NOAH TRIAL&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimball FA, Ruppel PL, Noah ML, Decoster JM, De La Fuente P, Castillo JM, et al</AU>
<TI>The effect of endocervical PGE2-gel (Prepidil) gel on plasma levels of 13,14-dihydro-15-keto-PGE2 (PGEM) in women at term</TI>
<SO>Prostaglandins</SO>
<YR>1986</YR>
<VL>32</VL>
<PG>527-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Kristoffersen M, Sande HA, Sande OS. Ripening of the cervix with prostaglandin E2-gel. A randomized study with a new ready-to-use compound of triacetin-prostaglandin-E2-gel. Int J Gynaecol Obstet 1986;24:297-300. RS TO WRITE TO AUTHOR TO CONFIRM PART OF NOAH TRIAL&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristoffersen M, Sande HA, Sande OS</AU>
<TI>Ripening of the cervix with prostaglandin E2-gel. A randomized study with a new ready-to-use compound of triacetin-prostaglandin-E2-gel</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1986</YR>
<VL>24</VL>
<PG>297-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Noah ML, DeCoster JM, Fraser TJ, Orr JD. Preinduction cervical softening with endocervical PGE2 gel. A multi-center trial. Acta Obstet Gynecol Scand 1987;66:3-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Noah ML, DeCoster JM, Fraser TJ, Orr JD</AU>
<TI>Preinduction cervical softening with endocervical PGE2 gel. A multi-center trial</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1987</YR>
<VL>66</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pulle C, Granese D, Panama S, Celona A</AU>
<TI>Cervical ripening and induction of labour by single intracervical PGE2-gel application</TI>
<SO>Acta Therapeutica</SO>
<YR>1986</YR>
<VL>12</VL>
<PG>5-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Wiqvist I, Norstrom A, Wiqvist N. Induction of labor by intra-cervical PGE2 in viscous gel . Acta Obstetricia et Gynecologica Scandinavica 1986;65:485-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiqvist I, Norstrom A, Wiqvist N</AU>
<TI>Induction of labor by intra-cervical PGE2 in viscous gel</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1986</YR>
<VL>65</VL>
<PG>485-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Zahradnik HP, Quaas L, Kroner-Fehmel EE, Kieback DG, Lippert TH. [Cervix ripening using drugs before oxytocin labor induction. Clinical study of a new prostaglandin E2 triacetin gel]. Geburtshilfe Frauenheilkd 1987;47:190-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zahradnik HP, Quaas L, Kroner-Fehmel EE, Kieback DG, Lippert TH</AU>
<TI>Cervix ripening using drugs before oxytocin labor induction. Clinical study of a new prostaglandin E2 triacetin gel</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1987</YR>
<VL>47</VL>
<PG>190-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuutila-1995" NAME="Nuutila 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;10919&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuutila M, Kajanoja P</AU>
<TI>Cervical ripening prior to labour induction with intracervical prostaglandin E2 gel in patients with preeclampsia. A placebo controlled study</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>3</NO>
<PG>313-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuutila-1996" NAME="Nuutila 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Nuutila M, Kajanoja P. A randomized comparison of intravaginal and intracervical administration of prostaglandin E2 in cervical ripening . Acta Obstetricia et Gynecologica Scandinavica Supplement 1995;73:110-1&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuutila M, Kajanoja P</AU>
<TI>A randomized comparison of intravaginal and intracervical administration of prostaglandin E2 in cervical ripening</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica Supplement</SO>
<YR>1995</YR>
<VL>73</VL>
<PG>110-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[9205] also abstract [8646]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nuutila M, Kajanoja P</AU>
<TI>Local administration of prostaglandin E2 for cervical ripening and labor induction: the appropriate route and dose</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1996</YR>
<VL>75</VL>
<PG>135-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ottinger-1998" NAME="Ottinger 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Ottinger WS, Menard MK, Brost BC. A randomized clinical trial of prostaglandin E2 intracervical gel and a slow release vaginal pessary for preinduction cervical ripening. Am J Obstet Gynecol 1998;179:349-53.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ottinger WS, Menard MK, Brost BC</AU>
<TI>A randomized clinical trial of prostaglandin E2 intracervical gel and a slow release vaginal pessary for preinduction cervical ripening</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<PG>349-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owen-1991" NAME="Owen 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Owen J, Winkler CL, Harris BA, Jr., Hauth JC, Smith MC. A randomized, double-blind trial of prostaglandin E2 gel for cervical ripening and meta-analysis. Am J Obstet Gynecol 1991;165:991-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Owen J, Winkler CL, Harris BA, Jr., Hauth JC, Smith MC</AU>
<TI>A randomized, double-blind trial of prostaglandin E2 gel for cervical ripening and meta-analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>165</VL>
<PG>991-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen J, Winkler CL, Hauth JC, Harris BA, Smith MC</AU>
<TI>A randomised double blind trial of prostaglandin E2 gel for cervical ripening and a meta analysis</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>313</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peccerillo-1995" NAME="Peccerillo 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peccerillo JA, Egan JFX, Borgida A, Campbell WA</AU>
<TI>Comparison of intracervical PGE2 to intravaginal PGE2 for preinduction cervical ripening</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez-Picanol-1990" NAME="Perez Picanol 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perez Picanol E, Gamissans O, Lecumberri J, Jimenez M, Vernet M</AU>
<TI>Ripening the cervix with intracervical PGE2 gel in term pregnancies with premature rupture of membranes</TI>
<SO>Proceedings of 12th European Congress of Perinatal Medicine; 1990 Sept 11-14; Lyon, France</SO>
<YR>1990</YR>
<PG>197</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-2003" NAME="Perry 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Perry MY, Leaphart WL. A randomized controlled trial using intracervical versus posterior fornix placement of dinoprostone. Obstetrics &amp;amp; Gynecology 2003;101(4):35S&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry MY, Leaphart WL</AU>
<TI>A randomized controlled trial using intracervical versus posterior fornix placement of dinoprostone</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2003</YR>
<VL>101</VL>
<NO>4</NO>
<PG>35S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[13053] and [13052] Same abstract, printed twice (page 35S)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry MY, Leaphart WL</AU>
<TI>Randomized trial of intracervical versus posterior fornix dinoprostone for induction of labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>11S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perry MY, Leaphart WL</AU>
<TI>Randomized trial of intracervical versus posterior fornix dinoprostone for induction of labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2004</YR>
<VL>103</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulsen-1991" NAME="Poulsen 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Poulsen HK, Moller LK, Westergaard JG, Thomsen SG, Giersson RT, Arngrimsson R. Open randomized comparison of prostaglandin E2 given by intracervical gel or vagitory for preinduction cervical ripening and induction of labor. Acta Obstet Gynecol Scand 1991;70:549-53.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulsen HK, Moller LK, Westergaard JG, Thomsen SG, Giersson RT, Arngrimsson R</AU>
<TI>Open randomized comparison of prostaglandin E2 given by intracervical gel or vagitory for preinduction cervical ripening and induction of labor</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>549-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsey-2003" NAME="Ramsey 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Ramsey PS, Harris D, Ogburn Jr PL, , Heise RH, Magtibay PM, Ramin KD . Comparative efficacy and cost of the prostaglandin analogs dinoprostone and misoprostol as labour preinduction agents. American journal of Obstetrics and Gynecology 2003;1885(2):560-5&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramsey PS, Harris D, Ogburn PL, Heise RH, Magtibay PM, Ramin KD</AU>
<TI>Comparative efficacy and cost of the prostaglandin analogs dinoprostone and misoprostol as labour preinduction agents</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>188</VL>
<NO>2</NO>
<PG>560-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ramsey PS, Meyer L, Walkes BA, Harris D, Ogburn Jr PL, Heise RH, Ramin KD . Cardiotocographic abnormalities associated with dinoprostone and misoprostol cervical ripening. Obstetrics &amp;amp; Gynecology 2005;105(1):85-90&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsey PS, Meyer L, Walkes BA, Harris D, Ogburn PL, Heise RH, et al</AU>
<TI>Cardiotocographic abnormalities associated with dinoprostone and misoprostol cervical ripening</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2005</YR>
<VL>105</VL>
<NO>1</NO>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rath-1999" NAME="Rath 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;[12222]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rath W, Heyl W, Kemp B</AU>
<TI>Intracervical versus intravaginal PGE2 gel for induction of labor</TI>
<SO>Perinatal Medizin</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>81-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[13299] WILL BE INCLUDED - BOTH PAPERS IN GERMAN - NEEDS DATA PULLING BY MICHEL. &lt;br&gt;Commercially funded by Upjohn Co, Kalamazoo, Mich.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rath W, Kemp B, Heyl W</AU>
<TI>Prostaglandin E2 as a vaginal gel, intracervical gel or vaginal tablet for induction of labor: a prospective, randomized, multicenter trial</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1999</YR>
<VL>59</VL>
<PG>323-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richardson-1991" NAME="Richardson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richardson CJ, Evans JF, Meisel RL</AU>
<TI>Duration of intracervical prostaglandin and caesarean section</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rix-1996" NAME="Rix 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;M&amp;#248;ller M. Trial to assess the effects of cervical ripening and induction of labour by prostaglandin administration. Personal communication ---------------;&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Møller M</AU>
<TI>Trial to assess the effects of cervical ripening and induction of labour by prostaglandin administration</TI>
<SO>Personal communication</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rix P, Andersen K, Ladehoff P, M&amp;#248;ller AM, Zdravkovic M. PGE2 vaginal tablets compared to ready prepared cervical PGE2 gel in ability to induce cervical ripening and labour by low Bishop scores . Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6-9; Vienna, Austria 1988;151&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rix P, Andersen K, Ladehoff P, Møller AM, Zdravkovic M</AU>
<TI>PGE2 vaginal tablets compared to ready prepared cervical PGE2 gel in ability to induce cervical ripening and labour by low Bishop scores</TI>
<SO>Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6-9; Vienna, Austria 1988</SO>
<YR>1988</YR>
<PG>151</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rix P, Ladehoff P, Moller AM, Tilma KA, Zdravkovic M. Cervical ripening and induction of delivery by local administration of prostaglandin E2 gel or vaginal tablets is equally effective. Acta Obstet Gynecol Scand 1996;75:45-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rix P, Ladehoff P, Moller AM, Tilma KA, Zdravkovic M</AU>
<TI>Cervical ripening and induction of delivery by local administration of prostaglandin E2 gel or vaginal tablets is equally effective</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1996</YR>
<VL>75</VL>
<PG>45-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seeras-1995" NAME="Seeras 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Seeras RC. Induction of labor utilizing vaginal vs. intracervical prostaglandin E2. Int J Gynaecol Obstet 1995;48:163-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seeras RC</AU>
<TI>Induction of labor utilizing vaginal vs. intracervical prostaglandin E2</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1995</YR>
<VL>48</VL>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stempel-1997" NAME="Stempel 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Stempel JE, Prins RP, Dean S. Preinduction cervical ripening: a randomized prospective comparison of the efficacy and safety of intravaginal and intracervical prostaglandin E2 gel. Am J Obstet Gynecol 1997;176:1305-9; discussion 1309-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stempel JE, Prins RP, Dean S</AU>
<TI>Preinduction cervical ripening: a randomized prospective comparison of the efficacy and safety of intravaginal and intracervical prostaglandin E2 gel</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>1305-9; discussion 1309-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiver-1991" NAME="Stiver 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Stiver KH, Davis MJ, Golichowski AM. Repeated intracervical prostaglandin administration for cervical ripening . American Journal of Obstetrics and Gynecology 1991;164:315&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiver KH, Davis MJ, Golichowski AM</AU>
<TI>Repeated intracervical prostaglandin administration for cervical ripening</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>315</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strobelt-2006" NAME="Strobelt 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Strobelt N, Meregalli V, Ratti M, Mariani S, Zani G, Morana S. Randomized study on removable PGE2 vaginal insert versus PGE2 cervical gel for cervical priming and labor induction in low-bishop-score pregnancy. Acta Obstetricia et Gynecologica Scandinavica 2006;85(3):302-5&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Strobelt N, Meregalli V, Ratti M, Mariani S, Zani G, Morana S</AU>
<TI>Randomized study on removable PGE2 vaginal insert versus PGE2 cervical gel for cervical priming and labor induction in low-bishop-score pregnancy</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>3</NO>
<PG>302-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Strobelt N, Ratti M, Zani G, Meregalli V. Randomized study on two dinoprostone administration routes for cervical priming and labor induction in low bishop pregnancy [abstract]. American Journal of Obstetrics and Gynecology 2003;189(6):S206&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strobelt N, Ratti M, Zani G, Meregalli V</AU>
<TI>Randomized study on two dinoprostone administration routes for cervical priming and labor induction in low bishop pregnancy</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>6</NO>
<PG>S206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiery-1984" NAME="Thiery 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiery M, Decoster JM, Parewijck W, Noah ML, Derom R, Van Kets H, et al</AU>
<TI>Endocervical prostaglandin E2 gel for preinduction cervical softening</TI>
<SO>Prostaglandins</SO>
<YR>1984</YR>
<VL>27</VL>
<PG>429-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trofatter-1985" NAME="Trofatter 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Trofatter KF, Jr., Bowers D, Gall SA, Killam AP. Preinduction cervical ripening with prostaglandin E2 (Prepidil) gel. Am J Obstet Gynecol 1985;153:268-71.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trofatter KF, Bowers D, Gall SA, Killam AP</AU>
<TI>Preinduction cervical ripening with prostaglandin E2 (Prepidil) gel</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1985</YR>
<VL>153</VL>
<PG>268-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Trofatter-1993" NAME="Trofatter 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Haas S, Lucas MJ. Impact of prepidil pre-induction cervical treatment . American Journal of Obstetrics and Gynecology 1993;168:361. RS IN CONTACT WITH AUTHOR - MIKE LUCAS. Mike confirmed this study is an additional report of Trofatter 1993.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas S, Lucas MJ</AU>
<TI>Impact of prepidil pre-induction cervical treatment</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>361</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;RS IN CONTACT WITH AUTHOR - MIKE LUCAS (April 2007). Mike confirmed this study is an additional report of Trofatter 1993.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lucas MJ, Leveno KJ, Williams ML, Brewster S</AU>
<TI>Efficacy of prostaglandin E2 gel in cervical ripening: preliminary results</TI>
<SO>Proceedings of 6th Annual Meeting of the Society of Perinatal Obstetricians; 1986 Jan 30-Feb 1; San Antonio, Texas, USA</SO>
<YR>1986</YR>
<PG>240-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Trofatter KF, Jr. Effect of preinduction cervical softening with dinoprostone gel on outcome of oxytocin-induced labor. Clin Ther 1993;15:838-44.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Trofatter KF</AU>
<TI>Effect of preinduction cervical softening with dinoprostone gel on outcome of oxytocin-induced labor</TI>
<SO>Clinical Therapeutics</SO>
<YR>1993</YR>
<VL>15</VL>
<PG>838-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Yonekura ML, Songster G, Smith-Wallace T. Preinduction cervical priming with PGE2 intracervical gel. Am J Perinatol 1985;2:305-10. RS tried to contact authors (April 2007) - not successful, therefore presuming is part of the Trofatter group. &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yonekura ML, Songster G, Smith-Wallace T</AU>
<TI>Preinduction cervical priming with PGE2 intracervical gel</TI>
<SO>American Journal of Perinatology</SO>
<YR>1985</YR>
<VL>2</VL>
<PG>305-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Troostwijk-1992" NAME="Troostwijk 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Troostwijk AL, van Veen JB, Doesburg WH. Pre-induction intracervical application of a highly viscous prostaglandin E2 gel in pregnant women with an unripe uterine cervix: a double-blind placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol 1992;43:105-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Troostwijk AL, van Veen JB, Doesburg WH</AU>
<TI>Pre-induction intracervical application of a highly viscous prostaglandin E2 gel in pregnant women with an unripe uterine cervix: a double-blind placebo-controlled trial</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1992</YR>
<VL>43</VL>
<PG>105-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulmsten-1982" NAME="Ulmsten 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Ulmsten U, Wingerup L, Belfrage P, Ekman G, Wiqvist N. Intracervical application of prostaglandin gel for induction of term labor. Obstet Gynecol 1982;59:336-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulmsten U, Wingerup L, Belfrage P, Ekman G, Wiqvist N</AU>
<TI>Intracervical application of prostaglandin gel for induction of term labor</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1982</YR>
<VL>59</VL>
<PG>336-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulmsten-1985" NAME="Ulmsten 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Ulmsten U, Ekman G, Belfrage P, Bygdeman M, Nyberg C. Intracervical versus intravaginal PGE2 for induction of labor at term in patients with an unfavorable cervix. Arch Gynecol 1985;236:243-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ulmsten U, Ekman G, Belfrage P, Bygdeman M, Nyberg C</AU>
<TI>Intracervical versus intravaginal PGE2 for induction of labor at term in patients with an unfavorable cervix</TI>
<SO>Archives of Gynecology</SO>
<YR>1985</YR>
<VL>236</VL>
<PG>243-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wieland-1999" NAME="Wieland 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Wieland D, Friedman F, Jr. Comparing two dinoprostone agents for preinduction cervical ripening at term. A randomized trial. J Reprod Med 1999;44:724-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wieland D, Friedman F</AU>
<TI>Comparing two dinoprostone agents for preinduction cervical ripening at term. A randomized trial</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1999</YR>
<VL>44</VL>
<PG>724-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wingerup-1978" NAME="Wingerup 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Wingerup L, Andersson KE, Ulmsten U. Ripening of the uterine cervix and induction of labour at term with prostaglandin E2 in viscous gel. Acta Obstet Gynecol Scand 1978;57:403-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wingerup L, Andersson KE, Ulmsten U</AU>
<TI>Ripening of the uterine cervix and induction of labour at term with prostaglandin E2 in viscous gel</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1978</YR>
<VL>57</VL>
<PG>403-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuen-1996" NAME="Yuen 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yuen PM, Pang HYY, Chung T, Chang A</AU>
<TI>Cervical ripening before induction of labour in patients with an unfavourable cervix. A comparative randomised study of the Atad Ripener device, Prostaglandin E2 vaginal pessary and prostglandin E2 intracervical gel</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1996</YR>
<VL>36</VL>
<PG>291-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yuen PM, Pang YYH</AU>
<TI>A randomized study of two different methods for cervical ripening</TI>
<SO>Proceedings of 2nd International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists; 1993 Sept 7-10; Hong Kong</SO>
<YR>1993</YR>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanini-1989" NAME="Zanini 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Zanini A, Ghidini A, Norchi S, Beretta E, Cortinovis I, Bottino S. Pre-induction cervical ripening with prostaglandin E2 gel: intracervical versus intravaginal route. Obstet Gynecol 1990;76:681-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanini A, Ghidini A, Norchi S, Beretta E, Cortinovis I, Bottino S</AU>
<TI>Pre-induction cervical ripening with prostaglandin E2 gel: intracervical versus intravaginal route</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1990</YR>
<VL>76</VL>
<PG>681-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Zanini A, Norchi S, Beretta E, Cortinovis I, Fenaroli G, Scian A. [Cervical ripening and induction of labor in term pregnancy using prostaglandin E2. Controlled clinical study comparing the intracervical and intravaginal routes]. Ann Ostet Ginecol Med Perinat 1989;110:209-16.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zanini A, Norchi S, Beretta E, Cortinovis I, Fenaroli G, Scian A</AU>
<TI>Cervical ripening and induction of labor in term pregnancy using prostaglandin E2. Controlled clinical study comparing the intracervical and intravaginal routes</TI>
<TO>Maturazione cervicale e induzione del travaglio di parto in gravidanze a termine con prostaglandina E2. Studio clinico controllato tra via intracervicale e intravaginale</TO>
<SO>Annali di Ostetricia, Ginecologia, Medicina Perinatale.</SO>
<YR>1989</YR>
<VL>110</VL>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aggarwal-2006" NAME="Aggarwal 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;Aggarwal N, Kirthika KS, Suri V, Malhotra S. Comparative evaluation of vaginal PGE-1 analogue (misoprostol) and intracervical PGE-2 gel for cervical ripening and induction of labor [abstract]. 49th All India Congress of Obstetrics and Gynaecology; 2006 Jan 6-9; Cochin, Kerala State, India 2006:95&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aggarwal N, Kirthika KS, Suri V, Malhotra S</AU>
<TI>Comparative evaluation of vaginal PGE-1 analogue (misoprostol) and intracervical PGE-2 gel for cervical ripening and induction of labor [abstract]</TI>
<SO>49th All India Congress of Obstetrics and Gynaecology; 2006 Jan 6-9; Cochin, Kerala State, India</SO>
<YR>2006</YR>
<PG>95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bredow-1993" NAME="Bredow 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Bredow V, Straube W. Fetal outcome following to cervical condition appropriated induction of labour with prostaglandin E2 in correlation to cervical condition . Zentralblatt fur Gynakologie 1993;115:530-6&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bredow V, Straube W</AU>
<TI>Fetal outcome following to cervical condition appropriated induction of labour with prostaglandin E2 in correlation to cervical condition</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1993</YR>
<VL>115</VL>
<PG>530-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cararach-1994" NAME="Cararach 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Cararach V, Sentis J, Botet F, Costa J, Manau D, Arimany MC</AU>
<TI>Cervical prostaglandin E2 compared with expectant management or systematic induction in PROM with bad cervical conditions</TI>
<SO>Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5-8; Helsinki, Finland</SO>
<YR>1994</YR>
<PG>405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Cararach V, Sentis J, Botet F, Foradada C, Manau D, Figueras F, Mateos D, Arimany C, Costa J. Cervical prostaglandin E1 compared with expectant management and with systematic induction in PROM near term, with bad cervical conditions. I-maternal results. 3rd World Congress of Perinatal Medicine; 1996 Oct 20-24; San Francisco, USA 1996;44&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cararach V, Sentis J, Botet F, Foradada C, Manau D, Figueras F, et al</AU>
<TI>Cervical prostaglandin E1 compared with expectant management and with systematic induction in PROM near term, with bad cervical conditions. I-maternal results</TI>
<SO>3rd World Congress of Perinatal Medicine; 1996 Oct 20-24; San Francisco, USA</SO>
<YR>1996</YR>
<PG>44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Foradada C, Cararach V, Sentis J, Botet F, Manau D, Figueras F, Arimany C, Mateos D, Costa J. Cervical prostaglandin E1 compared with expectant management and with systematic induction in PROM near term, with bad cervical conditions. II-fetal and neonatal results [abstract]. 3rd World Congress of Perinatal Medicine; 1996 Oct 20-24; San Francisco, USA 1996;51-2&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Foradada C, Cararach V, Sentis J, Botet F, Manau D, Figueras F, et al</AU>
<TI>Cervical prostaglandin E1 compared with expectant management and with systematic induction in PROM near term, with bad cervical conditions. II-fetal and neonatal results [abstract]</TI>
<SO>3rd World Congress of Perinatal Medicine; 1996 Oct 20-24; San Francisco, USA</SO>
<YR>1996</YR>
<PG>51-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mateos D, Cararach V, Sentis J, Botet F, Figueras F, Arimany MC, Foradada C. Cervical prostaglandin E2 compared with expectant management or systematic induction in premature rupture of membranes with bad cervical conditions . Prenatal and Neonatal Medicine 1996;1 Suppl 1:85&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mateos D, Cararach V, Sentis J, Botet F, Figueras F, Arimany MC, et al</AU>
<TI>Cervical prostaglandin E2 compared with expectant management or systematic induction in premature rupture of membranes with bad cervical conditions</TI>
<SO>Prenatal and Neonatal Medicine</SO>
<YR>1996</YR>
<VL>1 Suppl 1</VL>
<PG>85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Aniello-2003" NAME="D'Aniello 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;D'Aniello G, Bocchi C, Florio P, Ignacchiti E, Guidoni CG, Centini G, Cito G, Picciolini E, Severi FM, Petraglia F. Cervical ripening and induction of labor by prostaglandin e2: a comparison between intracervical gel and vaginal pessary. Journal of Maternal-Fetal &amp;amp; Neonatal Medicine 2003;14(3):158-62&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Aniello G, Bocchi C, Florio P, Ignacchiti E, Guidoni CG, Centini G, et al</AU>
<TI>Cervical ripening and induction of labor by prostaglandin e2: a comparison between intracervical gel and vaginal pessary</TI>
<SO>Journal of Maternal-Fetal &amp; Neonatal Medicine</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>3</NO>
<PG>158-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egarter-1988" NAME="Egarter 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Egarter Von C, Husslein P. Sensitivity test before induction of labour using prostaglandin E2 vaginal tablets . Zentralblatt fur Gynakologie 1988;110:345-53.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egarter C, Husslein P</AU>
<TI>Sensitivity test before induction of labour using prostaglandin E2 vaginal tablets</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1988</YR>
<VL>110</VL>
<PG>345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekblad-1994" NAME="Ekblad 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Ekblad U, Erkkola R, Pirhonen J. Comparison of intravaginal and two intracervical prostaglandin E2 gels in pre-induction of labour. Ann Chir Gynaecol Suppl 1994;208:64-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ekblad U, Erkkola R, Pirhonen J</AU>
<TI>Comparison of intravaginal and two intracervical prostaglandin E2 gels in pre-induction of labour</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1994</YR>
<VL>83</VL>
<PG>64-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Facchinetti-2005" NAME="Facchinetti 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Facchinetti F, Venturini P, Verocchi G, Volpe A. Comparison of two preparations of dinoprostone for pre-induction of labour in nulliparous woman with very unfavourable cervical condition: a randomised clinical trial. European Journal of Obstetrics &amp;amp; Gynecology and Reproductive Biology 2005;119:189-93&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Facchinetti F, Venturini P, Verocchi G, Volpe A</AU>
<TI>Comparison of two preparations of dinoprostone for pre-induction of labour in nulliparous woman with very unfavourable cervical condition: a randomised clinical trial</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>2005</YR>
<VL>119</VL>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuchs-1984" NAME="Fuchs 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Fuchs AR, Goeschen K, Rasmussen AB, Rehnstrom JV. Cervical ripening and plasma prostaglandin levels. Comparison of endocervical and extra-amniotic PGE2. Prostaglandins 1984;28(2):217-27&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuchs AR, Goeschen K, Rasmussen AB, Rehnstrom JV</AU>
<TI>Cervical ripening and plasma prostaglandin levels. Comparison of endocervical and extra-amniotic</TI>
<SO>Prostaglandins</SO>
<YR>1984</YR>
<VL>28</VL>
<NO>2</NO>
<PG>217-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-1988" NAME="Garcia 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Garcia AA, Chavez AJ, Jimenez SG, Isquierdo PJC, Angles WD, Santos GJ, et al</AU>
<TI>Preinduction cervical ripening with PGE2: a double blind study</TI>
<SO>12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>197</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gittens-1996" NAME="Gittens 1996" YEAR="10154">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gittens L, Schenkel C, Strassberg S, Apuzzio J</AU>
<TI>Vaginal birth after cesarean section: comparison of outpatient use of prostaglandin gel to expectant management</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>174</VL>
<NO>1 Pt 2</NO>
<PG>354</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goeschen-1985" NAME="Goeschen 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Goeschen K, Fuchs AR, Fuchs F, Rasmussen AB, Rehnstrom JV, Saling E. Effect of beta-mimetic tocolysis on cervical ripening and plasma prostaglandin F2alpha metabolite after endocervical application of prostaglandin E2. Obstetrics &amp;amp; Gynecology 1985;65:166-71&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goeschen K, Fuchs AR, Fuchs F, Rasmussen AB, Rehnstrom JV, Saling E</AU>
<TI>Effect of beta-mimetic tocolysis on cervical ripening and plasma prostaglandin F2alpha metabolite after endocervical application of prostaglandin E2</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1985</YR>
<VL>65</VL>
<PG>166-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonen-1994" NAME="Gonen 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonen R, Samberg I, Degani S, Sharf M</AU>
<TI>Intracervical prostaglandin E2 for induction of labour in patients with premature rupture of membranes and an unfavourable cervix</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>362</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Gonen R, Samberg I, Degani S. Intracervical prostaglandin E2 for induction of labor in patients with premature rupture of membranes and an unripe cervix. Am J Perinatol 1994;11:436-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gonen R, Samberg I, Degani S</AU>
<TI>Intracervical prostaglandin E2 for induction of labor in patients with premature rupture of membranes and an unripe cervix</TI>
<SO>American Journal of Perinatology</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>436-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hennessey-1998" NAME="Hennessey 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Hennessey MH, Rayburn WF, Stewart JD, Liles EC. Pre-eclampsia and induction of labor: a randomized comparison of prostaglandin e2 as an intracervical gel, with oxytocin immediately, or as a sustained-release vaginal insert. American Journal of Obstetrics and Gynecology 1998;179(5):1204-9&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hennessey MH, Rayburn WF, Stewart JD, Liles EC</AU>
<TI>Pre-eclampsia and induction of labor: a randomized comparison of prostaglandin e2 as an intracervical gel, with oxytocin immediately, or as a sustained-release vaginal insert</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<NO>5</NO>
<PG>1204-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Stewart JD, Rayburn WF, Farmer K, Liles E, Schipul A, Stanley J. Effectiveness of prostaglandin E2 as an intracervical gel with immediate oxytocin, or as a sustained-release vaginal insert for induction of labour. American Journal of Obstetrics and Gynecology 1998;178(1 Pt 2):92&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart JD, Rayburn WF, Farmer K, Liles E, Schipul A, Stanley J</AU>
<TI>Effectiveness of prostaglandin E2 as an intracervical gel with immediate oxytocin, or as a sustained-release vaginal insert for induction of labour</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>178</VL>
<NO>1 Pt 2</NO>
<PG>92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart JD, Rayburn WF, Farmer KC, Liles EM, Schipul AHJr, Stanley JR</AU>
<TI>Effectiveness of prostaglandin e2 intracervical gel (prepidil), with immediate oxytocin, versus vaginal insert (cervidil) for induction of labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<NO>5</NO>
<PG>1175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henson-1987" NAME="Henson 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Henson BV. Cervical ripening with prostaglandin E2 . Personal communication ---------------;&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Henson BV</AU>
<TI>Cervical ripening with prostaglandin E2</TI>
<SO>Personal communication</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herabutya-1992" NAME="Herabutya 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Herabutya Y//Prasertsawat PO//Tongyai T//Isarangura N//Ayudthya N. Prolonged pregnancy: the management dilemma. Int J Gynaecol Obstet 1992;37:253-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herabutya Y, Prasertsawat PO, Tongyai T, Isarangura N, Ayudthya N</AU>
<TI>Prolonged pregnancy: the management dilemma</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1992</YR>
<VL>37</VL>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herabutya-1993" NAME="Herabutya 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Herabutya Y, Prasertsawat PO. Ripening of the unfavorable cervix with prostaglandin E2: intracervical versus intravaginal route. J Med Assoc Thai 1993;76 Suppl 1:63-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herabutya Y, Prasertsawat PO</AU>
<TI>Ripening of the unfavorable cervix with prostaglandin E2: intracervical versus intravaginal route</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1993</YR>
<VL>76 Suppl 1</VL>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iftikhar-1991" NAME="Iftikhar 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;[7181]&lt;br&gt;RS CONTACT AUTHORS UNABLE TO LOCATE AUTHOR 05/04/07&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Iftikhar M, Price J, Beattie RB, Heasley RN, Armstrong MJ</AU>
<TI>Pre-induction cervical ripening in primigravida with unfavourable cervix. A randomised controlled trial using PGE2 intracervical gel or vaginal pessary</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[6361]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Iftikhar M, Price J, Beattie RB, Heasley RN</AU>
<TI>Evaluation of PGE2 intracervical gel for cervical ripening in primigravidae with unfavourable cervicies</TI>
<SO>Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands</SO>
<YR>1991</YR>
<PG>139</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ingemarsson-1991" NAME="Ingemarsson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Ingemarson I, Heden L, Montan S, Sjoberg NO</AU>
<TI>Prostaglandin gel for ripening of the cervix in post term pregnancy</TI>
<SO>Personal communication</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamat-2002" NAME="Kamat 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Kamat DS, Kamat VD, Mulary AA, Kharat A, Thomas EV. Induction and augmentation of labour by intracervical and/or intravaginal PGE2 tablet (Primiprost). Journal of Obstetrics and Gynecology of India 2002;52(5):33-4&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamat DS, Kamat VD, Mulary AA, Kharat A, Thomas EV</AU>
<TI>Induction and augmentation of labour by intracervical and/or intravaginal PGE2 tablet (Primiprost)</TI>
<SO>Journal of Obstetrics and Gynecology of India</SO>
<YR>2002</YR>
<VL>52</VL>
<NO>5</NO>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaminski-1994" NAME="Kaminski 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Kaminski K, Rechberger T, Oleszczuk J, Jakowicki J, Oleszczuk J. Biochemical and clinical evaluation of the efficiency of intracervical extraamniotic prostaglandin F2 and intravenous oxytocin infusion to induce labour at term . Australian and New Zealand Journal of Obstetrics and Gynaecology 1994;34:409-13&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaminski K, Rechberger T, Oleszczuk J, Jakowicki J, Oleszczuk J</AU>
<TI>Biochemical and clinical evaluation of the efficiency of intracervical extraamniotic prostaglandin F2 and intravenous oxytocin infusion to induce labour at term</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1994</YR>
<VL>34</VL>
<PG>409-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kupietz-1994" NAME="Kupietz 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Kupietz R, Faber J, Heidegger H. Advantage of labor induction by intracervical prostaglandin E2 gel at night . Zentralblatt fur Gynakologie 1994;116:468-73&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kupietz R, Faber J, Heidegger H</AU>
<TI>Advantage of labor induction by intracervical prostaglandin E2 gel at night</TI>
<SO>Zentralblatt fur Gynakologie</SO>
<YR>1994</YR>
<VL>116</VL>
<PG>468-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lotshaw-1994" NAME="Lotshaw 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;[12909]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotshaw RR, Gordon HR</AU>
<TI>Optimal interval between prostaglandin E2 ripening of the cervix and oxytocin induction of labor: a prospective clinical trial</TI>
<SO>Journal of Maternal-Fetal Medicine</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luther-1983" NAME="Luther 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luther ER</AU>
<TI>Comparison of natural and synthetic PGE2 tablets in labour induction</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1983</YR>
<VL>128</VL>
<PG>1189-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyndrup-1992" NAME="Lyndrup 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Lyndrup J, Legarth J, Weber T, Nickelsen C, Guldbaek E. Predictive value of pelvic scores for induction of labor by local PGE2. European Journal of Obstetrics &amp;amp; Gynecology and Reproductive Biology 1992;47:17-23&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyndrup J, Legarth J, Weber T, Nickelsen C, Guldbaek E</AU>
<TI>Predictive value of pelvic scores for induction of labor by local PGE2</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackenzie-1988" NAME="Mackenzie 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Mackenzie IZ, Annan B, Jackson C, Hurley P, Hey F, Newman M. A randomized trial comparing a non-biodegradable polymer PGE2 pessary with a glyceride PGE2 pessary for labour induction. World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil 1988:199&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mackenzie IZ, Annan B, Jackson C, Hurley P, Hey F, Newman M</AU>
<TI>A randomized trial comparing a non-biodegradable polymer PGE2 pessary with a glyceride PGE2 pessary for labour induction</TI>
<SO>12th FIGO World Congress of Gynecology and Obstetrics; 1988 October 23-28; Brazil</SO>
<YR>1988</YR>
<PG>199</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Megalo-1998" NAME="Megalo 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Megalo A, Holhfeld P</AU>
<TI>Misoprostol (PGE1) as an alternative to PGE2 for pre-induction cervical ripening and labour induction</TI>
<SO>21st Conference of the Swiss Society of Gynecology and Obstetrics; 1998</SO>
<YR>1998</YR>
<PG>19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minaretzis-1993" NAME="Minaretzis 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Minaretzis D, Tsionu C, Papageorgiou I, Michalas S, Aravantinos D. Intracervical prostaglandin E2 gel for cervical ripening and labor induction: what is the appropriate dose? Gynecol Obstet Invest 1993;35:34-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minaretzis D, Tsionu C, Papageorgiou I, Michalas S, Aravantinos D</AU>
<TI>Intracervical prostaglandin E2 gel for cervical ripening and labor induction: what is the appropriate dose?</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1993</YR>
<VL>35</VL>
<PG>34-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mink-1994" NAME="Mink 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Mink D, Boos R, Heiss C, Schmidt W. [PgE2 gel and PgE2 vaginal tablets for induced labor--a prospective randomized study]. Geburtshilfe Frauenheilkd 1994;54:409-13.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mink D, Boos R, Heiss C, Schmidt W</AU>
<TI>PgE2 gel and PgE2 vaginal tablets for induced labor--a prospective randomized study</TI>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1994</YR>
<VL>54</VL>
<PG>409-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1995" NAME="Muller 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Muller T, Rempen A. [Induced labor with prostaglandins: 0.5 mg PGE2 intracervical gel versus 3 mg PGE2 vaginal tablet]. Z Geburtshilfe Perinatol 1995;199:30-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller T, Rempen A</AU>
<TI>Induced labor with prostaglandins: 0.5 mg PGE2 intracervical gel versus 3 mg PGE2 vaginal tablet</TI>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1995</YR>
<VL>199</VL>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-2000" NAME="Muller 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;[12065]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller T, Schildhauer K, Gross M, Dietl J</AU>
<TI>Induction of labour with prostaglandins with unripe cervix: 0.5mg intracervical PG-E2 versus 3 mg PG-E2 vaginal tablet</TI>
<TO>Gebursteinleitung mit Prostaglandinen bei unreifer Zervix: 0.5 mg PGE2 Intrazervicalgel versus 3 mg PGE2 Vaginal-tablette</TO>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>2000</YR>
<VL>60</VL>
<NO>Suppl 1</NO>
<PG>S71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noah-1985" NAME="Noah 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noah ML, Thiery M, Parewijck W, Decoster JM</AU>
<TI>Assessment of a two dose scheme of PGE2 gel for preinduction cervical softening</TI>
<SO>Prostaglandins</SO>
<YR>1985</YR>
<VL>30</VL>
<PG>305-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuutila-1997" NAME="Nuutila 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;[12514] Focus of trial fetal doppler flow, but possible that authors collected data relevant to this review, therefore RS emailed M Nuutila (10/04/07) for data - no response. RS emailed O Ylikorkala (23/04/07) - no reponse (27/04/07).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuutila M, Cacciatore B, Ylikorkala O</AU>
<TI>Effect of local prostaglandin E2 on uterine and fetal Doppler flow in pregnancy-induced hypertension</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>357-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Parewijck-1987" NAME="Parewijck 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Parewijck W. Cervical ripening with intracervical application of prostaglandin E2 gel . Personal communication ---------------;&lt;br&gt;1984 (1306)&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Parewijck W</AU>
<TI>Cervical ripening with intracervical application of prostaglandin E2 gel</TI>
<SO>Personal communication</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Paul-1988" NAME="Paul 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Paul R, Romero R. Clinical trial of induction vs expectant management in post-term pregnancy . Personal communication 1988;&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Paul R, Romero R</AU>
<TI>Clinical trial of induction vs expectant management in post-term pregnancy</TI>
<SO>Personal communication</SO>
<YR>1988</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penna-1991" NAME="Penna 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Penna LK, MacLachlan NA, Dunlop D, Spencer JAD</AU>
<TI>Intracervical or intravaginal prostaglandin E2 gel for cervical ripening in the unfavourable cervix - a randomised trial</TI>
<SO>Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands</SO>
<YR>1991</YR>
<PG>141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polvi-1994" NAME="Polvi 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Polvi HJ, Pirhonen JP, Erkkola RU. Vaginal and intracervical prostaglandin E2 for cervical ripening: a doppler study of hemodynamic effects . American Journal of Perinatology 1994;11:337-9. Focus of trial doppler flow, but possible that authors collected data relevant to this review, therefore RS emailed JP Pirhonen and JP Pirhonen (24/04/07) for data - no response.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polvi HJ, Pirhonen JP, Erkkola RU</AU>
<TI>Vaginal and intracervical prostaglandin E2 for cervical ripening: a doppler study of hemodynamic effects</TI>
<SO>American Journal of Perinatology</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>337-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rath-1985" NAME="Rath 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Rath W, Adelmann-Grill BC, Schauer A, Hilgers R, Harder D, Kuhn W. Clinical, morphological and biochemical aspects of cervical ripening by intracervically applied sulprostone-gel . Archives of Gynecology 1985;237(Suppl 1):342&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rath W, Adelmann-Grill BC, Schauer A, Hilgers R, Harder D, Kuhn W</AU>
<TI>Clinical, morphological and biochemical aspects of cervical ripening by intracervically applied sulprostone-gel</TI>
<SO>Archives of Gynecology</SO>
<YR>1985</YR>
<VL>237</VL>
<NO>Suppl 1</NO>
<PG>342</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rayburn-1988" NAME="Rayburn 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Rayburn W, Gosen R, Ramadei C, Woods R, Scott J, Jr. Outpatient cervical ripening with prostaglandin E2 gel in uncomplicated postdate pregnancies. Am J Obstet Gynecol 1988;158:1417-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rayburn W, Gosen R, Ramadei C, Woods R, Scott J</AU>
<TI>Outpatient cervical ripening with prostaglandin E2 gel in uncomplicated postdate pregnancies</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1988</YR>
<VL>158</VL>
<PG>1417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rayburn-1999" NAME="Rayburn 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rayburn W, Lucas M, Gittens L, Goodwin TM, Baxi L, Gall S et al</AU>
<TI>Attempted vaginal birth after cesarean section: a multicenter comparison of outpatient prostaglandin E2 gel with expectant management [abstract]</TI>
<SO>Primary Care Update for Ob/Gyns</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>4</NO>
<PG>182-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Rayburn WF, Gittens LN, Lucas MJ, Gall SA, Martin ME. Weekly administration of prostaglandin e2 gel compared with expectant management in women with previous cesareans. Prepidil gel study group. Obstetrics &amp;amp; Gynecology 1999;94(2):250-4&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rayburn WF, Gittens LN, Lucas MJ, Gall SA, Martin ME</AU>
<TI>Weekly administration of prostaglandin e2 gel compared with expectant management in women with previous cesareans. Prepidil gel study group</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1999</YR>
<VL>94</VL>
<NO>2</NO>
<PG>250-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichel-1985" NAME="Reichel 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Reichel R, Husslein P, Goschen K, Rasche M, Sinzinger H. Resorption of prostaglandin e2 following various methods of local administration for ripening of the cervix and end the induction of labor . Wiener Klinische Wochenschrift 1985;97(11):500-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichel R, Husslein P, Goschen K, Rasche M, Sinzinger H</AU>
<TI>Resorption of prostaglandin e2 following various methods of local administration for ripening of the cervix and end the induction of labor</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1985</YR>
<VL>97</VL>
<NO>11</NO>
<PG>500-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1986" NAME="Roberts 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Morrison JC. Cervical ripening techiques . Personal communication 1993;&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Morrison JC</AU>
<TI>Cervical ripening techiques</TI>
<SO>Personal communication</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roberts WE, North DH, Speed JE, Martin JN, Palmer SM, Morrison JC</AU>
<TI>Comparative study of prostaglandin, laminaria and minidose oxytocin for ripening of the unfavourable cervix prior to induction of labour</TI>
<SO>Journal of Perinatology</SO>
<YR>1986</YR>
<VL>6</VL>
<PG>16-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahraoui-2005" NAME="Sahraoui 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Sahraoui W, Hajji S, Bibi M, Nouira M, Essaidi H, Khair H. Management of pregnancies beyond forty-one week's gestation with an unfavorable cervix. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 2005;34(5):454-62. PAPER IN ITALIAN - MICHEL TO TRANSLATE.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahraoui W, Hajji S, Bibi M, Nouira M, Essaidi H, Khair H</AU>
<TI>Management of pregnancies beyond forty-one week's gestation with an unfavorable cervix</TI>
<SO>Journal de Gynecologie, Obstetrique et Biologie de la Reproduction</SO>
<YR>2005</YR>
<VL>34</VL>
<NO>5</NO>
<PG>454-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez_x002d_Ramos-1995" NAME="Sanchez-Ramos 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Sanchez-Ramos L, Farah LA, Kaunitz AM, Adair CD, Del Valle GO, Fuqua P. Preinduction cervical ripening with commercially available prostaglandin E2 gel: a randomized, double-blind comparison with a hospital-compounded preparation. Am J Obstet Gynecol 1995;173:1079-84.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Farah LA, Kaunitz AM, Adair CD, Del Valle GO, Fuqua P</AU>
<TI>Preinduction cervical ripening with commercially available prostaglandin E2 gel: a randomized, double-blind comparison with a hospital-compounded preparation</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>1079-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[8743]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez-Ramos L, Farah LA, Kaunitz AM, Adair CD, Walker C, Del Valle GO, et al</AU>
<TI>Preinduction cervical ripening with commercially available prostaglandin E2 gel: a randomized, double-blind comparison with a hospital-compounded preparation</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schneider-1994" NAME="Schneider 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Schneider KTM, Luftner D, Rath W. Efficacy and safety of a 2-tier prostaglandin labor induction schedule . Journal of Perinatal Medicine 1994;22:399-407&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider KTM, Luftner D, Rath W</AU>
<TI>Efficacy and safety of a 2-tier prostaglandin labor induction schedule</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>399-407</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaala-1989" NAME="Shaala 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Shaala S, Darwish E, Anwar M, Rocca M, Ismail AA. Cervical prostaglandin injection: a novel method of administration for ripening the cervix and induction of labor. Int J Gynaecol Obstet 1989;30:221-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaala S, Darwish E, Anwar M, Rocca M, Ismail AA</AU>
<TI>Cervical prostaglandin injection: a novel method of administration for ripening the cervix and induction of labor</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1989</YR>
<VL>30</VL>
<PG>221-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skajaa-1991" NAME="Skajaa 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;[4257]&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Skajaa K, Mamsen A, Secher NJ</AU>
<TI>Cervical ripening with prostaglandin E2 in different vehicle forms</TI>
<SO>Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6-9; Vienna, Austria</SO>
<YR>1988</YR>
<PG>196</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Skajaa K, Mamsen A, Secher NJ. Influence of vehicle form on efficiency of prostaglandin E2 gel for cervical ripening. Eur J Obstet Gynecol Reprod Biol 1991;42:177-80.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Skajaa K, Mamsen A, Secher NJ</AU>
<TI>Influence of vehicle form on efficiency of prostaglandin E2 gel for cervical ripening</TI>
<SO>European Journal of Obstetrics &amp; Gynecology and Reproductive Biology</SO>
<YR>1991</YR>
<VL>42</VL>
<PG>177-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tey-1995" NAME="Tey 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tey A, Eriksen NL, Blanco JD</AU>
<TI>A prospective randomised trial of induction versus expectant management in nondiabetic pregnancies with macrosomia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>172</VL>
<PG>293</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Dessel-1991" NAME="van Dessel 1991" YEAR="2nd E">
<REFERENCE NOTES="&lt;p&gt;van Dessel T, Frijns JHM, Kok FTJGT, Wallenburg HCS. Prostaglandins and dilatation of the human cervix. Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands 1991;121&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>van Dessel T, Frijns JHM, Kok FTJGT, Wallenburg HCS</AU>
<TI>Prostaglandins and dilatation of the human cervix</TI>
<SO>Proceedings of 2nd European Congress on Prostaglandins in Reproduction; 1991 April 30-May 3; The Hague, Netherlands</SO>
<YR>1991</YR>
<PG>121</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voss-1996" NAME="Voss 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Voss DH, Cumminsky KC, Cook VD, Nethers MS, Spinnato JA, Gall SA. Effect of three concentrations of intracervical prostaglandin E2 gel for cervical ripening. J Matern Fetal Med 1996;5:186-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Voss DH, Cumminsky KC, Cook VD, Nethers MS, Spinnato JA, Gall SA</AU>
<TI>Effect of three concentrations of intracervical prostaglandin E2 gel for cervical ripening</TI>
<SO>Journal of Maternal-Fetal Medicine</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>186-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-1997" NAME="Webb 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb GW, Raynor BD, Huddleston JF, Fandall HW</AU>
<TI>Induction of labour with an unfavourable cervix: a randomized prospective trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<PG>22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1985" NAME="Williams 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Williams JK, Wilkerson WG, O'Brien WF, Knuppel RA. Use of prostaglandin E2 topical cervical gel in high-risk patients: a critical analysis. Obstet Gynecol 1985;66:769-73.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams JK, Wilkerson WG, O'Brien WF, Knuppel RA</AU>
<TI>Use of prostaglandin E2 topical cervical gel in high-risk patients: a critical analysis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1985</YR>
<VL>66</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wyldes-1992" NAME="Wyldes 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Wyldes MP. Trial to compare 0.5mg PGE2 intracervical gel (Prepadil) vs vaginal PGE2 gel (1mg or 2mg) in induction of labour. Personal communication ---------------; Mike Wyldes confirmed that trial never commenced (26/04/07).&lt;/p&gt;" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Wyldes MP</AU>
<TI>Trial to compare 0.5mg PGE2 intracervical gel (Prepadil) vs vaginal PGE2 gel (1mg or 2mg) in induction of labour</TI>
<SO>Personal communication</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yacoob-1993" NAME="Yacoob 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Yacoob T, Lloyd M, Unwin A, Harrison RF. Intracervical prostaglandin E2, 0.5mg; gel or tablet for cervical ripening and induction of labour with an unfavourable cervix? Journal of Obstetrics and Gynaecology 1993;13:167-70&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yacoob T, Lloyd M, Unwin A, Harrison RF</AU>
<TI>Intracervical prostaglandin E2, 0.5mg; gel or tablet for cervical ripening and induction of labour with an unfavourable cervix?</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>13</VL>
<PG>167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-02-04 10:49:01 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-02-04 10:49:01 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alfirevic-2006" NAME="Alfirevic 2006" TYPE="COCHRANE_REVIEW">
<AU>Alfirevic Z, Weeks A</AU>
<TI>Oral misoprostol for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001338. DOI: 10.1002/14651858.CD001338.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2001a" NAME="Boulvain 2001a" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Kelly A, Lohse C, Stan C, Irion O</AU>
<TI>Mechanical methods for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001233. DOI: 10.1002/14651858.CD001233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2001b" NAME="Boulvain 2001b" NOTES="&lt;p&gt;This record should be cited as: Boulvain M, Stan C, Irion O. Elective delivery in diabetic pregnant women. Cochrane Database of Systematic Reviews 2001, Issue 2. Art. No.: CD001997. DOI: 10.1002/14651858.CD001997. &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Stan C, Irion O</AU>
<TI>Elective delivery in diabetic pregnant women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001997. DOI: 10.1002/14651858.CD001997"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2005" NAME="Boulvain 2005" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Stan C, Irion O</AU>
<TI>Membrane sweeping for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000451. DOI: 10.1002/14651858.CD000451.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bricker-2000" NAME="Bricker 2000" TYPE="COCHRANE_REVIEW">
<AU>Bricker L, Luckas M</AU>
<TI>Amniotomy alone for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002862. DOI: 10.1002/14651858.CD002862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chez-1995" NAME="Chez 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chez RA</AU>
<TI>Cervical ripening and labor induction after previous cesarean delivery</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtis-1987" NAME="Curtis 1987" NOTES="&lt;p&gt;Curtis P, Evans S, Resnick J. Uterine hyperstimulation. The need for standard terminology. J Reprod Med 1987;32:91-95.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Curtis P, Evans S, Resnick J</AU>
<TI>Uterine hyperstimulation. The need for standard terminology</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flenady-2002" NAME="Flenady 2002" NOTES="&lt;p&gt;This record should be cited as: Flenady V, King J. Antibiotics for prelabour rupture of membranes at or near term. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD001807. DOI: 10.1002/14651858.CD001807. &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Flenady V, King J</AU>
<TI>Antibiotics for prelabour rupture of membranes at or near term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD001807. DOI: 10.1002/14651858.CD001807"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-French-2001" NAME="French 2001" TYPE="COCHRANE_REVIEW">
<AU>French L</AU>
<TI>Oral prostaglandin E2 for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003098. DOI: 10.1002/14651858.CD003098"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-G_x00fc_lmezoglu-2006" NAME="Gülmezoglu 2006" NOTES="&lt;p&gt;This record should be cited as: G&amp;#252;lmezoglu AM, Crowther CA, Middleton P. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004945. DOI: 10.1002/14651858.CD004945.pub2. &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Gülmezoglu AM, Crowther CA, Middleton P</AU>
<TI>Induction of labour for improving birth outcomes for women at or beyond term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD004945. DOI: 10.1002/14651858.CD004945.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyer-2003" NAME="Hofmeyer 2003" NOTES="&lt;p&gt;Vaginal misoprostol for induction of labourbe cited as: Hofmeyr GJ, G&amp;#252;lmezoglu AM. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD000941. DOI: 10.1002/14651858.CD000941. &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyer GJ, Gulmezoglu AM</AU>
<TI>Vaginal misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000941. DOI: 10.1002/14651858.CD000941"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2000" NAME="Hofmeyr 2000" NOTES="&lt;p&gt;Hofmeyr GJ, Alfirevic Z, Kelly T, Kavanagh J, Thomas J, Brocklehurst P, Neilson JP. Methods for cervical ripening and labour induction in late pregnancy: generic protocol. (Protocol) Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD002074. DOI: 10.1002/14651858.CD002074. &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Alfirevic Z, Kelly T, Kavanagh J, Thomas J, Brocklehurst P et al</AU>
<TI>Methods for cervical ripening and labour induction in late pregnancy: generic protocol</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002074. DOI: 10.1002/14651858.CD002074"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2003" NAME="Hofmeyr 2003" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Gülmezoglu AM</AU>
<TI>Vaginal misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000941. DOI: 10.1002/14651858.CD000941"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Howarth-2001" NAME="Howarth 2001" TYPE="COCHRANE_REVIEW">
<AU>Howarth GR, Botha DJ</AU>
<TI>Amniotomy plus intravenous oxytocin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003250. DOI: 10.1002/14651858.CD003250"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huszar-1984" NAME="Huszar 1984" TYPE="JOURNAL_ARTICLE">
<AU>Huszar G, Naftolin F</AU>
<TI>The myometrium and uterine cervix in normal and preterme labour</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>311</VL>
<NO>9</NO>
<PG>571-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2001" NAME="Hutton 2001" NOTES="&lt;p&gt;Hutton E, Mozurkewich E. Extra-amniotic prostaglandin for induction of labour. Cochrane Database of Systematic Reviews 2001, Issue 2.&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Hutton E, Mozurkewich E</AU>
<TI>Extra-amniotic prostaglandin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003092. DOI: 10.1002/14651858.CD003092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Irion-1998a" NAME="Irion 1998a" NOTES="&lt;p&gt;This record should be cited as: Irion O, Boulvain M. Induction of labour for suspected fetal macrosomia. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000938. DOI: 10.1002/14651858.CD000938.&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Irion O, Boulvain M</AU>
<TI>Induction of labour for suspected fetal macrosomia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000938. DOI: 10.1002/14651858.CD000938"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2001b" NAME="Kavanagh 2001b" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Sexual intercourse for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003093. DOI: 10.1002/14651858.CD003093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2005" NAME="Kavanagh 2005" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Breast stimulation for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003392. DOI: 10.1002/14651858.CD003392.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2006a" NAME="Kavanagh 2006a" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Corticosteroids for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003100. DOI: 10.1002/14651858.CD003100.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2006b" NAME="Kavanagh 2006b" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Hyaluronidase for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003097. DOI: 10.1002/14651858.CD003097.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Keirse-1993" NAME="Keirse 1993" TYPE="JOURNAL_ARTICLE">
<AU>Keirse MJ</AU>
<TI>Prostaglandins in preinduction cervical ripening. Meta-analysis of worldwide clinical experience</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1993</YR>
<VL>38</VL>
<PG>89-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001a" NAME="Kelly 2001a" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Tan B</AU>
<TI>Intravenous oxytocin alone for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003246. DOI: 10.1002/14651858.CD003246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001b" NAME="Kelly 2001b" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Castor oil, bath and/or enema for cervical priming and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003099. DOI: 10.1002/14651858.CD003099"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001c" NAME="Kelly 2001c" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Relaxin for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003103. DOI: 10.1002/14651858.CD003103"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2003" NAME="Kelly 2003" NOTES="&lt;p&gt;Kelly AJ, Kavanagh J, Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database of Systematic Reviews 2003, Issue 4, &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003101. DOI: 10.1002/14651858.CD003101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2008" MODIFIED="2008-02-04 10:49:01 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2008" NOTES="&lt;p&gt;Nitric oxide donors for cervical ripening and induction of labour&lt;br&gt;Kelly AJ, Kavanagh J Nitric oxide donors for cervical ripening and induction of labour&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 10:49:01 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Kelly 2008</AU>
<TI>Nitric oxide donors for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-02-04 10:49:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-02-04 10:49:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006901"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Luckas-2000" NAME="Luckas 2000" NOTES="&lt;p&gt;Luckas M, Bricker L. Intravenous prostaglandin for induction of labour. Cochrane Database of Systematic Reviews 2000, Issue 4&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Luckas M, Bricker L</AU>
<TI>Intravenous prostaglandin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002864. DOI: 10.1002/14651858.CD002864"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mastrogiannis-1995" NAME="Mastrogiannis 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mastrogiannis DS, Knuppel RA</AU>
<TI>Labor induced using methods that do not involve oxytocin</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>259-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muzonzini-2004" NAME="Muzonzini 2004" NOTES="&lt;p&gt;Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004221. DOI: 10.1002/14651858.CD004221.pub2&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Muzonzini G, Hofmeyr GJ</AU>
<TI>Buccal or sublingual misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD004221. DOI: 10.1002/14651858.CD004221.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neilson-2000" NAME="Neilson 2000" TYPE="COCHRANE_REVIEW">
<AU>Neilson JP</AU>
<TI>Mifepristone for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002865. DOI: 10.1002/14651858.CD002865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Raskin-1999" NAME="Raskin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Raskin KS, Dachauer JD, Doeden AL, Rayburn WF</AU>
<TI>Uterine rupture after use of a prostaglandin E2 vaginal insert during vaginal birth after cesarean. A report of two cases</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1999</YR>
<VL>44</VL>
<NO>6</NO>
<PG>571-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rath-1993" NAME="Rath 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rath W, Osmers R, Adelmann-Grill BC, Stuhlsatz HW, Szevereny M, Kuhn W</AU>
<TI>Biochemical changes in human cervical tissue after intracervical application of prostaglandins E2</TI>
<SO>Prostaglandins</SO>
<YR>1993</YR>
<VL>45</VL>
<PG>375-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RCOG-2007" NAME="RCOG 2007" TYPE="OTHER">
<AU>Varma M, Gupta JK, Smith GCS</AU>
<TI>Birth after previous caesarean birth</TI>
<SO>RCOG Green-top Guideline No. 45</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2003" NAME="RevMan 2003" NOTES="&lt;p&gt;Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003&lt;/p&gt;" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2003</YR>
<EN>4.2 for Windows</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2003" NAME="Smith 2003" TYPE="COCHRANE_REVIEW">
<AU>Smith CA</AU>
<TI>Homoeopathy for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003399. DOI: 10.1002/14651858.CD003399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2001" NAME="Thomas 2001" TYPE="COCHRANE_REVIEW">
<AU>Thomas J, Kelly AJ, Kavanagh J</AU>
<TI>Oestrogens alone or with amniotomy for cervical ripening or induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD003393. DOI: 10.1002/14651858.CD003393"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vause-1999" NAME="Vause 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vause S, Macintosh M</AU>
<TI>Use of prostaglandins to induce labour in women with a caesarean section scar</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<PG>1056-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bernstein-1991">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: concealment of the allocation by opening drug boxes. Prepackaged preparations were used that had been coded by the pharmacy. <BR/>Blinding: 'double-blind'.<BR/>Follow up: 17 exclusion, but ITT analysis possible.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>397 women were enrolled, 203 in experimental group and 194 in control group. <BR/>Eligibility: gestational age of at least 36 weeks, parity of 3 or less, a Bishop score of 4 or less, intact membranes and a medical or obstetric indication for induction, as decided by the attending physician. <BR/>Exclusion: any contraindication to vaginal delivery, a history of CS or major uterine surgery, a known hypersensitivity to prostaglandins, any previous attempt at cervical ripening or induction, suspected or clinically evident fetal compromise, vaginal bleeding, rupture membranes or fetal death in utero. <BR/>On admission to hospital the women were observed for 30 minutes before gel insertion. During this time their vital signs were recorded, the FHR and uterine activity were assessed with the use of a nonstress test, and the initial laboratory test (complete blood count, renal and liver function test and urinanalysis) were performed. Evidence of any abnormalities or labour was sufficient for exclusion from the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg 1 dose.<BR/>Control group: IC placebo gel 1 dose.<BR/>If labour begun women were managed and monitored by the attending physician as deemed appropriate. Amniotomy was not performed until the cervix had dilated to 3 cm or more. Under no circumstances were any other uterotonic drugs such as oxytocin administered until at least 6 hours after the gel had been inserted unless delivery had occurred. Women not in labour in 12 hours after the administration were induced with oxytocin according to the induction protocol in each institution. Unless contraindicated by a particular medical problem (fetal or maternal), induction with oxytocin was continued either until labour started or for a maximum of 12 hours. Management of women who could not be induced and of labour was left to the discretion of the attending physician.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: uterine hyperstimulation with FHR changes, CS., uterine hyperstimulation without FHR changes. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre.<BR/>Setting: Canada.<BR/>Additional outcomes reported: Bishop score at 12 hours after gel treatment, spontaneous labour, interval from gel administration to delivery, uterine hypercontractility, Apgar score at 1 and 5 minutes, neonatal jaundice, FHR abnormalities.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Buttino-1990">
<CHAR_METHODS>
<P>Randomisation: RCT. Randomisation was generated in the pharmacy. <BR/>Allocation concealment: sequentially-numbered syringes which were visual identical. <BR/>Blinding: 'double blind' study.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>43 women were enrolled , 23 in experimental group and 20 in control group. <BR/>Eligibility: with a pregnancy of at least 41 weeks and 6 days of gestation; free of any contraindications to the use of prostaglandins. <BR/>Exclusion: no information provided. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg.<BR/>Control: IC placebo gel.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, uterine hyperstimulation with FHR change, CS.<BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA. <BR/>Additional outcomes reported: change in Bishop score, spontaneous labour, length of labour, interval from dosage to delivery, delivery within 72 hours, Apgar score at 1 minute, Apgar score at 5 minutes, birthweight. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cabrol-1988">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear.<BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>208 women were enrolled, 104 in experimental group and 104 in control group. <BR/>Eligibility: pregnancy at term, unripe cervix, a medical indication for induction. <BR/>Exclusion: no information provided. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: IC gel PGE2 0.5 mg (1 dose).<BR/>Control group: IC placebo gel (1 dose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: hyperstimulation, CS, PPH, diarrhoea.<BR/>Fetal/infant: Apgar score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: France.<BR/>Additional outcomes reported: delivery within 12 hours.<BR/>The paper was written in French and needed to be translated. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chyu-1997">
<CHAR_METHODS>
<P>Randomisation: RCT, computer-generated random numbers. <BR/>Allocation concealment: unclear. <BR/>Blinding: unclear. <BR/>Follow up: 12 women were excluded because of violation of study protocol, 7 from the gel group and 5 from pessary group. No participants withdrew from the study. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>85 women were enrolled, 43 in the gel group and 42 in the pessary group. <BR/>Eligibility: (1) Bishop score no more than 7, (2) cervical dilatation of &lt; 4 cm, (3) no more than 2 cm of dilatation if effacement exceeded 70%, (4) reassuring fetal wellbeing, defined as the present of either a reactive nonstress test or a biophysical profile score &gt; 8 (of 10). <BR/>Exclusion: (1) results of cervical examination not meeting the criteria for inclusion, (2) suspicion or evidence of fetal distress, defined as biophysical profile score &lt; 8 (of 10) or the presence of late or severe variable decelerations, (3) current vaginal bleeding, (4) more than 6 previous term pregnancies, (5) presence of a contraindication to oxytocic drugs, (6) fever of undetermined cause, (7) active and severe asthma, (8) allergy to prostaglandins, or (9) chorioamnionitis. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Gel group: 0.5 mg dinoprostone for IC application. At 6-hour intervals the cervix was re-examined, and if the cervix continued to meet the inclusion criteria, the dose was repeated up to a maximum of 3 total doses. <BR/>Pessary group: 10 mg intravaginal controlled-release dinoprostone pessary, single dose. The pessary was removed after 12 hours; it was to be removed earlier only with the onset of active labour or with the occurrence of uterine hyperstimulation accompanied by an abnormal fetal heart tracing. <BR/>If active labour had not already begun, oxytocin infusion was initiated 6 hours after the final dose of gel was administered or 30 minutes after the pessary was removed. Amniotomy was performed at the discretion of the attending physician. Oxytocin induction was to be continued for a minimum of 14 hours unless contraindications arose. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS , instrumental vaginal delivery, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes, diarrhoea, postpartum haemorrhage.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: USA.<BR/>Additional outcomes reported: change of Bishop score, time to active labour, ripening time, latent labour, length of active labour, length of second stage of labour, time to vaginal labour, hospital stay, vaginal delivery, treatment failure, fever, birthweight, arterial and venous cord pH &lt; 7.2. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Corrado-2001">
<CHAR_METHODS>
<P>Randomisation: RCT. Randomisation generated by computer. <BR/>Allocation concealment: women were randomly assigned by computer. <BR/>Blinding: unclear. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>233 women were enrolled, 122 in the IC group and 111 in the intravaginal group. <BR/>Eligibility: evaluated for labour induction, absence of spontaneous labour, intact membranes, a Bishop score no more than 5, with gestational age at least 34 weeks and reactive nonstress test. <BR/>Exclusion: twin pregnancies, previous CS, previous uterine surgery or breech presenting fetus. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel dinoprostone 0.5 mg.<BR/>Control: intravaginal gel dinoprostone 1 mg. <BR/>An intravaginal dose of 2 mg of dinoprostone gel was applied after 4 hours, if the Bishop score was still &lt;6, and repeated 4 hours later. Sometimes, oxytocin was given for the augmentation of labour when the Bishop score became favourable. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, oxytocin augmentation, instrumental vaginal delivery. <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Italy.<BR/>Additional outcomes reported: spontaneous delivery, spontaneous delivery within 24 hours, time from treatment to vaginal delivery, birthweight, Apgar score at 1 minute, Apgar score at 5 minutes, uterine hyperstimulation, hypersensitivity to prostaglandin gel. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Darroca-1996">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated allocation sequence. <BR/>Allocation concealment: using centrally-prepared syringes.<BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>118 women were enrolled, 61 in experimental group and 57 in control group. <BR/>Eligibility: confirmed indications for induction of labour, with a gestational age before 41 completed weeks. <BR/>Exclusion: a scarred uterus, history of hypersensitivity to PGE2 or the base used to carry the medication, a Bishop score of 6 or more.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg.<BR/>Control: IC placebo gel.<BR/>If the NST or CTS was reassuring, the participant was given the first dose of gel and monitored for an additional hour. If the post-dose NST or CST was reassuring, the participant was sent home. In either case, the participant was re-examined in 14-16 hours and another Bishop score was assigned. If the Bishop score was still less than 6, the participant was given another dose of the same gel and oxytocin induction was begun immediately; if the Bishop score was at least 6, oxytocin induction was begun without a second dose of gel. Amniotomy was accomplished as early as possible.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: USA.<BR/>Additional outcomes reported: a more than 2-point change in Bishop score, interval from insertion of the gel to complete dilation, Apgar score &lt; 9 at 1 minute, Apgar score &lt; 9 at 5 minute, mean umbilical artery pH.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Duhl-1997">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear.<BR/>Allocation concealment: unclear. <BR/>Blinding: unclear.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>74 women were enrolled, 24 in intravaginal gel group, 27 in intravaginal time release group and 23 in IC gel group. <BR/>Eligibility: a medical indication for inpatient induction of labour. <BR/>Exclusion: no information provided. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intravaginal gel group: intravaginal gel PGE2 3 mg, every 4 to 6 hours until intravenous oxytocin was started. <BR/>Intravaginal time release group: 10 mg time release intravaginal insert with dinoprostone, every 12 hours until intravenous oxytocin was started. <BR/>IC gel group: IC gel dinoprostone 0.5 mg, every 6 hours until intravenous oxytocin was started. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: no outcomes reported.<BR/>Fetal/infant: no outcomes reported.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: change in Bishop score, labour initiation, uterine hyperstimulation. <BR/>Abstract only. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ekman-1983">
<CHAR_METHODS>
<P>Randomisation: random allocation stratified for parity. No other details reported.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>60 women were enrolled, 30 (15 nulliparous women and 15 multiparous women) were in IC application group and 30 (15 nulliparous women and 15 multiparous women) in intravaginal application group. <BR/>Eligibility: term women with an unripe cervix, intact membranes, vertex presentation, no uterine contraction and obstetric indications for induction.<BR/>Exclusion: placenta previa and multiple pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC application group: IC PGE2 0.5 mg in 2 ml of gel.<BR/>Intravaginal application group: Intravaginal PGE2 4 mg in 3 ml of gel.<BR/>In all participants in whom labour was not induced but in whom a favourable cervical state (cervical score &gt; 5) was registered 5 hours after application of gel, intravenous infusion of oxytocin was instituted. Amniotomy was not undertaken until labour was well established and the cervix was dilated to at least 4 cm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vomiting, CS.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minute.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Sweden.<BR/>Additional outcomes reported: favourable cervical state after 5 hours, favourable cervical state after 5 hours (women with highly unfavourable cervix), delivery within 12 hours, intrauterine pressure, painful uterine contraction, bleeding, rupturing of membranes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-El_x002d_Din-2000">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear.<BR/>Blinding: unclear. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>149 women were enrolled, 52 in the misoprostol group, 49 in the tablet PGE2 group and 48 in the prepidil group. <BR/>Eligibility: women with unfavourable cervix. <BR/>Exclusion: no information provided. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Misoprostol group: intravaginal misoprostol 50 µg every 4 hours for 24 hours or until adequate labour was achieved. <BR/>Tablet PGE2 group: intravaginal tablet PGE2 3 mg every 4 hours for 24 hours or until adequate labour was achieved.<BR/>Prepidil group: IC prepidil gel (PGE2 gel) every 6 hours (maximum 3 doses) for 24 hours or until adequate labour was achieved. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS. <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Egypt.<BR/>Additional outcomes reported: interval from treatment to delivery, tachysystole and hyperstimulation, abnormal FHR trace. <BR/>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gilson-1993">
<CHAR_METHODS>
<P>Randomisation: RCT. No details of generation of randomisation. <BR/>Allocation concealment: the assignment was blinded to both physician and participant, the randomisation having been carried out in pharmacy. <BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>79 women were enrolled, 41 in experimental group and 38 in control group. <BR/>Eligibility: admitted for the induction of labour, single pregnancy, intact membranes, no evidence of fetal compromise, with a Bishop score of 4 or less.<BR/>Exclusion: with a history of asthma, glaucoma, ruptured membranes, breech presentation, abnormal vaginal bleeding, or with 2 or more CS. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel dinoprostone 0.5 mg. <BR/>Control: IC placebo gel. <BR/>12 hours after the gel had been placed, oxytocin induction was begun. Amniotomy was done when the participant was in active labour and cervical dilatation allowed it. If the maternal and fetal surveillance was reassuring, the participant was rested overnight and oxytocin was readministered the following day. The oxytocin infusion rate was not allowed to exceed 20 milliunits per minute. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS. <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: 12-hour Bishop score, change in Bishop score, gel-instillation interval, oxytocin-administration time, spontaneous labour after gel, hyperstimulation, fetal distress, infant weight, Apgar score at 5 minutes. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gr_x00fc_nberger-1986">
<CHAR_METHODS>
<P>Randomisation: 'prospective randomised study' .<BR/>Allocation concealment: no information provided. <BR/>Blinding: no information provided. <BR/>Follow up: no loss of participants up to 24 hours after randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 women were enrolled, 15 in experimental group and 15 in control group.<BR/>Eligibility: 41-42 weeks' gestation, unfavourable cervix.<BR/>Exclusion: maternal or fetal risk factors, twin pregnancies, breech presentation, previous CS, previous operations on the uterine cervix.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: 1.5 mg PGE2 instilled into cervical cap.<BR/>Control: 3 ml 0.9% saline instilled into cervical cap. <BR/>For all women 6 hours later if contractions regular cervical cap was removed, if no contractions each group received a repeat of intervention for 6 hours. If after 24 hours labour not commenced a 'cross-over' was made to the respective alternative group on the morning of the second day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Maternal: not delivered within 24 hours. <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single-centre. <BR/>Setting: Austria. <BR/>Additional outcomes:maternal serum 13, 14- Dihydro-15-Keto-PGF and progesterone. <BR/>A number of attempts made to contact author and co-author to verify if all deliveries were vaginal. Attempts were unsuccessful - April 2007.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hales-1994">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated randomisation schedule.<BR/>Allocation concealment: syringes were sent from the pharmacy to the labour and delivery unit for each enrolled participant . <BR/>Blinding: 'double blind'. <BR/>Follow up: 8 were excluded, 2 for unsuspected ruptured membranes and 6 for failure to properly follow the redosing protocol.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>108 women were enrolled, 52 in IC gel group, 48 in intravaginal group and 8 excluded. <BR/>Eligibility: all inpatients deemed to have a medical indication for induction of labour in spite of an unfavourable cervix (BS equal to or less than 4). Each had undergone electronic FHR monitoring, and a reactive nonstress test result had to be present. <BR/>Exclusion: vaginal bleeding, ruptured membranes, noncephalic fetal presentation, history of asthma, or uterine contractions more frequently than every 8 minutes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC gel group: IC gel PGE2 0.5 mg + intravaginal placebo gel.<BR/>Intravaginal gel group: intravaginal gel PGE2 j2.5 mg + IC placebo gel.<BR/>Each enrollee was administered simultaneous doses of an IC, then an intravaginal, preparation of the gel. 1 preparation contained PGE2, whereas the other was placebo (methylcellulose only). <BR/>Each participant was re-examined 6 hours after dosing. Those whose cervix remained unfavourable without labour were given a second and third pair of the same batch of syringes. If the cervix favourable (Bishop score &gt; 6), an early amniotomy was performed if the fetal head was applied to the cervix, and oxytocin infusion was instituted if necessary. If no cervical change (Bishop score change no more than 3 from original predosing) or regular contractions occurred after the third dose, oxytocin was infused for induction of labour.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved in 24 hours, CS, vomiting, diarrhea, oxytocin augmentation. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: USA.<BR/>Additional outcomes reported: oxytocin need (for induce), instillation to vaginal delivery (hour), vaginal delivery within 36 hours, vaginal delivery within 48 hours, CS (for failed induction), CS (for failure to progress), CS (for suspected fetal distress), Bishop score change &gt; 3, regular contractions, active labour, maternal temperature &gt; 100 F, hyperstimulation, abnormal FHR pattern, infant sex, birthweight (&lt; 2500 gm), birthweight (&gt; 4000 gm), Apgar score &lt; 7 at 1 minute. <BR/>Note: the gel was noted to spill out of the cervix during IC application in the majority (85.0%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Heinzl-1980">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: 'double blind'. <BR/>Follow up: 4 participants were dropped for documentation errors. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>124 women were enrolled, 60 in experimental group, 60 in control group and 4 dropped. <BR/>Eligibility: singleton, &gt; 36 gestational weeks, Bishop score less than 6, vertex. <BR/>Exclusion: previous LSCS, other uterine scar.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGF2a 5 mg. <BR/>Control: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation without FHR changes, instrumental vaginal delivery, nausea, vomiting. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/Single centre: single centre.<BR/>Setting: Switzerland. <BR/>Additional outcomes reported: birth within 36 hours. <BR/>This paper was written in German and needed to be translated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hidar-2000">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated sequence. <BR/>Allocation concealment: unclear. <BR/>Blinding: none.<BR/>Follow up: all women.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>88 women were enrolled, 44 in experimental group and 44 in control group. <BR/>Eligibility: term, singleton, live fetus, unfavourable cervix (BS &lt; 5), ruptured membranes, no previous uterine scar. <BR/>Exclusion: previous uterine scar, fever, urgent delivery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experiment: IC gel PGE2 0.5 mg (1 dose), followed by oxytocin administration. <BR/>Control: conservative management for up to 24 hours. <BR/>24 hours after, oxytocin administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, oxytocin augmentation, instrumental vaginal delivery, vomiting, postpartum haemorrhage.<BR/>Fetal/infant: perinatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: France. <BR/>Additional outcomes reported: intervals form PROM to delivery, interval from inclusion to start of labour, duration of labour, amnionitis, mode of delivery, Apgar score, uterine tachysystole. <BR/>This paper was written in French and needed to be translated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hutchon-1980">
<CHAR_METHODS>
<P>Randomisation: RCT, no details of generation of randomisation.<BR/>Allocation concealment: by a set of vials identified by number only. <BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>67 women were enrolled, 32 in experimental group and 35 in control group. <BR/>Eligibility: a modified Bishop score of 4 or less, singleton pregnancy, cephalic presentation, normally sited placenta, no history of antepartum haemorrhage, an unscarred uterus, no previous cervical surgery, an obstetric indication for induction. <BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2, 450 µg for the initial 14 participants and 650 µg for the subsequent 18 participant . <BR/>Control: IC placebo gel. <BR/>All participant were requested to remain in bed for 2 hours and amniotomy was carried out on the morning of induction. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, meconium stained liquor. <BR/>Fetal/infant: serious neonatal morbidity or perinatal death. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: UK.<BR/>Additional outcomes reported: established labour or delivery before planned induction, induction delivery interval, length of labour, fetal distress, improvement of cervical score. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Irion-1998">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated allocation sequence. <BR/>Allocation concealment: by central randomisation. <BR/>Blinding: unclear. <BR/>Follow up: no women excluded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>247 women were enrolled, 122 in the IC group and 125 in the vaginal group. <BR/>Eligibility: gestational age greater than 30 completed weeks, singleton, cephalic presentation, Bishop score 4 or less, intact membranes, absence of spontaneous labour, and reassuring electronic fetal monitoring. <BR/>Exclusion: asthma.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: lC gel PGE2 0.5 mg. <BR/>Vaginal group: intravaginal gel PGE2 2 mg. <BR/>If the Bishop score was 4 or less, another dose of PGE2 was given after 6 hours, and up to 2 additional doses were given 6 hours apart on the second day. An oxytocin infusion was begun when the Bishop score was 5 or greater in absence of spontaneous labour, or if labour had not begun on the third day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, serious maternal morbidity or death, oxytocin augmentation, uterine rupture, epidural analgesia, instrumental delivery, maternal side-effects (nausea, vomiting, diarrhoea and fever). <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Switzerland. <BR/>Additional outcomes reported: cervical ripening, time to cervical ripening, interval from treatment to vaginal delivery, time from gel application to the onset of cervical dilatation, time from the onset of cervical dilatation to full dilatation, oxytocin induction, vaginal discomfort, arterial cord pH, maternal hemoglobin loss, length of maternal hospital stay, length of neonatal hospital stay, uterine hyperstimulation. <BR/>Also reported as abstract (Pedrazzoli et al.)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Keirse-1995">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear.<BR/>Allocation concealment: by numbered, opaque, sealed envelopes stratified for parity (nulliparous, parous) and Bishop score (no more than 5, &gt; 5). <BR/>Blinding: unclear. <BR/>Follow up: 3 women were excluded after trial entry. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>285 women were enrolled, 143 in cervical group, 141 in vaginal group and 1 whose case record was lost. <BR/>Eligibility: a singleton pregnancy of at least 37 weeks with a live fetus in vertex position and a medical or obstetric reason to justify induction of labour. <BR/>Exclusion: a previous CS or an earlier induction attempt in the current pregnancy. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cervical group: endocervical PGE2 0.5 mg in triacetin gel was inserted in the cervical canal. <BR/>Vaginal group: vaginal PGE2 was introduced in the posterior vaginal fornix. <BR/>If after 6 hours the membranes were still intact and the women were not in progressive labour, a further dose of prostaglandin, 0.5 mg endocervically or 1.0 vaginally, was administered. This could be repeated after a further 6 hours if necessary and if the membranes were still intact and the clinicians were free to use either 1.0 or 2.0 mg of PGE2 for women in the vaginal group. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved in 24 hours, uterine hyperstimulation with FHR changes, CS, oxytocin augment, uterine hyperstimulation without FHR changes, instrumental vaginal delivery, meconium stained liquor, PPH.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes, NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Supported by an educational grant from Upjohn Co., Kalamazoo. <BR/>Setting: Netherlands. <BR/>Additional outcomes reported: not delivered (within 12 hours, 24 hours or 36 hours), operative delivery, no vaginal delivery &lt; 26 hours, use of tocolytic agent, manual removal of placenta, postpartum bleeding (&gt; 500 ml or &gt; 1000 ml), blood transfusion, fever, Apgar score &lt; 7 at 1 minute, resuscitation at birth, meconium aspiration, not discharged with mother. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kemp-2000">
<CHAR_METHODS>
<P>Randomisation: RCT, using a stratified block randomisation.<BR/>Allocation concealment: unclear. <BR/>Blinding: unclear. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>470 women were enrolled, 241 in IC group and 229 in vaginal group. <BR/>Eligibility: a Bishop score of 3 and 4, singleton pregnancy with vertex presentation and a medical reason for induction of labour.<BR/>Exclusion: contraindications for prostaglandins, previous uterine surgery with incision of the uterine cavity, previous caesarean delivery by longitudinal section, marked uterine anomaly, abnormal FHR (Fischer score &lt; 7), multiple gestation or nonvertex presentation. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: IC gel PGE2 0.5 mg. <BR/>Vaginal group: intravaginal gel PGE2 2 mg. <BR/>The prostaglandin preparation was administered sequentially every 6-8 hours up to 3 times daily until the cervix became favourable (Bishop score &gt; 7). Following 3 unsuccessful applications, the participant had 24 hours of rest before proceeding according to the clinical situation. In participants with a Bishop score &gt; 7 oxytocin was administered 8 hours after the last PGE2 application. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved in 24 hours, CS, oxytocin augmentation, maternal side-effects.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Setting: Germany.<BR/>Additional outcomes reported: changes in Bishop scores, induction-delivery interval, uterine hyperstimulation, prolonged uterine contractions, tocolytic treatment, umbilical artery pH &lt; 7.20. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Larmon-2002">
<CHAR_METHODS>
<P>Randomisation: RCT. Sequence prepared with a table of random numbers.<BR/>Allocation concealment: opaque, numbered and sealed envelopes.<BR/>Blinding: unclear. <BR/>Follow up: 8 women were excluded after randomisation. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>84 women were enrolled, 41 in experimental group and 43 in control group. <BR/>Eligibility: women at term, unfavourable cervix (BS &lt; 7), no pregnancy complications.<BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC PGE2 gel 0.5 mg weekly.<BR/>Control: IC placebo gel weekly. <BR/>Participants were instructed to proceed to the labour and delivery suite if membranes ruptured, regular uterine contractions began, or vaginal bleeding occurred.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, instrumental vaginal delivery, oxytocin augmentation, meconium stained liquor. <BR/>Fetal/infant: NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: USA.<BR/>Additional outcomes reported: spontaneous vaginal delivery, Bishop score and change in Bishop score (admission), days to admission, maternal complications (endomyometritis, chorioamnionitis, septic pelvic vein thrombophlebitis, pre-eclampsia), birth weight, Apgar score at 1 minute, Apgar score at 5 minute, arterial cord blood pH, transient tachypnea of the newborn, meconium aspiration.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Laube-1986">
<CHAR_METHODS>
<P>Randomisation: RCT. Randomisation had been accomplished before the study. No details of generation of randomisation. <BR/>Allocation concealment: numbered syringes sequentially released by the hospital pharmacy. <BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>45 women were enrolled, 15 in each group. <BR/>Eligibility: unfavourable cervixes as indicated by Bishop scores of 4 or less, singleton pregnancies and cephalic presentations, reactive nonstress tests, afebrile, medical or obstetric complications justifying induction of labour, of parity 0 to 3. <BR/>Exclusion: previous uterine scar, vaginal bleeding, premature rupture of membranes, allergy to prostaglandins, history of asthma or glaucoma, evidence of fetal distress, or evidence of spontaneous labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.25 mg group: IC gel PGE2 0.25 mg. <BR/>0.5 mg group: IC gel PGE2 0.5 mg.<BR/>Control: IC placebo gel.<BR/>If the participant was not in labour after 12 hours observation, labour was induced by intravenous oxytocin infusion. If no appreciable change in the Bishop score was noted after the observation period, Laminaria digitata were inserted into the cervix and left in place for four hours before oxytocin induction. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation without FHR changes, maternal side-effects. <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Supported in part by Upjohn Company, Kalamazoo, MI.<BR/>Setting: USA.<BR/>Additional outcomes reported: post treatment Bishop score, success of softening, time to labour, time to vaginal delivery, hypotension, fetal deep variable decelerations, prolonged bradycardia. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Legarth-1988">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generating the allocation sequence not specified. <BR/>Allocation concealment: sealed envelopes.<BR/>Blinding: unclear.<BR/>Follow up: 9 women were excluded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 women were enrolled, 56 in the vaginal group and 57 in the IC group (9 women being excluded). <BR/>Eligibility: women with a cervix defined as being at least 1 cm in length, the internal cervical os just passable for one fingertip, singleton pregnancy, the fetus in the cephalic presentation, and a normal nonstress CTG test. <BR/>Exclusion: no information provided. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vaginal group: a suppository containing 2.5 mg PGE2 in a basis of 5 g of Witepsol S55 was placed in the posterior vaginal fornix. <BR/>IC group: 5 ml cervical gel containing 1 mg PGE2 in a basis of 5 g hydroxylpropylmethy 1 cellulose were applied within the cervical canal at the internal os by means of a 20 cm long and 4 mm thick plastic tube. <BR/>If labour was not established within 4 hours the application of the suppository or cervical gel was repeated. <BR/>Women who were not in labour the following morning and still had an unripe cervix were treated as the day before. If the cervix was ripe (internal os permitting entry of at least 1 finger or cervix shorter than 1 cm), induction by IV oxytocin was started using 0.4 milliunits per minute. This dose was increased by 1 milliunit every 15 minutes until satisfactory uterine activity was achieved or the dose level of oxytocin was 25 milliunits per minute. Amniotomy was performed when the isthmus os was more than 3 cm in diameter. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS, oxytocin augmentation, instrumental vaginal delivery. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Denmark.<BR/>Additional outcomes reported: CS within 48 hours after the induction and before the second stage of labour, delivery after 48 hours, fetal distress, cervical score (0, 4 and 24 hours after start of induction), interval from induction to labour, interval from induction to spontaneous rupture of the membranes, interval from induction to delivery, induction unsuccessful, oxytocin induction, amniotomy, delivery without oxytocin, spontaneous vaginal delivery, delivery with vacuum or forceps for fetal distress, Apgar score at 1 minute, Apgar score &lt; 7 at 1 minute, Apgar score at 5 minutes, umbilical pH, umbilical pH &lt; 7.15.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lien-1998">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated sequence. <BR/>Allocation concealment: Coded drug boxes.<BR/>Blinding: 'double blind'.<BR/>Follow up: 2 participants were excluded for not meeting the inclusion criteria.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>92 women were enrolled, 43 in experimental group, 47 in control group and 2 excluded. <BR/>Eligibility: a gestation age of at least 40 weeks 3 days, a Bishop score no more than 6, an amniotic fluid index &gt; 5 cm, and a reactive nonstress test. <BR/>Exclusion: evidence of hyperstimulation or suspicious FHR patterns on antepartum testing, grand multiparity (at least 5 previous deliveries), nonvertex fetal presentation, multiple gestation, previous CS major uterine surgery, placenta previa, or other contraindications for vaginal delivery. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg.<BR/>Control: IC placebo gel. <BR/>Study packets for each participant included a maximum of 4 dose study gel. Participants could receive a subsequent gel insertion in 3 to 4 days if they still met inclusion criteria. Elective induction would not be performed until 42 weeks' gestation unless the Bishop score was &gt; 9 or an obstetric factor other than postdate pregnancy developed, necessitating labour induction.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, instrumental vaginal delivery, maternal nausea and vomiting, maternal diarrhoea, maternal side-effects. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Setting: USA. <BR/>Additional outcomes reported: contractions, FHR deceleration, interval from study enrollment to delivery, hyperstimulation, birthweight, birthweight &gt; 4000 g, maternal complications (chorioamnionitis, endometritis).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lopes-1991">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generating the allocation sequence and of concealment of the allocation not specified.<BR/>Allocation concealment: unclear.<BR/>Blinding: unclear. <BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 women were enrolled, 24 in group 1, 26 in group 2, 28 in group 3 and 22 in group 4. <BR/>Eligibility: a medical indication for delivery within 48 hours, an unfavourable cervical state with a Bishop score equal or less than 5 points. <BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>If Bishop score equal or less than 3 points: <BR/>group 1: IC gel PGE2 0.5 mg (Prepidil).<BR/>group 2: IC PGE2 1.5 mg (Prostine) containing IC resorbable support. <BR/>If Bishop score 4-5: <BR/>group 3: IC gel PGE2 0.5 mg.<BR/>group 4: 2.25 mg PGE2 containing intravaginal administration of a resorbable support. <BR/>Induction of labour with intravenous oxytocin-amniotomy association was performed only when Bishop score reached 6 points. When Bishop score was below 6, a second administration of PGE2 was allowed 12 hours after the first application.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: France. <BR/>Additional outcomes reported: increase of Bishop score, delivery within 12 hours, labour length, Apgar score.<BR/>The original paper was written in French and needed to be translated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lyndrup-1991">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generating the allocation sequence not specified. <BR/>Allocation concealment: sealed envelopes (nulliparous and parous separately). <BR/>Blinding: unclear.<BR/>Follow up: after allocation, 5 participants were excluded from the study material (4 participants did not fulfil the criteria for inclusion and 1 participant never received the proper treatment). Furthermore, in 5 participant s the protocol was violated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>130 women were enrolled, 64 in the IC group, 61 in the vaginal group, and 5 excluded. <BR/>Eligibility: women with singleton pregnancy, cephalic presentation, an unfavourable cervix (at least 1 cm long and the internal os not wider than just 1 fingertip), requiring induction of labour. <BR/>Exclusion: women already in labour, demonstrating a pathological nonstress test, with cardiopulmonary diseases, glaucoma, or previous uterine surgery exposing the uterine cavity or distorting the cervix.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC: IC gel PGE2 0.5 mg, once a day. <BR/>Vaginal group: PGE2 2.5 mg in vaginal pessaries. The pessary was placed in the posterior vaginal fornix, and if labour was not established within 3 hours, application was repeated. <BR/>If the participant did not deliver within the first 24 hours and labour was not established, further induction depended on the cervical status at the beginning of the next 24-hour period. If the cervix was still unfavourable (at least 1 cm long and internal os not wider than 1 fingertip), the procedure was repeated. If the cervix was now favourable further induction was performed using IV oxytocin titration (starting with 3 mU/min and stepwise increasing the dose to a maximum of 30 mU/minute).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, oxytocin augmentation, instrumental vaginal delivery, women not satisfied. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Denmark.<BR/>Additional outcomes: oxytocin induction, amniotomy, spontaneous vaginal delivery (within 2 days or after 2 days), continuation of pregnancy (considering vaginal delivery as the event or onset of labour as the event), duration of labour (life table analysis), improvement in cervical ripening (after 3 or 24 hours), Apgar score at 1 minute, pH in umbilical artery, SEB in umbilical artery, vaginal discomfort.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-McKenna-1999">
<CHAR_METHODS>
<P>Randomisation: RCT. Allocation sequence generated by a table of random numbers. <BR/>Allocation concealment: central randomisation.<BR/>Blinding: 'double blind'.<BR/>Follow up: 4 participants were excluded after randomisation for not meeting the inclusion criteria at the time of planned gel administration.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>65 women were enrolled, 30 in experimental group and 31 in control group. <BR/>Eligibility: at least 37 completed gestational weeks, maternal age of at least 18 years, an unfavourable cervix for induction (Bishop score 8 or less), a well-dated pregnancy, and lack of a current indication for induction of labour. <BR/>Control: multiple gestations, contraindications to trials of labour, insulin-dependent diabetes, or chronic hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC PGE2 0.5 mg as outpatient, once. <BR/>Control: IC placebo as outpatient, once.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, PPH, uterine hyperstimulation with FHR changes. <BR/>Fetal/infant: NICU, Apgar score &lt; 7 at 5 minutes. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA<BR/>Additional outcomes reported: days to admission, inductions, change in Bishop score, labour duration, delivery within 2 days, birthweight, maternal or neonatal stay, hemoglobin change, infectious morbidity. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Milliez-1993">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generating the allocation sequence not specified. <BR/>Allocation concealment: by choosing an envelope. <BR/>Blinding: no information provided. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>84 women were enrolled, 42 in each group. <BR/>Eligibility: high-risk pregnancy, indication for induction of labour, Bishop score less than 5. <BR/>Exclusion: breech presentation, previous CS, uterine contractions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>0.5 mg group: IC gel PGE2 0.5 mg, 1 dose. Participants who did not in labour 12 hours after application had labour induced with oxytocin, irrespective of their Bishop score, or earlier than 12 hours in case of maternal or fetal distress. <BR/>0.25 mg group: IC gel PGE2 0.25 mg. The participants who did not labour after the first ripening procedure had repeated daily application of 0.25 mg PGE2 until spontaneous onset of labour occurred or induction of labour with oxytocin was decided. Labour was induced because of a Bishop score improved to 6 or more, or because of a rapid deterioration of the maternal or fetal condition, necessitating a prompt delivery and requiring therefore a break in the sequence of repeated maturations of the cervix.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS. uterine hypertension with FHR changes. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: France. <BR/>Additional outcomes reported: cervical ripening, uterine contraction, spontaneous onset of labour, oxytocin induction, FHR decelerations, birthweight, Apgar score at 1 minute, Apgar score at 5 minutes. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nager-1987">
<CHAR_METHODS>
<P>Randomisation: RCT, using a random-number generator keyed to participant entry number. <BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.<BR/>Follow up: 1 participant was lost to follow up.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>35 women were enrolled, 19 in experimental group and 15 in control group (was there 1 woman lost?).<BR/>Eligibility: women with medical, obstetric, or fetal indications for labour induction and had an unfavourable Bishop score, less than or equal to 4. <BR/>Exclusion: women with a history of asthma, glaucoma, hypersensitivity to prostaglandins, vaginal bleeding, ruptured membranes, labour, previous caesarean delivery, or previous attempt at labour induction in this pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: women were given IC 0.5 mg PGE2 in a total volume of 2.5 ml IC using a 12 FG Luer mount catheter. The catheter was passed transcervically under direct visualisation or by palpation until resistance or the amniotic membranes were reached. The 2.5 ml of gel containing the preparation was then discharged from a preloaded syringe attached to the catheter. <BR/>Control: no medication.<BR/>After 12 hours, oxytocin induction was begun by specified protocol, beginning at 0.4 mU/minute and escalating every 20 minutes to a maximal infusion rate of 20 mU/minute. For purpose of standardisation amniotomy was performed when the active phase labour was achieved. Continuos uterine activity and FHR monitoring was used for all participant . All participants received at least 12 hours of oxytocin before unsuccessful induction or failed labour was diagnosed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: Single centre.<BR/>Setting: USA.<BR/>Additional outcomes reported: Bishop score (t =12 hours), delivery (from t = 0 hour), induction to delivery, maximum dose of oxytocin, duration of oxytocin, onset of labour (from t = 0 hour), onset of labour (from t = 0 hour), rupture of membranes (from t = 0 hour), estimated blood loss (ml), CS for failed induction, spontaneous rupture of membranes, labour before oxytocin, delivery before oxytocin, labour before end of 12-hour induction period, Apgar score at 1 minute, Apgar score at 5 minutes, fetal weight, suspected uterine hypertonus.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-NICHHD-1994">
<CHAR_METHODS>
<P>Randomisation: RCT, computer-assigned randomisation scheme arranged by the data coordinating centre. Randomisation was stratified by the clinical site and week of gestation. <BR/>Allocation concealment: unclear. <BR/>Blinding: both the participants and the investigators were blinded to the study groups. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>265 women were enrolled, 174 in experimental group and 91 in control group. <BR/>Eligibility: term between 280 and 301 days. <BR/>Exclusion: medical or obstetric complications requiring induction of labour, CS, or frequent monitoring of maternal or fetal condition; an estimated fetal weight exceeding 4500 gm by clinical or ultrasonographic examination; Bishop score (maximum score of 13) of 7 of greater; nonstress test not reassuring (nonreactive or showing decelerations); the largest pocket of amniotic fluid &lt; 2.0 cm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg (1 dose) followed 12 hours later with oxytocin.<BR/>Control: IC placebo gel (1 dose) followed 12 hours later with oxytocin.<BR/>Subjects underwent induction within 24 hours after randomisation. When clinically feasible, amniotomy was performed before the administration of oxytocin. If amniotomy was not feasible, oxytocin infusion was initiated according to uniform protocol. If the participant had not entered the active phase of labour after 24 hours of oxytocin administration, a CS was performed or induction of labour was continued for a longer time.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, serious neonatal morbidity or perinatal death, serious maternal morbidity or death, uterine hyperstimulation without FHR changes, meconium stained liquor, use of blood transfusion, maternal death.<BR/>Fetal/infant: Apgar score &lt; 4 at 5 minutes, perinatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Setting: USA. <BR/>Additional outcomes reported: intracranial hemorrhage, mechanical ventilation, nerve injury, seizures, babies with at least 1 adverse outcome, randomisation-delivery interval, maternal infection, vaginal delivery, late decelerations in labour, meconium aspiration pneumonia, birthweight. <BR/>Data only presented on ICPG compared with placebo presented. Expectant management arm excluded.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nimrod-1984">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: identical syringes dispensed by the hospital pharmacy in sequential order when requested. <BR/>Blinding: ''double blind'.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>45 women were enrolled, 15 in each group. <BR/>Eligibility: a modified Bishop score of 4 or less. <BR/>Exclusion: contractions present during the evaluation period.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group 1: IC gel PGE2 0.5 mg (1 dose). <BR/>Experimental group 2: IC gel PGE2 0.25 mg (1 dose).<BR/>Control: IC placebo gel (1 dose).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes, nausea, diarrhoea. <BR/>Fetal/infant: serious neonatal morbidity or death, NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Canada.<BR/>Additional outcomes reported: spontaneous labour, length of labour, Apgar score at 1 minute, Apgar score at 5 minutes, birthweight, congenital anomaly.<BR/>Comparison of ICPG to ICPG data not presented as both doses fall into low dose category (0.25 and 0.5 mg).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Noah-1987">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: open study. <BR/>Follow up: 4 women (3 gel and 1 control) excluded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>820 women were enrolled, 416 in experimental group and 404 in control group. <BR/>Eligibility: Bishop score of 0-5, a medical-obstetrical indication for labour induction, intact membranes.<BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg (1 dose).<BR/>Control: no treatment. <BR/>At the end of 12 hours, all participants not in labour were treated with an intravenous infusion of oxytocin as the 'initial' induction attempt. Oxytocin was started at 1.0 mU/minute and escalated at 30 to 60 minute intervals as required to a maximum dose of 16 mU/minute. Amniotomy was performed after labour had started. If labour had not started within 12 hours, the attempt at labour induction could be judged a failure.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, serious maternal morbidity or death, vomiting, diarrhea.<BR/>Fetal/infant: serious neonatal morbidity or death, Apgar score &lt; 7 at 5 minutes. </P>
<P>Keiback 1986 - instrumental delivery: 5/50 in PGE2 group and 10/50 placebo group. <BR/>Kristoffersen 1986 - instrumental delivery: 7/25 in PGE2 group and 5/25 placebo group. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: Multicentre study.<BR/>Setting: Europe and Africa (1983-1984).<BR/>Additional outcomes reported: successful induction of labour on the initial attempt, the mode of delivery, Bishop score progression during 1st 12 hours, induction - delivery interval, FHR changes and unclassified fetal distress, uterine contractile abnormalities, uterine hyperstimulation, Apgar score &lt; 7 at 1 minute, alkaline phosphatase, glutamic oxalacetic transaminase, creatinine, uric acid, complete blood counts and urinalysis. <BR/>Some individual centres published their own data. These data have not been entered into the meta-analysis, as it is already reported in the Noah 1987 paper which is the full multi-centre trial report. However, some centres (Keiback 1986; Kristoffersen 1986) published additional data. These additional data have not been entered into Review Manager, but are presented in this table (outcomes) and in the text of the review (Description of studies).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nuutila-1995">
<CHAR_METHODS>
<P>Randomisation: RCT. No details given. <BR/>Allocation concealment: unclear. <BR/>Blinding: unclear. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>45 women were enrolled, 24 in experimental group and 21 in control group. <BR/>Eligibility: otherwise healthy, admitted due to pre-eclampsia which was defined as blood pressure constantly &gt; 140/90 mmHg and proteinuria &gt; 0.5 g/L, singleton, vertex presentation, unripe cervix (Bishop score 5 or less), and no sign of fetal compromise. <BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg.<BR/>Control: IC placebo gel. <BR/>If there were no contractions, or if Bishop score remained 5 or less after 6 hours, a second gel was applied. The labour was induced, or augmented if regular contractions had begun and Bishop score was more than 5, by amniotomy and/or oxytocin infusion (5 IU in 500 mL).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, maternal side-effects, nausea, vomiting, diarrhoea. <BR/>Fetal/infant: Apgar score &lt; 7 (at 5 minutes?). <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Finland. <BR/>Additional outcomes reported: Bishop score, interval from treatment to labour, interval from treatment to delivery, spontaneous labour, induction failure, umbilical artery pH, birthweight. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nuutila-1996">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: by sealed opaque envelopes. <BR/>Blinding: no information provided. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>110 women were enrolled, 35 in group A, 36 in group B and 39 in group C. <BR/>Eligibility: with a decision of induction of labour, a high risk of pregnancy, unfavourable cervix (Bishop score 5 or less), singleton, intact membranes, vertex presentation. <BR/>Exclusion: hemorrhage during the third trimester of pregnancy, asthma, glaucoma and a history of hypersensitivity to prostaglandins. <BR/>Unfavourable cervix (BS &lt; 6) and indication for labour induction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A: IC gel PGE2 0.5 mg (2 doses, 6 hourly).<BR/>Group B: intravaginal gel PGE2 1 mg. <BR/>Group B: intravaginal gel PGE2 2 mg. <BR/>The gel was reapplied, maximally twice at 6-hour intervals, if Bishop score remained 5 or less and if there were no regular contractions. If labour had not started but Bishop scores were more than 5, induction was performed by amniotomy and/or oxytocin infusion (5 IU in 500 mL with accelerating infusion rate 5-20 drops/minute corresponding to up to 10 mIU/minute).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation with FHR changes, maternal side-effects. <BR/>Fetal/infant: Apgar score &lt; 7 (at 5 minutes?).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Finland. <BR/>Additional outcomes reported: ripening failure, ripening time, labour time, umbilical artery pH 7.15 or less.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ottinger-1998">
<CHAR_METHODS>
<P>Randomisation: RCT. Allocation sequence by a table of random numbers. <BR/>Allocation concealment: sealed, opaque, numbered envelopes.<BR/>Blinding: no information provided. <BR/>Follow up: two women were excluded for breach of protocol.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>92 women were enrolled, 45 in the IC group, 45 in the vaginal group and 2 excluded. <BR/>Eligibility: (1) age 14 to 40 years, (2) singleton gestation, (3) cephalic presentation, (4) intact membranes, (5) reassuring fetal testing (reactive nonstress test or biophysical profile score at least 6), (6) Bishop score 8 or less, and (7) requiring induction of labour for medical or obstetric indications. <BR/>Exclusion: (1) active vaginal bleeding, (2) history of adult asthma or glaucoma, (3) cerclage (this pregnancy), or (4) multifetal gestations. <BR/>Prior CS (if low transverse or low vertical without extension) was not an exclusion criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: IC PGE2 0.5 mg gel. A repeat IC gel (for a maximum 2 doses) was placed at 6 hours if spontaneous labour or rupture of membranes had not occurred. <BR/>Intravaginal group: intravaginal PGE2 10 mg controlled-release pessary. The pessary was placed in the posterior vaginal fornix and removed after 12 hours. The pessary was removed before 12 hours if spontaneous labour (contractions every 2 to 3 minutes), tachysystole (contractions every 1 to 2 minutes), or rupture of membranes occurred. Vaginal pessaries were removed at least 30 minutes before the start of oxytocin. <BR/>If spontaneous labour had not begun by 12 hours after treatment, oxytocin infusion was begun at 1 mU and increased every 15 to 20 minutes until adequate labour was achieved. All participants were given at least 12 hours of oxytocin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes, oxytocin augmentation.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: vaginal delivery, time intervals from start of induction to various labour end points (rupture of membranes, complete dilatation, vaginal delivery), birthweight, Apgar scores at 1 minute, Apgar scores at 5 minutes, Apgar score &lt; 7 at 1 minute. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Owen-1991">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: Randomisation was performed in the pharmacy and directed by the contents of the next sealed envelope. <BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 women were enrolled, 47 in experimental group and 53 in control group.<BR/>Eligibility: a maternal or fetal indication for labour induction, a Bishop score no more than 4, no evidence of fetal distress, and intact membranes. <BR/>Exclusion: hypersensitivity to prostaglandins, history of asthma or glaucoma, vaginal bleeding, failure of a previous attempt at labour induction, contraindications to labour induction, or spontaneous contractions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg. <BR/>Control: IC gel placebo. <BR/>After a monitored 12 hour interval oxytocin was started, unless spontaneous labour had begun.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: uterine hyperstimulation with FHR changes, CS, nausea, vomitting, diarrhoea. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/Single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: Bishop score change, failed labour induction, dystocia, interval from treatment to delivery, fever, umbilical arterial pH &lt; 7.2, fetal distress. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Peccerillo-1995">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: unclear. <BR/>Follow up: 2 participants were excluded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>69 women were enrolled, 31 in experimental group, 36 in control group and 2 excluded. <BR/>Eligibility: presenting for induction, at least 37 weeks' gestation, Bishop score no more than 6. <BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC PGE2 0.5 mg. <BR/>Control: Intravaginal PGE2 2.5 mg. <BR/>Subsequent doses were administer every 4 hours followed by oxytocin augmentation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/Single centre: single centre. <BR/>Setting: USA. <BR/>Additional outcomes reported: change in Bishop score, duration of induction. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Perez-Picanol-1990">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: no information provided. <BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>71 women were enrolled, 35 in experimental group and 36 in control group. <BR/>Eligibility: termed pregnancy, premature rupture of membranes &lt; 12 hours, and low Bishop score (no more than 4).<BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg. <BR/>Control: no treatment. <BR/>6 hours later a conventional administration of oxytocin was started in both groups for stimulation or induction of labour.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: uterine hyperstimulation with FHR changes, CS. <BR/>Fetal/infant: NICU.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Spain. <BR/>Additional outcomes reported: change in Bishop score, administration-delivery interval, oxytocin administration-delivery interval, vaginal delivery within 12 hours, Apgar score at 1 and 5 minutes, umbilical artery pH. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Perry-2003">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: Shuffled opaque sealed envelopes were placed into a covered box with subsequent blind retrieval. <BR/>Blinding: with the exception of the resident placing the dinoprostone, the staff and participants were blinded to the site of placement. <BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>63 women were enrolled, 33 in experimental group and 30 in control group. <BR/>Eligibility: admitted to the labour and delivery unit for dinoprostone induction with a singleton, cephalic fetus greater than or equal to 36 weeks' gestation with an initial Bishop score less than 6. <BR/>Exclusion: cervical dilatation greater than 2 cm, a history of prior caesarean delivery or hysterotomy, ruptured membranes, intrauterine growth restriction, known fetal anomalies, a nonreassuring FHR pattern, prior use of cervical ripening agents in the current pregnancy, other contraindications to vaginal delivery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental group: IC sustained-release PGE2 10 mg insert. <BR/>Control group: Intravaginal (posterior fornix) insertion of the same sustained-release PGE2 insert.<BR/>The dinoprostone insert remained in place for 12 hours or until labour ensured, at which time augmentation with oxytocin was initiated. In participants requiring further cervical ripening, subsequent doses were placed in the posterior fornix.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, oxytocin augmentation. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA. <BR/>Additional outcomes reported: change in Bishop scores, time to delivery, time to initial request for pain medications, time to ruptured membranes, artificial rupture of membranes, time to active labour, tachysystole, hyperstimulation, maternal fever, birthweight, Apgar scores, umbilical artery pH.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Poulsen-1991">
<CHAR_METHODS>
<P>Randomisation: RCT. Block of 10 randomisation. <BR/>Allocation concealment: sealed envelopes.<BR/>Blinding: open study. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>226 women were enrolled, 116 in the IC gel group and 110 in the vagitory group. <BR/>Eligibility: at term (259 to 303 days menstrual age), healthy, singleton pregnancy in a cephalic presentation, no history of previous CS or cervical conization and not in labour, an unfavourable cervix according to a modified cervical score of no more than 4 points.<BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intracervical gel group: 0.5 mg PGE2 in 2 ml of viscous slow-release gel applied intracervically.<BR/>Vaginal group: 2.5 mg PGE2 in a vagitory placed in the posterior vaginal fornix. <BR/>When labour became established, the membranes were ruptured artificially as soon as possible. At 12 hours after administration of the drug, the woman was reassessed and if possible the membranes ruptured. Oxytocin infusion (10 IE/500 ml isotonic saline) was commenced 2 hours later when indicated. If rupture of the membranes was not feasible (cervical score no more than 4 points), the women was given the same substance again using the same observation schedule. The cervix was assessed again at 24 hours if required. Otherwise, routine labour ward management at the obstetricians' discretion was applied.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS,uterine hyperstimulation without FHR changes, nausea, diarrhea, meconium stained liquor, instrumental vaginal delivery (figures not given). <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre.<BR/>Setting: Denmark and Iceland.<BR/>Additional outcomes reported: abnormal FHR, contractions, strong contractions, analgesic, in labour/delivery by 12 hours, in labour/delivery by 24 hours, total not in labour, delivery (at no more than 12 hours, at 12-24 hours, at 24-36 hours, at 36-48 hours), oxytocin requirement, Apgar scores at 1 and 5 minute, blood loss &gt; 500 ml, neonatal illness, time from priming to rupture of membranes, time from priming to established labour and priming to delivery, fetal death.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ramsey-2003">
<CHAR_METHODS>
<P>Randomisation: a prospective randomised clinical trial. Randomisation was done independently through the central hospital pharmacy using dynamic allocation with stratification by parity (primiparous vs multiparous) and initial Bishop score (no more than 2 or &gt; 2). <BR/>Allocation concealment: unclear.<BR/>Blinding: blinding of caregiver.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>111 women were enrolled, 35 in dinoprostone 0.5 mg gel intracervically group (1), 38 in dinoprostone 10 mg intravaginally insert group (2) and 38 in misoprostol group (3). Groups 1 and 2 presented in the review. <BR/>Eligibility: (1) an unfavorable cervical Bishop score equal to or less than 5, (2) a singleton pregnancy with vertex presentation and no contraindication to vaginal delivery, (3) the absence of spontaneous uterine contractions (ie, &lt; 4 spontaneous contractions per hour), and (4) a reactive nonstress test. <BR/>Exclusion: (1) a known hypersensitivity to prostaglandins, (2) ruptured membranes, (3) suspected chorioamnionitis, (4) parity of &gt; 5, (5) a previous caesarean delivery or history of uterine surgical procedures, and (6) previous attempted induction of labour for this pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dinoprostone gel group: dinoprostone gel 0.5 mg administered intracervically initially, with 1-time repeat dosing 6 hours later. <BR/>Dinoprostone insert group: dinoprostone vaginal insert 10 mg administered into the posterior fornix for a total 12 hours.<BR/>Misoprostol group: misoprostol 50 µg intravaginally in the posterior fornix initially, with 1-time repeat dosing 6 hours later.<BR/>All study candidates were admitted to the labour and delivery unit 12 hours before the scheduled induction of labour; cardiotocography was performed to rule out fetal distress and the presence of uterine contractions. <BR/>Women with an established contraction pattern of &gt; 3 contractions in 10 minutes, with rupture of membranes, or with an abnormality of the fetal heart tracing did not undergo redosing with the study agent. The dinoprostone vaginal insert was continued in the setting of an established contraction pattern in the absence of rupture of membranes or an abnormality of the fetal heart tracing. <BR/>Participants who were not in an adequate labour pattern after the preinduction interval received standard oxytocin infusion at an initial rate of 2 mU/minute, with 2 mU/minute incremental increases at 20-minute intervals to a maximum of 30 mU/minute until an adequate labour pattern (at least 200 Montevideo units every 10 minutes, as measured by intrauterine pressure catheter) was obtained. Participants with active-phase labour (at least 4 cm dilation with regular uterine contractions) with arrest of dilation (no change in cervical dilation for at least 2 hours), despite adequate labour pattern contractions received oxytocin augmentation according to the above protocol. Continuous electronic FHR and tocodynamic monitoring was used throughout labour. Standardised intrapartum treatment guidelines were used for all participants . Women in whom uterine hyperstimulation developed received a single dose of subcutaneous terbutaline (0.25 mg), along with a position change and oxygen administration. Participants who demonstrated no significant cervical change during the initial 24-hour period were retreated with the original cervical ripening regimen for an additional 12 hours before the oxytocin therapy was reinitiated.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: (vaginal?) delivery not achieved within 24 hours, uterine hyperstimulation with FHR changes, CS, cervix unfavorable after 12 hours, oxytocin augmentation, meconium stained liquor (meconium passage), PPH.<BR/>Fetal/infant: NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: USA.<BR/>Commercially funded by Upjohn Co, Kalamazoo, Mich.<BR/>Additional outcomes reported: <BR/>For women: change in Bishop score over initial 12 hours, time to active labour, time to complete dilation, time to delivery, time to vaginal delivery, total hours of oxytocin infusion, total amount of oxytocin, chorioamnionitis, cost, the cost that was incurred per participant to achieve a 1-point change in the cervical Bishop score, complete dilation within 24 hours, delivery within 48 hours of treatment initiation, additional 12 hours of cervical ripening for a persistent unfavourable cervix after the initial 24-hour inductions, overall mean cost per participant, incidence of cardiotocographic abnormalities (overall, hypertonus, tachysystole, hyperstimulation syndrome) during the initial 24 hours of induction, mean number of abnormal cardiotocographic events (overall, hypertonus, tachysystole, hyperstimulation syndrome) per participant during the initial 24 hours of induction, time to abnormal cardiotocographic events occurring, abnormal cardiotocographic patterns within 6 hours of initial dosing.<BR/>For neonatal outcomes: birthweight, Apgar score at 1 minute, Apgar score at 5 minutes, venous cord pH, aterial pH, supplemental oxygen.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rath-1999">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: unclear. <BR/>Follow up: 2 women were excluded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>470 women were enrolled. The outcomes of 242 in the IC group and 226 in the intravaginal group were analysed. <BR/>Eligibility: Bishop score 3-4, singleton, cephalic, primiparous, intact membranes, live fetus, ruptured membranes, 34 to 42 gestational weeks, diabetes or hypertension. <BR/>Exclusion: malpresentations, multiparous, previous classical CS, no reassuring CTG.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: IC gel PGE2 0.5 mg. <BR/>Intravaginal group: intravaginal gel PGE2 2 mg. <BR/>The application were repeated at intervals of 6 hours if necessary.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Setting: Germany.<BR/>Additional outcomes reported: cervical ripening effect, induction-delivery interval, hyperstimulation, Apgar score 7 or less at 5 minutes, cord blood pH &lt; 7.10, cord blood pH &lt; 7.20, cord blood pH &lt; 7.00. <BR/>The original paper was written in German and needed to be translated.<BR/>Data from trial - uterine hyperstimulation with and without FHR changes: IC = 24/242; intravaginal = 21/226. Apgar score less than or = to 7: IC = 3/242; intravaginal = 6/226. Cord blood &lt; 7.10: IC = 3/242; intravaginal = 2/226, &lt; 7.20: IC = 19/242; intravaginal = 27/226, &lt; 7.0: IC = 0/242; intravaginal = 1/226. These data have not been entered into Review Manager.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Richardson-1991">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear.<BR/>Allocation concealment: unclear. <BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 women were enrolled, 21 in experimental group and 27 in control group. <BR/>Eligibility: cervix &lt; 2 cm dilated and &lt; 50% effaced, &gt; 37 weeks' gestation, intact membranes, vertex presentation, singleton, and a reactive nonstress test. <BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg. <BR/>Control: IC placebo gel.<BR/>Oxytocin induction of labour was followed 4 hours after treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: fetal distress, vaginal delivery. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rix-1996">
<CHAR_METHODS>
<P>Randomisation: a prospective, randomised study. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: by sealed, numbered envelopes.<BR/>Blinding: unclear.<BR/>Follow up: 27 participants dropped out, 15 in IC gel group and 12 in vaginal tablets group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>208 women were enrolled, 110 in IC gel group and 98 in vaginal tablets group.<BR/>Eligibility: Bishop score not greater than 5, a fetus in cephalic presentation, intact membranes and no contraindications to prostaglandin administration.<BR/>Exclusion: previous precipitate labour, Potter syndrome.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC PGE2 gel 0.5 mg. <BR/>Control: PGE2 vaginal tablets 3 mg.<BR/>6 and 12 hours later the procedure was repeated and continued the following day for a maximum of 6 applications, if necessary, until ripening of the cervix was seen, defined by cervical dilatation beyond 3 cm, or labour induced. <BR/>Amniotomy was performed if no further progress was seen once ripening was obtained, followed one hour later by IV oxytocin stimulation, if necessary.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, instrumental vaginal delivery (figures not given)<BR/>Fetal/infant: serious neonatal morbidity (birth asphyxia).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Denmark.<BR/>Commercially funded by Upjohn Co, Kalamazoo, Mich.<BR/>Additional outcomes reported: ripening of the cervix (6, 12, 24, 36 and 42 hours from start of induction), cumulative number of deliveries during the study shown by 6 hours interval, mean induction-delivery intervals, amniotomy, oxytocin stimulation (unclear definition), pethidine analgesia, precipitous active phase of delivery, instrumental delivery, augmentation of second stage labour by oxytocin, atonic postpartum bleeding, failed induction of labour, gastrointestinal symptoms, vaginal pain and birth weight.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Seeras-1995">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: sealed, opaque envelopes. <BR/>Blinding: unclear. <BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>68 women were enrolled, 37 in the IC group and 31 in the vaginal group. <BR/>Eligibility: admitted for elective induction of labour. a gestational age &gt; 37 completed weeks, intact membranes, not in labour.<BR/>Exclusion: previous CS, surgery to the uterine corpus, malpresentation and other contraindications to vaginal delivery, presence of active liver disease, severe cardiac disease, glaucoma, severe asthma or allergy to prostaglandin.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: IC gel PGE2 0.5 mg 6 hourly, max 3 doses.<BR/>Vaginal group: intravaginal gel PGE2 2 mg 6 hourly, max 3 doses.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, serious maternal morbidity or death, oxytocin augmentation, uterine hyperstimulation without FHR changes, epidural analgesia, instrumental vaginal delivery, nausea and vomiting, PPH. <BR/>Fetal/infant: serious neonatal morbidity or perinatal death, Apgar score &lt; 7 at 5 minutes, NICU admission, perinatal death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: UK.<BR/>Additional outcomes reported: successful induction, oxytocin induction, induction-labour interval, induction-delivery interval, spontaneous vertex delivery, delivery within 24 hours, abnormal FHR, Apgar score &lt; 7 at 1 minute, use of pethidine. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stempel-1997">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated allocation sequence. <BR/>Allocation concealment: participants were allocated by use of a pharmacy-prepared randomisation list. <BR/>Blinding: no information provided. <BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>83 women were enrolled, 39 in the cervical gel group and 44 in the vaginal gel group. <BR/>Eligibility: requiring cervical ripening for the induction of labour, singleton pregnancy with live fetus in the vertex presentation a Bishop score not greater than 6. <BR/>Control: pregnancy with an contraindication for gel use: hypersensitivity, placenta previa, malpresentation, unexplained vaginal bleeding, regular contractions in spite of an unripe cervix, or evidence of fetal distress.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC gel group: IC gel PGE2 0.5 mg.<BR/>Intravaginal gel group: intravaginal gel PGE2 5 mg.<BR/>Gel administration could be repeated twice at 6-hour intervals if the cervix remained unfavourable and the participant was not having contractions. Oxytocin was administered 6 to 12 hours after the last gel. Oxytocin was started at 1 to 2 mIU and increased by 1 to 2 mIU every 15 minutes until adequate labour was achieved.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hypertension with FHR changes, oxytocin augmentation.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: spontaneous labour, the need for and success of oxytocin induction of labour, failed induction, the interval from first gel insertion to oxytocin imitation, Bishop score change, duration of labour, vaginal delivery, birthweight, Apgar score at 1 minute, Apgar score at 5 minutes, pH umbilical vein, pH umbilical artery.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stiver-1991">
<CHAR_METHODS>
<P>Randomisation: RCT, method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: 'double blind'. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 women were enrolled, 15 in group A and 13 in group B. <BR/>Eligibility: primigravid, at least 37 weeks' gestation with indications for delivery and Bishop score 5 or less. <BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A: IC gel PGE2 0.2 mg. <BR/>Group B: IC gel PGE2 0.5 mg.<BR/>Same application was repeated at intervals of 6 hours until spontaneous rupture of membranes or labour occurred, dilatation was at least 4 cm, or 5 doses were given, at which time oxytocin induction or augmentation was begun.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS. <BR/>Fetal/infant: no outcomes reported. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA. <BR/>Additional outcomes reported: spontaneous labour, doses needed to achieve 75% effacement, doses needed to reach at least 3 cm dilatation, Bishop score 9 or greater after each dose. <BR/>Abstract only. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Strobelt-2006">
<CHAR_METHODS>
<P>Randomisation: a prospective randomised study, with parity-based randomisation.<BR/>Allocation concealment: not used. The participants were allocated by a parity-based open randomisation list. <BR/>Blinding: unclear.<BR/>Follow up: no loss of participants reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>107 women were enrolled, 56 in experimental group and 51 in control group.<BR/>Eligibility: single pregnancy, cephalic presentation, gestational age at least 37 and equal to or less than 41 weeks, Bishop score at admission equal to or less than 4. <BR/>Exclusion: PROM, history of previous CS, vaginal bleeding, suspicious or ominous non-stress test at admission, placenta previa, chorioamnionitis, HELLP syndrome, sonographically expected birth weight &gt; 4000 g, and maternal clinical contraindications to the administration of PGE2 analogs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: dinoprostone 10-mg vaginal insert , with the continuous, controlled release of 0.3 mg of dinoprostone per hour. Vaginal insert was removed in the case of PROM, onset of labour, or abnormal CTG pattern. Participants with PROM underwent oxytocin induction and IV ampicillin administration 2 hours thereafter if not in labour. Participants with intact membranes not labouring after 12 hours from induction received 2 mg of dinoprostone vaginal gel for at least 2 applications with an 8-hour interval if Bishop score was still 0-4, or underwent amniotomy and eventually oxytocin infusion if Bishop score had become equal to or more than 5. <BR/>Control: dinoprostone 0.5-mg cervical gel. Control participants received at least 2 doses of 0.5-mg dinoprostone cervical gel under sterile speculum examination with a 6-hour interval. Fetal monitoring, PROM management, vaginal dinoprostone administration and/or induction with amniotomy and oxytocin were managed following the same protocols of study participants.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre (it was conducted in 2 hospitals). <BR/>Setting: Italy. <BR/>Additional outcomes reported: Induction-to-delivery time, rate of CS for fetal distress, incidence of uterine hyperstimulation, incidence of umbilical artery pH &lt; 7.01, rate of vaginal gel required as a second-line induction procedure, suspicious/ominous CTS in labour, stained amniotic fluid, atypical vaginal bleeding, oxytocin before labour, oxytocin in labour, blood loss at delivery, blood loss after vaginal delivery.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Thiery-1984">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: 'double blind'. <BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>121 women were enrolled, 40 in gel group, 41 in tablet group and 40 in control group. <BR/>Eligibility: between the ages of 16-35 years, in good health, having a normal pregnancy at term (38-42 weeks' gestation), with a singleton fetus in vertex presentation, an intact uterus, no contraindications for labour induction and vaginal delivery, not in labour, intact membranes, Bishop score (4) of 5 or less, and no contraindications for treatment with prostaglandins.<BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Gel group: IC gel PGE2 0.5 mg and intravaginal placebo tablets.<BR/>Tablet group: IC placebo gel and intravaginal tablets 2 mg PGE2.<BR/>Control group: IC placebo gel and intravaginal placebo tablets. <BR/>If the cervix was ripe (Bishop score more than 6) after a 12 hour observation period, labour induction was started by conventional methods (low amniotomy +/- intravenous oxytocin).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, cervix unfavourable/unchanged after 12 hours, vomiting, diarrhea, uterine hyperstimulation with FHR changes, PPH.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Belgium.<BR/>Additional outcomes reported: labour within 12 hours after treatment, mean changes in Bishop score in 12 hours, more than 1 softening procedure before delivery, mean treatment delivery interval, softening efficacy stratified by admission Bishop score, gastrointestinal upset, uterine contractile abnormality, FHR abnormalities, Apgar score &lt; 7 at 1 minute, FHR patterns, laboratory assays (liver enzymes, alkaline phosphatase, uric acid, creatinine, complete blood count, urinalysis, scalp pH and umbilical artery blood pH).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Trofatter-1985">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: both participants and therapist were blinded to the study group. <BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>59 women were enrolled, 30 in experimental group and 29 in control group.<BR/>Eligibility: medical or obstetric indications for induction of labour, Bishop score 4 or less, a reactive nonstress test or a negative contraction stress test. <BR/>Exclusion: hypersensitivity to prostaglandins, history of asthma, glaucoma, elevated intraocular pressure, vaginal bleeding, ruptured membranes, previous CS, previous attempt at induction of labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg. <BR/>Control: no treatment. Participants had the sterile cathether inserted into the cervix but received no gel. <BR/>Both groups had oxytocin after 12 hours if not in labour. Any participants who subsequently developed uterine contractions was managed and monitored as appropriate for her care in labour.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation with FHR changes, instrumental vaginal delivery. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre<BR/>Supported by The Upjohn Company, Kalamazoo, Michigan. <BR/>Setting: USA. <BR/>Additional outcomes reported: Bishop score, time until complete dilatation, induction-to-delivery interval, rupture of membranes-to-delivery interval, labour prior to oxytocin, delivery prior to oxytocin, spontaneous delivery, estimated loss of blood, birthweight, Apgar score at 1 and 5 minutes, cord arterial pH. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Trofatter-1993">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear. <BR/>Blinding: open study.<BR/>Follow up: 26 (13 in each group) were excluded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>514 women were enrolled, 265 in experimental group and 249 in control group.<BR/>Eligibility: a pregnancy at or near term, medically indicated inductions, unfavourable cervix (BS &lt; 5).<BR/>Exclusion: no information provided.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: 0.5 mg of dinoprostone cervical gel by endocervical administration.<BR/>Control: no treatment. <BR/>Both groups had oxytocin after 12 hours if not in labour.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, gastrointestinal side-effects, hyperstimulation with and without FHR changes, uterine rupture. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
<P>Lucas 1986 - Oxytocin augmentation: 22/27 in PGE2 group and 23/23 placebo group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Setting: USA. <BR/>Additional outcomes: Bishop score after 12 hours from treatment, initiation of labour, induction-delivery interval, side-effects, fever, abnormal FHR, Apgar score &lt; 7 at 1 minute. <BR/>Some individual centres (Lucas 1986 and Yonekura 1985) published their own data. These data have not been entered into the meta-analysis, as they are already reported in the Trofatter 1993 paper which is the full multi-centre trial report. However, one of the centres ( Lucas 1986) published additional data. These additional data have not been entered into Review Manager, but are presented in this table (outcomes) and in the text of the review (Description of studies). <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Troostwijk-1992">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated allocation sequence.<BR/>Allocation concealment: coded identical preparation was kept by the pharmacist. <BR/>Blinding: 'double blind'.<BR/>Follow up: 1 women in experimental group was not included in the evaluation because of emergency CS. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>139 women were enrolled, 71 in experimental group and 68 in placebo group.<BR/>Eligibility: a gestational age of more than 36 weeks, an unripe cervix (BS &lt; 6) and intact membranes, a medical or obstetric indication for induction of labour or a justified elective induction. <BR/>Exclusion: more or less regular uterine contractions, an unavailing previous attempt at the induction of labour, multiple gestation, breech presentation, fetal growth retardation with an estimated birthweight below 2500 g, suspected fetal distress, intrauterine fetal death, and contraindications to the use of preparation (such as hypersensitivity to prostaglandins, a history of asthma or glaucoma, previous CS or other uterine surgery, and uterine bleeding of uncertain etiology).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg. <BR/>Control: IC placebo gel. <BR/>After the following 9-hour study period and disclosure of the code, participants who received the placebo-preparation, could get a subsequent treatment with active preparation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation without FHR changes, instrumental vaginal delivery, maternal side-effects. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre. <BR/>Setting: Netherlands.<BR/>Additional outcomes reported: successful cervical ripening, spontaneous delivery, birthweight, pH of the umbilical cord blood.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ulmsten-1982">
<CHAR_METHODS>
<P>Randomisation: this trial included 2 parts, so only the information about the RCT part is included in this table. Method of generation of the allocation sequence was unclear. <BR/>Allocation concealment: unclear.<BR/>Blinding: 'double blind'.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 women were enrolled in the RCT, 25 in experimental group and 25 in control group. <BR/>Eligibility: nulliparas women with an unfavourable cervical state at term, labour requiring to be induced for medical or strong psychosocial reasons. <BR/>Exclusion: breech presentation, multiple pregnancy, or low-implanted placenta.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 0.5 mg. <BR/>Control: IC gel placebo. <BR/>From 15 to 30 minutes before to 1 hour after gel application, participants were monitored by external cardiotocography. Participants in whom no abnormalities were registered and labour failed to be induced were referred to the antenatal care unit of the department. Those in whom labour was established were supervised according to the routine of the department, which included external or internal cardiotocography; scalp blood samples were taken when indicated. Amniotomy was not performed until the cervix was dilated 4 cm or more and labour was well established. Oxytocin or other stimulating agents were not infused.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: multi-centre.<BR/>Setting: Sweden.<BR/>Additional outcomes: cervical score after treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ulmsten-1985">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear.<BR/>Blinding: for 58 nulliparous women, 'double blind' was employed in this study; for 25 participants of mixed parity, it was open.<BR/>Follow up: no loss of participants reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>83 women were enrolled, among which 19 in IC PGE2 gel group (blind study), 19 in intravaginal PGE2 group (blind study), 20 in placebo group (blind study) and 25 in IC PGE2 gel group (open study). <BR/>Eligibility: <BR/>For blind study: pregnant women at term, nulliparous, unfavourable cervical scores (Bishop score of 5 or less). <BR/>For open study: women of mixed parity and unfavourable cervical scores (Bishop score of 5 or less). <BR/>Exclusion: no information provided. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC PGE2 gel 0.5 mg + an inactive suppository.<BR/>Control: a suppository containing 2 mg PGE2 + IC inactive gel.<BR/>An amniotomy was never done until labour was well established and the cervix at least 4 cm dilated. Participants not in labour but with a favourable cervical score 24 hours after the start of the treatment were induced by an IV oxytocin infusion. The infusion started with a dose of 2 mu/minute. It was subsequently increased with 2 mu every 30 minutes until labour was well established. The maximum dose infused was not allowed to exceed 24 mu/minutes. If the cervix was still unfavourable 24 hours from start of treatment, the participant was given IC PGE2 gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: vaginal delivery not achieved within 24 hours, CS.<BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Sweden.<BR/>Additional outcomes reported: cervical score after 16-20 hours after treatment, increased myometrial activity, maternal gastrointestinal discomfort, hyperpyrexia, signs of infection, children's health at 1 week and at 6 months. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wieland-1999">
<CHAR_METHODS>
<P>Randomisation: RCT. Generation of the allocation sequence by shuffling cards. <BR/>Allocation concealment: opaque sealed sequentially numbered envelopes.<BR/>Blinding: no information provided. <BR/>Follow up: 9 were excluded for protocol violations.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>78 women were enrolled, 35 in the IC group, 34 in the intravaginal group and 9 excluded. <BR/>Eligibility: term gestation, cephalic presentation, Bishop score &lt; 5, reactive nonstress test or negative oxytocin challenge test, and approval for vaginal delivery. <BR/>Exclusion: previous uterine surgery or presented with a history of ruptured membranes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: IC gel PGE2 l 0.5 mg. Dosing was repeated every 4 to 6 hours for a total of up to 3 doses during the course of the night. <BR/>Intravaginal group: intravaginal PGE2 10 mg insert, removed 12 hours later. <BR/>In the case of hyperstimulation or tachysystole, the insert was removed; if the gel was used, terbutaline was administered subcutaneously.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, instrumental delivery, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes. <BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: USA.<BR/>Additional outcomes reported: change in Bishop score, change in Bishop score at least 3 points, labour without oxytocin, time interval from admission to delivery, failed induction, spontaneous vaginal delivery, cost. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wingerup-1978">
<CHAR_METHODS>
<P>Randomisation: RCT. Method of generation of the allocation sequence unclear. <BR/>Allocation concealment: unclear.<BR/>Blinding: unclear.<BR/>Follow up: no loss of participants reported. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 women were enrolled, 10 in experimental group and 10 in control group. <BR/>Eligibility: pregnancy at term, unfavourable cervical state (modified Bishop score not great than 5), nulliparae, vertex presentation, intact membranes. <BR/>Exclusion: low implanted placentas.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: IC gel PGE2 1 mg.<BR/>Control: IC placebo gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, instrumental delivery, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes, maternal side-effects, epidural analgesia. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre.<BR/>Setting: Sweden.<BR/>Additional outcomes reported: vaginal delivery, change in Bishop score.<BR/>Also report outcomes for 41 women not randomised.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yuen-1996">
<CHAR_METHODS>
<P>Randomisation: RCT. Computer-generated allocation sequence. <BR/>Allocation concealment: sealed opaque envelopes. <BR/>Blinding: no information provided.<BR/>Follow up: 5 were excluded for protocol violations.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>119 women were enrolled, 38 in group A, 41 in group B and 40 in group C.<BR/>Eligibility: requiring induction of labour, a singleton pregnancy in a vertex presentation, a cervical Bishop score of 4 or less.<BR/>Exclusion: ruptured membranes, 2 or more previous CS, regular uterine contractions and conditions necessitating immediately delivery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Group A: insertion of the Atad Ripener Device. <BR/>Group B: IC insertion of 0.5 mg PGE2 gel.<BR/>Group C: intravaginal placement of 3 mg of PGE2 pessary. Repeated 6 hours later if the cervix remained unfavourable (Bishop score &lt; 6) and there were no significant uterine contractions. <BR/>In all 3 groups, if the Bishop score was 6 or above, induction of labour was carried out by rupturing the membranes and/or intravenous administration of oxytocin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation with FHR changes, instrumental delivery, uterine hyperstimulation without FHR changes. <BR/>Fetal/infant: Apgar score &lt; 7 at 5 minutes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Hong Kong.<BR/>Additional outcomes reported: complications during the ripening period, successful cervical ripening, Bishop score change, vaginal delivery, duration of labour, postdelivery uterine atony, birthweight, Apgar score &lt; 7 at 1 minute.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zanini-1989">
<CHAR_METHODS>
<P>Randomisation: RCT. Allocation sequence from a table of numbers. <BR/>Allocation concealment: unclear.<BR/>Blinding: no information provided. <BR/>Follow up: 6 were excluded for protocol violations. <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>106 women were enrolled, 52 in the IC group, 48 in the intravaginal group and 6 excluded. <BR/>Eligibility: singleton pregnancy, vertex presentation, intact membranes, Bishop score less than 6, and gestational age more than 35 weeks. <BR/>Exclusion: a history of asthma, glaucoma, previous CS delivery, uterine surgery, second- or third-trimester haemorrhage, or parity above 5.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IC group: IC gel PGE2 0.5 mg.<BR/>Intravaginal group: intravaginal gel PGE2 3 mg.<BR/>If the Bishop score was greater than 5, labour was induced by artificial rupture of membranes, followed by intravenous oxytocin 2 hours later if necessary. If the Bishop score was 5 or less, the gel was reapplied for a total of 3 times, alternating the route of administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Women: CS, uterine hyperstimulation with FHR changes, uterine hyperstimulation without FHR changes, instrumental delivery, maternal side-effects, nausea, vomiting, diarrhoea.<BR/>Fetal/infant: no outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Multicentre/single centre: single centre. <BR/>Setting: Italy.<BR/>Additional outcomes reported: Bishop score change, maternal fever, spontaneous vaginal delivery.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BS: Bishop score<BR/>CS: caesarean section<BR/>CST: contraction stress test<BR/>CTG: cardiotocography<BR/>FHR: fetal heart rate<BR/>HELLP: hemolysis, elevated liver enzymes, low platelets<BR/>IC: intracervical<BR/>ICPG: intracervical prostaglandin<BR/>ITT: intention to treat <BR/>IV: intravenous<BR/>LSCS: low-segment CS<BR/>NICU: neonatal intensive care unit<BR/>NST: nonstress test <BR/>PG: prostaglandin<BR/>PPH: postpartum haemorrhage <BR/>PROM: premature rupture of the membranes<BR/>RCT: randomised controlled trial<BR/>VD: vaginal delivery<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aggarwal-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparing vaginal misoprostol with intracervical prostaglandin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bredow-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cararach-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial assessing 3 types of management of premature rupture of membranes of 34 weeks or more, therefore excluded. Women randomised to either induction of labour at 12 hours of PROM, PGE2 0.5 mg intracervical gel or expectant management until 48 hours of PROM.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Aniello-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women were 'consecutively enrolled' into the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Egarter-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Method of randomisation not described and inconsistencies in data. We tried to contact the author but have been unsuccessful.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ekblad-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inadequate method of randomisation (alternation). In addition, results were unclearly reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Facchinetti-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women received either 0.5 mg intracervical dinoprostone gel, or 10 mg vaginal dinoprostone insert. After 6 hours, women (in either group) with a Bishop score of less than 4 received another dose of gel, while those with Bishop scores between 4 and 6 received 2 mg dinoprostone gel by the vaginal route. After 12 hours, the vaginal insert was removed. After 24 hours of treatment, 2 mg dinoprostone administered to women in both groups who were not experiencing regular uterine contractions. 6 hours later, every woman who was not in labour had her labour induced with an oxytocin infusion. Amniotomy was performed only in women in labour with at least 5 cm of cervical dilatation. Oxytocin augmentation was done in the second stage of labour if necessary. Trial does not meet eligibility criteria of review. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fuchs-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clear if an RCT. Compared endocervical PGE2 with extra-amniotic PGE2.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garcia-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report does not state if trial randomised, gestation of women, or give any numerical data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gittens-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of intracervical prostaglandin for induction versus expectant management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goeschen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clear if a randomised controlled trial. Also both groups received prostaglandin gel.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gonen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of intracervical prostaglandin, followed by oxytocin after 6 hours, for induction of labour versus expectant management, followed by oxytocin after 24 hours, in women with PROM.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hennessey-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 0.5 mg intracervical gel (Prepidil) with oxytocin administered 30 minutes after instillation or 10 mg sustained-release vaginal insert (Cervidil).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henson-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women recruited in preterm pregnancy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herabutya-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of intracervical prostaglandin for induction versus expectant management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Herabutya-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of intracervical to intravaginal PGE2. In protocol, any participant requiring more than 1 dose of either preparation or those sent home who then returned in spontaneous labour were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iftikhar-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>No outcome data reported. 126 women randomised. 63 women allocated to 0.5 mg intracervical gel 2 doses and 63 women to intravaginal pessary 2 mg doses. Unable to locate authors to obtain data (05/04/07).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ingemarsson-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only and data not presented, R Smyth contacted I Ingemarsson for additional information. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kamat-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Doesn't appear to be an RCT. report states 'the cases were divided into 2 groups' . Unable to locate authors to obtain verification (23/04/07).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaminski-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial compares intracervical PGE2 with oxytocin IV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kupietz-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial compares intracervical PGE2 0.5 mg administered in the morning compared with at night.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lotshaw-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>All women received intracervical PGE gel 0.5 mg either 6 hour or 1 hour prior to administration of oxytocin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luther-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of synthetic to natural prostaglandin E2. Same dose in both arms (0.5 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lyndrup-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Presentation of data from 4 prospective, randomised trials: 2 of which compared vaginal PGE2 with oxytocin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mackenzie-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prostaglandin administered vaginally, not intracervically.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Megalo-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial comparing vaginal misoprostol to intracervical followed by intravaginal PGE2.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Minaretzis-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>During a first period all women were allocated to IC PGE2 0.5 mg (40 women), during a second period to IC PGE2 1.5 mg (35 women), then to 2.5 mg (35 women). Despite blinding of clinicians and the fact that women were included consecutively, this method was considered as inappropriate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mink-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Protocol of administration unclear. Method of randomisation and concealment of allocation unclear. Results reported unclearly.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muller-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of IC PGE2 0.5 mg and intravaginal PGE2 tablets 3 mg. Exclusion because of inadequate method of randomisation and concealment of allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muller-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of IC PGE2 0.5 mg and intravaginal PGE2 tablets 3 mg. Exclusion because of a large number of exclusions: 302 women included, 176 reported (62 in the IC group and 102 in the IV group).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noah-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 2 doses 0.25 mg 6-hourly to 1 dose 0.5 mg PGE2 (followed 6 hours later by a dose of placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nuutila-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Focus of this trial was fetal doppler flow, but possible that authors collected data relevant to this review, therefore R Smyth emailed M Nuutila (10/04/07) and O Ylikorkala (23/04/07) for additional data - no response received (27/04/07).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Parewijck-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unpublished trial. Authors have been written to - no response.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paul-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of intracervical prostaglandin for induction versus expectant management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Penna-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Complex trial design with varying dose in each arm dependent on bishops score. If Bishops score &gt; 7 in either arm then participants underwent ARM and oxytocin alone. Data not divided according to dose allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Polvi-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Focus of trial doppler flow, but possible that authors collected data relevant to this review, therefore R Smyth emailed JP Pirhonen and JP Pirhonen (24/04/07) for data - no response.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rath-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of different dosages of PGE2 intracervical gel (25, 50, 100 micrograms).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rayburn-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unclear wether intervention was intracervical or vaginal. High dose (2.5 mg) more compatible with intravaginal use.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rayburn-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of IC 0.5 mg prostaglandin for induction versus expectant management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reichel-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial reports lab data only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roberts-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prostaglandin administration on the external cervix. Dose more likely to be compatible with intravaginal administration than intracervical (3 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sahraoui-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparing PGE2 gel with expectant management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sanchez_x002d_Ramos-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of commercial with compounded prostaglandin E2. Same dose in both arms (0.5 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schneider-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clear if a randomised trial as all women with medium to ripe cervix received vaginal tablets and all women with unripe cervix received cervical gel. Also 13% of women recruited with less than or up to 37 weeks' gestation, and 47% postrandomisation exclusions based on data errors.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shaala-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mode of induction involved direct injection of prostaglandin into the body of the cervix.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Skajaa-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of solid with liquid prostaglandin E2. Same dose in both arms (0.5 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tey-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of induction with intracervical prostaglandin versus expectant management for fetuses with suspected macrosomia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Dessel-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women were already in early labour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Voss-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of varying doses of intracervical prostaglandins. Numerous postrandomisation exclusions. (only 229 of original 291 participants analysed)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Webb-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No denominator data given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Williams-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>PGE2 3 mg and 5 mg administered "onto the portio vaginalis of the cervix". Probably comparison of vaginal PG and placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wyldes-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mike Wyldes confirmed that trial never commenced (26/04/07).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yacoob-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 0.5 mg intracervical PGE2 gel compared with 0.5 mg 0.5 mg oral tablet.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ARM: <BR/>IC: intracervical<BR/>PROM: premature rupture of membranes<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bernstein-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Buttino-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cabrol-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chyu-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Corrado-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Darroca-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Duhl-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ekman-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Din-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gilson-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gr_x00fc_nberger-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hales-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heinzl-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hidar-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hutchon-1980">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Irion-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Keirse-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kemp-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Larmon-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Laube-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Legarth-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lien-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lopes-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lyndrup-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-McKenna-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Milliez-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-NICHHD-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nager-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nimrod-1984">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Noah-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nuutila-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nuutila-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ottinger-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Owen-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Peccerillo-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Perez-Picanol-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Perry-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Poulsen-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ramsey-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rath-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Richardson-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rix-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Seeras-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stempel-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stiver-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Strobelt-2006">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Thiery-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Trofatter-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Trofatter-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Troostwijk-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ulmsten-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ulmsten-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wieland-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wingerup-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Yuen-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zanini-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-02-04 10:24:30 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all women</NAME>
<DICH_OUTCOME CHI2="8.926709991876443" CI_END="0.7891594963588041" CI_START="0.47284763835657917" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.610861853564231" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="71" I2="66.39299358072476" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10283521302866216" LOG_CI_START="-0.3252787757114776" LOG_EFFECT_SIZE="-0.2140569943700699" METHOD="MH" NO="1" P_CHI2="0.03028138278277992" P_Q="0.0" P_Z="1.6185415565212057E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="98" WEIGHT="100.0" Z="3.7721388251856243">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6792016448479565" CI_START="0.6390075477865573" EFFECT_SIZE="1.035868005738881" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.22510285098408747" LOG_CI_START="-0.19449401204082806" LOG_EFFECT_SIZE="0.015304419471629702" ORDER="1" O_E="0.0" SE="0.2464732743788054" STUDY_ID="STD-Gilson-1993" TOTAL_1="41" TOTAL_2="38" VAR="0.06074907498300988" WEIGHT="24.788663037233608"/>
<DICH_DATA CI_END="0.6473062288383313" CI_START="0.08227085650850907" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.18889021387330937" LOG_CI_START="-1.0847539813010392" LOG_EFFECT_SIZE="-0.6368220975871743" ORDER="2" O_E="0.0" SE="0.5262348115842176" STUDY_ID="STD-Gr_x00fc_nberger-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.27692307692307694" WEIGHT="18.26252291193609"/>
<DICH_DATA CI_END="0.8778763218228536" CI_START="0.4220530703073121" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.05656666465574887" LOG_CI_START="-0.3746329360229608" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="3" O_E="0.0" SE="0.18683370225453605" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.03490683229813663" WEIGHT="32.31061745957924"/>
<DICH_DATA CI_END="0.8085477076710451" CI_START="0.2706961649600281" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09229434982435981" LOG_CI_START="-0.5675178969760607" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="4" O_E="0.0" SE="0.2791486639914064" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.07792397660818713" WEIGHT="24.638196591251063"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0550499432743554" CI_END="2.053477303501448" CI_START="0.717512103820584" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2138347581871034" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3124899070832419" LOG_CI_START="-0.14417076835264334" LOG_EFFECT_SIZE="0.0841595693652993" METHOD="MH" NO="2" P_CHI2="0.9620723634761463" P_Q="0.0" P_Z="0.4700381238079827" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1169" TOTAL_2="1127" WEIGHT="100.0" Z="0.7224170320903661">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5790929814244183" CI_START="0.08852876242539406" EFFECT_SIZE="0.47783251231527096" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41146699959882244" LOG_CI_START="-1.0529156068927585" LOG_EFFECT_SIZE="-0.320724303646968" ORDER="5" O_E="0.0" SE="0.860185591863964" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.7399192524503581" WEIGHT="16.821346456958107"/>
<DICH_DATA CI_END="61.047417644575326" CI_START="0.1128733248000426" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7856672976595884" LOG_CI_START="-0.9474086821756369" LOG_EFFECT_SIZE="0.41912930774197565" ORDER="6" O_E="0.0" SE="1.6054223594995034" STUDY_ID="STD-Buttino-1990" TOTAL_1="23" TOTAL_2="20" VAR="2.5773809523809526" WEIGHT="2.193127928871057"/>
<DICH_DATA CI_END="5.8145010647209014" CI_START="0.05136725509428902" EFFECT_SIZE="0.5465116279069767" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7645124543808894" LOG_CI_START="-1.2893136409965902" LOG_EFFECT_SIZE="-0.2624005933078503" ORDER="7" O_E="0.0" SE="1.2064276150278685" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="1.4554675903018308" WEIGHT="7.858708411787955"/>
<DICH_DATA CI_END="73.15840614780981" CI_START="0.131085556818331" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864264235230413" LOG_CI_START="-0.8824451568198217" LOG_EFFECT_SIZE="0.49090953920529573" ORDER="8" O_E="0.0" SE="1.613430693321079" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="2.6031586021505375" WEIGHT="2.0234216010417487"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.547458733910922" CI_START="0.06124217077393126" EFFECT_SIZE="0.9757869249394673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1916594127820033" LOG_CI_START="-1.2129494238125864" LOG_EFFECT_SIZE="-0.010645005515291586" ORDER="10" O_E="0.0" SE="1.4124791336213725" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="1.995097302915783" WEIGHT="4.162508431175306"/>
<DICH_DATA CI_END="80.90695094581207" CI_START="0.14078672928397634" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9079858346868268" LOG_CI_START="-0.8514382803527396" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="11" O_E="0.0" SE="1.6208993845439064" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="2.6273148148148144" WEIGHT="1.9351128784156386"/>
<DICH_DATA CI_END="4.755728837117656" CI_START="0.22245994671022398" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6772170839826519" LOG_CI_START="-0.6527481711486287" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="12" O_E="0.0" SE="0.7812281742983034" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="0.6103174603174603" WEIGHT="12.162593267506743"/>
<DICH_DATA CI_END="15.439679023172555" CI_START="0.06476818582168423" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1886382675078813" LOG_CI_START="-1.188638267507881" LOG_EFFECT_SIZE="0.0" ORDER="13" O_E="0.0" SE="1.3964240043768943" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="1.9500000000000002" WEIGHT="4.112114866633232"/>
<DICH_DATA CI_END="68.49925482736059" CI_START="0.12304834708771084" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.835685847023438" LOG_CI_START="-0.9099242158133338" LOG_EFFECT_SIZE="0.46288081560505223" ORDER="14" O_E="0.0" SE="1.6127849418993234" STUDY_ID="STD-Trofatter-1985" TOTAL_1="30" TOTAL_2="29" VAR="2.6010752688172043" WEIGHT="2.0897632928791836"/>
<DICH_DATA CI_END="2.8873555274666884" CI_START="0.6469359394977696" EFFECT_SIZE="1.3667238421955403" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.4605002629629864" LOG_CI_START="-0.1891387216497299" LOG_EFFECT_SIZE="0.13568077065662823" ORDER="15" O_E="0.0" SE="0.3816011553263465" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.14561944174640243" WEIGHT="46.64130286473102"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.643453968626375" CI_END="1.0042128856431995" CI_START="0.7713138180800057" CI_STUDY="95" CI_TOTAL="95" DF="25.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8800927649916208" ESTIMABLE="YES" EVENTS_1="344" EVENTS_2="360" I2="15.6643486064102" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0018257897607273886" LOG_CI_START="-0.11276888818610699" LOG_EFFECT_SIZE="-0.055471549212689805" METHOD="MH" NO="3" P_CHI2="0.23791728748657848" P_Q="0.0" P_Z="0.05776074090201182" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1941" TOTAL_2="1793" WEIGHT="100.0" Z="1.897509388244964">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1094877942752686" CI_START="0.610995759250993" EFFECT_SIZE="0.823342175066313" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="65" LOG_CI_END="0.045122528823046085" LOG_CI_START="-0.2139618040623301" LOG_EFFECT_SIZE="-0.08441963761964202" ORDER="17" O_E="0.0" SE="0.15218741962500143" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.023161010692116273" WEIGHT="17.93363231127825"/>
<DICH_DATA CI_END="1.652897299704868" CI_START="0.23340082013830332" EFFECT_SIZE="0.6211180124223602" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.21824587017333408" LOG_CI_START="-0.6318976222370336" LOG_EFFECT_SIZE="-0.20682587603184974" ORDER="18" O_E="0.0" SE="0.49937849572000764" STUDY_ID="STD-Buttino-1990" TOTAL_1="23" TOTAL_2="20" VAR="0.24937888198757768" WEIGHT="2.020257808084408"/>
<DICH_DATA CI_END="2.037241117325494" CI_START="0.7901810122997563" EFFECT_SIZE="1.2687747035573123" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.3090424328916178" LOG_CI_START="-0.1022734104335095" LOG_EFFECT_SIZE="0.10338451122905416" ORDER="19" O_E="0.0" SE="0.24160896241544122" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="0.05837489071946608" WEIGHT="6.2908620357072085"/>
<DICH_DATA CI_END="0.8796179197370865" CI_START="0.1960789338303065" EFFECT_SIZE="0.41530054644808745" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.0557059316945344" LOG_CI_START="-0.7075690632047418" LOG_EFFECT_SIZE="-0.3816374974496381" ORDER="20" O_E="0.0" SE="0.38290763022363755" STUDY_ID="STD-Darroca-1996" TOTAL_1="61" TOTAL_2="57" VAR="0.14661825328348194" WEIGHT="5.020762825081442"/>
<DICH_DATA CI_END="5.656596099825026" CI_START="1.0798956072970651" EFFECT_SIZE="2.4715447154471546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.752555169746318" LOG_CI_START="0.03338177459239377" LOG_EFFECT_SIZE="0.3929684721693558" ORDER="21" O_E="0.0" SE="0.4224460122791354" STUDY_ID="STD-Gilson-1993" TOTAL_1="41" TOTAL_2="38" VAR="0.17846063329054343" WEIGHT="1.6801861069201092"/>
<DICH_DATA CI_END="1.9074420741216958" CI_START="0.1310655790766886" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2804513580181161" LOG_CI_START="-0.8825113493460784" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="22" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="0.4666666666666667" WEIGHT="1.6187158834962025"/>
<DICH_DATA CI_END="6.786269078583867" CI_START="0.14735637335038831" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.831631075619647" LOG_CI_START="-0.8316310756196469" LOG_EFFECT_SIZE="0.0" ORDER="23" O_E="0.0" SE="0.9770084209183945" STUDY_ID="STD-Hidar-2000" TOTAL_1="44" TOTAL_2="44" VAR="0.9545454545454546" WEIGHT="0.5395719611654008"/>
<DICH_DATA CI_END="1.7624413690069978" CI_START="0.48598192784055994" EFFECT_SIZE="0.9254807692307693" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.24611467826470476" LOG_CI_START="-0.3133798805011888" LOG_EFFECT_SIZE="-0.033632601118242046" ORDER="24" O_E="0.0" SE="0.3286498733618184" STUDY_ID="STD-Hutchon-1980" TOTAL_1="32" TOTAL_2="35" VAR="0.10801073926073927" WEIGHT="3.3501781469374143"/>
<DICH_DATA CI_END="1.4036355513649912" CI_START="0.19590920708202725" EFFECT_SIZE="0.524390243902439" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.14725435951922244" LOG_CI_START="-0.7079451531274827" LOG_EFFECT_SIZE="-0.2803453968041301" ORDER="25" O_E="0.0" SE="0.5023484270345361" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.25235394214407264" WEIGHT="2.6336250485454094"/>
<DICH_DATA CI_END="29.09617312841034" CI_START="0.5499004947965868" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.463835872198758" LOG_CI_START="-0.25971588954283337" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="26" O_E="0.0" SE="1.0124228365658292" STUDY_ID="STD-Laube-1986" TOTAL_1="30" TOTAL_2="15" VAR="1.025" WEIGHT="0.3597146407769339"/>
<DICH_DATA CI_END="2.171926286915611" CI_START="0.30941135653770097" EFFECT_SIZE="0.8197674418604651" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.33684508163088095" LOG_CI_START="-0.5094637501352189" LOG_EFFECT_SIZE="-0.08630933425216901" ORDER="27" O_E="0.0" SE="0.49712599707568844" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="0.24713425696849742" WEIGHT="2.062363940454421"/>
<DICH_DATA CI_END="5.644885970160622" CI_START="0.3362816565246326" EFFECT_SIZE="1.3777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.751655173359268" LOG_CI_START="-0.4732968219134475" LOG_EFFECT_SIZE="0.1391791757229102" ORDER="28" O_E="0.0" SE="0.7195428656333623" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="0.5177419354838709" WEIGHT="0.7960897787686243"/>
<DICH_DATA CI_END="1.4245407152639462" CI_START="0.22322579502098866" EFFECT_SIZE="0.5639097744360902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.15367486646546774" LOG_CI_START="-0.6512556216162392" LOG_EFFECT_SIZE="-0.24879037757538572" ORDER="30" O_E="0.0" SE="0.47282015316937137" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.2235588972431078" WEIGHT="2.1106785539705384"/>
<DICH_DATA CI_END="2.1522476012402794" CI_START="0.7550597229360039" EFFECT_SIZE="1.2747844827586208" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" LOG_CI_END="0.33289223245286903" LOG_CI_START="-0.12201869563473237" LOG_EFFECT_SIZE="0.10543676840906833" ORDER="29" O_E="0.0" SE="0.2672169310040684" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.07140488821523304" WEIGHT="5.668559773148965"/>
<DICH_DATA CI_END="81.01190363542146" CI_START="0.2663500355480702" EFFECT_SIZE="4.645161290322581" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9085488374385386" LOG_CI_START="-0.5745472409165846" LOG_EFFECT_SIZE="0.667000798260977" ORDER="31" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.1274641577060933" WEIGHT="0.17794394463965346"/>
<DICH_DATA CI_END="1.0403889276813372" CI_START="0.5822443738127394" EFFECT_SIZE="0.778306237749337" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="84" LOG_CI_END="0.017195721577963327" LOG_CI_START="-0.23489469933065688" LOG_EFFECT_SIZE="-0.10884948887634678" ORDER="32" O_E="0.0" SE="0.14807916110943237" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.021927437954873223" WEIGHT="22.93974323131138"/>
<DICH_DATA CI_END="0.952123221685224" CI_START="0.12865981756350753" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.0213068425452209" LOG_CI_START="-0.890557068754228" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="33" O_E="0.0" SE="0.5106018857331861" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="0.2607142857142857" WEIGHT="2.877717126215471"/>
<DICH_DATA CI_END="1.6990345829103743" CI_START="0.49408371963049585" EFFECT_SIZE="0.9162234042553191" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.23020221878328295" LOG_CI_START="-0.3061994561513159" LOG_EFFECT_SIZE="-0.037998618684016446" ORDER="34" O_E="0.0" SE="0.31508499908769727" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="0.09927855665009419" WEIGHT="4.057581147963814"/>
<DICH_DATA CI_END="2.285112885394374" CI_START="0.4629789584731531" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3589076592386504" LOG_CI_START="-0.3344387464046273" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="35" O_E="0.0" SE="0.4072751107949218" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="0.16587301587301584" WEIGHT="2.393875602353539"/>
<DICH_DATA CI_END="4.368712583785111" CI_START="0.5448763491790272" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6403534735532197" LOG_CI_START="-0.263702042607834" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="36" O_E="0.0" SE="0.5310466853399822" STUDY_ID="STD-Richardson-1991" TOTAL_1="21" TOTAL_2="27" VAR="0.28201058201058204" WEIGHT="1.1803136650493145"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="37" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="0.1348929902913502"/>
<DICH_DATA CI_END="1.9200796047704887" CI_START="0.38452909597517687" EFFECT_SIZE="0.8592592592592593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2833192345347404" LOG_CI_START="-0.41507079307091566" LOG_EFFECT_SIZE="-0.06587577926808763" ORDER="38" O_E="0.0" SE="0.4102377593019542" STUDY_ID="STD-Trofatter-1985" TOTAL_1="30" TOTAL_2="29" VAR="0.1682950191570881" WEIGHT="2.4692276188925124"/>
<DICH_DATA CI_END="1.5731201962247119" CI_START="0.561235378298487" EFFECT_SIZE="0.939622641509434" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.19676190670647986" LOG_CI_START="-0.25085496038862287" LOG_EFFECT_SIZE="-0.027046526841071502" ORDER="39" O_E="0.0" SE="0.26293236347089044" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.06913342776038844" WEIGHT="7.232783681769673"/>
<DICH_DATA CI_END="2.051870718624773" CI_START="0.22808412707665382" EFFECT_SIZE="0.6841046277665996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.31214999388781633" LOG_CI_START="-0.6419049372699703" LOG_EFFECT_SIZE="-0.16487747169107697" ORDER="40" O_E="0.0" SE="0.560416589210159" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.3140667534619482" WEIGHT="1.9292608971165772"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="41" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="42" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="1.5772103480219408"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="43" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.9442509320394514"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.243833651184607" CI_END="2.9641039060952394" CI_START="0.18974913005095934" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7499574238329948" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.4718934236840957" LOG_CI_START="-0.7218202065520287" LOG_EFFECT_SIZE="-0.1249633914339665" METHOD="MH" NO="4" P_CHI2="0.5369145995305045" P_Q="0.0" P_Z="0.6815448542909031" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="649" TOTAL_2="544" WEIGHT="99.99999999999999" Z="0.4103559520353436">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.77100889559638" CI_START="0.07133077502654675" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2245591892972547" LOG_CI_START="-1.1467230572365155" LOG_EFFECT_SIZE="0.03891806603036966" ORDER="44" O_E="0.0" SE="1.3929029296503657" STUDY_ID="STD-Hutchon-1980" TOTAL_1="32" TOTAL_2="35" VAR="1.9401785714285715" WEIGHT="19.90467013277078"/>
<DICH_DATA CI_END="14.869904372908374" CI_START="0.16554597343459843" EFFECT_SIZE="1.5689655172413792" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1723081756200207" LOG_CI_START="-0.781081378103708" LOG_EFFECT_SIZE="0.19561339875815628" ORDER="45" O_E="0.0" SE="1.147430693291556" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="1.3165971959075407" WEIGHT="27.364226934886997"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="46" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.05268174261779" CI_START="0.009398954331199527" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077424999045629" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" ORDER="47" O_E="0.0" SE="1.5476140647907184" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.3951092935380496" WEIGHT="52.73110293234221"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.961425538310726" CI_START="0.013290113837882468" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3252818035426731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.9009908375858846" LOG_CI_START="-1.876471299045797" LOG_EFFECT_SIZE="-0.4877402307299564" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.49122322433986876" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="494" WEIGHT="100.0" Z="0.6883645853774167">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="48" O_E="0.0" SE="0.0" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.961425538310726" CI_START="0.013290113837882468" EFFECT_SIZE="0.3252818035426731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009908375858846" LOG_CI_START="-1.876471299045797" LOG_EFFECT_SIZE="-0.4877402307299564" ORDER="49" O_E="0.0" SE="1.6314950077167616" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.661775960204716" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Cervix unfavourable/unchanged after 12-24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1178050550323508" CI_START="0.3984867066985564" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6674057649667405" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.048366069287483104" LOG_CI_START="-0.39958616185571755" LOG_EFFECT_SIZE="-0.1756100462841172" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.12436102748317357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.5367235259076175">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1178050550323508" CI_START="0.39848670669855646" EFFECT_SIZE="0.6674057649667405" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.048366069287483104" LOG_CI_START="-0.3995861618557175" LOG_EFFECT_SIZE="-0.1756100462841172" ORDER="51" O_E="0.0" SE="0.26312935797282194" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.06923705902718948" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.902856337830725" CI_END="2.333920812789424" CI_START="1.0893650160844541" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5945192641558752" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.36808611685416726" LOG_CI_START="0.0371734242091586" LOG_EFFECT_SIZE="0.20262977053166295" METHOD="MH" NO="8" P_CHI2="0.4462895035574844" P_Q="0.0" P_Z="0.01638104909522963" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1344" TOTAL_2="1187" WEIGHT="100.00000000000003" Z="2.4003132020307256">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.566952764380952" CI_START="0.24707625775171935" EFFECT_SIZE="0.7963875205254516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.40941787710251243" LOG_CI_START="-0.6071689851637357" LOG_EFFECT_SIZE="-0.09887555403061167" ORDER="52" O_E="0.0" SE="0.5971481550813205" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.35658591911702475" WEIGHT="14.855917281335202"/>
<DICH_DATA CI_END="15.353612511371136" CI_START="0.06162708264303716" EFFECT_SIZE="0.9727272727272728" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1862105758502974" LOG_CI_START="-1.210228390796328" LOG_EFFECT_SIZE="-0.01200890747301538" ORDER="53" O_E="0.0" SE="1.4076801115724296" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="1.9815632965165677" WEIGHT="2.4545712457375477"/>
<DICH_DATA CI_END="35.88938623485869" CI_START="0.0668025523135909" EFFECT_SIZE="1.5483870967741935" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5549660312757505" LOG_CI_START="-1.1752069441931212" LOG_EFFECT_SIZE="0.18987954354131453" ORDER="54" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Laube-1986" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="1.5968956257327351"/>
<DICH_DATA CI_END="77.5279602100532" CI_START="0.20637715679156027" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8894583576677944" LOG_CI_START="-0.6853383750118697" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="56" O_E="0.0" SE="1.5124483462254175" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="2.2875" WEIGHT="1.3450554553662823"/>
<DICH_DATA CI_END="2.8453436427798486" CI_START="0.024031980973341326" EFFECT_SIZE="0.2614942528735632" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4541347252655028" LOG_CI_START="-1.6192104285164775" LOG_EFFECT_SIZE="-0.5825378516254873" ORDER="55" O_E="0.0" SE="1.2178932065555697" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="1.4832638625742074" WEIGHT="6.358813111256145"/>
<DICH_DATA CI_END="81.01190363542146" CI_START="0.2663500355480702" EFFECT_SIZE="4.645161290322581" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9085488374385386" LOG_CI_START="-0.5745472409165846" LOG_EFFECT_SIZE="0.667000798260977" ORDER="57" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.1274641577060933" WEIGHT="1.5968956257327351"/>
<DICH_DATA CI_END="5.395712591876742" CI_START="1.4015196715582885" EFFECT_SIZE="2.7499449702839533" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="11" LOG_CI_END="0.7320488084783225" LOG_CI_START="0.1465991978431896" LOG_EFFECT_SIZE="0.43932400316075604" ORDER="58" O_E="0.0" SE="0.34389599930938847" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.11826445834100291" WEIGHT="26.958471766451563"/>
<DICH_DATA CI_END="2.3085716743005325" CI_START="0.6588130721204618" EFFECT_SIZE="1.233254716981132" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.36334336265150835" LOG_CI_START="-0.18123779217766248" LOG_EFFECT_SIZE="0.09105278523692298" ORDER="59" O_E="0.0" SE="0.3198896660668474" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.10232939845635913" WEIGHT="39.943436713445394"/>
<DICH_DATA CI_END="7.70876581994063" CI_START="0.013237495530407182" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8869848526950544" LOG_CI_START="-1.8781941735224057" LOG_EFFECT_SIZE="-0.49560466041367557" ORDER="60" O_E="0.0" SE="1.6242798478570708" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="2.638285024154589" WEIGHT="3.7089188726695785"/>
<DICH_DATA CI_END="72.88490151495549" CI_START="0.13613930723311707" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8626375712827092" LOG_CI_START="-0.8660164637035079" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="61" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="1.1810243022728333"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.000424043213091" CI_END="1.501581376715621" CI_START="0.6996818978557856" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0250021011906703" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.17654887333212582" LOG_CI_START="-0.1550993619933051" LOG_EFFECT_SIZE="0.01072475566941037" METHOD="MH" NO="11" P_CHI2="0.6766192357673844" P_Q="0.0" P_Z="0.8991290683683367" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="277" WEIGHT="99.99999999999999" Z="0.12676162642270664">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2766354889097595" CI_START="0.30519110330845245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5154281307445581" LOG_CI_START="-0.5154281307445581" LOG_EFFECT_SIZE="0.0" ORDER="63" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="0.3666666666666667" WEIGHT="12.475103248925041"/>
<DICH_DATA CI_END="2.236925874185413" CI_START="0.7250356747124597" EFFECT_SIZE="1.2735191637630663" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.3496515929631376" LOG_CI_START="-0.13964062384336362" LOG_EFFECT_SIZE="0.10500548455988695" ORDER="64" O_E="0.0" SE="0.2874126701876741" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.08260604298440873" WEIGHT="34.098615547061776"/>
<DICH_DATA CI_END="8.205804789926459" CI_START="0.5823681495405606" EFFECT_SIZE="2.186046511627907" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9141211812067952" LOG_CI_START="-0.23480238516657093" LOG_EFFECT_SIZE="0.33965939802011214" ORDER="65" O_E="0.0" SE="0.6748833901510918" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="0.4554675903018308" WEIGHT="7.1523925293836905"/>
<DICH_DATA CI_END="1.832591692081128" CI_START="0.2868205734377687" EFFECT_SIZE="0.725" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2630657133915494" LOG_CI_START="-0.5423897002495621" LOG_EFFECT_SIZE="-0.13966199342900631" ORDER="66" O_E="0.0" SE="0.473128497041389" STUDY_ID="STD-Trofatter-1985" TOTAL_1="30" TOTAL_2="29" VAR="0.22385057471264364" WEIGHT="20.298473082996676"/>
<DICH_DATA CI_END="4.5822738168103605" CI_START="0.20017972615014737" EFFECT_SIZE="0.9577464788732394" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6610810371835261" LOG_CI_START="-0.698579909209204" LOG_EFFECT_SIZE="-0.01874943601283899" ORDER="67" O_E="0.0" SE="0.7986715703413212" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.637876277271472" WEIGHT="7.646610048981392"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="68" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="14.586274567973893"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="69" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="3.7425309746775124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.565893899459641" CI_END="1.806169059693282" CI_START="0.8011838191464073" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2029436500805593" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="29" I2="22.054454378601324" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.25675839838923453" LOG_CI_START="-0.0962678303799456" LOG_EFFECT_SIZE="0.08024528400464447" METHOD="MH" NO="12" P_CHI2="0.2772192650244697" P_Q="0.0" P_Z="0.37291495116976336" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="169" WEIGHT="99.99999999999999" Z="0.8910265230242967">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.216455316511646" CI_START="0.8392227365489677" EFFECT_SIZE="2.4609375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8583239268634621" LOG_CI_START="-0.07612275857999781" LOG_EFFECT_SIZE="0.39110058414173215" ORDER="70" O_E="0.0" SE="0.5488986086151818" STUDY_ID="STD-Hutchon-1980" TOTAL_1="32" TOTAL_2="35" VAR="0.3012896825396825" WEIGHT="11.033808464628173"/>
<DICH_DATA CI_END="2.2997112369608055" CI_START="0.21257557981330055" EFFECT_SIZE="0.6991869918699187" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3616733072925474" LOG_CI_START="-0.6724866276842076" LOG_EFFECT_SIZE="-0.1554066601958302" ORDER="71" O_E="0.0" SE="0.607470664979585" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.3690206088107392" WEIGHT="16.91399098902544"/>
<DICH_DATA CI_END="1.8260772080978263" CI_START="0.6974702111432558" EFFECT_SIZE="1.1285541439806412" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="19" LOG_CI_END="0.2615191359266336" LOG_CI_START="-0.15647433631583285" LOG_EFFECT_SIZE="0.05252239980540041" ORDER="72" O_E="0.0" SE="0.2455314346962825" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.06028568542401484" WEIGHT="72.05220054634638"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.017333939375384" CI_END="1.3437957205775921" CI_START="0.6161964902919714" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9099682448796128" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.12833325371122709" LOG_CI_START="-0.21028077964967012" LOG_EFFECT_SIZE="-0.040973762969221526" METHOD="MH" NO="13" P_CHI2="0.5347638177631591" P_Q="0.0" P_Z="0.635265856035207" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1333" TOTAL_2="1220" WEIGHT="100.00000000000001" Z="0.4743282428886417">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.616977911783003" CI_START="0.3083532583170012" EFFECT_SIZE="2.918181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4411761525900024" LOG_CI_START="-0.5109514580967084" LOG_EFFECT_SIZE="0.465112347246647" ORDER="73" O_E="0.0" SE="1.1466894217048926" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="1.314896629849901" WEIGHT="2.154171028796588"/>
<DICH_DATA CI_END="1.6039497392059792" CI_START="0.4784558167962253" EFFECT_SIZE="0.8760245901639344" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.20519075526516917" LOG_CI_START="-0.3201581611422075" LOG_EFFECT_SIZE="-0.05748370293851918" ORDER="74" O_E="0.0" SE="0.3085925540167699" STUDY_ID="STD-Darroca-1996" TOTAL_1="61" TOTAL_2="57" VAR="0.09522936439459302" WEIGHT="35.14916722117773"/>
<DICH_DATA CI_END="8.695084862642968" CI_START="0.01520760372642119" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392738250043677" LOG_CI_START="-1.817939212664893" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="75" O_E="0.0" SE="1.6196005867515793" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="2.62310606060606" WEIGHT="3.04862030379691"/>
<DICH_DATA CI_END="4.129808085649786" CI_START="0.010320641440566405" EFFECT_SIZE="0.2064516129032258" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6159298702327053" LOG_CI_START="-1.9862933099334763" LOG_EFFECT_SIZE="-0.6851817198503856" ORDER="76" O_E="0.0" SE="1.5285587772421023" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="2.336491935483871" WEIGHT="5.227672622912932"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="77" O_E="0.0" SE="0.0" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.247657783070237" CI_START="0.4350059459135274" EFFECT_SIZE="1.3593220338983052" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6281495201000067" LOG_CI_START="-0.3615048068159679" LOG_EFFECT_SIZE="0.13332235664201936" ORDER="78" O_E="0.0" SE="0.5813278504983695" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="401" VAR="0.33794206976505464" WEIGHT="10.780598714081918"/>
<DICH_DATA CI_END="4.487245911235435" CI_START="0.042655618565665326" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.651979870506141" LOG_CI_START="-1.3700237557894768" LOG_EFFECT_SIZE="-0.359021942641668" ORDER="79" O_E="0.0" SE="1.1877349391654206" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="1.4107142857142856" WEIGHT="4.5328980678677295"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.577129902321556" CI_START="0.0970071395216797" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41113631006800627" LOG_CI_START="-1.0131963013959686" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="81" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="0.7" WEIGHT="8.499183877251992"/>
<DICH_DATA CI_END="3.304048628219007" CI_START="0.6417413785449313" EFFECT_SIZE="1.456140350877193" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5190464305405258" LOG_CI_START="-0.1926399571333608" LOG_EFFECT_SIZE="0.16320323670358253" ORDER="82" O_E="0.0" SE="0.41804810702407663" STUDY_ID="STD-Trofatter-1993" TOTAL_1="266" TOTAL_2="249" VAR="0.17476421978641382" WEIGHT="19.75441378848667"/>
<DICH_DATA CI_END="1.5976131360447412" CI_START="0.022966218719633766" EFFECT_SIZE="0.19154929577464788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20347162277419556" LOG_CI_START="-1.6389105034719111" LOG_EFFECT_SIZE="-0.7177194403488578" ORDER="83" O_E="0.0" SE="1.0822243808955725" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="1.1712096106048053" WEIGHT="10.853274375627544"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="84" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="85" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="86" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4154581180872698" CI_END="1.0659960642895612" CI_START="0.09595421833578396" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31982310594753305" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.027755601256706102" LOG_CI_START="-1.0179359280709375" LOG_EFFECT_SIZE="-0.49509016340711576" METHOD="MH" NO="14" P_CHI2="0.7019155327156306" P_Q="0.0" P_Z="0.06346524050371768" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="125" WEIGHT="99.99999999999999" Z="1.855918044974346">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.21959785535643" CI_START="0.06781552301168733" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2100400822200992" LOG_CI_START="-1.168670884500397" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="87" O_E="0.0" SE="1.3972665966608064" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="1.9523539421440725" WEIGHT="9.71485917490237"/>
<DICH_DATA CI_END="5.403402016095713" CI_START="0.049403032320983614" EFFECT_SIZE="0.5166666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7326672804906897" LOG_CI_START="-1.3062463935894315" LOG_EFFECT_SIZE="-0.28678955654937094" ORDER="88" O_E="0.0" SE="1.1976679849401242" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="1.4344086021505376" WEIGHT="19.577325166536564"/>
<DICH_DATA CI_END="2.541530096324976" CI_START="0.024591485298708176" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.40509525690335824" LOG_CI_START="-1.609215239559283" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="89" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="1.4" WEIGHT="26.53815189241623"/>
<DICH_DATA CI_END="2.0455425257222895" CI_START="0.006375362961899061" EFFECT_SIZE="0.11419753086419752" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3108085126755321" LOG_CI_START="-2.1954950849547665" LOG_EFFECT_SIZE="-0.9423432861396172" ORDER="90" O_E="0.0" SE="1.4722151396509335" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="2.1674174174174174" WEIGHT="44.16966376614483"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.052681742617788" CI_START="0.009398954331199527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.6077424999045626" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.29108380340280504" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="494" WEIGHT="100.0" Z="1.055747066061469">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="91" O_E="0.0" SE="0.0" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.05268174261779" CI_START="0.009398954331199527" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077424999045629" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" ORDER="92" O_E="0.0" SE="1.5476140647907184" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.3951092935380496" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.920829990112196" CI_END="1.4664399354164899" CI_START="0.9454230021852026" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1774574498748278" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.16626427921469752" LOG_CI_START="-0.024373835499807876" LOG_EFFECT_SIZE="0.07094522185744485" METHOD="MH" NO="18" P_CHI2="0.7888498653745731" P_Q="0.0" P_Z="0.14462409415748406" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="739" TOTAL_2="686" WEIGHT="100.00000000000001" Z="1.4587857199913403">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.16551325742054" CI_START="0.23627803006982864" EFFECT_SIZE="4.864864864864865" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.000718220732357" LOG_CI_START="-0.6265766586597351" LOG_EFFECT_SIZE="0.687070781036311" ORDER="93" O_E="0.0" SE="1.543286017474315" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="2.381731731731732" WEIGHT="0.5084003079125087"/>
<DICH_DATA CI_END="35.88938623485869" CI_START="0.0668025523135909" EFFECT_SIZE="1.5483870967741935" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5549660312757505" LOG_CI_START="-1.1752069441931212" LOG_EFFECT_SIZE="0.18987954354131453" ORDER="94" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Laube-1986" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="0.6615928101242133"/>
<DICH_DATA CI_END="4.485869000911839" CI_START="0.010632174841293059" EFFECT_SIZE="0.21839080459770116" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6518465868992417" LOG_CI_START="-1.9733778902308208" LOG_EFFECT_SIZE="-0.6607656516657895" ORDER="95" O_E="0.0" SE="1.5420698529369423" STUDY_ID="STD-Lien-1998" TOTAL_1="86" TOTAL_2="94" VAR="2.377979431336963" WEIGHT="2.3974237864214007"/>
<DICH_DATA CI_END="3.987709581650965" CI_START="0.007422505812621207" EFFECT_SIZE="0.17204301075268819" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6007235218364254" LOG_CI_START="-2.1294494536324464" LOG_EFFECT_SIZE="-0.7643629658980103" ORDER="96" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="1.9847784303726403"/>
<DICH_DATA CI_END="63.43384490572215" CI_START="0.10905251884056036" EFFECT_SIZE="2.6301369863013697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.802321036018798" LOG_CI_START="-0.9623642988526109" LOG_EFFECT_SIZE="0.4199783685830937" ORDER="97" O_E="0.0" SE="1.6239898511165887" STUDY_ID="STD-Nuutila-1995" TOTAL_1="72" TOTAL_2="63" VAR="2.63734303652968" WEIGHT="0.5344772619581296"/>
<DICH_DATA CI_END="2.838485111047003" CI_START="0.35230059728273166" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45308662052476206" LOG_CI_START="-0.453086620524762" LOG_EFFECT_SIZE="0.0" ORDER="98" O_E="0.0" SE="0.532290647422377" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="0.28333333333333327" WEIGHT="6.018360401775103"/>
<DICH_DATA CI_END="1.5093313014113512" CI_START="0.9540648886387496" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="83" LOG_CI_END="0.1787845787963972" LOG_CI_START="-0.02042208670114762" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="99" O_E="0.0" SE="0.11701498140215548" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.013692505872546794" WEIGHT="85.84554931066369"/>
<DICH_DATA CI_END="8.333707722971917" CI_START="0.24765401951254082" EFFECT_SIZE="1.4366197183098592" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9208382649565896" LOG_CI_START="-0.606154618870905" LOG_EFFECT_SIZE="0.1573418230428423" ORDER="100" O_E="0.0" SE="0.8969631786969511" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.8045429439381386" WEIGHT="2.049417690772337"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="101" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.472680254365788" CI_START="0.1862832190772611" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="1.3318862571530972" LOG_CI_START="-0.7298262658251347" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.5670866141370015" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="96" WEIGHT="100.0" Z="0.572347447271999">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="103" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="104" O_E="0.0" SE="0.0" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="105" O_E="0.0" SE="0.0" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.019819690887750076" CI_END="4.625192446375698" CI_START="1.1130879383412986" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2689746416758547" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.6651298077042895" LOG_CI_START="0.0465294766686784" LOG_EFFECT_SIZE="0.355829642186484" METHOD="MH" NO="20" P_CHI2="0.9901390956747478" P_Q="0.0" P_Z="0.024145221372551807" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="516" TOTAL_2="499" WEIGHT="100.0" Z="2.254810572602602">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="106" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="9.396545387725102"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="107" O_E="0.0" SE="0.0" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.911116206652446" CI_START="1.055561031976571" EFFECT_SIZE="2.2768361581920904" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.6911802105133649" LOG_CI_START="0.02348334904524084" LOG_EFFECT_SIZE="0.3573317797793028" ORDER="108" O_E="0.0" SE="0.39220844157914514" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.1538274616459417" WEIGHT="85.60529217199559"/>
<DICH_DATA CI_END="61.53995727256356" CI_START="0.11325324730290753" EFFECT_SIZE="2.64" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.789157190379163" LOG_CI_START="-0.9459493366395004" LOG_EFFECT_SIZE="0.4216039268698311" ORDER="109" O_E="0.0" SE="1.6066151129664257" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="2.581212121212121" WEIGHT="4.998162440279309"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2720393947955837" CI_END="5.650592323335287" CI_START="0.22557128039913094" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1289868667917449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="55.986678651319316" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.7520939751243607" LOG_CI_START="-0.6467161952833702" LOG_EFFECT_SIZE="0.05268888992049534" METHOD="MH" NO="21" P_CHI2="0.13172657401798615" P_Q="0.0" P_Z="0.8826176777338725" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="143" WEIGHT="100.0" Z="0.14765166684406547">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.16551325742054" CI_START="0.23627803006982864" EFFECT_SIZE="4.864864864864865" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.000718220732357" LOG_CI_START="-0.6265766586597351" LOG_EFFECT_SIZE="0.687070781036311" ORDER="110" O_E="0.0" SE="1.543286017474315" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="2.381731731731732" WEIGHT="20.391651031894934"/>
<DICH_DATA CI_END="3.987709581650965" CI_START="0.007422505812621207" EFFECT_SIZE="0.17204301075268819" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6007235218364254" LOG_CI_START="-2.1294494536324464" LOG_EFFECT_SIZE="-0.7643629658980103" ORDER="111" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="79.60834896810506"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="112" O_E="0.0" SE="0.0" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.048512484827704955" CI_END="13.032111529504474" CI_START="0.818401534163671" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2658077207849407" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="1.1150147880316608" LOG_CI_START="-0.08703356517298307" LOG_EFFECT_SIZE="0.5139906114293389" METHOD="MH" NO="23" P_CHI2="0.9971991678314205" P_Q="0.0" P_Z="0.09370998373735942" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="269" WEIGHT="100.0" Z="1.6761440321556174">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.25145218614753" CI_START="0.4420009251415571" EFFECT_SIZE="3.890909090909091" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5346789893484658" LOG_CI_START="-0.35457682163857157" LOG_EFFECT_SIZE="0.590051083854947" ORDER="113" O_E="0.0" SE="1.1097582153408767" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="1.2315632965165677" WEIGHT="38.09482632827658"/>
<DICH_DATA CI_END="73.15840614780981" CI_START="0.131085556818331" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864264235230413" LOG_CI_START="-0.8824451568198217" LOG_EFFECT_SIZE="0.49090953920529573" ORDER="114" O_E="0.0" SE="1.613430693321079" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="2.6031586021505375" WEIGHT="18.489458637107976"/>
<DICH_DATA CI_END="54.17908446913287" CI_START="0.12752869161232291" EFFECT_SIZE="2.6285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7338316619492158" LOG_CI_START="-0.8943920959586567" LOG_EFFECT_SIZE="0.4197197829952796" ORDER="115" O_E="0.0" SE="1.5438316453125072" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="2.383416149068323" WEIGHT="24.62803932271541"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="116" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="18.78767571190004"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.902208524429669" CI_START="0.2243765246049395" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.6903917808212061" LOG_CI_START="-0.6490225831015041" LOG_EFFECT_SIZE="0.02068459885985105" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.9517291312501786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.0605355144635521">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.9022085244296685" CI_START="0.22437652460493956" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6903917808212061" LOG_CI_START="-0.649022583101504" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="117" O_E="0.0" SE="0.786778627576232" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.6190206088107392" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="403" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="8.926709991876443" CI_END="0.7891594963588041" CI_START="0.47284763835657917" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.610861853564231" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="71" I2="66.39299358072476" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.10283521302866216" LOG_CI_START="-0.3252787757114776" LOG_EFFECT_SIZE="-0.2140569943700699" METHOD="MH" NO="1" P_CHI2="0.03028138278277992" P_Q="0.0" P_Z="1.6185415565212057E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="98" WEIGHT="100.0" Z="3.7721388251856243">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6792016448479565" CI_START="0.6390075477865573" EFFECT_SIZE="1.035868005738881" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.22510285098408747" LOG_CI_START="-0.19449401204082806" LOG_EFFECT_SIZE="0.015304419471629702" ORDER="119" O_E="0.0" SE="0.2464732743788054" STUDY_ID="STD-Gilson-1993" TOTAL_1="41" TOTAL_2="38" VAR="0.06074907498300988" WEIGHT="24.788663037233608"/>
<DICH_DATA CI_END="0.6473062288383313" CI_START="0.08227085650850907" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.18889021387330937" LOG_CI_START="-1.0847539813010392" LOG_EFFECT_SIZE="-0.6368220975871743" ORDER="120" O_E="0.0" SE="0.5262348115842176" STUDY_ID="STD-Gr_x00fc_nberger-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.27692307692307694" WEIGHT="18.26252291193609"/>
<DICH_DATA CI_END="0.8778763218228536" CI_START="0.4220530703073121" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.05656666465574887" LOG_CI_START="-0.3746329360229608" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="121" O_E="0.0" SE="0.18683370225453605" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.03490683229813663" WEIGHT="32.31061745957924"/>
<DICH_DATA CI_END="0.8085477076710451" CI_START="0.2706961649600281" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09229434982435981" LOG_CI_START="-0.5675178969760607" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="122" O_E="0.0" SE="0.2791486639914064" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.07792397660818713" WEIGHT="24.638196591251063"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0550499432743554" CI_END="2.053477303501448" CI_START="0.717512103820584" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2138347581871034" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3124899070832419" LOG_CI_START="-0.14417076835264334" LOG_EFFECT_SIZE="0.0841595693652993" METHOD="MH" NO="2" P_CHI2="0.9620723634761463" P_Q="0.0" P_Z="0.4700381238079827" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1169" TOTAL_2="1127" WEIGHT="100.0" Z="0.7224170320903661">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5790929814244183" CI_START="0.08852876242539406" EFFECT_SIZE="0.47783251231527096" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41146699959882244" LOG_CI_START="-1.0529156068927585" LOG_EFFECT_SIZE="-0.320724303646968" ORDER="123" O_E="0.0" SE="0.860185591863964" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.7399192524503581" WEIGHT="16.821346456958107"/>
<DICH_DATA CI_END="61.047417644575326" CI_START="0.1128733248000426" EFFECT_SIZE="2.625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7856672976595884" LOG_CI_START="-0.9474086821756369" LOG_EFFECT_SIZE="0.41912930774197565" ORDER="124" O_E="0.0" SE="1.6054223594995034" STUDY_ID="STD-Buttino-1990" TOTAL_1="23" TOTAL_2="20" VAR="2.5773809523809526" WEIGHT="2.193127928871057"/>
<DICH_DATA CI_END="5.8145010647209014" CI_START="0.05136725509428902" EFFECT_SIZE="0.5465116279069767" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7645124543808894" LOG_CI_START="-1.2893136409965902" LOG_EFFECT_SIZE="-0.2624005933078503" ORDER="125" O_E="0.0" SE="1.2064276150278685" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="1.4554675903018308" WEIGHT="7.858708411787955"/>
<DICH_DATA CI_END="73.15840614780981" CI_START="0.131085556818331" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864264235230413" LOG_CI_START="-0.8824451568198217" LOG_EFFECT_SIZE="0.49090953920529573" ORDER="126" O_E="0.0" SE="1.613430693321079" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="2.6031586021505375" WEIGHT="2.0234216010417487"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="127" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.547458733910922" CI_START="0.06124217077393126" EFFECT_SIZE="0.9757869249394673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1916594127820033" LOG_CI_START="-1.2129494238125864" LOG_EFFECT_SIZE="-0.010645005515291586" ORDER="128" O_E="0.0" SE="1.4124791336213725" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="1.995097302915783" WEIGHT="4.162508431175306"/>
<DICH_DATA CI_END="80.90695094581207" CI_START="0.14078672928397634" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9079858346868268" LOG_CI_START="-0.8514382803527396" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="129" O_E="0.0" SE="1.6208993845439064" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="2.6273148148148144" WEIGHT="1.9351128784156386"/>
<DICH_DATA CI_END="4.755728837117656" CI_START="0.22245994671022398" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6772170839826519" LOG_CI_START="-0.6527481711486287" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="130" O_E="0.0" SE="0.7812281742983034" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="0.6103174603174603" WEIGHT="12.162593267506743"/>
<DICH_DATA CI_END="15.439679023172555" CI_START="0.06476818582168423" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1886382675078813" LOG_CI_START="-1.188638267507881" LOG_EFFECT_SIZE="0.0" ORDER="131" O_E="0.0" SE="1.3964240043768943" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="1.9500000000000002" WEIGHT="4.112114866633232"/>
<DICH_DATA CI_END="68.49925482736059" CI_START="0.12304834708771084" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.835685847023438" LOG_CI_START="-0.9099242158133338" LOG_EFFECT_SIZE="0.46288081560505223" ORDER="132" O_E="0.0" SE="1.6127849418993234" STUDY_ID="STD-Trofatter-1985" TOTAL_1="30" TOTAL_2="29" VAR="2.6010752688172043" WEIGHT="2.0897632928791836"/>
<DICH_DATA CI_END="2.8873555274666884" CI_START="0.6469359394977696" EFFECT_SIZE="1.3667238421955403" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.4605002629629864" LOG_CI_START="-0.1891387216497299" LOG_EFFECT_SIZE="0.13568077065662823" ORDER="133" O_E="0.0" SE="0.3816011553263465" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.14561944174640243" WEIGHT="46.64130286473102"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="134" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.658402668793" CI_END="1.0051814333964801" CI_START="0.7719341275716333" CI_STUDY="95" CI_TOTAL="95" DF="25.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8808710761740992" ESTIMABLE="YES" EVENTS_1="343" EVENTS_2="359" I2="15.706856235027916" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.0022444581856350897" LOG_CI_START="-0.11241975828179904" LOG_EFFECT_SIZE="-0.05508765004808197" METHOD="MH" NO="3" P_CHI2="0.2373347456828856" P_Q="0.0" P_Z="0.05966858158352007" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1931" TOTAL_2="1785" WEIGHT="99.99999999999997" Z="1.883234602974006">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1094877942752686" CI_START="0.610995759250993" EFFECT_SIZE="0.823342175066313" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="65" LOG_CI_END="0.045122528823046085" LOG_CI_START="-0.2139618040623301" LOG_EFFECT_SIZE="-0.08441963761964202" ORDER="135" O_E="0.0" SE="0.15218741962500143" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.023161010692116273" WEIGHT="17.994235689532122"/>
<DICH_DATA CI_END="1.6602339510792705" CI_START="0.2280993137177385" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.22016929075313357" LOG_CI_START="-0.6418760213829199" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="136" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Buttino-1990" TOTAL_1="13" TOTAL_2="12" VAR="0.2564102564102564" WEIGHT="1.6891534743828776"/>
<DICH_DATA CI_END="2.037241117325494" CI_START="0.7901810122997563" EFFECT_SIZE="1.2687747035573123" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.3090424328916178" LOG_CI_START="-0.1022734104335095" LOG_EFFECT_SIZE="0.10338451122905416" ORDER="137" O_E="0.0" SE="0.24160896241544122" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="0.05837489071946608" WEIGHT="6.3121208350890345"/>
<DICH_DATA CI_END="0.8796179197370865" CI_START="0.1960789338303065" EFFECT_SIZE="0.41530054644808745" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.0557059316945344" LOG_CI_START="-0.7075690632047418" LOG_EFFECT_SIZE="-0.3816374974496381" ORDER="138" O_E="0.0" SE="0.38290763022363755" STUDY_ID="STD-Darroca-1996" TOTAL_1="61" TOTAL_2="57" VAR="0.14661825328348194" WEIGHT="5.037729560170576"/>
<DICH_DATA CI_END="5.656596099825026" CI_START="1.0798956072970651" EFFECT_SIZE="2.4715447154471546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.752555169746318" LOG_CI_START="0.03338177459239377" LOG_EFFECT_SIZE="0.3929684721693558" ORDER="139" O_E="0.0" SE="0.4224460122791354" STUDY_ID="STD-Gilson-1993" TOTAL_1="41" TOTAL_2="38" VAR="0.17846063329054343" WEIGHT="1.6858639836830083"/>
<DICH_DATA CI_END="1.9074420741216958" CI_START="0.1310655790766886" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2804513580181161" LOG_CI_START="-0.8825113493460784" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="140" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="0.4666666666666667" WEIGHT="1.6241860330604592"/>
<DICH_DATA CI_END="6.786269078583867" CI_START="0.14735637335038831" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.831631075619647" LOG_CI_START="-0.8316310756196469" LOG_EFFECT_SIZE="0.0" ORDER="141" O_E="0.0" SE="0.9770084209183945" STUDY_ID="STD-Hidar-2000" TOTAL_1="44" TOTAL_2="44" VAR="0.9545454545454546" WEIGHT="0.5413953443534864"/>
<DICH_DATA CI_END="1.7624413690069978" CI_START="0.48598192784055994" EFFECT_SIZE="0.9254807692307693" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.24611467826470476" LOG_CI_START="-0.3133798805011888" LOG_EFFECT_SIZE="-0.033632601118242046" ORDER="142" O_E="0.0" SE="0.3286498733618184" STUDY_ID="STD-Hutchon-1980" TOTAL_1="32" TOTAL_2="35" VAR="0.10801073926073927" WEIGHT="3.3614994515082137"/>
<DICH_DATA CI_END="1.4036355513649912" CI_START="0.19590920708202725" EFFECT_SIZE="0.524390243902439" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.14725435951922244" LOG_CI_START="-0.7079451531274827" LOG_EFFECT_SIZE="-0.2803453968041301" ORDER="143" O_E="0.0" SE="0.5023484270345361" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.25235394214407264" WEIGHT="2.6425248950586835"/>
<DICH_DATA CI_END="29.09617312841034" CI_START="0.5499004947965868" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.463835872198758" LOG_CI_START="-0.25971588954283337" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="144" O_E="0.0" SE="1.0124228365658292" STUDY_ID="STD-Laube-1986" TOTAL_1="30" TOTAL_2="15" VAR="1.025" WEIGHT="0.3609302295689909"/>
<DICH_DATA CI_END="2.171926286915611" CI_START="0.30941135653770097" EFFECT_SIZE="0.8197674418604651" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.33684508163088095" LOG_CI_START="-0.5094637501352189" LOG_EFFECT_SIZE="-0.08630933425216901" ORDER="145" O_E="0.0" SE="0.49712599707568844" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="0.24713425696849742" WEIGHT="2.069333316195548"/>
<DICH_DATA CI_END="5.644885970160622" CI_START="0.3362816565246326" EFFECT_SIZE="1.3777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.751655173359268" LOG_CI_START="-0.4732968219134475" LOG_EFFECT_SIZE="0.1391791757229102" ORDER="146" O_E="0.0" SE="0.7195428656333623" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="0.5177419354838709" WEIGHT="0.7987800162592422"/>
<DICH_DATA CI_END="1.4245407152639462" CI_START="0.22322579502098866" EFFECT_SIZE="0.5639097744360902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.15367486646546774" LOG_CI_START="-0.6512556216162392" LOG_EFFECT_SIZE="-0.24879037757538572" ORDER="148" O_E="0.0" SE="0.47282015316937137" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.2235588972431078" WEIGHT="2.1178111999709905"/>
<DICH_DATA CI_END="2.1522476012402794" CI_START="0.7550597229360039" EFFECT_SIZE="1.2747844827586208" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="16" LOG_CI_END="0.33289223245286903" LOG_CI_START="-0.12201869563473237" LOG_EFFECT_SIZE="0.10543676840906833" ORDER="147" O_E="0.0" SE="0.2672169310040684" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.07140488821523304" WEIGHT="5.6877156176607775"/>
<DICH_DATA CI_END="81.01190363542146" CI_START="0.2663500355480702" EFFECT_SIZE="4.645161290322581" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9085488374385386" LOG_CI_START="-0.5745472409165846" LOG_EFFECT_SIZE="0.667000798260977" ORDER="149" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.1274641577060933" WEIGHT="0.17854527313785187"/>
<DICH_DATA CI_END="1.0403889276813372" CI_START="0.5822443738127394" EFFECT_SIZE="0.778306237749337" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="84" LOG_CI_END="0.017195721577963327" LOG_CI_START="-0.23489469933065688" LOG_EFFECT_SIZE="-0.10884948887634678" ORDER="150" O_E="0.0" SE="0.14807916110943237" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.021927437954873223" WEIGHT="23.017263831263662"/>
<DICH_DATA CI_END="0.952123221685224" CI_START="0.12865981756350753" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.0213068425452209" LOG_CI_START="-0.890557068754228" LOG_EFFECT_SIZE="-0.4559319556497244" ORDER="151" O_E="0.0" SE="0.5106018857331861" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="0.2607142857142857" WEIGHT="2.887441836551927"/>
<DICH_DATA CI_END="1.6990345829103743" CI_START="0.49408371963049585" EFFECT_SIZE="0.9162234042553191" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.23020221878328295" LOG_CI_START="-0.3061994561513159" LOG_EFFECT_SIZE="-0.037998618684016446" ORDER="152" O_E="0.0" SE="0.31508499908769727" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="0.09927855665009419" WEIGHT="4.071292989538217"/>
<DICH_DATA CI_END="2.285112885394374" CI_START="0.4629789584731531" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3589076592386504" LOG_CI_START="-0.3344387464046273" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="153" O_E="0.0" SE="0.4072751107949218" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="0.16587301587301584" WEIGHT="2.401965260159834"/>
<DICH_DATA CI_END="4.368712583785111" CI_START="0.5448763491790272" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6403534735532197" LOG_CI_START="-0.263702042607834" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="154" O_E="0.0" SE="0.5310466853399822" STUDY_ID="STD-Richardson-1991" TOTAL_1="21" TOTAL_2="27" VAR="0.28201058201058204" WEIGHT="1.1843023157732513"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="155" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="0.1353488360883716"/>
<DICH_DATA CI_END="1.9200796047704887" CI_START="0.38452909597517687" EFFECT_SIZE="0.8592592592592593" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.2833192345347404" LOG_CI_START="-0.41507079307091566" LOG_EFFECT_SIZE="-0.06587577926808763" ORDER="156" O_E="0.0" SE="0.4102377593019542" STUDY_ID="STD-Trofatter-1985" TOTAL_1="30" TOTAL_2="29" VAR="0.1682950191570881" WEIGHT="2.4775719148379887"/>
<DICH_DATA CI_END="1.5731201962247119" CI_START="0.561235378298487" EFFECT_SIZE="0.939622641509434" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.19676190670647986" LOG_CI_START="-0.25085496038862287" LOG_EFFECT_SIZE="-0.027046526841071502" ORDER="157" O_E="0.0" SE="0.26293236347089044" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.06913342776038844" WEIGHT="7.257225530341481"/>
<DICH_DATA CI_END="2.051870718624773" CI_START="0.22808412707665382" EFFECT_SIZE="0.6841046277665996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.31214999388781633" LOG_CI_START="-0.6419049372699703" LOG_EFFECT_SIZE="-0.16487747169107697" ORDER="158" O_E="0.0" SE="0.560416589210159" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.3140667534619482" WEIGHT="1.9357804758538324"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="159" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="160" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="1.58254023734096"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="161" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="0.9474418526186011"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.243833651184607" CI_END="2.9641039060952394" CI_START="0.18974913005095934" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7499574238329948" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.4718934236840957" LOG_CI_START="-0.7218202065520287" LOG_EFFECT_SIZE="-0.1249633914339665" METHOD="MH" NO="4" P_CHI2="0.5369145995305045" P_Q="0.0" P_Z="0.6815448542909031" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="649" TOTAL_2="544" WEIGHT="99.99999999999999" Z="0.4103559520353436">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.77100889559638" CI_START="0.07133077502654675" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2245591892972547" LOG_CI_START="-1.1467230572365155" LOG_EFFECT_SIZE="0.03891806603036966" ORDER="162" O_E="0.0" SE="1.3929029296503657" STUDY_ID="STD-Hutchon-1980" TOTAL_1="32" TOTAL_2="35" VAR="1.9401785714285715" WEIGHT="19.90467013277078"/>
<DICH_DATA CI_END="14.869904372908374" CI_START="0.16554597343459843" EFFECT_SIZE="1.5689655172413792" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1723081756200207" LOG_CI_START="-0.781081378103708" LOG_EFFECT_SIZE="0.19561339875815628" ORDER="163" O_E="0.0" SE="1.147430693291556" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="1.3165971959075407" WEIGHT="27.364226934886997"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="164" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.05268174261779" CI_START="0.009398954331199527" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077424999045629" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" ORDER="165" O_E="0.0" SE="1.5476140647907184" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.3951092935380496" WEIGHT="52.73110293234221"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.961425538310726" CI_START="0.013290113837882468" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3252818035426731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.9009908375858846" LOG_CI_START="-1.876471299045797" LOG_EFFECT_SIZE="-0.4877402307299564" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.49122322433986876" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="494" WEIGHT="100.0" Z="0.6883645853774167">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="166" O_E="0.0" SE="0.0" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.961425538310726" CI_START="0.013290113837882468" EFFECT_SIZE="0.3252818035426731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009908375858846" LOG_CI_START="-1.876471299045797" LOG_EFFECT_SIZE="-0.4877402307299564" ORDER="167" O_E="0.0" SE="1.6314950077167616" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.661775960204716" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Cervix unfavourable/unchanged after 12-24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="168" O_E="0.0" SE="0.0" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1178050550323508" CI_START="0.3984867066985564" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6674057649667405" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.048366069287483104" LOG_CI_START="-0.39958616185571755" LOG_EFFECT_SIZE="-0.1756100462841172" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.12436102748317357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.5367235259076175">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1178050550323508" CI_START="0.39848670669855646" EFFECT_SIZE="0.6674057649667405" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.048366069287483104" LOG_CI_START="-0.3995861618557175" LOG_EFFECT_SIZE="-0.1756100462841172" ORDER="169" O_E="0.0" SE="0.26312935797282194" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.06923705902718948" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.902856337830725" CI_END="2.333920812789424" CI_START="1.0893650160844544" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5945192641558752" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.36808611685416726" LOG_CI_START="0.03717342420915869" LOG_EFFECT_SIZE="0.20262977053166295" METHOD="MH" NO="8" P_CHI2="0.4462895035574844" P_Q="0.0" P_Z="0.016381049095229607" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1344" TOTAL_2="1187" WEIGHT="100.0" Z="2.400313202030726">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.566952764380952" CI_START="0.24707625775171935" EFFECT_SIZE="0.7963875205254516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.40941787710251243" LOG_CI_START="-0.6071689851637357" LOG_EFFECT_SIZE="-0.09887555403061167" ORDER="170" O_E="0.0" SE="0.5971481550813205" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.35658591911702475" WEIGHT="14.8559172813352"/>
<DICH_DATA CI_END="15.353612511371136" CI_START="0.06162708264303716" EFFECT_SIZE="0.9727272727272728" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1862105758502974" LOG_CI_START="-1.210228390796328" LOG_EFFECT_SIZE="-0.01200890747301538" ORDER="171" O_E="0.0" SE="1.4076801115724296" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="1.9815632965165677" WEIGHT="2.4545712457375473"/>
<DICH_DATA CI_END="35.88938623485869" CI_START="0.0668025523135909" EFFECT_SIZE="1.5483870967741935" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5549660312757505" LOG_CI_START="-1.1752069441931212" LOG_EFFECT_SIZE="0.18987954354131453" ORDER="172" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Laube-1986" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="1.596895625732735"/>
<DICH_DATA CI_END="77.5279602100532" CI_START="0.20637715679156027" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8894583576677944" LOG_CI_START="-0.6853383750118697" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="174" O_E="0.0" SE="1.5124483462254175" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="2.2875" WEIGHT="1.3450554553662821"/>
<DICH_DATA CI_END="2.8453436427798486" CI_START="0.024031980973341326" EFFECT_SIZE="0.2614942528735632" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.4541347252655028" LOG_CI_START="-1.6192104285164775" LOG_EFFECT_SIZE="-0.5825378516254873" ORDER="173" O_E="0.0" SE="1.2178932065555697" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="1.4832638625742074" WEIGHT="6.358813111256144"/>
<DICH_DATA CI_END="81.01190363542146" CI_START="0.2663500355480702" EFFECT_SIZE="4.645161290322581" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9085488374385386" LOG_CI_START="-0.5745472409165846" LOG_EFFECT_SIZE="0.667000798260977" ORDER="175" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.1274641577060933" WEIGHT="1.596895625732735"/>
<DICH_DATA CI_END="5.395712591876742" CI_START="1.4015196715582885" EFFECT_SIZE="2.7499449702839533" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="11" LOG_CI_END="0.7320488084783225" LOG_CI_START="0.1465991978431896" LOG_EFFECT_SIZE="0.43932400316075604" ORDER="176" O_E="0.0" SE="0.34389599930938847" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.11826445834100291" WEIGHT="26.95847176645156"/>
<DICH_DATA CI_END="2.3085716743005325" CI_START="0.6588130721204618" EFFECT_SIZE="1.233254716981132" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.36334336265150835" LOG_CI_START="-0.18123779217766248" LOG_EFFECT_SIZE="0.09105278523692298" ORDER="177" O_E="0.0" SE="0.3198896660668474" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.10232939845635913" WEIGHT="39.94343671344539"/>
<DICH_DATA CI_END="7.70876581994063" CI_START="0.013237495530407182" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8869848526950544" LOG_CI_START="-1.8781941735224057" LOG_EFFECT_SIZE="-0.49560466041367557" ORDER="178" O_E="0.0" SE="1.6242798478570708" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="2.638285024154589" WEIGHT="3.708918872669578"/>
<DICH_DATA CI_END="72.88490151495549" CI_START="0.13613930723311707" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8626375712827092" LOG_CI_START="-0.8660164637035079" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="179" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="1.181024302272833"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="180" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.00042404321309" CI_END="1.5015813767156205" CI_START="0.6996818978557855" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.02500210119067" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.1765488733321257" LOG_CI_START="-0.15509936199330518" LOG_EFFECT_SIZE="0.010724755669410276" METHOD="MH" NO="11" P_CHI2="0.6766192357673845" P_Q="0.0" P_Z="0.8991290683683376" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="277" WEIGHT="99.99999999999997" Z="0.12676162642270553">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2766354889097595" CI_START="0.30519110330845245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5154281307445581" LOG_CI_START="-0.5154281307445581" LOG_EFFECT_SIZE="0.0" ORDER="181" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="0.3666666666666667" WEIGHT="12.475103248925041"/>
<DICH_DATA CI_END="2.236925874185413" CI_START="0.7250356747124597" EFFECT_SIZE="1.2735191637630663" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.3496515929631376" LOG_CI_START="-0.13964062384336362" LOG_EFFECT_SIZE="0.10500548455988695" ORDER="182" O_E="0.0" SE="0.2874126701876741" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.08260604298440873" WEIGHT="34.098615547061776"/>
<DICH_DATA CI_END="8.205804789926459" CI_START="0.5823681495405606" EFFECT_SIZE="2.186046511627907" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9141211812067952" LOG_CI_START="-0.23480238516657093" LOG_EFFECT_SIZE="0.33965939802011214" ORDER="183" O_E="0.0" SE="0.6748833901510918" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="0.4554675903018308" WEIGHT="7.1523925293836905"/>
<DICH_DATA CI_END="1.832591692081128" CI_START="0.2868205734377687" EFFECT_SIZE="0.725" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2630657133915494" LOG_CI_START="-0.5423897002495621" LOG_EFFECT_SIZE="-0.13966199342900631" ORDER="184" O_E="0.0" SE="0.473128497041389" STUDY_ID="STD-Trofatter-1985" TOTAL_1="30" TOTAL_2="29" VAR="0.22385057471264364" WEIGHT="20.298473082996676"/>
<DICH_DATA CI_END="4.5822738168103605" CI_START="0.20017972615014737" EFFECT_SIZE="0.9577464788732394" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6610810371835261" LOG_CI_START="-0.698579909209204" LOG_EFFECT_SIZE="-0.01874943601283899" ORDER="185" O_E="0.0" SE="0.7986715703413212" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.637876277271472" WEIGHT="7.646610048981392"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="186" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="14.586274567973893"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="187" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="3.7425309746775124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5658938994596405" CI_END="1.8061690596932822" CI_START="0.8011838191464076" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2029436500805595" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="29" I2="22.054454378601307" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.2567583983892346" LOG_CI_START="-0.09626783037994548" LOG_EFFECT_SIZE="0.08024528400464455" METHOD="MH" NO="12" P_CHI2="0.2772192650244699" P_Q="0.0" P_Z="0.3729149511697629" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="169" WEIGHT="100.0" Z="0.8910265230242977">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.216455316511646" CI_START="0.8392227365489677" EFFECT_SIZE="2.4609375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8583239268634621" LOG_CI_START="-0.07612275857999781" LOG_EFFECT_SIZE="0.39110058414173215" ORDER="188" O_E="0.0" SE="0.5488986086151818" STUDY_ID="STD-Hutchon-1980" TOTAL_1="32" TOTAL_2="35" VAR="0.3012896825396825" WEIGHT="11.033808464628173"/>
<DICH_DATA CI_END="2.2997112369608055" CI_START="0.21257557981330055" EFFECT_SIZE="0.6991869918699187" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3616733072925474" LOG_CI_START="-0.6724866276842076" LOG_EFFECT_SIZE="-0.1554066601958302" ORDER="189" O_E="0.0" SE="0.607470664979585" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.3690206088107392" WEIGHT="16.91399098902544"/>
<DICH_DATA CI_END="1.8260772080978263" CI_START="0.6974702111432558" EFFECT_SIZE="1.1285541439806412" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="19" LOG_CI_END="0.2615191359266336" LOG_CI_START="-0.15647433631583285" LOG_EFFECT_SIZE="0.05252239980540041" ORDER="190" O_E="0.0" SE="0.2455314346962825" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.06028568542401484" WEIGHT="72.05220054634638"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.017333939375385" CI_END="1.3437957205775921" CI_START="0.6161964902919714" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9099682448796128" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.12833325371122709" LOG_CI_START="-0.21028077964967012" LOG_EFFECT_SIZE="-0.040973762969221526" METHOD="MH" NO="13" P_CHI2="0.5347638177631591" P_Q="0.0" P_Z="0.635265856035207" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1333" TOTAL_2="1220" WEIGHT="100.00000000000001" Z="0.4743282428886417">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="27.616977911783003" CI_START="0.3083532583170012" EFFECT_SIZE="2.918181818181818" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4411761525900024" LOG_CI_START="-0.5109514580967084" LOG_EFFECT_SIZE="0.465112347246647" ORDER="191" O_E="0.0" SE="1.1466894217048926" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="1.314896629849901" WEIGHT="2.154171028796588"/>
<DICH_DATA CI_END="1.6039497392059792" CI_START="0.4784558167962253" EFFECT_SIZE="0.8760245901639344" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.20519075526516917" LOG_CI_START="-0.3201581611422075" LOG_EFFECT_SIZE="-0.05748370293851918" ORDER="192" O_E="0.0" SE="0.3085925540167699" STUDY_ID="STD-Darroca-1996" TOTAL_1="61" TOTAL_2="57" VAR="0.09522936439459302" WEIGHT="35.14916722117773"/>
<DICH_DATA CI_END="8.695084862642968" CI_START="0.01520760372642119" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9392738250043677" LOG_CI_START="-1.817939212664893" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="193" O_E="0.0" SE="1.6196005867515793" STUDY_ID="STD-Lien-1998" TOTAL_1="43" TOTAL_2="47" VAR="2.62310606060606" WEIGHT="3.04862030379691"/>
<DICH_DATA CI_END="4.129808085649786" CI_START="0.010320641440566405" EFFECT_SIZE="0.2064516129032258" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6159298702327053" LOG_CI_START="-1.9862933099334763" LOG_EFFECT_SIZE="-0.6851817198503856" ORDER="194" O_E="0.0" SE="1.5285587772421023" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="2.336491935483871" WEIGHT="5.227672622912932"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="195" O_E="0.0" SE="0.0" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.247657783070237" CI_START="0.4350059459135274" EFFECT_SIZE="1.3593220338983052" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6281495201000067" LOG_CI_START="-0.3615048068159679" LOG_EFFECT_SIZE="0.13332235664201936" ORDER="196" O_E="0.0" SE="0.5813278504983695" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="401" VAR="0.33794206976505464" WEIGHT="10.780598714081918"/>
<DICH_DATA CI_END="4.487245911235435" CI_START="0.042655618565665326" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.651979870506141" LOG_CI_START="-1.3700237557894768" LOG_EFFECT_SIZE="-0.359021942641668" ORDER="197" O_E="0.0" SE="1.1877349391654206" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="1.4107142857142856" WEIGHT="4.5328980678677295"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="198" O_E="0.0" SE="0.0" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.577129902321556" CI_START="0.0970071395216797" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41113631006800627" LOG_CI_START="-1.0131963013959686" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="199" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="0.7" WEIGHT="8.499183877251992"/>
<DICH_DATA CI_END="3.304048628219007" CI_START="0.6417413785449313" EFFECT_SIZE="1.456140350877193" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5190464305405258" LOG_CI_START="-0.1926399571333608" LOG_EFFECT_SIZE="0.16320323670358253" ORDER="200" O_E="0.0" SE="0.41804810702407663" STUDY_ID="STD-Trofatter-1993" TOTAL_1="266" TOTAL_2="249" VAR="0.17476421978641382" WEIGHT="19.75441378848667"/>
<DICH_DATA CI_END="1.5976131360447412" CI_START="0.022966218719633766" EFFECT_SIZE="0.19154929577464788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20347162277419556" LOG_CI_START="-1.6389105034719111" LOG_EFFECT_SIZE="-0.7177194403488578" ORDER="201" O_E="0.0" SE="1.0822243808955725" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="1.1712096106048053" WEIGHT="10.853274375627544"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="202" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="203" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="204" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.41545811808727" CI_END="1.0659960642895612" CI_START="0.09595421833578396" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31982310594753305" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.027755601256706102" LOG_CI_START="-1.0179359280709375" LOG_EFFECT_SIZE="-0.49509016340711576" METHOD="MH" NO="14" P_CHI2="0.7019155327156306" P_Q="0.0" P_Z="0.06346524050371768" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="125" WEIGHT="100.0" Z="1.855918044974346">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.21959785535643" CI_START="0.06781552301168733" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2100400822200992" LOG_CI_START="-1.168670884500397" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="205" O_E="0.0" SE="1.3972665966608064" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="1.9523539421440725" WEIGHT="9.71485917490237"/>
<DICH_DATA CI_END="5.403402016095713" CI_START="0.049403032320983614" EFFECT_SIZE="0.5166666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7326672804906897" LOG_CI_START="-1.3062463935894315" LOG_EFFECT_SIZE="-0.28678955654937094" ORDER="206" O_E="0.0" SE="1.1976679849401242" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="1.4344086021505376" WEIGHT="19.577325166536564"/>
<DICH_DATA CI_END="2.541530096324976" CI_START="0.024591485298708176" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.40509525690335824" LOG_CI_START="-1.609215239559283" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="207" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="1.4" WEIGHT="26.53815189241623"/>
<DICH_DATA CI_END="2.0455425257222895" CI_START="0.006375362961899061" EFFECT_SIZE="0.11419753086419752" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3108085126755321" LOG_CI_START="-2.1954950849547665" LOG_EFFECT_SIZE="-0.9423432861396172" ORDER="208" O_E="0.0" SE="1.4722151396509335" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="2.1674174174174174" WEIGHT="44.16966376614483"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.052681742617788" CI_START="0.009398954331199527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.6077424999045626" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.29108380340280504" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="587" TOTAL_2="494" WEIGHT="100.0" Z="1.055747066061469">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="209" O_E="0.0" SE="0.0" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.05268174261779" CI_START="0.009398954331199527" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077424999045629" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" ORDER="210" O_E="0.0" SE="1.5476140647907184" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.3951092935380496" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9208299901121966" CI_END="1.4664399354164894" CI_START="0.9454230021852023" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1774574498748274" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.16626427921469739" LOG_CI_START="-0.024373835499808028" LOG_EFFECT_SIZE="0.07094522185744469" METHOD="MH" NO="18" P_CHI2="0.788849865374573" P_Q="0.0" P_Z="0.14462409415748498" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="739" TOTAL_2="686" WEIGHT="99.99999999999999" Z="1.458785719991337">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.16551325742054" CI_START="0.23627803006982864" EFFECT_SIZE="4.864864864864865" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.000718220732357" LOG_CI_START="-0.6265766586597351" LOG_EFFECT_SIZE="0.687070781036311" ORDER="211" O_E="0.0" SE="1.543286017474315" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="2.381731731731732" WEIGHT="0.5084003079125086"/>
<DICH_DATA CI_END="35.88938623485869" CI_START="0.0668025523135909" EFFECT_SIZE="1.5483870967741935" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5549660312757505" LOG_CI_START="-1.1752069441931212" LOG_EFFECT_SIZE="0.18987954354131453" ORDER="212" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Laube-1986" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="0.6615928101242132"/>
<DICH_DATA CI_END="4.485869000911839" CI_START="0.010632174841293059" EFFECT_SIZE="0.21839080459770116" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6518465868992417" LOG_CI_START="-1.9733778902308208" LOG_EFFECT_SIZE="-0.6607656516657895" ORDER="213" O_E="0.0" SE="1.5420698529369423" STUDY_ID="STD-Lien-1998" TOTAL_1="86" TOTAL_2="94" VAR="2.377979431336963" WEIGHT="2.3974237864214003"/>
<DICH_DATA CI_END="3.987709581650965" CI_START="0.007422505812621207" EFFECT_SIZE="0.17204301075268819" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6007235218364254" LOG_CI_START="-2.1294494536324464" LOG_EFFECT_SIZE="-0.7643629658980103" ORDER="214" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="1.98477843037264"/>
<DICH_DATA CI_END="63.43384490572215" CI_START="0.10905251884056036" EFFECT_SIZE="2.6301369863013697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.802321036018798" LOG_CI_START="-0.9623642988526109" LOG_EFFECT_SIZE="0.4199783685830937" ORDER="215" O_E="0.0" SE="1.6239898511165887" STUDY_ID="STD-Nuutila-1995" TOTAL_1="72" TOTAL_2="63" VAR="2.63734303652968" WEIGHT="0.5344772619581295"/>
<DICH_DATA CI_END="2.838485111047003" CI_START="0.35230059728273166" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45308662052476206" LOG_CI_START="-0.453086620524762" LOG_EFFECT_SIZE="0.0" ORDER="216" O_E="0.0" SE="0.532290647422377" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="0.28333333333333327" WEIGHT="6.018360401775102"/>
<DICH_DATA CI_END="1.5093313014113512" CI_START="0.9540648886387496" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="83" LOG_CI_END="0.1787845787963972" LOG_CI_START="-0.02042208670114762" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="217" O_E="0.0" SE="0.11701498140215548" STUDY_ID="STD-Trofatter-1993" TOTAL_1="265" TOTAL_2="249" VAR="0.013692505872546794" WEIGHT="85.84554931066366"/>
<DICH_DATA CI_END="8.333707722971917" CI_START="0.24765401951254082" EFFECT_SIZE="1.4366197183098592" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9208382649565896" LOG_CI_START="-0.606154618870905" LOG_EFFECT_SIZE="0.1573418230428423" ORDER="218" O_E="0.0" SE="0.8969631786969511" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.8045429439381386" WEIGHT="2.0494176907723367"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="219" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="220" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.472680254365788" CI_START="0.1862832190772611" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="1.3318862571530972" LOG_CI_START="-0.7298262658251347" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.5670866141370015" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="96" WEIGHT="100.0" Z="0.572347447271999">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="221" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="222" O_E="0.0" SE="0.0" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="223" O_E="0.0" SE="0.0" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.019819690887750076" CI_END="4.625192446375698" CI_START="1.1130879383412986" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2689746416758547" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.6651298077042895" LOG_CI_START="0.0465294766686784" LOG_EFFECT_SIZE="0.355829642186484" METHOD="MH" NO="20" P_CHI2="0.9901390956747478" P_Q="0.0" P_Z="0.024145221372551807" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="516" TOTAL_2="499" WEIGHT="100.0" Z="2.254810572602602">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="224" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="9.396545387725102"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="225" O_E="0.0" SE="0.0" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.911116206652446" CI_START="1.055561031976571" EFFECT_SIZE="2.2768361581920904" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.6911802105133649" LOG_CI_START="0.02348334904524084" LOG_EFFECT_SIZE="0.3573317797793028" ORDER="226" O_E="0.0" SE="0.39220844157914514" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.1538274616459417" WEIGHT="85.60529217199559"/>
<DICH_DATA CI_END="61.53995727256356" CI_START="0.11325324730290753" EFFECT_SIZE="2.64" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.789157190379163" LOG_CI_START="-0.9459493366395004" LOG_EFFECT_SIZE="0.4216039268698311" ORDER="227" O_E="0.0" SE="1.6066151129664257" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="2.581212121212121" WEIGHT="4.998162440279309"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2720393947955837" CI_END="5.650592323335287" CI_START="0.22557128039913094" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1289868667917449" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="55.986678651319316" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="0.7520939751243607" LOG_CI_START="-0.6467161952833702" LOG_EFFECT_SIZE="0.05268888992049534" METHOD="MH" NO="21" P_CHI2="0.13172657401798615" P_Q="0.0" P_Z="0.8826176777338725" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="143" WEIGHT="100.0" Z="0.14765166684406547">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.16551325742054" CI_START="0.23627803006982864" EFFECT_SIZE="4.864864864864865" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.000718220732357" LOG_CI_START="-0.6265766586597351" LOG_EFFECT_SIZE="0.687070781036311" ORDER="228" O_E="0.0" SE="1.543286017474315" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="2.381731731731732" WEIGHT="20.391651031894934"/>
<DICH_DATA CI_END="3.987709581650965" CI_START="0.007422505812621207" EFFECT_SIZE="0.17204301075268819" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6007235218364254" LOG_CI_START="-2.1294494536324464" LOG_EFFECT_SIZE="-0.7643629658980103" ORDER="229" O_E="0.0" SE="1.603717120364604" STUDY_ID="STD-Nimrod-1984" TOTAL_1="30" TOTAL_2="15" VAR="2.5719086021505375" WEIGHT="79.60834896810506"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="230" O_E="0.0" SE="0.0" STUDY_ID="STD-Nuutila-1995" TOTAL_1="24" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.048512484827704955" CI_END="13.03211152950448" CI_START="0.8184015341636711" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.265807720784941" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="1.115014788031661" LOG_CI_START="-0.087033565172983" LOG_EFFECT_SIZE="0.513990611429339" METHOD="MH" NO="23" P_CHI2="0.9971991678314205" P_Q="0.0" P_Z="0.09370998373735935" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="269" WEIGHT="100.0" Z="1.6761440321556178">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.25145218614753" CI_START="0.4420009251415571" EFFECT_SIZE="3.890909090909091" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5346789893484658" LOG_CI_START="-0.35457682163857157" LOG_EFFECT_SIZE="0.590051083854947" ORDER="231" O_E="0.0" SE="1.1097582153408767" STUDY_ID="STD-Cabrol-1988" TOTAL_1="110" TOTAL_2="107" VAR="1.2315632965165677" WEIGHT="38.09482632827658"/>
<DICH_DATA CI_END="73.15840614780981" CI_START="0.131085556818331" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864264235230413" LOG_CI_START="-0.8824451568198217" LOG_EFFECT_SIZE="0.49090953920529573" ORDER="232" O_E="0.0" SE="1.613430693321079" STUDY_ID="STD-McKenna-1999" TOTAL_1="30" TOTAL_2="31" VAR="2.6031586021505375" WEIGHT="18.489458637107976"/>
<DICH_DATA CI_END="54.17908446913287" CI_START="0.12752869161232291" EFFECT_SIZE="2.6285714285714286" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7338316619492158" LOG_CI_START="-0.8943920959586567" LOG_EFFECT_SIZE="0.4197197829952796" ORDER="233" O_E="0.0" SE="1.5438316453125072" STUDY_ID="STD-NICHHD-1994" TOTAL_1="174" TOTAL_2="91" VAR="2.383416149068323" WEIGHT="24.62803932271541"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="234" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="18.78767571190004"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.902208524429669" CI_START="0.2243765246049395" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.6903917808212061" LOG_CI_START="-0.6490225831015041" LOG_EFFECT_SIZE="0.02068459885985105" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.9517291312501786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.0605355144635521">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.9022085244296685" CI_START="0.22437652460493956" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6903917808212061" LOG_CI_START="-0.649022583101504" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="235" O_E="0.0" SE="0.786778627576232" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.6190206088107392" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="403" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all women, intact membranes, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="7.0159296595968765" CI_END="1.0600853838195576" CI_START="0.4547838159542463" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.694341181330029" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" I2="85.74672141086633" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.02534084661220158" LOG_CI_START="-0.3421949986167252" LOG_EFFECT_SIZE="-0.15842707600226183" METHOD="MH" NO="1" P_CHI2="0.008078783416989865" P_Q="0.0" P_Z="0.0910867128661019" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="53" WEIGHT="100.0" Z="1.68969294925242">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6792016448479565" CI_START="0.6390075477865573" EFFECT_SIZE="1.035868005738881" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.22510285098408747" LOG_CI_START="-0.19449401204082806" LOG_EFFECT_SIZE="0.015304419471629702" ORDER="237" O_E="0.0" SE="0.2464732743788054" STUDY_ID="STD-Gilson-1993" TOTAL_1="41" TOTAL_2="38" VAR="0.06074907498300988" WEIGHT="57.57951259809996"/>
<DICH_DATA CI_END="0.6473062288383313" CI_START="0.08227085650850907" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.18889021387330937" LOG_CI_START="-1.0847539813010392" LOG_EFFECT_SIZE="-0.6368220975871743" ORDER="238" O_E="0.0" SE="0.5262348115842176" STUDY_ID="STD-Gr_x00fc_nberger-1986" TOTAL_1="15" TOTAL_2="15" VAR="0.27692307692307694" WEIGHT="42.42048740190004"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1933750667968968" CI_END="2.572909452308626" CI_START="0.27512491840963144" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8413509987762421" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.4104245024735917" LOG_CI_START="-0.560470073231879" LOG_EFFECT_SIZE="-0.07502278537914371" METHOD="MH" NO="2" P_CHI2="0.7545937401048322" P_Q="0.0" P_Z="0.7619661127953768" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="713" TOTAL_2="700" WEIGHT="100.0" Z="0.3028999461783095">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5790929814244183" CI_START="0.08852876242539406" EFFECT_SIZE="0.47783251231527096" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41146699959882244" LOG_CI_START="-1.0529156068927585" LOG_EFFECT_SIZE="-0.320724303646968" ORDER="239" O_E="0.0" SE="0.860185591863964" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.7399192524503581" WEIGHT="62.22964387045634"/>
<DICH_DATA CI_END="15.547458733910922" CI_START="0.06124217077393126" EFFECT_SIZE="0.9757869249394673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1916594127820033" LOG_CI_START="-1.2129494238125864" LOG_EFFECT_SIZE="-0.010645005515291586" ORDER="240" O_E="0.0" SE="1.4124791336213725" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="1.995097302915783" WEIGHT="15.398970465450672"/>
<DICH_DATA CI_END="80.90695094581207" CI_START="0.14078672928397634" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9079858346868268" LOG_CI_START="-0.8514382803527396" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="241" O_E="0.0" SE="1.6208993845439064" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="2.6273148148148144" WEIGHT="7.158843412509756"/>
<DICH_DATA CI_END="15.439679023172555" CI_START="0.06476818582168423" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1886382675078813" LOG_CI_START="-1.188638267507881" LOG_EFFECT_SIZE="0.0" ORDER="242" O_E="0.0" SE="1.3964240043768943" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="1.9500000000000002" WEIGHT="15.212542251583232"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="243" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.211139153707514" CI_END="0.9761821599644576" CI_START="0.6835429050738737" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8168613037128115" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="204" I2="19.72269832166245" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.01046913347502064" LOG_CI_START="-0.16523422015684827" LOG_EFFECT_SIZE="-0.08785167681593449" METHOD="MH" NO="3" P_CHI2="0.26151373955491075" P_Q="0.0" P_Z="0.02607259569688109" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="945" TOTAL_2="924" WEIGHT="100.00000000000001" Z="2.225128757814368">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1094877942752686" CI_START="0.610995759250993" EFFECT_SIZE="0.823342175066313" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="65" LOG_CI_END="0.045122528823046085" LOG_CI_START="-0.2139618040623301" LOG_EFFECT_SIZE="-0.08441963761964202" ORDER="244" O_E="0.0" SE="0.15218741962500143" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.023161010692116273" WEIGHT="32.03431575101646"/>
<DICH_DATA CI_END="5.656596099825026" CI_START="1.0798956072970651" EFFECT_SIZE="2.4715447154471546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.752555169746318" LOG_CI_START="0.03338177459239377" LOG_EFFECT_SIZE="0.3929684721693558" ORDER="245" O_E="0.0" SE="0.4224460122791354" STUDY_ID="STD-Gilson-1993" TOTAL_1="41" TOTAL_2="38" VAR="0.17846063329054343" WEIGHT="3.001266633291062"/>
<DICH_DATA CI_END="1.9074420741216958" CI_START="0.1310655790766886" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2804513580181161" LOG_CI_START="-0.8825113493460784" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="246" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="0.4666666666666667" WEIGHT="2.89146419548773"/>
<DICH_DATA CI_END="1.4036355513649912" CI_START="0.19590920708202725" EFFECT_SIZE="0.524390243902439" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.14725435951922244" LOG_CI_START="-0.7079451531274827" LOG_EFFECT_SIZE="-0.2803453968041301" ORDER="247" O_E="0.0" SE="0.5023484270345361" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.25235394214407264" WEIGHT="4.704366349801466"/>
<DICH_DATA CI_END="1.4245407152639462" CI_START="0.22322579502098866" EFFECT_SIZE="0.5639097744360902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.15367486646546774" LOG_CI_START="-0.6512556216162392" LOG_EFFECT_SIZE="-0.24879037757538572" ORDER="248" O_E="0.0" SE="0.47282015316937137" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.2235588972431078" WEIGHT="3.7702425294104716"/>
<DICH_DATA CI_END="1.0403889276813372" CI_START="0.5822443738127394" EFFECT_SIZE="0.778306237749337" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="84" LOG_CI_END="0.017195721577963327" LOG_CI_START="-0.23489469933065688" LOG_EFFECT_SIZE="-0.10884948887634678" ORDER="249" O_E="0.0" SE="0.14807916110943237" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.021927437954873223" WEIGHT="40.97658328017171"/>
<DICH_DATA CI_END="1.6990345829103743" CI_START="0.49408371963049585" EFFECT_SIZE="0.9162234042553191" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.23020221878328295" LOG_CI_START="-0.3061994561513159" LOG_EFFECT_SIZE="-0.037998618684016446" ORDER="250" O_E="0.0" SE="0.31508499908769727" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="0.09927855665009419" WEIGHT="7.247936916689244"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="251" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="0.24095534962397752"/>
<DICH_DATA CI_END="2.051870718624773" CI_START="0.22808412707665382" EFFECT_SIZE="0.6841046277665996" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.31214999388781633" LOG_CI_START="-0.6419049372699703" LOG_EFFECT_SIZE="-0.16487747169107697" ORDER="252" O_E="0.0" SE="0.560416589210159" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.3140667534619482" WEIGHT="3.4461815471400525"/>
<DICH_DATA CI_END="2.4521888362810533" CI_START="0.008322427279400224" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3895539109512145" LOG_CI_START="-2.079749990979728" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="253" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="1.6866874473678426"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.052681742617788" CI_START="0.009398954331199527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.6077424999045626" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.29108380340280504" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="403" WEIGHT="100.0" Z="1.055747066061469">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.05268174261779" CI_START="0.009398954331199527" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077424999045629" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" ORDER="254" O_E="0.0" SE="1.5476140647907184" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.3951092935380496" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.961425538310726" CI_START="0.013290113837882468" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3252818035426731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.9009908375858846" LOG_CI_START="-1.876471299045797" LOG_EFFECT_SIZE="-0.4877402307299564" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.49122322433986876" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="403" WEIGHT="100.0" Z="0.6883645853774167">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.961425538310726" CI_START="0.013290113837882468" EFFECT_SIZE="0.3252818035426731" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9009908375858846" LOG_CI_START="-1.876471299045797" LOG_EFFECT_SIZE="-0.4877402307299564" ORDER="255" O_E="0.0" SE="1.6314950077167616" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.661775960204716" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Cervix unfavourable/unchanged after 12-24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1178050550323508" CI_START="0.3984867066985564" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6674057649667405" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.048366069287483104" LOG_CI_START="-0.39958616185571755" LOG_EFFECT_SIZE="-0.1756100462841172" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.12436102748317357" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="99.99999999999999" Z="1.5367235259076175">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1178050550323508" CI_START="0.39848670669855646" EFFECT_SIZE="0.6674057649667405" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.048366069287483104" LOG_CI_START="-0.3995861618557175" LOG_EFFECT_SIZE="-0.1756100462841172" ORDER="256" O_E="0.0" SE="0.26312935797282194" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.06923705902718948" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.715338164679687" CI_END="3.382234159737634" CI_START="1.1524062270451798" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9742613066680335" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="18" I2="36.377839823418256" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.5292036714940098" LOG_CI_START="0.061605596331781795" LOG_EFFECT_SIZE="0.2954046339128958" METHOD="MH" NO="8" P_CHI2="0.1938683234508498" P_Q="0.0" P_Z="0.013271081140002269" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="716" TOTAL_2="690" WEIGHT="100.0" Z="2.4764107214711855">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.566952764380952" CI_START="0.24707625775171935" EFFECT_SIZE="0.7963875205254516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.40941787710251243" LOG_CI_START="-0.6071689851637357" LOG_EFFECT_SIZE="-0.09887555403061167" ORDER="257" O_E="0.0" SE="0.5971481550813205" STUDY_ID="STD-Bernstein-1991" TOTAL_1="203" TOTAL_2="194" VAR="0.35658591911702475" WEIGHT="31.697111252232745"/>
<DICH_DATA CI_END="77.5279602100532" CI_START="0.20637715679156027" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8894583576677944" LOG_CI_START="-0.6853383750118697" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="258" O_E="0.0" SE="1.5124483462254175" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="2.2875" WEIGHT="2.8698579563803137"/>
<DICH_DATA CI_END="5.395712591876742" CI_START="1.4015196715582885" EFFECT_SIZE="2.7499449702839533" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="11" LOG_CI_END="0.7320488084783225" LOG_CI_START="0.1465991978431896" LOG_EFFECT_SIZE="0.43932400316075604" ORDER="259" O_E="0.0" SE="0.34389599930938847" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.11826445834100291" WEIGHT="57.51955012868719"/>
<DICH_DATA CI_END="7.70876581994063" CI_START="0.013237495530407182" EFFECT_SIZE="0.3194444444444444" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8869848526950544" LOG_CI_START="-1.8781941735224057" LOG_EFFECT_SIZE="-0.49560466041367557" ORDER="260" O_E="0.0" SE="1.6242798478570708" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="2.638285024154589" WEIGHT="7.913480662699758"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="261" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8721701715961366" CI_END="1.8024841142496357" CI_START="0.6863769844179777" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1122875576036866" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="0.255871445860745" LOG_CI_START="-0.16343728767079233" LOG_EFFECT_SIZE="0.04621707909497631" METHOD="MH" NO="11" P_CHI2="0.8321381522179041" P_Q="0.0" P_Z="0.6656959183652962" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="182" TOTAL_2="181" WEIGHT="99.99999999999997" Z="0.4320625985243379">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2766354889097595" CI_START="0.30519110330845245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5154281307445581" LOG_CI_START="-0.5154281307445581" LOG_EFFECT_SIZE="0.0" ORDER="262" O_E="0.0" SE="0.6055300708194984" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="0.3666666666666667" WEIGHT="21.522580645161288"/>
<DICH_DATA CI_END="2.236925874185413" CI_START="0.7250356747124597" EFFECT_SIZE="1.2735191637630663" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.3496515929631376" LOG_CI_START="-0.13964062384336362" LOG_EFFECT_SIZE="0.10500548455988695" ORDER="263" O_E="0.0" SE="0.2874126701876741" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.08260604298440873" WEIGHT="58.82838709677418"/>
<DICH_DATA CI_END="4.5822738168103605" CI_START="0.20017972615014737" EFFECT_SIZE="0.9577464788732394" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6610810371835261" LOG_CI_START="-0.698579909209204" LOG_EFFECT_SIZE="-0.01874943601283899" ORDER="264" O_E="0.0" SE="0.7986715703413212" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.637876277271472" WEIGHT="13.192258064516126"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="265" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="6.4567741935483856"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.299711236960806" CI_START="0.2125755798133005" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6991869918699187" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.36167330729254743" LOG_CI_START="-0.6724866276842079" LOG_EFFECT_SIZE="-0.1554066601958302" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.5558205982364007" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.5890606406993091">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2997112369608055" CI_START="0.21257557981330055" EFFECT_SIZE="0.6991869918699187" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3616733072925474" LOG_CI_START="-0.6724866276842076" LOG_EFFECT_SIZE="-0.1554066601958302" ORDER="266" O_E="0.0" SE="0.607470664979585" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.3690206088107392" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9030885149692973" CI_END="1.5483094383218814" CI_START="0.31317288899223517" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6963393855392703" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="31.107853250518207" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.1898577612084723" LOG_CI_START="-0.5042158413481108" LOG_EFFECT_SIZE="-0.15717904006981925" METHOD="MH" NO="13" P_CHI2="0.2342083788236542" P_Q="0.0" P_Z="0.37470108707031247" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="581" TOTAL_2="572" WEIGHT="100.0" Z="0.8877019858605251">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.247657783070237" CI_START="0.4350059459135274" EFFECT_SIZE="1.3593220338983052" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6281495201000067" LOG_CI_START="-0.3615048068159679" LOG_EFFECT_SIZE="0.13332235664201936" ORDER="267" O_E="0.0" SE="0.5813278504983695" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="401" VAR="0.33794206976505464" WEIGHT="35.77665128998363"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="268" O_E="0.0" SE="0.0" STUDY_ID="STD-Owen-1991" TOTAL_1="47" TOTAL_2="53" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.577129902321556" CI_START="0.0970071395216797" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41113631006800627" LOG_CI_START="-1.0131963013959686" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="269" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="0.7" WEIGHT="28.205514915299442"/>
<DICH_DATA CI_END="1.5976131360447412" CI_START="0.022966218719633766" EFFECT_SIZE="0.19154929577464788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.20347162277419556" LOG_CI_START="-1.6389105034719111" LOG_EFFECT_SIZE="-0.7177194403488578" ORDER="270" O_E="0.0" SE="1.0822243808955725" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="1.1712096106048053" WEIGHT="36.017833794716914"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="271" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.21959785535643" CI_START="0.06781552301168733" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="1.2100400822200992" LOG_CI_START="-1.168670884500397" LOG_EFFECT_SIZE="0.02068459885985105" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.9728081045314725" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.034086586699400366">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.21959785535643" CI_START="0.06781552301168733" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2100400822200992" LOG_CI_START="-1.168670884500397" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="272" O_E="0.0" SE="1.3972665966608064" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="1.9523539421440725" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.052681742617788" CI_START="0.009398954331199527" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.6077424999045626" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" METHOD="MH" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.29108380340280504" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="403" WEIGHT="100.0" Z="1.055747066061469">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.05268174261779" CI_START="0.009398954331199527" EFFECT_SIZE="0.19516908212560385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077424999045629" LOG_CI_START="-2.026920460597188" LOG_EFFECT_SIZE="-0.7095889803463128" ORDER="273" O_E="0.0" SE="1.5476140647907184" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="2.3951092935380496" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1212126831156317" CI_END="2.7219480388453583" CI_START="0.45339816089898355" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.110912343470483" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.43487983039776185" LOG_CI_START="-0.34352024581744806" LOG_EFFECT_SIZE="0.045679792290156916" METHOD="MH" NO="18" P_CHI2="0.7277230010519178" P_Q="0.0" P_Z="0.8180623429910296" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="118" WEIGHT="100.0" Z="0.2300378698452871">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.838485111047003" CI_START="0.35230059728273166" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45308662052476206" LOG_CI_START="-0.453086620524762" LOG_EFFECT_SIZE="0.0" ORDER="274" O_E="0.0" SE="0.532290647422377" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="0.28333333333333327" WEIGHT="74.59749552772809"/>
<DICH_DATA CI_END="8.333707722971917" CI_START="0.24765401951254082" EFFECT_SIZE="1.4366197183098592" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9208382649565896" LOG_CI_START="-0.606154618870905" LOG_EFFECT_SIZE="0.1573418230428423" ORDER="275" O_E="0.0" SE="0.8969631786969511" STUDY_ID="STD-Troostwijk-1992" TOTAL_1="71" TOTAL_2="68" VAR="0.8045429439381386" WEIGHT="25.402504472271914"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="276" O_E="0.0" SE="0.0" STUDY_ID="STD-Wingerup-1978" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.472680254365788" CI_START="0.1862832190772611" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="1.3318862571530972" LOG_CI_START="-0.7298262658251347" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.5670866141370015" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="75" WEIGHT="100.0" Z="0.572347447271999">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="277" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="278" O_E="0.0" SE="0.0" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01037148957704482" CI_END="4.673408099582758" CI_START="1.0827314123322285" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2494545454545456" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.6696337069087992" LOG_CI_START="0.03452073676499581" LOG_EFFECT_SIZE="0.35207722183689755" METHOD="MH" NO="20" P_CHI2="0.9188832709332316" P_Q="0.0" P_Z="0.02977831875880136" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="492" TOTAL_2="478" WEIGHT="100.0" Z="2.173026554381322">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.472680254365798" CI_START="0.18628321907726103" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3318862571530974" LOG_CI_START="-0.7298262658251348" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="279" O_E="0.0" SE="1.2110601416389968" STUDY_ID="STD-Heinzl-1980" TOTAL_1="60" TOTAL_2="60" VAR="1.4666666666666668" WEIGHT="9.890909090909092"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="280" O_E="0.0" SE="0.0" STUDY_ID="STD-Nager-1987" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.911116206652446" CI_START="1.055561031976571" EFFECT_SIZE="2.2768361581920904" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.6911802105133649" LOG_CI_START="0.02348334904524084" LOG_EFFECT_SIZE="0.3573317797793028" ORDER="281" O_E="0.0" SE="0.39220844157914514" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.1538274616459417" WEIGHT="90.10909090909091"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="71.50812704867249" CI_START="0.12585982001561988" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.49713856173232074" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6789989027057507">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="282" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.902208524429669" CI_START="0.2243765246049395" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="0.6903917808212061" LOG_CI_START="-0.6490225831015041" LOG_EFFECT_SIZE="0.02068459885985105" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="0.9517291312501786" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" WEIGHT="100.0" Z="0.0605355144635521">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.9022085244296685" CI_START="0.22437652460493956" EFFECT_SIZE="1.048780487804878" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6903917808212061" LOG_CI_START="-0.649022583101504" LOG_EFFECT_SIZE="0.02068459885985105" ORDER="283" O_E="0.0" SE="0.786778627576232" STUDY_ID="STD-Larmon-2002" TOTAL_1="41" TOTAL_2="43" VAR="0.6190206088107392" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="403" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Noah-1987" TOTAL_1="413" TOTAL_2="403" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all women, ruptured membranes, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.755728837117656" CI_START="0.22245994671022398" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.6772170839826519" LOG_CI_START="-0.6527481711486287" LOG_EFFECT_SIZE="0.012234456417011586" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.9712347323000775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="0.03605972991437388">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.755728837117656" CI_START="0.22245994671022398" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6772170839826519" LOG_CI_START="-0.6527481711486287" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="285" O_E="0.0" SE="0.7812281742983034" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="0.6103174603174603" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.14717327317198E-4" CI_END="2.145033161403812" CI_START="0.48818628166215033" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0233160621761657" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.3314340106015653" LOG_CI_START="-0.3114144286921549" LOG_EFFECT_SIZE="0.010009790954705217" METHOD="MH" NO="3" P_CHI2="0.9786717377696216" P_Q="0.0" P_Z="0.9513295943902778" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="80" WEIGHT="100.0" Z="0.06103718564068288">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.786269078583867" CI_START="0.14735637335038831" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.831631075619647" LOG_CI_START="-0.8316310756196469" LOG_EFFECT_SIZE="0.0" ORDER="286" O_E="0.0" SE="0.9770084209183945" STUDY_ID="STD-Hidar-2000" TOTAL_1="44" TOTAL_2="44" VAR="0.9545454545454546" WEIGHT="18.39378238341969"/>
<DICH_DATA CI_END="2.285112885394374" CI_START="0.4629789584731531" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3589076592386504" LOG_CI_START="-0.3344387464046273" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="287" O_E="0.0" SE="0.4072751107949218" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="0.16587301587301584" WEIGHT="81.60621761658031"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0455425257222895" CI_START="0.006375362961899061" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11419753086419751" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="0.3108085126755321" LOG_CI_START="-2.1954950849547665" LOG_EFFECT_SIZE="-0.9423432861396173" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.14052174116414629" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="36" WEIGHT="100.0" Z="1.4738508963184396">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0455425257222895" CI_START="0.006375362961899061" EFFECT_SIZE="0.11419753086419752" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3108085126755321" LOG_CI_START="-2.1954950849547665" LOG_EFFECT_SIZE="-0.9423432861396172" ORDER="288" O_E="0.0" SE="1.4722151396509335" STUDY_ID="STD-Perez-Picanol-1990" TOTAL_1="35" TOTAL_2="36" VAR="2.1674174174174174" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Intracervical prostaglandin (PGE2) v placebo/no treatment: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.6379862856740829" CI_END="0.7464867508495125" CI_START="0.4019295530961342" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5477545857052498" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-0.1269778960220228" LOG_CI_START="-0.39585005980770205" LOG_EFFECT_SIZE="-0.2614139779148624" METHOD="MH" NO="1" P_CHI2="0.4244411756765445" P_Q="0.0" P_Z="1.3829720467927484E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="45" WEIGHT="100.0" Z="3.8111939484883854">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8778763218228536" CI_START="0.4220530703073121" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" LOG_CI_END="-0.05656666465574887" LOG_CI_START="-0.3746329360229608" LOG_EFFECT_SIZE="-0.21559980033935483" ORDER="289" O_E="0.0" SE="0.18683370225453605" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.03490683229813663" WEIGHT="56.73624288425047"/>
<DICH_DATA CI_END="0.8085477076710451" CI_START="0.2706961649600281" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09229434982435981" LOG_CI_START="-0.5675178969760607" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="290" O_E="0.0" SE="0.2791486639914064" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.07792397660818713" WEIGHT="43.26375711574953"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.421415449004012" CI_END="2.5182080625389043" CI_START="0.6389933780128905" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2685102586975916" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="70.77233048997005" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.4010916100766486" LOG_CI_START="-0.19450364247909985" LOG_EFFECT_SIZE="0.1032939837987744" METHOD="MH" NO="3" P_CHI2="0.06435591125924911" P_Q="0.0" P_Z="0.4966105656214377" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="59" WEIGHT="100.0" Z="0.6798324439173125">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.418631692997226" CI_START="0.901782381539746" EFFECT_SIZE="2.210526315789474" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.733889632810713" LOG_CI_START="-0.04489825392056991" LOG_EFFECT_SIZE="0.34449568944507153" ORDER="291" O_E="0.0" SE="0.45746385972816855" STUDY_ID="STD-Gilson-1993" TOTAL_1="19" TOTAL_2="14" VAR="0.20927318295739347" WEIGHT="44.067796610169495"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="292" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="293" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="55.932203389830505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.6589967959105" CI_START="0.0707601678088729" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="1.1947639352470683" LOG_CI_START="-1.1502111458247637" LOG_EFFECT_SIZE="0.02227639471115221" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.9702953485892204" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.03723786379793897">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.658996795910493" CI_START="0.07076016780887293" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194763935247068" LOG_CI_START="-1.1502111458247635" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="294" O_E="0.0" SE="1.3774499704354535" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="1.8973684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8105883556187499" CI_START="0.1529935335051035" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.3085757964754068" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="99.99999999999999" Z="1.018215021248635">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="295" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="296" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="297" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="298" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1982" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="1.581791918301982E-31" CI_END="0.8085477076710452" CI_START="0.27069616496002813" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46783625730994155" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="100.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.09229434982435976" LOG_CI_START="-0.5675178969760606" LOG_EFFECT_SIZE="-0.32990612340021025" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0065033005178818945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="2.72126296779326">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8085477076710451" CI_START="0.2706961649600281" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09229434982435981" LOG_CI_START="-0.5675178969760607" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="299" O_E="0.0" SE="0.2791486639914064" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.07792397660818713" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.421415449004012" CI_END="2.5182080625389043" CI_START="0.6389933780128905" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2685102586975916" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="70.77233048997005" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.4010916100766486" LOG_CI_START="-0.19450364247909985" LOG_EFFECT_SIZE="0.1032939837987744" METHOD="MH" NO="3" P_CHI2="0.06435591125924911" P_Q="0.0" P_Z="0.4966105656214377" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="34" WEIGHT="100.0" Z="0.6798324439173125">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.418631692997226" CI_START="0.901782381539746" EFFECT_SIZE="2.210526315789474" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.733889632810713" LOG_CI_START="-0.04489825392056991" LOG_EFFECT_SIZE="0.34449568944507153" ORDER="300" O_E="0.0" SE="0.45746385972816855" STUDY_ID="STD-Gilson-1993" TOTAL_1="19" TOTAL_2="14" VAR="0.20927318295739347" WEIGHT="44.067796610169495"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="301" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="55.932203389830505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.6589967959105" CI_START="0.0707601678088729" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="1.1947639352470683" LOG_CI_START="-1.1502111458247637" LOG_EFFECT_SIZE="0.02227639471115221" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.9702953485892204" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.03723786379793897">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.658996795910493" CI_START="0.07076016780887293" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194763935247068" LOG_CI_START="-1.1502111458247635" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="302" O_E="0.0" SE="1.3774499704354535" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="1.8973684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8105883556187499" CI_START="0.1529935335051035" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.11" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.3085757964754068" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="99.99999999999999" Z="1.018215021248635">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="303" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="304" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Intracervical prostaglandin vs placebo/no treatment: all primiparae, intact membranes, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.418631692997226" CI_START="0.901782381539746" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.210526315789474" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.733889632810713" LOG_CI_START="-0.04489825392056991" LOG_EFFECT_SIZE="0.34449568944507153" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.08292261876314753" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="14" WEIGHT="100.0" Z="1.7339744380862714">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.418631692997226" CI_START="0.901782381539746" EFFECT_SIZE="2.210526315789474" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.733889632810713" LOG_CI_START="-0.04489825392056991" LOG_EFFECT_SIZE="0.34449568944507153" ORDER="305" O_E="0.0" SE="0.45746385972816855" STUDY_ID="STD-Gilson-1993" TOTAL_1="19" TOTAL_2="14" VAR="0.20927318295739347" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all multiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.760797354253286" CI_START="0.4423771233486558" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="1.0318444529030866" LOG_CI_START="-0.3542073397963247" LOG_EFFECT_SIZE="0.33881855655338095" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.33795119593305334" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.9582212896174067">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.760797354253292" CI_START="0.4423771233486557" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0318444529030868" LOG_CI_START="-0.3542073397963248" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="306" O_E="0.0" SE="0.8141736840986621" STUDY_ID="STD-Gilson-1993" TOTAL_1="22" TOTAL_2="24" VAR="0.662878787878788" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all multiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.760797354253286" CI_START="0.4423771233486558" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="1.0318444529030866" LOG_CI_START="-0.3542073397963247" LOG_EFFECT_SIZE="0.33881855655338095" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.33795119593305334" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.9582212896174067">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.760797354253292" CI_START="0.4423771233486557" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0318444529030868" LOG_CI_START="-0.3542073397963248" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="307" O_E="0.0" SE="0.8141736840986621" STUDY_ID="STD-Gilson-1993" TOTAL_1="22" TOTAL_2="24" VAR="0.662878787878788" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Intracervical prostaglandin (PGE2) vs placebo/no treatment: all multiparae, intact memb, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.760797354253286" CI_START="0.4423771233486558" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="1.0318444529030866" LOG_CI_START="-0.3542073397963247" LOG_EFFECT_SIZE="0.33881855655338095" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.33795119593305334" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="24" WEIGHT="100.0" Z="0.9582212896174067">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.760797354253292" CI_START="0.4423771233486557" EFFECT_SIZE="2.1818181818181817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0318444529030868" LOG_CI_START="-0.3542073397963248" LOG_EFFECT_SIZE="0.33881855655338095" ORDER="308" O_E="0.0" SE="0.8141736840986621" STUDY_ID="STD-Gilson-1993" TOTAL_1="22" TOTAL_2="24" VAR="0.662878787878788" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Intracervical prostaglandin lower vs higher dose: all women</NAME>
<DICH_OUTCOME CHI2="1.315778838937033" CI_END="1.441948266459518" CI_START="0.4274908176702483" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7851239669421488" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="23.999385732038267" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.15894967925012546" LOG_CI_START="-0.36907320930532994" LOG_EFFECT_SIZE="-0.10506176502760228" METHOD="MH" NO="1" P_CHI2="0.2513511572166808" P_Q="0.0" P_Z="0.43541685792970575" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.7799558696012242">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.328959688920238" CI_START="0.28495839867028494" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.12351180777116395" LOG_CI_START="-0.5452185384009502" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="309" O_E="0.0" SE="0.39281551561010075" STUDY_ID="STD-Milliez-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.1543040293040293" WEIGHT="75.20661157024794"/>
<DICH_DATA CI_END="3.6203763686169754" CI_START="0.4668022956534762" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.558753721449455" LOG_CI_START="-0.3308670168357815" LOG_EFFECT_SIZE="0.11394335230683678" ORDER="310" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Stiver-1991" TOTAL_1="15" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="24.793388429752067"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6305839436008545" CI_START="0.3966304105261347" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.5599764826360275" LOG_CI_START="-0.4016139905407779" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.7468598069356736" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.32278271225304517">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6305839436008545" CI_START="0.3966304105261347" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5599764826360275" LOG_CI_START="-0.4016139905407779" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="311" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Milliez-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.319047619047619" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6694674802165995" CI_START="0.23899592546038773" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-0.1742705142539117" LOG_CI_START="-0.6216095030901635" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="4.883688205633024E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="3.487056145201107">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6694674802165995" CI_START="0.23899592546038773" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.1742705142539117" LOG_CI_START="-0.6216095030901635" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="312" O_E="0.0" SE="0.2627691364061218" STUDY_ID="STD-Milliez-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.06904761904761905" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Intracervical prostaglandin lower vs higher dose: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="1.315778838937033" CI_END="1.441948266459518" CI_START="0.4274908176702483" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7851239669421488" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="23.999385732038267" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.15894967925012546" LOG_CI_START="-0.36907320930532994" LOG_EFFECT_SIZE="-0.10506176502760228" METHOD="MH" NO="1" P_CHI2="0.2513511572166808" P_Q="0.0" P_Z="0.43541685792970575" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.7799558696012242">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>0.25 mg PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>0.50 mg PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.25 mg PGE2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.50 mg PGE2</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.328959688920238" CI_START="0.28495839867028494" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.12351180777116395" LOG_CI_START="-0.5452185384009502" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="313" O_E="0.0" SE="0.39281551561010075" STUDY_ID="STD-Milliez-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.1543040293040293" WEIGHT="75.20661157024794"/>
<DICH_DATA CI_END="3.6203763686169754" CI_START="0.4668022956534762" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.558753721449455" LOG_CI_START="-0.3308670168357815" LOG_EFFECT_SIZE="0.11394335230683678" ORDER="314" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Stiver-1991" TOTAL_1="15" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="24.793388429752067"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6305839436008545" CI_START="0.3966304105261347" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.5599764826360275" LOG_CI_START="-0.4016139905407779" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.7468598069356736" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.32278271225304517">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6305839436008545" CI_START="0.3966304105261347" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5599764826360275" LOG_CI_START="-0.4016139905407779" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="315" O_E="0.0" SE="0.5648430038936652" STUDY_ID="STD-Milliez-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.319047619047619" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6694674802165995" CI_START="0.23899592546038773" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-0.1742705142539117" LOG_CI_START="-0.6216095030901635" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="4.883688205633024E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="3.487056145201107">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours low dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours high dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6694674802165995" CI_START="0.23899592546038773" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="30" LOG_CI_END="-0.1742705142539117" LOG_CI_START="-0.6216095030901635" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="316" O_E="0.0" SE="0.2627691364061218" STUDY_ID="STD-Milliez-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.06904761904761905" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" NO="13">
<NAME>Intracervical prostaglandin lower vs higher dose: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6203763686169754" CI_START="0.4668022956534762" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.558753721449455" LOG_CI_START="-0.3308670168357815" LOG_EFFECT_SIZE="0.11394335230683678" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6156199842743051" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.5020675827086103">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.25 mg PGE2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.50 mg PGE2</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6203763686169754" CI_START="0.4668022956534762" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.558753721449455" LOG_CI_START="-0.3308670168357815" LOG_EFFECT_SIZE="0.11394335230683678" ORDER="317" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Stiver-1991" TOTAL_1="15" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" NO="14">
<NAME>Intracervical prostaglandin lower vs higher dose: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6203763686169754" CI_START="0.4668022956534762" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.558753721449455" LOG_CI_START="-0.3308670168357815" LOG_EFFECT_SIZE="0.11394335230683678" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6156199842743051" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.5020675827086103">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Low dose PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>High dose PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.25 mg PGE2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.50 mg PGE2</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6203763686169754" CI_START="0.4668022956534762" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.558753721449455" LOG_CI_START="-0.3308670168357815" LOG_EFFECT_SIZE="0.11394335230683678" ORDER="318" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Stiver-1991" TOTAL_1="15" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" NO="20">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all women</NAME>
<DICH_OUTCOME CHI2="31.97571191506318" CI_END="1.4098101492291077" CI_START="1.1176689854092807" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2552693253276779" ESTIMABLE="YES" EVENTS_1="410" EVENTS_2="315" I2="68.72626315072227" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.1491606327308852" LOG_CI_START="0.04831319970773588" LOG_EFFECT_SIZE="0.09873691621931055" METHOD="MH" NO="1" P_CHI2="4.041872636543209E-4" P_Q="0.0" P_Z="1.240948199878031E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1122" TOTAL_2="1078" WEIGHT="99.99999999999999" Z="3.837892426869707">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3069812799665868" CI_START="0.6638886736960186" EFFECT_SIZE="0.9314988290398126" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.11626936717852775" LOG_CI_START="-0.17790474059133726" LOG_EFFECT_SIZE="-0.03081768670640474" ORDER="319" O_E="0.0" SE="0.17279932708933723" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.02985960744252776" WEIGHT="13.715756299684411"/>
<DICH_DATA CI_END="1.1962022489978994" CI_START="0.789267031588584" EFFECT_SIZE="0.97165991902834" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.07780461460046488" LOG_CI_START="-0.10277603769658433" LOG_EFFECT_SIZE="-0.012485711548059728" ORDER="320" O_E="0.0" SE="0.10607396904793205" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.011251686909581646" WEIGHT="12.324051378659448"/>
<DICH_DATA CI_END="1.57472062445261" CI_START="0.7244360927471779" EFFECT_SIZE="1.068075117370892" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.19720351557271068" LOG_CI_START="-0.13999992046392368" LOG_EFFECT_SIZE="0.028601797554393477" ORDER="321" O_E="0.0" SE="0.19807496751184767" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.03923369275481951" WEIGHT="11.305982184746586"/>
<DICH_DATA CI_END="2.4512425303413665" CI_START="1.2704021523015954" EFFECT_SIZE="1.7646710136336692" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="42" LOG_CI_END="0.38938628325453745" LOG_CI_START="0.1039412208606615" LOG_EFFECT_SIZE="0.24666375205759952" ORDER="322" O_E="0.0" SE="0.1676718426260098" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.028113846809601394" WEIGHT="13.431825313850343"/>
<DICH_DATA CI_END="4.1033869835640875" CI_START="1.4252699156035287" EFFECT_SIZE="2.4183535762483133" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.6131424764846473" LOG_CI_START="0.1538971182089092" LOG_EFFECT_SIZE="0.38351979734677827" ORDER="323" O_E="0.0" SE="0.2697629967523553" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.07277207441681127" WEIGHT="4.089840059289639"/>
<DICH_DATA CI_END="2.7778396262654743" CI_START="0.7616359343909251" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.4437071688895549" LOG_CI_START="-0.11825257389415549" LOG_EFFECT_SIZE="0.16272729749769974" ORDER="324" O_E="0.0" SE="0.33009793465674164" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.10896464646464646" WEIGHT="3.430277458634967"/>
<DICH_DATA CI_END="1.4069746121062945" CI_START="0.7577924314881198" EFFECT_SIZE="1.0325670498084292" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" LOG_CI_END="0.1482862609588256" LOG_CI_START="-0.12044973658987246" LOG_EFFECT_SIZE="0.013918262184476567" ORDER="325" O_E="0.0" SE="0.15785685522474732" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.024918786741446836" WEIGHT="14.405509520574842"/>
<DICH_DATA CI_END="1.7094739947338837" CI_START="0.7602338520524323" EFFECT_SIZE="1.14" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.23286249850524962" LOG_CI_START="-0.11905279583230446" LOG_EFFECT_SIZE="0.05690485133647255" ORDER="326" O_E="0.0" SE="0.20671678590268097" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.04273182957393484" WEIGHT="5.980558458392221"/>
<DICH_DATA CI_END="2.294712619067593" CI_START="1.0800050270939199" EFFECT_SIZE="1.5742621015348288" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="35" LOG_CI_END="0.3607283039177005" LOG_CI_START="0.033425776999975856" LOG_EFFECT_SIZE="0.19707704045883817" ORDER="327" O_E="0.0" SE="0.19225912448510948" STUDY_ID="STD-Rath-1999" TOTAL_1="242" TOTAL_2="226" VAR="0.03696357094778083" WEIGHT="11.287665141662073"/>
<DICH_DATA CI_END="2.4459176182544256" CI_START="0.9508869422310191" EFFECT_SIZE="1.5250544662309369" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.38844182533312444" LOG_CI_START="-0.021871116379133193" LOG_EFFECT_SIZE="0.18328535447699562" ORDER="328" O_E="0.0" SE="0.24101985304359846" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.0580905695611578" WEIGHT="5.350883104548683"/>
<DICH_DATA CI_END="0.9488661246391552" CI_START="0.2997729996448298" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="-0.022795057785415497" LOG_CI_START="-0.5232074863420597" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="329" O_E="0.0" SE="0.29394473761564405" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.08640350877192982" WEIGHT="4.677651079956774"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.305389395530412" CI_END="1.492937124227412" CI_START="0.38909719687842664" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7621664189352778" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-020.02" LOG_CI_END="0.17404151758698946" LOG_CI_START="-0.40994189791539526" LOG_EFFECT_SIZE="-0.1179501901642029" METHOD="MH" NO="2" P_CHI2="0.7440069791855776" P_Q="0.0" P_Z="0.42851907178237303" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="703" TOTAL_2="725" WEIGHT="100.0" Z="0.7917283900694752">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.137559058351389" CI_START="0.014402141787243155" EFFECT_SIZE="0.34234234234234234" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9104941534807701" LOG_CI_START="-1.8415729178204643" LOG_EFFECT_SIZE="-0.46553938216984725" ORDER="330" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="8.352543429894348"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="331" O_E="0.0" SE="0.0" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1214686175061974" CI_START="0.03460014351373879" EFFECT_SIZE="0.3286384976525822" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49435897299711784" LOG_CI_START="-1.4609220998460797" LOG_EFFECT_SIZE="-0.4832815634244808" ORDER="332" O_E="0.0" SE="1.1485417809855023" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="1.3191482226693494" WEIGHT="17.05090809437892"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="333" O_E="0.0" SE="0.0" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.190781592665074" CI_START="0.011289421398428319" EFFECT_SIZE="0.26436781609195403" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7917454826151455" LOG_CI_START="-1.9473283158171968" LOG_EFFECT_SIZE="-0.5777914166010256" ORDER="334" O_E="0.0" SE="1.608945507833131" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="2.5887056471764116" WEIGHT="9.442194365914869"/>
<DICH_DATA CI_END="28.311269081090536" CI_START="0.11706529015561468" EFFECT_SIZE="1.8205128205128205" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4519593374880801" LOG_CI_START="-0.931571854102928" LOG_EFFECT_SIZE="0.26019374169257603" ORDER="335" O_E="0.0" SE="1.4000980206102431" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="1.960274467316721" WEIGHT="4.001832847246678"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="336" O_E="0.0" SE="0.0" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.15509104376217" CI_START="0.043608692016736256" EFFECT_SIZE="0.47413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.712236339736774" LOG_CI_START="-1.3604269392021233" LOG_EFFECT_SIZE="-0.32409529973267465" ORDER="337" O_E="0.0" SE="1.2174926698974078" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="1.4822884012539186" WEIGHT="11.586881581771639"/>
<DICH_DATA CI_END="3.405584464032359" CI_START="0.4711216125718147" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5321916559615373" LOG_CI_START="-0.3268669721672419" LOG_EFFECT_SIZE="0.10266234189714771" ORDER="338" O_E="0.0" SE="0.5046152905716361" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.25463659147869677" WEIGHT="32.470087380189064"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Stempel-1997" TOTAL_1="39" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="340" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="2.7878075596358536"/>
<DICH_DATA CI_END="3.9074989067326817" CI_START="0.009675918759737532" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5918988651813" LOG_CI_START="-2.0143077866873607" LOG_EFFECT_SIZE="-0.7112044607530305" ORDER="341" O_E="0.0" SE="1.5308986882386417" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="2.3436507936507938" WEIGHT="14.307744740968621"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="342" O_E="0.0" SE="0.0" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.84226213689923" CI_END="1.215409034694934" CI_START="0.9332413933359489" CI_STUDY="95" CI_TOTAL="95" DF="26.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0650211364155178" ESTIMABLE="YES" EVENTS_1="363" EVENTS_2="337" I2="0.0" I2_Q="0.0" ID="CMP-020.03" LOG_CI_END="0.08472246033413128" LOG_CI_START="-0.030006006592057717" LOG_EFFECT_SIZE="0.027358226871036794" METHOD="MH" NO="3" P_CHI2="0.8814367055536109" P_Q="0.0" P_Z="0.3499178636262317" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1906" TOTAL_2="1875" WEIGHT="99.99999999999999" Z="0.9347486423331257">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.295416209760943" CI_START="0.9664880353757405" EFFECT_SIZE="2.466666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7990244479668573" LOG_CI_START="-0.014803517944229825" LOG_EFFECT_SIZE="0.39211046501131375" ORDER="343" O_E="0.0" SE="0.4780465756895749" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="0.2285285285285285" WEIGHT="1.461372113280683"/>
<DICH_DATA CI_END="1.7288008718872945" CI_START="0.32053906950874267" EFFECT_SIZE="0.7444113263785395" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.23774497290326527" LOG_CI_START="-0.4941190281172472" LOG_EFFECT_SIZE="-0.12818702760699097" ORDER="344" O_E="0.0" SE="0.4299005369846816" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.1848144716997176" WEIGHT="3.4135617656093316"/>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="345" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="1.1853351585498872"/>
<DICH_DATA CI_END="2.1394533663452178" CI_START="0.2485139597532066" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3303028246083761" LOG_CI_START="-0.6046492106589992" LOG_EFFECT_SIZE="-0.1371731930253116" ORDER="346" O_E="0.0" SE="0.5491954536032717" STUDY_ID="STD-El_x002d_Din-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.3016156462585034" WEIGHT="2.052951614808052"/>
<DICH_DATA CI_END="2.331408122561638" CI_START="0.5920088285042477" EFFECT_SIZE="1.1748251748251748" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3676183052073158" LOG_CI_START="-0.22767181668571365" LOG_EFFECT_SIZE="0.06997324426080104" ORDER="347" O_E="0.0" SE="0.34967636433359317" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.12227355977355979" WEIGHT="3.3900585534526773"/>
<DICH_DATA CI_END="1.9234385073419273" CI_START="0.8638292084503612" EFFECT_SIZE="1.2890005288207298" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.284078306395904" LOG_CI_START="-0.0635721153448345" LOG_EFFECT_SIZE="0.11025309552553472" ORDER="348" O_E="0.0" SE="0.2042115786278517" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.04170236884567926" WEIGHT="9.07477240816938"/>
<DICH_DATA CI_END="3.021152967753493" CI_START="0.5719843426248314" EFFECT_SIZE="1.3145539906103287" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4801727151340536" LOG_CI_START="-0.2426158593270905" LOG_EFFECT_SIZE="0.11877842790348153" ORDER="349" O_E="0.0" SE="0.4245695864996226" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.18025933378046052" WEIGHT="2.685919029480064"/>
<DICH_DATA CI_END="1.6427031309531541" CI_START="0.865560422855015" EFFECT_SIZE="1.1924172158489952" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="51" LOG_CI_END="0.21555908489691913" LOG_CI_START="-0.06270260959497831" LOG_EFFECT_SIZE="0.07642823765097041" ORDER="350" O_E="0.0" SE="0.163452296762143" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.02671665331681967" WEIGHT="15.498887695464536"/>
<DICH_DATA CI_END="2.211653210227933" CI_START="0.3341376536453985" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.34471703009577304" LOG_CI_START="-0.4760745813837285" LOG_EFFECT_SIZE="-0.06567877564397773" ORDER="351" O_E="0.0" SE="0.482137055567063" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.2324561403508772" WEIGHT="2.3916497004369406"/>
<DICH_DATA CI_END="5.142682235171369" CI_START="0.12004376520746443" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7111896902213181" LOG_CI_START="-0.9206603912613439" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="352" O_E="0.0" SE="0.9585568156510959" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="0.9188311688311689" WEIGHT="0.6637876887879369"/>
<DICH_DATA CI_END="1.9053621419675966" CI_START="0.6034304687975657" EFFECT_SIZE="1.072265625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2799775318808865" LOG_CI_START="-0.21937276493236413" LOG_EFFECT_SIZE="0.03030238347426115" ORDER="353" O_E="0.0" SE="0.2933208361719377" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.08603711293260473" WEIGHT="4.855132809420338"/>
<DICH_DATA CI_END="1.4954350427230212" CI_START="0.27607341539705244" EFFECT_SIZE="0.6425339366515838" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="0.174767553308738" LOG_CI_START="-0.5589754119128463" LOG_EFFECT_SIZE="-0.19210392930205417" ORDER="354" O_E="0.0" SE="0.43100424985741403" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="0.18576466339515219" WEIGHT="3.5721691369026147"/>
<DICH_DATA CI_END="1.6844083977629603" CI_START="0.42506100795497403" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.22644739796612254" LOG_CI_START="-0.371548732263346" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="355" O_E="0.0" SE="0.3512658870253748" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.12338772338772339" WEIGHT="3.8523392652871333"/>
<DICH_DATA CI_END="2.237013939702587" CI_START="0.3391059814285512" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.34966869036263354" LOG_CI_START="-0.46966454971320426" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="356" O_E="0.0" SE="0.481280400985496" STUDY_ID="STD-Peccerillo-1995" TOTAL_1="31" TOTAL_2="36" VAR="0.23163082437275984" WEIGHT="2.193754621793821"/>
<DICH_DATA CI_END="2.7485639734791887" CI_START="0.497047299758468" EFFECT_SIZE="1.1688311688311688" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4391058497265867" LOG_CI_START="-0.3036022811929008" LOG_EFFECT_SIZE="0.06775178426684299" ORDER="357" O_E="0.0" SE="0.4362704325666482" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.19033189033189032" WEIGHT="2.17311445734146"/>
<DICH_DATA CI_END="2.1531230824176957" CI_START="0.49014519281782254" EFFECT_SIZE="1.0272988505747127" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3330688568030305" LOG_CI_START="-0.30967525242199345" LOG_EFFECT_SIZE="0.01169680219051853" ORDER="358" O_E="0.0" SE="0.37755107139343247" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.14254481151032874" WEIGHT="3.650412700666909"/>
<DICH_DATA CI_END="4.652365301456785" CI_START="0.39589254397481366" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6676738079863876" LOG_CI_START="-0.4024226774372058" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="359" O_E="0.0" SE="0.6285799726008515" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.3951127819548872" WEIGHT="1.1366227547738643"/>
<DICH_DATA CI_END="1.783694667119325" CI_START="0.9416538748144286" EFFECT_SIZE="1.2960026986001012" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="49" LOG_CI_END="0.25132051386623455" LOG_CI_START="-0.02610870217684992" LOG_EFFECT_SIZE="0.11260590584469231" ORDER="360" O_E="0.0" SE="0.16296329480047547" STUDY_ID="STD-Rath-1999" TOTAL_1="242" TOTAL_2="226" VAR="0.026557035452226672" WEIGHT="15.016778109064704"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="361" O_E="0.0" SE="0.0" STUDY_ID="STD-Richardson-1991" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4661591448706992" CI_START="0.4277407461011015" EFFECT_SIZE="0.7919191919191919" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.1661811135438086" LOG_CI_START="-0.36881937737003156" LOG_EFFECT_SIZE="-0.10131913191311148" ORDER="362" O_E="0.0" SE="0.31426193665793095" STUDY_ID="STD-Rix-1996" TOTAL_1="110" TOTAL_2="98" VAR="0.0987605648319934" WEIGHT="5.64173945655956"/>
<DICH_DATA CI_END="4.616294603211986" CI_START="0.2703360076906147" EFFECT_SIZE="1.117117117117117" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6642935168865485" LOG_CI_START="-0.5680961041353932" LOG_EFFECT_SIZE="0.0480987063755776" ORDER="363" O_E="0.0" SE="0.723911763815299" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.5240482417901773" WEIGHT="0.9674426661693932"/>
<DICH_DATA CI_END="2.931418778371528" CI_START="0.43420845247346274" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.46707786557054265" LOG_CI_START="-0.36230172665116617" LOG_EFFECT_SIZE="0.05238806945968822" ORDER="364" O_E="0.0" SE="0.48718167796622575" STUDY_ID="STD-Stempel-1997" TOTAL_1="39" TOTAL_2="44" VAR="0.2373459873459873" WEIGHT="1.9493764956874653"/>
<DICH_DATA CI_END="2.0779392669387473" CI_START="0.48755737482639344" EFFECT_SIZE="1.0065359477124183" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3176328500455952" LOG_CI_START="-0.3119742700078667" LOG_EFFECT_SIZE="0.0028292900188642534" ORDER="365" O_E="0.0" SE="0.3698343389249118" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.13677743824802652" WEIGHT="3.3898369954791168"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="366" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="0.1463817515076668"/>
<DICH_DATA CI_END="1.4139606492320238" CI_START="0.1298999865997085" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15043732313896063" LOG_CI_START="-0.8863908937281496" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="367" O_E="0.0" SE="0.6090380269701879" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.37092731829573933" WEIGHT="2.074336527462303"/>
<DICH_DATA CI_END="1.6722857022266164" CI_START="0.3777556053060831" EFFECT_SIZE="0.7948051948051948" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2233104766321436" LOG_CI_START="-0.4227890826859849" LOG_EFFECT_SIZE="-0.09973930302692065" ORDER="368" O_E="0.0" SE="0.37952207938786786" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="0.14403700874289108" WEIGHT="3.3069133046500476"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5572084962688248" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="369" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="1.481668948187359"/>
<DICH_DATA CI_END="1.4227199692045693" CI_START="0.18484655031342975" EFFECT_SIZE="0.5128205128205128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.1531194272823733" LOG_CI_START="-0.7331886500074094" LOG_EFFECT_SIZE="-0.29003461136251807" ORDER="370" O_E="0.0" SE="0.5206217518957583" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.2710470085470086" WEIGHT="2.773684271006736"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="371" O_E="0.0" SE="0.0" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="372" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.05" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="211" TOTAL_2="204" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="373" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="374" O_E="0.0" SE="0.0" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="375" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.616401167883843" CI_END="1.1558466851479017" CI_START="0.9078603438149618" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0243765757648688" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="300" I2="40.91231758060364" I2_Q="0.0" ID="CMP-020.07" LOG_CI_END="0.06290023182672605" LOG_CI_START="-0.04198095387465188" LOG_EFFECT_SIZE="0.010459638976037106" METHOD="MH" NO="7" P_CHI2="0.06833650561915938" P_Q="0.0" P_Z="0.6958501812050399" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="996" TOTAL_2="962" WEIGHT="100.0" Z="0.39092837380183815">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5642857731829913" CI_START="0.613733129766819" EFFECT_SIZE="0.9798234552332913" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.19431609551360027" LOG_CI_START="-0.2120204325469793" LOG_EFFECT_SIZE="-0.008852168516689544" ORDER="376" O_E="0.0" SE="0.23868408798103774" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.056970093855339764" WEIGHT="8.969408976719302"/>
<DICH_DATA CI_END="2.331408122561638" CI_START="0.5920088285042477" EFFECT_SIZE="1.1748251748251748" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3676183052073158" LOG_CI_START="-0.22767181668571365" LOG_EFFECT_SIZE="0.06997324426080104" ORDER="377" O_E="0.0" SE="0.34967636433359317" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.12227355977355979" WEIGHT="3.768622165136323"/>
<DICH_DATA CI_END="1.6566925787021856" CI_START="0.5132671348907573" EFFECT_SIZE="0.9221311475409836" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.21924192678994753" LOG_CI_START="-0.28965654324468143" LOG_EFFECT_SIZE="-0.03520730822736695" ORDER="378" O_E="0.0" SE="0.29892948038639505" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.08935883424408014" WEIGHT="6.508478017986912"/>
<DICH_DATA CI_END="1.5424817014185026" CI_START="0.5843573750484679" EFFECT_SIZE="0.9494001043296818" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.18822002066631102" LOG_CI_START="-0.23332147045228657" LOG_EFFECT_SIZE="-0.0225507248929878" ORDER="379" O_E="0.0" SE="0.24761555854709855" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06131346483459159" WEIGHT="8.95755677548769"/>
<DICH_DATA CI_END="1.2599646537922178" CI_START="0.7543124049067086" EFFECT_SIZE="0.974888182357062" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" LOG_CI_END="0.10035836188080684" LOG_CI_START="-0.12244875011484846" LOG_EFFECT_SIZE="-0.011045194117020853" ORDER="380" O_E="0.0" SE="0.13087800049923984" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.017129051014679025" WEIGHT="26.013361671787962"/>
<DICH_DATA CI_END="1.5311979112346663" CI_START="0.4619054318306297" EFFECT_SIZE="0.8409926470588235" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.1850313279955445" LOG_CI_START="-0.3354469305869703" LOG_EFFECT_SIZE="-0.07520780129571285" ORDER="381" O_E="0.0" SE="0.3057315055003009" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.09347175345548055" WEIGHT="5.7346306512843634"/>
<DICH_DATA CI_END="1.571729812929991" CI_START="0.8837591555608987" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.1963778910426403" LOG_CI_START="-0.05366607397130375" LOG_EFFECT_SIZE="0.07135590853566827" ORDER="382" O_E="0.0" SE="0.1468770627867795" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.021572871572871567" WEIGHT="9.223900404179812"/>
<DICH_DATA CI_END="1.1296053653640439" CI_START="0.5456946845045478" EFFECT_SIZE="0.7851239669421488" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.05292674651090118" LOG_CI_START="-0.26305027656610575" LOG_EFFECT_SIZE="-0.10506176502760228" ORDER="383" O_E="0.0" SE="0.18560646746692377" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.03444976076555024" WEIGHT="7.59246223745413"/>
<DICH_DATA CI_END="1.3388368861375306" CI_START="0.9939426188468702" EFFECT_SIZE="1.1535714285714285" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" LOG_CI_END="0.12672766904674287" LOG_CI_START="-0.0026386870689756904" LOG_EFFECT_SIZE="0.06204449098888362" ORDER="384" O_E="0.0" SE="0.07599043795616373" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.0057745466607695695" WEIGHT="10.108384004580616"/>
<DICH_DATA CI_END="6.930145644165142" CI_START="0.5514817540841652" EFFECT_SIZE="1.954954954954955" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8407423618546033" LOG_CI_START="-0.2584688517308592" LOG_EFFECT_SIZE="0.29113675506187203" ORDER="385" O_E="0.0" SE="0.6456821080433622" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.4169053846473201" WEIGHT="1.075475782420125"/>
<DICH_DATA CI_END="2.4790857287876475" CI_START="1.1616000685227186" EFFECT_SIZE="1.696969696969697" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" LOG_CI_END="0.3942915452816011" LOG_CI_START="0.06505662897502476" LOG_EFFECT_SIZE="0.22967408712831291" ORDER="386" O_E="0.0" SE="0.1933942195776028" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.037401324166030044" WEIGHT="6.908689087776868"/>
<DICH_DATA CI_END="0.9652635558535889" CI_START="0.19223985931326396" EFFECT_SIZE="0.4307692307692308" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.015354090567863797" LOG_CI_START="-0.7161565600334088" LOG_EFFECT_SIZE="-0.3657553253006363" ORDER="387" O_E="0.0" SE="0.4116548395922328" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.16945970695970694" WEIGHT="5.139030225185895"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.613840959000737" CI_END="1.1495579960405644" CI_START="0.5624339369306076" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8040835960540138" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-020.08" LOG_CI_END="0.06053088663184705" LOG_CI_START="-0.24992848212580923" LOG_EFFECT_SIZE="-0.09469879774698109" METHOD="MH" NO="8" P_CHI2="0.8978485987147944" P_Q="0.0" P_Z="0.23181845285109814" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="846" TOTAL_2="835" WEIGHT="100.0" Z="1.195687755895745">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.135716153037741" CI_START="0.010201710902903432" EFFECT_SIZE="0.20540540540540542" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6165507241382008" LOG_CI_START="-1.991326987710608" LOG_EFFECT_SIZE="-0.6873881317862036" ORDER="388" O_E="0.0" SE="1.531880277142861" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.3466571834992886" WEIGHT="4.072923893255105"/>
<DICH_DATA CI_END="2.8177477536337507" CI_START="0.1424447604602849" EFFECT_SIZE="0.6335403726708074" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.44990211222676235" LOG_CI_START="-0.8463535207666267" LOG_EFFECT_SIZE="-0.19822570426993216" ORDER="389" O_E="0.0" SE="0.7614269753891851" STUDY_ID="STD-Duhl-1997" TOTAL_1="23" TOTAL_2="51" VAR="0.5797710388503227" WEIGHT="7.184887656837896"/>
<DICH_DATA CI_END="14.351608110052847" CI_START="0.05937111711685543" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1569005668674324" LOG_CI_START="-1.2264247793858563" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="390" O_E="0.0" SE="1.3999771060399158" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.9599358974358976" WEIGHT="1.7172327766156659"/>
<DICH_DATA CI_END="2.6483015026680636" CI_START="0.09175969562706825" EFFECT_SIZE="0.49295774647887325" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42296742695009537" LOG_CI_START="-1.0373480356876947" LOG_EFFECT_SIZE="-0.3071903043687996" ORDER="391" O_E="0.0" SE="0.8577965314315605" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.7358148893360161" WEIGHT="6.65158358645457"/>
<DICH_DATA CI_END="1.407828600979414" CI_START="0.5659559153410323" EFFECT_SIZE="0.8926191374324154" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.14854978393965634" LOG_CI_START="-0.24721739649684682" LOG_EFFECT_SIZE="-0.04933380627859521" ORDER="392" O_E="0.0" SE="0.23247560086754074" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.05404490499872411" WEIGHT="55.8803284469083"/>
<DICH_DATA CI_END="1.951484656911305" CI_START="0.07908682968491929" EFFECT_SIZE="0.39285714285714285" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.2903651410925684" LOG_CI_START="-1.1018958334605569" LOG_EFFECT_SIZE="-0.4057653461839942" ORDER="393" O_E="0.0" SE="0.8178209882554793" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="0.6688311688311689" WEIGHT="7.3973104223444075"/>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="394" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="4.12796340532612"/>
<DICH_DATA CI_END="4.164933703007989" CI_START="0.19842963656176835" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6196080927423374" LOG_CI_START="-0.7023934630587876" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="395" O_E="0.0" SE="0.7765502578908225" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.603030303030303" WEIGHT="5.189439709552836"/>
<DICH_DATA CI_END="97.71268963612164" CI_START="0.2302837404157544" EFFECT_SIZE="4.743589743589744" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9899509678239824" LOG_CI_START="-0.6377367250709531" LOG_EFFECT_SIZE="0.6761071213765146" ORDER="396" O_E="0.0" SE="1.5435167580703433" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="2.3824439824439825" WEIGHT="0.847318804251151"/>
<DICH_DATA CI_END="7.049177464499069" CI_START="0.22405983586143138" EFFECT_SIZE="1.2567567567567568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8481384441588127" LOG_CI_START="-0.6496359865128948" LOG_EFFECT_SIZE="0.09925122882295893" ORDER="397" O_E="0.0" SE="0.8798001146795659" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.7740482417901773" WEIGHT="3.5937563764015628"/>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="398" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="0.825592681065224"/>
<DICH_DATA CI_END="7.689287448668567" CI_START="0.013658483466521182" EFFECT_SIZE="0.32407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8858860964400181" LOG_CI_START="-1.864597518713366" LOG_EFFECT_SIZE="-0.4893557111366741" ORDER="399" O_E="0.0" SE="1.6156476906545747" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="2.6103174603174604" WEIGHT="2.5116622409871603"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="400" O_E="0.0" SE="0.0" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.09" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Uterine rupture</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="401" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.05773966837014719" CI_END="1.2525719900269068" CI_START="0.9140690543006779" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0700174271325738" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-020.10" LOG_CI_END="0.09780269579514404" LOG_CI_START="-0.03902099379691438" LOG_EFFECT_SIZE="0.029390850999114832" METHOD="MH" NO="10" P_CHI2="0.8101048291670013" P_Q="0.0" P_Z="0.3997696661556088" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.8420326860794094">
<NAME>Epidural analgesia</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.239982415032324" CI_START="0.9060065806079148" EFFECT_SIZE="1.0599208592425098" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="87" LOG_CI_END="0.09341552620370377" LOG_CI_START="-0.04286864789567482" LOG_EFFECT_SIZE="0.02527343915401449" ORDER="402" O_E="0.0" SE="0.08005399848351687" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.006408642673198921" WEIGHT="87.77437396705018"/>
<DICH_DATA CI_END="2.112134899645715" CI_START="0.6180099035734969" EFFECT_SIZE="1.1425061425061425" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.3247216526405573" LOG_CI_START="-0.20900456531108952" LOG_EFFECT_SIZE="0.05785854366473387" ORDER="403" O_E="0.0" SE="0.3135134224121856" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.09829066603260153" WEIGHT="12.225626032949807"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.51170175148122" CI_END="1.1584642158998744" CI_START="0.7004395479962197" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9007963986133065" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="102" I2="5.379707699534791" I2_Q="0.0" ID="CMP-020.11" LOG_CI_END="0.063882623298852" LOG_CI_START="-0.1546293408986411" LOG_EFFECT_SIZE="-0.04537335879989455" METHOD="MH" NO="11" P_CHI2="0.3914401237585887" P_Q="0.0" P_Z="0.4156670877778461" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="574" TOTAL_2="556" WEIGHT="100.0" Z="0.8139613721565468">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5200063009166347" CI_START="0.2501817114497832" EFFECT_SIZE="0.6166666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1818453882392815" LOG_CI_START="-0.6017444408725787" LOG_EFFECT_SIZE="-0.2099495263166486" ORDER="404" O_E="0.0" SE="0.4602845444525178" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="0.21186186186186184" WEIGHT="9.543958611701807"/>
<DICH_DATA CI_END="1.2255560435528916" CI_START="0.48182542762847635" EFFECT_SIZE="0.7684426229508197" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.08833317593020137" LOG_CI_START="-0.3171102844801849" LOG_EFFECT_SIZE="-0.11438855427499177" ORDER="405" O_E="0.0" SE="0.23815949562255806" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.05671994535519125" WEIGHT="30.588752279196147"/>
<DICH_DATA CI_END="1.7624876761683648" CI_START="0.48853469960599044" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24612608895944366" LOG_CI_START="-0.31110458381377887" LOG_EFFECT_SIZE="-0.032489247427167606" ORDER="406" O_E="0.0" SE="0.327320055523307" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.1071384187477808" WEIGHT="16.566740292270644"/>
<DICH_DATA CI_END="2.066816229484576" CI_START="0.19116457243751045" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3153018631445367" LOG_CI_START="-0.7185925902006756" LOG_EFFECT_SIZE="-0.2016453635280694" ORDER="407" O_E="0.0" SE="0.6073147197550615" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="0.36883116883116884" WEIGHT="5.418847611755137"/>
<DICH_DATA CI_END="2.4273379255762912" CI_START="0.46204519868763866" EFFECT_SIZE="1.0590277777777777" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3851302415140314" LOG_CI_START="-0.33531553833892147" LOG_EFFECT_SIZE="0.024907351587554947" ORDER="408" O_E="0.0" SE="0.42319341734975074" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.1790926684881603" WEIGHT="8.917874926774168"/>
<DICH_DATA CI_END="2.593475870579404" CI_START="0.654950955846688" EFFECT_SIZE="1.3033033033033032" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.4138822117192451" LOG_CI_START="-0.18379121970686346" LOG_EFFECT_SIZE="0.11504549600619081" ORDER="409" O_E="0.0" SE="0.3510763321508963" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.12325459099652647" WEIGHT="9.47729125375242"/>
<DICH_DATA CI_END="2.9080662948391867" CI_START="0.1934275023228471" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4636043028591656" LOG_CI_START="-0.7134817760757655" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="410" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="3.870605436967955"/>
<DICH_DATA CI_END="8.150609039529751" CI_START="1.0420155332318335" EFFECT_SIZE="2.914285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9111900618227434" LOG_CI_START="0.017874193000540384" LOG_EFFECT_SIZE="0.4645321274116419" ORDER="411" O_E="0.0" SE="0.5247381633310296" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="0.2753501400560224" WEIGHT="3.9267011679385053"/>
<DICH_DATA CI_END="1.3288565127556677" CI_START="0.1881316738114724" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12347808923266526" LOG_CI_START="-0.7255380805606277" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="412" O_E="0.0" SE="0.498716300834401" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.24871794871794875" WEIGHT="9.676513592419887"/>
<DICH_DATA CI_END="4.928287746792142" CI_START="0.04322348093776479" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6926960569477116" LOG_CI_START="-1.364280260794098" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="413" O_E="0.0" SE="1.2082780712385282" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="1.4599358974358976" WEIGHT="2.012714827223337"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7631625695219707" CI_END="2.128581114797212" CI_START="0.5211816685941653" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0532698880856888" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-020.12" LOG_CI_END="0.32809020468351097" LOG_CI_START="-0.2830108680331428" LOG_EFFECT_SIZE="0.02253966832518411" METHOD="MH" NO="12" P_CHI2="0.6827810516414736" P_Q="0.0" P_Z="0.8850413478789186" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="293" TOTAL_2="288" WEIGHT="100.0" Z="0.14458144524096556">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.593206010672255" CI_START="0.36703878250827304" EFFECT_SIZE="1.971830985915493" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0250274182780577" LOG_CI_START="-0.43528804435973234" LOG_EFFECT_SIZE="0.2948696869591627" ORDER="414" O_E="0.0" SE="0.8577965314315605" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.7358148893360161" WEIGHT="14.254833327228305"/>
<DICH_DATA CI_END="2.1065713781932294" CI_START="0.3372781195111148" EFFECT_SIZE="0.842911877394636" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3235761791667643" LOG_CI_START="-0.47201183219891374" LOG_EFFECT_SIZE="-0.07421782651607471" ORDER="415" O_E="0.0" SE="0.46733233610037045" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.2183995123650296" WEIGHT="65.38603032223966"/>
<DICH_DATA CI_END="5.029145164581975" CI_START="0.23438884176692115" EFFECT_SIZE="1.0857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7014941715658538" LOG_CI_START="-0.6300630670327849" LOG_EFFECT_SIZE="0.03571555226653449" ORDER="416" O_E="0.0" SE="0.7821633132674748" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.6117794486215539" WEIGHT="20.359136350532033"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.643019524103465" CI_END="1.6800270666767136" CI_START="0.5083327872763703" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9241281520998688" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-020.13" LOG_CI_END="0.22531627863874906" LOG_CI_START="-0.29385187756076575" LOG_EFFECT_SIZE="-0.03426779946100837" METHOD="MH" NO="13" P_CHI2="0.8960903281920227" P_Q="0.0" P_Z="0.7958392185991168" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1027" TOTAL_2="1005" WEIGHT="99.99999999999999" Z="0.258735640739902">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.137559058351389" CI_START="0.014402141787243155" EFFECT_SIZE="0.34234234234234234" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9104941534807701" LOG_CI_START="-1.8415729178204643" LOG_EFFECT_SIZE="-0.46553938216984725" ORDER="417" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="6.780707901083519"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="418" O_E="0.0" SE="0.0" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.928287746792142" CI_START="0.04322348093776479" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6926960569477116" LOG_CI_START="-1.364280260794098" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="419" O_E="0.0" SE="1.2082780712385282" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.4599358974358976" WEIGHT="9.52964353665792"/>
<DICH_DATA CI_END="2.0918180543665583" CI_START="0.006193297489086655" EFFECT_SIZE="0.11382113821138211" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3205239070494482" LOG_CI_START="-2.2080780585717683" LOG_EFFECT_SIZE="-0.9437770757611599" ORDER="420" O_E="0.0" SE="1.4853133113875003" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.2061556329849012" WEIGHT="20.36861946841272"/>
<DICH_DATA CI_END="72.0003811846031" CI_START="0.12152730418332627" EFFECT_SIZE="2.958041958041958" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.857334795680317" LOG_CI_START="-0.9153261358603558" LOG_EFFECT_SIZE="0.47100432990998053" ORDER="421" O_E="0.0" SE="1.6286747560799544" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="2.6525814610920992" WEIGHT="2.3069119476944784"/>
<DICH_DATA CI_END="6.551094819355486" CI_START="0.38284280838705775" EFFECT_SIZE="1.5836791147994467" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.816313885376811" LOG_CI_START="-0.4169795066140591" LOG_EFFECT_SIZE="0.19966718938137595" ORDER="422" O_E="0.0" SE="0.724442643356186" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.5248171435128981" WEIGHT="14.09560613134958"/>
<DICH_DATA CI_END="21.060687049972" CI_START="0.18332166760237306" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3234725348050522" LOG_CI_START="-0.7367862008096718" LOG_EFFECT_SIZE="0.2933431669976902" ORDER="423" O_E="0.0" SE="1.2102061797453088" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="1.4645989974937343" WEIGHT="4.622104166010053"/>
<DICH_DATA CI_END="6.555615432182995" CI_START="0.13857543582639512" EFFECT_SIZE="0.953125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8166134689101281" LOG_CI_START="-0.8583137468563684" LOG_EFFECT_SIZE="-0.020850138973120137" ORDER="424" O_E="0.0" SE="0.983860537564674" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.9679815573770492" WEIGHT="9.383033636093952"/>
<DICH_DATA CI_END="21.280120118554144" CI_START="0.18796886379003092" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3279740750646463" LOG_CI_START="-0.7259140837366839" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="425" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="4.5815593926239995"/>
<DICH_DATA CI_END="6.655281347766423" CI_START="0.011839240266198875" EFFECT_SIZE="0.2807017543859649" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8231664197204929" LOG_CI_START="-1.9266761657536262" LOG_EFFECT_SIZE="-0.5517548730165667" ORDER="426" O_E="0.0" SE="1.615271146647826" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="2.6091008771929824" WEIGHT="7.4613967251305136"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="427" O_E="0.0" SE="0.0" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.928491935952064" CI_START="0.15163833770929122" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8406387158286682" LOG_CI_START="-0.819190985045122" LOG_EFFECT_SIZE="0.010723865391773066" ORDER="428" O_E="0.0" SE="0.9749921825827943" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="0.9506097560975609" WEIGHT="9.049993861973332"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="429" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.45532212106615" CI_START="0.12595282944426972" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.854034581366758" LOG_CI_START="-0.8997920719274333" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="430" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="2.2907796963119997"/>
<DICH_DATA CI_END="6.298162014230098" CI_START="0.135288835693967" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.799213828256879" LOG_CI_START="-0.8687380407753029" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="431" O_E="0.0" SE="0.9797631843644143" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.9599358974358974" WEIGHT="9.52964353665792"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5147677088304128" CI_END="1.463450525729987" CI_START="0.6044275182658649" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9405050607901327" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-020.14" LOG_CI_END="0.16537804500305317" LOG_CI_START="-0.2186557714028991" LOG_EFFECT_SIZE="-0.026638863199922987" METHOD="MH" NO="14" P_CHI2="0.468891626847986" P_Q="0.0" P_Z="0.7856916429231765" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="214" TOTAL_2="209" WEIGHT="100.0" Z="0.2719094529204029">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.492157276637085" CI_START="0.5584924037228736" EFFECT_SIZE="0.9128847157016171" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.17381460113650027" LOG_CI_START="-0.25298272952003653" LOG_EFFECT_SIZE="-0.03958406419176816" ORDER="432" O_E="0.0" SE="0.25070286470850933" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06285192637305313" WEIGHT="80.94736092641462"/>
<DICH_DATA CI_END="29.872852890628845" CI_START="0.355137811265585" EFFECT_SIZE="3.257142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4752767001901013" LOG_CI_START="-0.4496030862177075" LOG_EFFECT_SIZE="0.5128368069861969" ORDER="433" O_E="0.0" SE="1.1306839148445602" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="1.2784461152882205" WEIGHT="2.854597481594787"/>
<DICH_DATA CI_END="2.2819816189823543" CI_START="0.1968737309148568" EFFECT_SIZE="0.6702702702702703" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3583121419197571" LOG_CI_START="-0.7058122284013144" LOG_EFFECT_SIZE="-0.1737500432407787" ORDER="434" O_E="0.0" SE="0.6250719226271837" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.390714908456844" WEIGHT="16.19804159199059"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="435" O_E="0.0" SE="0.0" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.91346051193264" CI_END="1.443815828147329" CI_START="0.8799079574604878" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1271313305441557" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-020.18" LOG_CI_END="0.15951179855182257" LOG_CI_START="-0.055562754733524365" LOG_EFFECT_SIZE="0.051974521909149085" METHOD="MH" NO="18" P_CHI2="0.4481183476530062" P_Q="0.0" P_Z="0.3434948062070766" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1409" TOTAL_2="1401" WEIGHT="99.99999999999999" Z="0.947282600377815">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.23803152516251" CI_START="0.12961927608518836" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864736662920095" LOG_CI_START="-0.8873304083811396" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="436" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="0.47457498187257574"/>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="437" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="3.3669171011230032"/>
<DICH_DATA CI_END="6.424963292845577" CI_START="0.1326188130702585" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8078706507955264" LOG_CI_START="-0.8773948633139502" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="438" O_E="0.0" SE="0.9899333051867427" STUDY_ID="STD-Hales-1994" TOTAL_1="104" TOTAL_2="96" VAR="0.9799679487179488" WEIGHT="2.0009107343816708"/>
<DICH_DATA CI_END="1.4765116534173397" CI_START="0.6810569562929598" EFFECT_SIZE="1.0027903732124173" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.16923687899826878" LOG_CI_START="-0.16681656683993917" LOG_EFFECT_SIZE="0.0012101560791648392" ORDER="439" O_E="0.0" SE="0.19739945757674868" STUDY_ID="STD-Irion-1998" TOTAL_1="488" TOTAL_2="500" VAR="0.038966545851594606" WEIGHT="44.663742412583694"/>
<DICH_DATA CI_END="2.376669451057421" CI_START="0.575468235114549" EFFECT_SIZE="1.169486115544207" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.37596878393087" LOG_CI_START="-0.23997864370265473" LOG_EFFECT_SIZE="0.06799507011410764" ORDER="440" O_E="0.0" SE="0.36181056798087263" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.13090688710264167" WEIGHT="12.824986356010177"/>
<DICH_DATA CI_END="2.8481801597210152" CI_START="0.2137304774659444" EFFECT_SIZE="0.7802197802197802" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.45456745683913813" LOG_CI_START="-0.6701335440431746" LOG_EFFECT_SIZE="-0.10778304360201832" ORDER="441" O_E="0.0" SE="0.6606549352780141" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="0.436464943507197" WEIGHT="4.774900616138078"/>
<DICH_DATA CI_END="8.4490691962575" CI_START="0.579447502770372" EFFECT_SIZE="2.2126436781609193" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9268088669147475" LOG_CI_START="-0.23698590446294557" LOG_EFFECT_SIZE="0.34491148122590093" ORDER="442" O_E="0.0" SE="0.6836188095842854" STUDY_ID="STD-Poulsen-1991" TOTAL_1="232" TOTAL_2="220" VAR="0.46733467681743546" WEIGHT="2.962546526399002"/>
<DICH_DATA CI_END="5.443440209415893" CI_START="0.7057301728702595" EFFECT_SIZE="1.96" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7358734570048635" LOG_CI_START="-0.1513613142919114" LOG_EFFECT_SIZE="0.292256071356476" ORDER="443" O_E="0.0" SE="0.5211660965426749" STUDY_ID="STD-Rix-1996" TOTAL_1="110" TOTAL_2="98" VAR="0.27161410018552873" WEIGHT="5.087374740707835"/>
<DICH_DATA CI_END="1.7779932792379125" CI_START="0.024675720470582425" EFFECT_SIZE="0.20945945945945946" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2499301150169816" LOG_CI_START="-1.6077301581383512" LOG_EFFECT_SIZE="-0.6789000215606847" ORDER="444" O_E="0.0" SE="1.0911988400180987" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="1.190714908456844" WEIGHT="4.187426310640373"/>
<DICH_DATA CI_END="2.3873597788055614" CI_START="0.3233227609657686" EFFECT_SIZE="0.8785714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3779178727879926" LOG_CI_START="-0.4903637212656728" LOG_EFFECT_SIZE="-0.0562229242388401" ORDER="445" O_E="0.0" SE="0.5100329064103319" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="0.26013356562137047" WEIGHT="6.650700446662722"/>
<DICH_DATA CI_END="2.951434255065567" CI_START="0.9839622859680495" EFFECT_SIZE="1.7041420118343196" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.4700331134998702" LOG_CI_START="-0.007021547208755583" LOG_EFFECT_SIZE="0.23150578314555734" ORDER="446" O_E="0.0" SE="0.2802242691589025" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.07852564102564102" WEIGHT="13.005919773480858"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005369514017262393" CI_END="1.5036971737708367" CI_START="0.5360311322879682" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8977908991934588" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-020.19" LOG_CI_END="0.1771603834615772" LOG_CI_START="-0.2708099860754513" LOG_EFFECT_SIZE="-0.046824801306937024" METHOD="MH" NO="19" P_CHI2="0.941585719497653" P_Q="0.0" P_Z="0.6819991924132789" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="235" WEIGHT="100.0" Z="0.40973658253196">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5363232541222727" CI_START="0.5166805102320791" EFFECT_SIZE="0.8909479686386315" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.18648260417936136" LOG_CI_START="-0.28677792021996834" LOG_EFFECT_SIZE="-0.05014765802030352" ORDER="447" O_E="0.0" SE="0.2779955747095443" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.0772815395580898" WEIGHT="88.06352345190749"/>
<DICH_DATA CI_END="4.59878901887021" CI_START="0.19553563055248702" EFFECT_SIZE="0.9482758620689655" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6626434856683509" LOG_CI_START="-0.7087740938057377" LOG_EFFECT_SIZE="-0.02306530406869343" ORDER="448" O_E="0.0" SE="0.8055774748095835" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.6489550679205852" WEIGHT="11.936476548092518"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.53002242964486" CI_END="2.0642492410602022" CI_START="0.6604198928607603" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1675920788609713" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" I2="20.949317422425352" I2_Q="0.0" ID="CMP-020.20" LOG_CI_END="0.314762133595707" LOG_CI_START="-0.18017985359588726" LOG_EFFECT_SIZE="0.06729113999990988" METHOD="MH" NO="20" P_CHI2="0.28223623571045364" P_Q="0.0" P_Z="0.5940722650657615" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="204" TOTAL_2="203" WEIGHT="100.0" Z="0.5329441198829287">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="449" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="18.031979909308212"/>
<DICH_DATA CI_END="6.298162014230098" CI_START="0.135288835693967" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.799213828256879" LOG_CI_START="-0.8687380407753029" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="450" O_E="0.0" SE="0.9797631843644143" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.9599358974358974" WEIGHT="10.716148060388882"/>
<DICH_DATA CI_END="2.7642499987188587" CI_START="0.7750450851286126" EFFECT_SIZE="1.4637002341920375" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.44157731806332656" LOG_CI_START="-0.11067303342522392" LOG_EFFECT_SIZE="0.16545214231905137" ORDER="451" O_E="0.0" SE="0.3243945901477027" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.10523185011709602" WEIGHT="71.2518720303029"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.30632396261171246" CI_END="28.537109472676846" CI_START="0.8568484766438222" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.944894213173942" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.21" LOG_CI_END="1.4554099812649328" LOG_CI_START="-0.06709597104716732" LOG_EFFECT_SIZE="0.6941570051088827" METHOD="MH" NO="21" P_CHI2="0.8579907478223123" P_Q="0.0" P_Z="0.07390274758028141" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="320" WEIGHT="100.0" Z="1.787214989292471">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.23803152516251" CI_START="0.12961927608518836" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864736662920095" LOG_CI_START="-0.8873304083811396" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="452" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="32.87864978284787"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="453" O_E="0.0" SE="0.0" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="454" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="32.921474465078866"/>
<DICH_DATA CI_END="156.76667869560956" CI_START="0.46505626100139347" EFFECT_SIZE="8.538461538461538" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.195253757350487" LOG_CI_START="-0.3324945043908454" LOG_EFFECT_SIZE="0.9313796264798206" ORDER="455" O_E="0.0" SE="1.4848118415025537" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="2.204666204666205" WEIGHT="34.19987575207327"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4554001092849402" CI_START="0.18032584258684528" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5122950819672131" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-020.22" LOG_CI_END="0.16298240319629226" LOG_CI_START="-0.7439420298576384" LOG_EFFECT_SIZE="-0.2904798133306731" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.20929080474119843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="1.2555179938132324">
<NAME>Other</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4554001092849402" CI_START="0.18032584258684528" EFFECT_SIZE="0.5122950819672131" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16298240319629226" LOG_CI_START="-0.7439420298576384" LOG_EFFECT_SIZE="-0.2904798133306731" ORDER="456" O_E="0.0" SE="0.5327319013242258" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.2838032786885246" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9144613716285026" CI_END="1.4465453291952812" CI_START="0.546967197072127" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8895014582043811" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-020.23" LOG_CI_END="0.16033204732443113" LOG_CI_START="-0.26203871856189676" LOG_EFFECT_SIZE="-0.05085333561873282" METHOD="MH" NO="23" P_CHI2="0.8219367536331469" P_Q="0.0" P_Z="0.6369565144814564" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="256" WEIGHT="100.0" Z="0.47195835676405923">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.815108793485775" CI_START="0.06679227909762638" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.199072183810896" LOG_CI_START="-1.1752737372114805" LOG_EFFECT_SIZE="0.01189922329970769" ORDER="457" O_E="0.0" SE="1.3947025472104062" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="1.9451951951951953" WEIGHT="3.3888074302689213"/>
<DICH_DATA CI_END="1.4526455224544084" CI_START="0.5236350501591963" EFFECT_SIZE="0.8721560130010835" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.16215964979437983" LOG_CI_START="-0.28097129111046687" LOG_EFFECT_SIZE="-0.059405820658043514" ORDER="458" O_E="0.0" SE="0.2602973082210413" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06775468866711977" WEIGHT="89.96629465882177"/>
<DICH_DATA CI_END="8.583301772644782" CI_START="0.01519243270503358" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9336543817653437" LOG_CI_START="-1.8183726786862444" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="459" O_E="0.0" SE="1.6165543180629172" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="2.6132478632478633" WEIGHT="4.947658848192625"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="460" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="1.6972390627166802"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-020.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal complication</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="461" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.673007565344359" CI_START="0.10992472329414438" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6354166666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-020.26" LOG_CI_END="0.5650218228685513" LOG_CI_START="-0.9589046189261543" LOG_EFFECT_SIZE="-0.19694139802880142" METHOD="MH" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.6124470421703734" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="61" WEIGHT="100.00000000000001" Z="0.5065835680977282">
<NAME>Woman not satisfied</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.673007565344359" CI_START="0.10992472329414438" EFFECT_SIZE="0.6354166666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5650218228685513" LOG_CI_START="-0.9589046189261543" LOG_EFFECT_SIZE="-0.19694139802880142" ORDER="462" O_E="0.0" SE="0.8951619354677579" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.8013148907103824" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" NO="21">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="31.66605199274911" CI_END="1.4173862634283134" CI_START="1.1204563125136" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2602060887522795" ESTIMABLE="YES" EVENTS_1="382" EVENTS_2="292" I2="71.57839568361469" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.15148821948928218" LOG_CI_START="0.04939492771252784" LOG_EFFECT_SIZE="0.100441573600905" METHOD="MH" NO="1" P_CHI2="2.2739904774449204E-4" P_Q="0.0" P_Z="1.1501770380618763E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="980" TOTAL_2="938" WEIGHT="99.99999999999999" Z="3.8565093432147823">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3069812799665868" CI_START="0.6638886736960186" EFFECT_SIZE="0.9314988290398126" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.11626936717852775" LOG_CI_START="-0.17790474059133726" LOG_EFFECT_SIZE="-0.03081768670640474" ORDER="463" O_E="0.0" SE="0.17279932708933723" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.02985960744252776" WEIGHT="14.788199151525578"/>
<DICH_DATA CI_END="1.1962022489978994" CI_START="0.789267031588584" EFFECT_SIZE="0.97165991902834" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.07780461460046488" LOG_CI_START="-0.10277603769658433" LOG_EFFECT_SIZE="-0.012485711548059728" ORDER="464" O_E="0.0" SE="0.10607396904793205" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.011251686909581646" WEIGHT="13.28767602450349"/>
<DICH_DATA CI_END="2.4512425303413665" CI_START="1.2704021523015954" EFFECT_SIZE="1.7646710136336692" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="42" LOG_CI_END="0.38938628325453745" LOG_CI_START="0.1039412208606615" LOG_EFFECT_SIZE="0.24666375205759952" ORDER="465" O_E="0.0" SE="0.1676718426260098" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.028113846809601394" WEIGHT="14.482067439058524"/>
<DICH_DATA CI_END="4.1033869835640875" CI_START="1.4252699156035287" EFFECT_SIZE="2.4183535762483133" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.6131424764846473" LOG_CI_START="0.1538971182089092" LOG_EFFECT_SIZE="0.38351979734677827" ORDER="466" O_E="0.0" SE="0.2697629967523553" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.07277207441681127" WEIGHT="4.409626999282131"/>
<DICH_DATA CI_END="1.6169761089300323" CI_START="0.78271100791803" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.2087036031862372" LOG_CI_START="-0.10639855829147464" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="467" O_E="0.0" SE="0.1850925694328631" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.03425925925925924" WEIGHT="8.069438881277422"/>
<DICH_DATA CI_END="1.4069746121062945" CI_START="0.7577924314881198" EFFECT_SIZE="1.0325670498084292" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" LOG_CI_END="0.1482862609588256" LOG_CI_START="-0.12044973658987246" LOG_EFFECT_SIZE="0.013918262184476567" ORDER="468" O_E="0.0" SE="0.15785685522474732" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.024918786741446836" WEIGHT="15.531884572370261"/>
<DICH_DATA CI_END="1.7094739947338837" CI_START="0.7602338520524323" EFFECT_SIZE="1.14" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.23286249850524962" LOG_CI_START="-0.11905279583230446" LOG_EFFECT_SIZE="0.05690485133647255" ORDER="469" O_E="0.0" SE="0.20671678590268097" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.04273182957393484" WEIGHT="6.448181754445429"/>
<DICH_DATA CI_END="2.294712619067593" CI_START="1.0800050270939199" EFFECT_SIZE="1.5742621015348288" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="35" LOG_CI_END="0.3607283039177005" LOG_CI_START="0.033425776999975856" LOG_EFFECT_SIZE="0.19707704045883817" ORDER="470" O_E="0.0" SE="0.19225912448510948" STUDY_ID="STD-Rath-1999" TOTAL_1="242" TOTAL_2="226" VAR="0.03696357094778083" WEIGHT="12.17025415320865"/>
<DICH_DATA CI_END="2.4459176182544256" CI_START="0.9508869422310191" EFFECT_SIZE="1.5250544662309369" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.38844182533312444" LOG_CI_START="-0.021871116379133193" LOG_EFFECT_SIZE="0.18328535447699562" ORDER="471" O_E="0.0" SE="0.24101985304359846" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.0580905695611578" WEIGHT="5.769271723530121"/>
<DICH_DATA CI_END="0.9488661246391552" CI_START="0.2997729996448298" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="-0.022795057785415497" LOG_CI_START="-0.5232074863420597" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="472" O_E="0.0" SE="0.29394473761564405" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.08640350877192982" WEIGHT="5.04339930079839"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5514828884423526" CI_END="1.733253699429139" CI_START="0.4181042867157808" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8512818579632181" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-021.02" LOG_CI_END="0.2388621358230359" LOG_CI_START="-0.37871537971706837" LOG_EFFECT_SIZE="-0.0699266219470162" METHOD="MH" NO="2" P_CHI2="0.7371080561614564" P_Q="0.0" P_Z="0.657156257989989" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="585" WEIGHT="99.99999999999999" Z="0.4438427796609117">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.137559058351389" CI_START="0.014402141787243155" EFFECT_SIZE="0.34234234234234234" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9104941534807701" LOG_CI_START="-1.8415729178204643" LOG_EFFECT_SIZE="-0.46553938216984725" ORDER="473" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="10.069481459059029"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="474" O_E="0.0" SE="0.0" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="475" O_E="0.0" SE="0.0" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.190781592665074" CI_START="0.011289421398428319" EFFECT_SIZE="0.26436781609195403" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7917454826151455" LOG_CI_START="-1.9473283158171968" LOG_EFFECT_SIZE="-0.5777914166010256" ORDER="476" O_E="0.0" SE="1.608945507833131" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="2.5887056471764116" WEIGHT="11.383119632772031"/>
<DICH_DATA CI_END="28.311269081090536" CI_START="0.11706529015561468" EFFECT_SIZE="1.8205128205128205" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4519593374880801" LOG_CI_START="-0.931571854102928" LOG_EFFECT_SIZE="0.26019374169257603" ORDER="477" O_E="0.0" SE="1.4000980206102431" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="1.960274467316721" WEIGHT="4.8244444337015"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="478" O_E="0.0" SE="0.0" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.15509104376217" CI_START="0.043608692016736256" EFFECT_SIZE="0.47413793103448276" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.712236339736774" LOG_CI_START="-1.3604269392021233" LOG_EFFECT_SIZE="-0.32409529973267465" ORDER="479" O_E="0.0" SE="1.2174926698974078" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="1.4822884012539186" WEIGHT="13.968665980038836"/>
<DICH_DATA CI_END="3.405584464032359" CI_START="0.4711216125718147" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5321916559615373" LOG_CI_START="-0.3268669721672419" LOG_EFFECT_SIZE="0.10266234189714771" ORDER="480" O_E="0.0" SE="0.5046152905716361" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.25463659147869677" WEIGHT="39.14459656427982"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="481" O_E="0.0" SE="0.0" STUDY_ID="STD-Stempel-1997" TOTAL_1="39" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="482" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="3.360865677478184"/>
<DICH_DATA CI_END="3.9074989067326817" CI_START="0.009675918759737532" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5918988651813" LOG_CI_START="-2.0143077866873607" LOG_EFFECT_SIZE="-0.7112044607530305" ORDER="483" O_E="0.0" SE="1.5308986882386417" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="2.3436507936507938" WEIGHT="17.248826252670586"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="484" O_E="0.0" SE="0.0" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.654883638071833" CI_END="1.2109938382146013" CI_START="0.9285271786809137" CI_STUDY="95" CI_TOTAL="95" DF="25.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0603964786802031" ESTIMABLE="YES" EVENTS_1="357" EVENTS_2="333" I2="0.0" I2_Q="0.0" ID="CMP-021.03" LOG_CI_END="0.0831419333691419" LOG_CI_START="-0.032205379615751456" LOG_EFFECT_SIZE="0.025468276876695208" METHOD="MH" NO="3" P_CHI2="0.85668555502338" P_Q="0.0" P_Z="0.38676104099666464" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1807" TOTAL_2="1779" WEIGHT="99.99999999999996" Z="0.8655061680223851">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.295416209760943" CI_START="0.9664880353757405" EFFECT_SIZE="2.466666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7990244479668573" LOG_CI_START="-0.014803517944229825" LOG_EFFECT_SIZE="0.39211046501131375" ORDER="485" O_E="0.0" SE="0.4780465756895749" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="0.2285285285285285" WEIGHT="1.4792292553030664"/>
<DICH_DATA CI_END="1.7288008718872945" CI_START="0.32053906950874267" EFFECT_SIZE="0.7444113263785395" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.23774497290326527" LOG_CI_START="-0.4941190281172472" LOG_EFFECT_SIZE="-0.12818702760699097" ORDER="486" O_E="0.0" SE="0.4299005369846816" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.1848144716997176" WEIGHT="3.4552735628283306"/>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="487" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="1.1998192848569316"/>
<DICH_DATA CI_END="2.1394533663452178" CI_START="0.2485139597532066" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3303028246083761" LOG_CI_START="-0.6046492106589992" LOG_EFFECT_SIZE="-0.1371731930253116" ORDER="488" O_E="0.0" SE="0.5491954536032717" STUDY_ID="STD-El_x002d_Din-2000" TOTAL_1="48" TOTAL_2="49" VAR="0.3016156462585034" WEIGHT="2.078037524288294"/>
<DICH_DATA CI_END="2.331408122561638" CI_START="0.5920088285042477" EFFECT_SIZE="1.1748251748251748" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3676183052073158" LOG_CI_START="-0.22767181668571365" LOG_EFFECT_SIZE="0.06997324426080104" ORDER="489" O_E="0.0" SE="0.34967636433359317" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.12227355977355979" WEIGHT="3.431483154690824"/>
<DICH_DATA CI_END="1.9234385073419273" CI_START="0.8638292084503612" EFFECT_SIZE="1.2890005288207298" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.284078306395904" LOG_CI_START="-0.0635721153448345" LOG_EFFECT_SIZE="0.11025309552553472" ORDER="490" O_E="0.0" SE="0.2042115786278517" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.04170236884567926" WEIGHT="9.185661002690113"/>
<DICH_DATA CI_END="2.8146730175432193" CI_START="0.48870774639407244" EFFECT_SIZE="1.1728395061728396" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44942794983573264" LOG_CI_START="-0.3109507770153365" LOG_EFFECT_SIZE="0.06923858641019806" ORDER="491" O_E="0.0" SE="0.4466502280877199" STUDY_ID="STD-Keirse-1995" TOTAL_1="81" TOTAL_2="76" VAR="0.1994964262508122" WEIGHT="2.4760601802143047"/>
<DICH_DATA CI_END="1.6427031309531541" CI_START="0.865560422855015" EFFECT_SIZE="1.1924172158489952" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="51" LOG_CI_END="0.21555908489691913" LOG_CI_START="-0.06270260959497831" LOG_EFFECT_SIZE="0.07642823765097041" ORDER="492" O_E="0.0" SE="0.163452296762143" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.02671665331681967" WEIGHT="15.688275351251644"/>
<DICH_DATA CI_END="2.211653210227933" CI_START="0.3341376536453985" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.34471703009577304" LOG_CI_START="-0.4760745813837285" LOG_EFFECT_SIZE="-0.06567877564397773" ORDER="493" O_E="0.0" SE="0.482137055567063" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.2324561403508772" WEIGHT="2.420874309268853"/>
<DICH_DATA CI_END="5.142682235171369" CI_START="0.12004376520746443" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7111896902213181" LOG_CI_START="-0.9206603912613439" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="494" O_E="0.0" SE="0.9585568156510959" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="0.9188311688311689" WEIGHT="0.6718987995198817"/>
<DICH_DATA CI_END="1.9053621419675966" CI_START="0.6034304687975657" EFFECT_SIZE="1.072265625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2799775318808865" LOG_CI_START="-0.21937276493236413" LOG_EFFECT_SIZE="0.03030238347426115" ORDER="495" O_E="0.0" SE="0.2933208361719377" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.08603711293260473" WEIGHT="4.914459790773992"/>
<DICH_DATA CI_END="1.4954350427230212" CI_START="0.27607341539705244" EFFECT_SIZE="0.6425339366515838" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="0.174767553308738" LOG_CI_START="-0.5589754119128463" LOG_EFFECT_SIZE="-0.19210392930205417" ORDER="496" O_E="0.0" SE="0.43100424985741403" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="0.18576466339515219" WEIGHT="3.6158190266370256"/>
<DICH_DATA CI_END="1.6844083977629603" CI_START="0.42506100795497403" EFFECT_SIZE="0.8461538461538461" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.22644739796612254" LOG_CI_START="-0.371548732263346" LOG_EFFECT_SIZE="-0.07255066714861173" ORDER="497" O_E="0.0" SE="0.3512658870253748" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.12338772338772339" WEIGHT="3.899412675785028"/>
<DICH_DATA CI_END="2.237013939702587" CI_START="0.3391059814285512" EFFECT_SIZE="0.8709677419354839" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.34966869036263354" LOG_CI_START="-0.46966454971320426" LOG_EFFECT_SIZE="-0.05999792967528537" ORDER="498" O_E="0.0" SE="0.481280400985496" STUDY_ID="STD-Peccerillo-1995" TOTAL_1="31" TOTAL_2="36" VAR="0.23163082437275984" WEIGHT="2.220561064511336"/>
<DICH_DATA CI_END="2.7485639734791887" CI_START="0.497047299758468" EFFECT_SIZE="1.1688311688311688" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4391058497265867" LOG_CI_START="-0.3036022811929008" LOG_EFFECT_SIZE="0.06775178426684299" ORDER="499" O_E="0.0" SE="0.4362704325666482" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.19033189033189032" WEIGHT="2.1996686889043744"/>
<DICH_DATA CI_END="2.1531230824176957" CI_START="0.49014519281782254" EFFECT_SIZE="1.0272988505747127" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3330688568030305" LOG_CI_START="-0.30967525242199345" LOG_EFFECT_SIZE="0.01169680219051853" ORDER="500" O_E="0.0" SE="0.37755107139343247" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.14254481151032874" WEIGHT="3.695018682568249"/>
<DICH_DATA CI_END="4.652365301456785" CI_START="0.39589254397481366" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6676738079863876" LOG_CI_START="-0.4024226774372058" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="501" O_E="0.0" SE="0.6285799726008515" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.3951127819548872" WEIGHT="1.150511643013496"/>
<DICH_DATA CI_END="1.783694667119325" CI_START="0.9416538748144286" EFFECT_SIZE="1.2960026986001012" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="49" LOG_CI_END="0.25132051386623455" LOG_CI_START="-0.02610870217684992" LOG_EFFECT_SIZE="0.11260590584469231" ORDER="502" O_E="0.0" SE="0.16296329480047547" STUDY_ID="STD-Rath-1999" TOTAL_1="242" TOTAL_2="226" VAR="0.026557035452226672" WEIGHT="15.200274657941767"/>
<DICH_DATA CI_END="1.4661591448706992" CI_START="0.4277407461011015" EFFECT_SIZE="0.7919191919191919" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.1661811135438086" LOG_CI_START="-0.36881937737003156" LOG_EFFECT_SIZE="-0.10131913191311148" ORDER="503" O_E="0.0" SE="0.31426193665793095" STUDY_ID="STD-Rix-1996" TOTAL_1="110" TOTAL_2="98" VAR="0.0987605648319934" WEIGHT="5.71067832696328"/>
<DICH_DATA CI_END="2.931418778371528" CI_START="0.43420845247346274" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.46707786557054265" LOG_CI_START="-0.36230172665116617" LOG_EFFECT_SIZE="0.05238806945968822" ORDER="504" O_E="0.0" SE="0.48718167796622575" STUDY_ID="STD-Stempel-1997" TOTAL_1="39" TOTAL_2="44" VAR="0.2373459873459873" WEIGHT="1.9731967756984476"/>
<DICH_DATA CI_END="2.0779392669387473" CI_START="0.48755737482639344" EFFECT_SIZE="1.0065359477124183" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3176328500455952" LOG_CI_START="-0.3119742700078667" LOG_EFFECT_SIZE="0.0028292900188642534" ORDER="505" O_E="0.0" SE="0.3698343389249118" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.13677743824802652" WEIGHT="3.431258889403935"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="506" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="0.14817045385281383"/>
<DICH_DATA CI_END="1.4139606492320238" CI_START="0.1298999865997085" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15043732313896063" LOG_CI_START="-0.8863908937281496" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="507" O_E="0.0" SE="0.6090380269701879" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.37092731829573933" WEIGHT="2.09968374849963"/>
<DICH_DATA CI_END="1.6722857022266164" CI_START="0.3777556053060831" EFFECT_SIZE="0.7948051948051948" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2233104766321436" LOG_CI_START="-0.4227890826859849" LOG_EFFECT_SIZE="-0.09973930302692065" ORDER="508" O_E="0.0" SE="0.37952207938786786" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="0.14403700874289108" WEIGHT="3.347321917897961"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5572084962688248" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="509" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="1.4997741060711645"/>
<DICH_DATA CI_END="1.4227199692045693" CI_START="0.18484655031342975" EFFECT_SIZE="0.5128205128205128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.1531194272823733" LOG_CI_START="-0.7331886500074094" LOG_EFFECT_SIZE="-0.29003461136251807" ORDER="510" O_E="0.0" SE="0.5206217518957583" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.2710470085470086" WEIGHT="2.80757712656522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="511" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.05" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="173" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="512" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="513" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.029453007463573" CI_END="1.100702666495363" CI_START="0.8450942961008017" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.964467493054159" ESTIMABLE="YES" EVENTS_1="247" EVENTS_2="248" I2="38.60064581822879" I2_Q="0.0" ID="CMP-021.07" LOG_CI_END="0.04167001857229377" LOG_CI_START="-0.07309482952200107" LOG_EFFECT_SIZE="-0.015712405474853634" METHOD="MH" NO="7" P_CHI2="0.11084034662903108" P_Q="0.0" P_Z="0.5914916915728109" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="766" TOTAL_2="735" WEIGHT="100.00000000000001" Z="0.5366756346141849">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5642857731829913" CI_START="0.613733129766819" EFFECT_SIZE="0.9798234552332913" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.19431609551360027" LOG_CI_START="-0.2120204325469793" LOG_EFFECT_SIZE="-0.008852168516689544" ORDER="514" O_E="0.0" SE="0.23868408798103774" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.056970093855339764" WEIGHT="10.798934380095172"/>
<DICH_DATA CI_END="2.331408122561638" CI_START="0.5920088285042477" EFFECT_SIZE="1.1748251748251748" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3676183052073158" LOG_CI_START="-0.22767181668571365" LOG_EFFECT_SIZE="0.06997324426080104" ORDER="515" O_E="0.0" SE="0.34967636433359317" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.12227355977355979" WEIGHT="4.537322756751463"/>
<DICH_DATA CI_END="1.6566925787021856" CI_START="0.5132671348907573" EFFECT_SIZE="0.9221311475409836" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.21924192678994753" LOG_CI_START="-0.28965654324468143" LOG_EFFECT_SIZE="-0.03520730822736695" ORDER="516" O_E="0.0" SE="0.29892948038639505" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.08935883424408014" WEIGHT="7.836037715858533"/>
<DICH_DATA CI_END="1.2599646537922178" CI_START="0.7543124049067086" EFFECT_SIZE="0.974888182357062" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" LOG_CI_END="0.10035836188080684" LOG_CI_START="-0.12244875011484846" LOG_EFFECT_SIZE="-0.011045194117020853" ORDER="517" O_E="0.0" SE="0.13087800049923984" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.017129051014679025" WEIGHT="31.319408717838456"/>
<DICH_DATA CI_END="1.5311979112346663" CI_START="0.4619054318306297" EFFECT_SIZE="0.8409926470588235" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.1850313279955445" LOG_CI_START="-0.3354469305869703" LOG_EFFECT_SIZE="-0.07520780129571285" ORDER="518" O_E="0.0" SE="0.3057315055003009" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.09347175345548055" WEIGHT="6.904345677406423"/>
<DICH_DATA CI_END="1.571729812929991" CI_START="0.8837591555608987" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="28" LOG_CI_END="0.1963778910426403" LOG_CI_START="-0.05366607397130375" LOG_EFFECT_SIZE="0.07135590853566827" ORDER="519" O_E="0.0" SE="0.1468770627867795" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="0.021572871572871567" WEIGHT="11.105335418622461"/>
<DICH_DATA CI_END="1.1296053653640439" CI_START="0.5456946845045478" EFFECT_SIZE="0.7851239669421488" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.05292674651090118" LOG_CI_START="-0.26305027656610575" LOG_EFFECT_SIZE="-0.10506176502760228" ORDER="520" O_E="0.0" SE="0.18560646746692377" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.03444976076555024" WEIGHT="9.141126433015767"/>
<DICH_DATA CI_END="1.3388368861375306" CI_START="0.9939426188468702" EFFECT_SIZE="1.1535714285714285" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" LOG_CI_END="0.12672766904674287" LOG_CI_START="-0.0026386870689756904" LOG_EFFECT_SIZE="0.06204449098888362" ORDER="521" O_E="0.0" SE="0.07599043795616373" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.0057745466607695695" WEIGHT="12.170230595750642"/>
<DICH_DATA CI_END="0.9652635558535889" CI_START="0.19223985931326396" EFFECT_SIZE="0.4307692307692308" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.015354090567863797" LOG_CI_START="-0.7161565600334088" LOG_EFFECT_SIZE="-0.3657553253006363" ORDER="522" O_E="0.0" SE="0.4116548395922328" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.16945970695970694" WEIGHT="6.187258304661086"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.904374255853006" CI_END="1.214599236569008" CI_START="0.5593989880009747" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8242848923542512" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-021.08" LOG_CI_END="0.08443300381274968" LOG_CI_START="-0.25227832363840996" LOG_EFFECT_SIZE="-0.08392265991283014" METHOD="MH" NO="8" P_CHI2="0.7677462252156682" P_Q="0.0" P_Z="0.32856355586833574" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="644" TOTAL_2="613" WEIGHT="99.99999999999999" Z="0.9770113299191528">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.135716153037741" CI_START="0.010201710902903432" EFFECT_SIZE="0.20540540540540542" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6165507241382008" LOG_CI_START="-1.991326987710608" LOG_EFFECT_SIZE="-0.6873881317862036" ORDER="523" O_E="0.0" SE="1.531880277142861" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.3466571834992886" WEIGHT="4.932705729762375"/>
<DICH_DATA CI_END="14.351608110052847" CI_START="0.05937111711685543" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1569005668674324" LOG_CI_START="-1.2264247793858563" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="524" O_E="0.0" SE="1.3999771060399158" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.9599358974358976" WEIGHT="2.0797353887646772"/>
<DICH_DATA CI_END="1.407828600979414" CI_START="0.5659559153410323" EFFECT_SIZE="0.8926191374324154" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="33" LOG_CI_END="0.14854978393965634" LOG_CI_START="-0.24721739649684682" LOG_EFFECT_SIZE="-0.04933380627859521" ORDER="525" O_E="0.0" SE="0.23247560086754074" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.05404490499872411" WEIGHT="67.67649569085711"/>
<DICH_DATA CI_END="1.951484656911305" CI_START="0.07908682968491929" EFFECT_SIZE="0.39285714285714285" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.2903651410925684" LOG_CI_START="-1.1018958334605569" LOG_EFFECT_SIZE="-0.4057653461839942" ORDER="526" O_E="0.0" SE="0.8178209882554793" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="0.6688311688311689" WEIGHT="8.958860136217073"/>
<DICH_DATA CI_END="4.052347097392378" CI_START="0.009870822769781833" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6077066370895764" LOG_CI_START="-2.005646645761614" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="527" O_E="0.0" SE="1.5350966546541733" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="2.3565217391304345" WEIGHT="4.999363915299705"/>
<DICH_DATA CI_END="4.164933703007989" CI_START="0.19842963656176835" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6196080927423374" LOG_CI_START="-0.7023934630587876" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="528" O_E="0.0" SE="0.7765502578908225" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.603030303030303" WEIGHT="6.284914636376771"/>
<DICH_DATA CI_END="97.71268963612164" CI_START="0.2302837404157544" EFFECT_SIZE="4.743589743589744" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9899509678239824" LOG_CI_START="-0.6377367250709531" LOG_EFFECT_SIZE="0.6761071213765146" ORDER="529" O_E="0.0" SE="1.5435167580703433" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="2.3824439824439825" WEIGHT="1.0261852247194132"/>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="530" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="0.999872783059941"/>
<DICH_DATA CI_END="7.689287448668567" CI_START="0.013658483466521182" EFFECT_SIZE="0.32407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8858860964400181" LOG_CI_START="-1.864597518713366" LOG_EFFECT_SIZE="-0.4893557111366741" ORDER="531" O_E="0.0" SE="1.6156476906545747" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="2.6103174603174604" WEIGHT="3.041866494942919"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="532" O_E="0.0" SE="0.0" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.09" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Uterine rupture</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="533" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.239982415032324" CI_START="0.906006580607915" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0599208592425098" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-021.10" LOG_CI_END="0.09341552620370377" LOG_CI_START="-0.042868647895674766" LOG_EFFECT_SIZE="0.02527343915401449" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.46726432012176267" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="0.7269373841046556">
<NAME>Epidural analgesia</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.239982415032324" CI_START="0.9060065806079148" EFFECT_SIZE="1.0599208592425098" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="87" LOG_CI_END="0.09341552620370377" LOG_CI_START="-0.04286864789567482" LOG_EFFECT_SIZE="0.02527343915401449" ORDER="534" O_E="0.0" SE="0.08005399848351687" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.006408642673198921" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.088700804523649" CI_END="1.2042345690156533" CI_START="0.6864823789721155" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9092226414791517" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="83" I2="20.703367509789775" I2_Q="0.0" ID="CMP-021.11" LOG_CI_END="0.08071109000055608" LOG_CI_START="-0.16337060600682116" LOG_EFFECT_SIZE="-0.041329758003132516" METHOD="MH" NO="11" P_CHI2="0.25885550758224063" P_Q="0.0" P_Z="0.5068491596567701" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="476" TOTAL_2="461" WEIGHT="99.99999999999999" Z="0.6637518380194104">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5200063009166347" CI_START="0.2501817114497832" EFFECT_SIZE="0.6166666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1818453882392815" LOG_CI_START="-0.6017444408725787" LOG_EFFECT_SIZE="-0.2099495263166486" ORDER="535" O_E="0.0" SE="0.4602845444525178" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="0.21186186186186184" WEIGHT="11.790635069098846"/>
<DICH_DATA CI_END="1.2255560435528916" CI_START="0.48182542762847635" EFFECT_SIZE="0.7684426229508197" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.08833317593020137" LOG_CI_START="-0.3171102844801849" LOG_EFFECT_SIZE="-0.11438855427499177" ORDER="536" O_E="0.0" SE="0.23815949562255806" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.05671994535519125" WEIGHT="37.78943623046129"/>
<DICH_DATA CI_END="3.870203735165248" CI_START="0.668482020754955" EFFECT_SIZE="1.6084656084656084" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5877338277396058" LOG_CI_START="-0.17491026886858663" LOG_EFFECT_SIZE="0.20641177943550956" ORDER="537" O_E="0.0" SE="0.44798091749681523" STUDY_ID="STD-Keirse-1995" TOTAL_1="81" TOTAL_2="76" VAR="0.2006869024412884" WEIGHT="8.634574949488151"/>
<DICH_DATA CI_END="2.066816229484576" CI_START="0.19116457243751045" EFFECT_SIZE="0.6285714285714286" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3153018631445367" LOG_CI_START="-0.7185925902006756" LOG_EFFECT_SIZE="-0.2016453635280694" ORDER="538" O_E="0.0" SE="0.6073147197550615" STUDY_ID="STD-Lopes-1991" TOTAL_1="28" TOTAL_2="22" VAR="0.36883116883116884" WEIGHT="6.694460578121678"/>
<DICH_DATA CI_END="2.4273379255762912" CI_START="0.46204519868763866" EFFECT_SIZE="1.0590277777777777" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3851302415140314" LOG_CI_START="-0.33531553833892147" LOG_EFFECT_SIZE="0.024907351587554947" ORDER="539" O_E="0.0" SE="0.42319341734975074" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.1790926684881603" WEIGHT="11.01716940856596"/>
<DICH_DATA CI_END="2.9080662948391867" CI_START="0.1934275023228471" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4636043028591656" LOG_CI_START="-0.7134817760757655" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="540" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="4.781757555801199"/>
<DICH_DATA CI_END="8.150609039529751" CI_START="1.0420155332318335" EFFECT_SIZE="2.914285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9111900618227434" LOG_CI_START="0.017874193000540384" LOG_EFFECT_SIZE="0.4645321274116419" ORDER="541" O_E="0.0" SE="0.5247381633310296" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="0.2753501400560224" WEIGHT="4.851058389943245"/>
<DICH_DATA CI_END="1.3288565127556677" CI_START="0.1881316738114724" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12347808923266526" LOG_CI_START="-0.7255380805606277" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="542" O_E="0.0" SE="0.498716300834401" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.24871794871794875" WEIGHT="11.954393889502997"/>
<DICH_DATA CI_END="4.928287746792142" CI_START="0.04322348093776479" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6926960569477116" LOG_CI_START="-1.364280260794098" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="543" O_E="0.0" SE="1.2082780712385282" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="1.4599358974358976" WEIGHT="2.4865139290166236"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07718367236236295" CI_END="1.9745747667223186" CI_START="0.4107276751163149" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9005623261491665" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-021.12" LOG_CI_END="0.2954735828232223" LOG_CI_START="-0.386446033096279" LOG_EFFECT_SIZE="-0.04548622513652836" METHOD="MH" NO="12" P_CHI2="0.7811509325249328" P_Q="0.0" P_Z="0.7937287202612688" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="148" WEIGHT="99.99999999999999" Z="0.26147176581821685">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1065713781932294" CI_START="0.3372781195111148" EFFECT_SIZE="0.842911877394636" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3235761791667643" LOG_CI_START="-0.47201183219891374" LOG_EFFECT_SIZE="-0.07421782651607471" ORDER="544" O_E="0.0" SE="0.46733233610037045" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.2183995123650296" WEIGHT="76.2562286125953"/>
<DICH_DATA CI_END="5.029145164581975" CI_START="0.23438884176692115" EFFECT_SIZE="1.0857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7014941715658538" LOG_CI_START="-0.6300630670327849" LOG_EFFECT_SIZE="0.03571555226653449" ORDER="545" O_E="0.0" SE="0.7821633132674748" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.6117794486215539" WEIGHT="23.743771387404696"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.586337585094267" CI_END="1.7363809459379858" CI_START="0.49311925914779764" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9253339319722862" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-021.13" LOG_CI_END="0.2396450114909001" LOG_CI_START="-0.3070480354362551" LOG_EFFECT_SIZE="-0.033701511972677504" METHOD="MH" NO="13" P_CHI2="0.8687762755257442" P_Q="0.0" P_Z="0.809052616673571" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="848" TOTAL_2="834" WEIGHT="99.99999999999999" Z="0.2416483987212472">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.137559058351389" CI_START="0.014402141787243155" EFFECT_SIZE="0.34234234234234234" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9104941534807701" LOG_CI_START="-1.8415729178204643" LOG_EFFECT_SIZE="-0.46553938216984725" ORDER="546" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="7.514774245444492"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="547" O_E="0.0" SE="0.0" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.928287746792142" CI_START="0.04322348093776479" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6926960569477116" LOG_CI_START="-1.364280260794098" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="548" O_E="0.0" SE="1.2082780712385282" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.4599358974358976" WEIGHT="10.561304344949017"/>
<DICH_DATA CI_END="2.0918180543665583" CI_START="0.006193297489086655" EFFECT_SIZE="0.11382113821138211" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3205239070494482" LOG_CI_START="-2.2080780585717683" LOG_EFFECT_SIZE="-0.9437770757611599" ORDER="549" O_E="0.0" SE="1.4853133113875003" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.2061556329849012" WEIGHT="22.57368688187087"/>
<DICH_DATA CI_END="6.551094819355486" CI_START="0.38284280838705775" EFFECT_SIZE="1.5836791147994467" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.816313885376811" LOG_CI_START="-0.4169795066140591" LOG_EFFECT_SIZE="0.19966718938137595" ORDER="550" O_E="0.0" SE="0.724442643356186" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.5248171435128981" WEIGHT="15.621569233629579"/>
<DICH_DATA CI_END="21.060687049972" CI_START="0.18332166760237306" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3234725348050522" LOG_CI_START="-0.7367862008096718" LOG_EFFECT_SIZE="0.2933431669976902" ORDER="551" O_E="0.0" SE="1.2102061797453088" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="1.4645989974937343" WEIGHT="5.122484238104952"/>
<DICH_DATA CI_END="6.555615432182995" CI_START="0.13857543582639512" EFFECT_SIZE="0.953125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8166134689101281" LOG_CI_START="-0.8583137468563684" LOG_EFFECT_SIZE="-0.020850138973120137" ORDER="552" O_E="0.0" SE="0.983860537564674" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.9679815573770492" WEIGHT="10.398822739642108"/>
<DICH_DATA CI_END="21.280120118554144" CI_START="0.18796886379003092" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3279740750646463" LOG_CI_START="-0.7259140837366839" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="553" O_E="0.0" SE="1.2064640713902572" STUDY_ID="STD-Ottinger-1998" TOTAL_1="45" TOTAL_2="45" VAR="1.4555555555555557" WEIGHT="5.077550165840873"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="554" O_E="0.0" SE="0.0" STUDY_ID="STD-Strobelt-2006" TOTAL_1="51" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.928491935952064" CI_START="0.15163833770929122" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8406387158286682" LOG_CI_START="-0.819190985045122" LOG_EFFECT_SIZE="0.010723865391773066" ORDER="555" O_E="0.0" SE="0.9749921825827943" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="0.9506097560975609" WEIGHT="10.029728722648638"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="556" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.45532212106615" CI_START="0.12595282944426972" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.854034581366758" LOG_CI_START="-0.8997920719274333" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="557" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="2.5387750829204365"/>
<DICH_DATA CI_END="6.298162014230098" CI_START="0.135288835693967" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.799213828256879" LOG_CI_START="-0.8687380407753029" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="558" O_E="0.0" SE="0.9797631843644143" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.9599358974358974" WEIGHT="10.561304344949017"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.364933166466719" CI_END="1.500038774031226" CI_START="0.9082722396433413" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1672375837168685" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="100" I2="0.0" I2_Q="0.0" ID="CMP-021.18" LOG_CI_END="0.17610248514245672" LOG_CI_START="-0.04178395934894316" LOG_EFFECT_SIZE="0.06715926289675678" METHOD="MH" NO="18" P_CHI2="0.5991814542385476" P_Q="0.0" P_Z="0.2269543550373505" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1372" TOTAL_2="1370" WEIGHT="99.99999999999999" Z="1.2082416307554733">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.23803152516251" CI_START="0.12961927608518836" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864736662920095" LOG_CI_START="-0.8873304083811396" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="559" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="0.49531597325756754"/>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="560" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="3.514066026489499"/>
<DICH_DATA CI_END="6.424963292845577" CI_START="0.1326188130702585" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8078706507955264" LOG_CI_START="-0.8773948633139502" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="561" O_E="0.0" SE="0.9899333051867427" STUDY_ID="STD-Hales-1994" TOTAL_1="104" TOTAL_2="96" VAR="0.9799679487179488" WEIGHT="2.088359238599474"/>
<DICH_DATA CI_END="1.4765116534173397" CI_START="0.6810569562929598" EFFECT_SIZE="1.0027903732124173" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.16923687899826878" LOG_CI_START="-0.16681656683993917" LOG_EFFECT_SIZE="0.0012101560791648392" ORDER="562" O_E="0.0" SE="0.19739945757674868" STUDY_ID="STD-Irion-1998" TOTAL_1="488" TOTAL_2="500" VAR="0.038966545851594606" WEIGHT="46.6157422692673"/>
<DICH_DATA CI_END="2.376669451057421" CI_START="0.575468235114549" EFFECT_SIZE="1.169486115544207" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.37596878393087" LOG_CI_START="-0.23997864370265473" LOG_EFFECT_SIZE="0.06799507011410764" ORDER="563" O_E="0.0" SE="0.36181056798087263" STUDY_ID="STD-Kemp-2000" TOTAL_1="241" TOTAL_2="229" VAR="0.13090688710264167" WEIGHT="13.38549405591684"/>
<DICH_DATA CI_END="2.8481801597210152" CI_START="0.2137304774659444" EFFECT_SIZE="0.7802197802197802" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.45456745683913813" LOG_CI_START="-0.6701335440431746" LOG_EFFECT_SIZE="-0.10778304360201832" ORDER="564" O_E="0.0" SE="0.6606549352780141" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="0.436464943507197" WEIGHT="4.983584546657836"/>
<DICH_DATA CI_END="8.4490691962575" CI_START="0.579447502770372" EFFECT_SIZE="2.2126436781609193" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9268088669147475" LOG_CI_START="-0.23698590446294557" LOG_EFFECT_SIZE="0.34491148122590093" ORDER="565" O_E="0.0" SE="0.6836188095842854" STUDY_ID="STD-Poulsen-1991" TOTAL_1="232" TOTAL_2="220" VAR="0.46733467681743546" WEIGHT="3.092022698402897"/>
<DICH_DATA CI_END="5.443440209415893" CI_START="0.7057301728702595" EFFECT_SIZE="1.96" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7358734570048635" LOG_CI_START="-0.1513613142919114" LOG_EFFECT_SIZE="0.292256071356476" ORDER="566" O_E="0.0" SE="0.5211660965426749" STUDY_ID="STD-Rix-1996" TOTAL_1="110" TOTAL_2="98" VAR="0.27161410018552873" WEIGHT="5.309715149915452"/>
<DICH_DATA CI_END="2.3873597788055614" CI_START="0.3233227609657686" EFFECT_SIZE="0.8785714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3779178727879926" LOG_CI_START="-0.4903637212656728" LOG_EFFECT_SIZE="-0.0562229242388401" ORDER="567" O_E="0.0" SE="0.5100329064103319" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="0.26013356562137047" WEIGHT="6.941364990596542"/>
<DICH_DATA CI_END="2.951434255065567" CI_START="0.9839622859680495" EFFECT_SIZE="1.7041420118343196" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.4700331134998702" LOG_CI_START="-0.007021547208755583" LOG_EFFECT_SIZE="0.23150578314555734" ORDER="568" O_E="0.0" SE="0.2802242691589025" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.07852564102564102" WEIGHT="13.57433505089658"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005369514017262393" CI_END="1.5036971737708367" CI_START="0.5360311322879682" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8977908991934588" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-021.19" LOG_CI_END="0.1771603834615772" LOG_CI_START="-0.2708099860754513" LOG_EFFECT_SIZE="-0.046824801306937024" METHOD="MH" NO="19" P_CHI2="0.941585719497653" P_Q="0.0" P_Z="0.6819991924132789" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="235" WEIGHT="100.0" Z="0.40973658253196">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5363232541222727" CI_START="0.5166805102320791" EFFECT_SIZE="0.8909479686386315" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.18648260417936136" LOG_CI_START="-0.28677792021996834" LOG_EFFECT_SIZE="-0.05014765802030352" ORDER="569" O_E="0.0" SE="0.2779955747095443" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.0772815395580898" WEIGHT="88.06352345190749"/>
<DICH_DATA CI_END="4.59878901887021" CI_START="0.19553563055248702" EFFECT_SIZE="0.9482758620689655" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6626434856683509" LOG_CI_START="-0.7087740938057377" LOG_EFFECT_SIZE="-0.02306530406869343" ORDER="570" O_E="0.0" SE="0.8055774748095835" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="0.6489550679205852" WEIGHT="11.936476548092518"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.53002242964486" CI_END="2.0642492410602022" CI_START="0.6604198928607603" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1675920788609713" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" I2="20.949317422425352" I2_Q="0.0" ID="CMP-021.20" LOG_CI_END="0.314762133595707" LOG_CI_START="-0.18017985359588726" LOG_EFFECT_SIZE="0.06729113999990988" METHOD="MH" NO="20" P_CHI2="0.28223623571045364" P_Q="0.0" P_Z="0.5940722650657615" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="204" TOTAL_2="203" WEIGHT="100.0" Z="0.5329441198829287">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="571" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="18.031979909308212"/>
<DICH_DATA CI_END="6.298162014230098" CI_START="0.135288835693967" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.799213828256879" LOG_CI_START="-0.8687380407753029" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="572" O_E="0.0" SE="0.9797631843644143" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.9599358974358974" WEIGHT="10.716148060388882"/>
<DICH_DATA CI_END="2.7642499987188587" CI_START="0.7750450851286126" EFFECT_SIZE="1.4637002341920375" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.44157731806332656" LOG_CI_START="-0.11067303342522392" LOG_EFFECT_SIZE="0.16545214231905137" ORDER="573" O_E="0.0" SE="0.3243945901477027" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.10523185011709602" WEIGHT="71.2518720303029"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.30632396261171246" CI_END="28.53710947267686" CI_START="0.856848476643822" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.944894213173943" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.21" LOG_CI_END="1.455409981264933" LOG_CI_START="-0.06709597104716743" LOG_EFFECT_SIZE="0.6941570051088828" METHOD="MH" NO="21" P_CHI2="0.8579907478223123" P_Q="0.0" P_Z="0.07390274758028144" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="320" WEIGHT="100.0" Z="1.7872149892924707">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.23803152516251" CI_START="0.12961927608518836" EFFECT_SIZE="3.081081081081081" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864736662920095" LOG_CI_START="-0.8873304083811396" LOG_EFFECT_SIZE="0.4887031272694776" ORDER="574" O_E="0.0" SE="1.6165778206340564" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="2.6133238501659553" WEIGHT="32.87864978284787"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="575" O_E="0.0" SE="0.0" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="576" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="32.921474465078866"/>
<DICH_DATA CI_END="156.76667869560956" CI_START="0.46505626100139347" EFFECT_SIZE="8.538461538461538" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.195253757350487" LOG_CI_START="-0.3324945043908454" LOG_EFFECT_SIZE="0.9313796264798206" ORDER="577" O_E="0.0" SE="1.4848118415025537" STUDY_ID="STD-Poulsen-1991" TOTAL_1="116" TOTAL_2="110" VAR="2.204666204666205" WEIGHT="34.19987575207327"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4554001092849402" CI_START="0.18032584258684528" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5122950819672131" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-021.22" LOG_CI_END="0.16298240319629226" LOG_CI_START="-0.7439420298576384" LOG_EFFECT_SIZE="-0.2904798133306731" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.20929080474119843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="1.2555179938132324">
<NAME>Other</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4554001092849402" CI_START="0.18032584258684528" EFFECT_SIZE="0.5122950819672131" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16298240319629226" LOG_CI_START="-0.7439420298576384" LOG_EFFECT_SIZE="-0.2904798133306731" ORDER="578" O_E="0.0" SE="0.5327319013242258" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.2838032786885246" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.26449534710583766" CI_END="12.65720306521852" CI_START="0.2311132918487198" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7103356004013825" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-021.23" LOG_CI_END="1.1023377477397223" LOG_CI_START="-0.6361750765435945" LOG_EFFECT_SIZE="0.2330813355980638" METHOD="MH" NO="23" P_CHI2="0.6070485210404186" P_Q="0.0" P_Z="0.5992062506767108" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="78" WEIGHT="100.0" Z="0.5255423104848507">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.815108793485775" CI_START="0.06679227909762638" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.199072183810896" LOG_CI_START="-1.1752737372114805" LOG_EFFECT_SIZE="0.01189922329970769" ORDER="579" O_E="0.0" SE="1.3947025472104062" STUDY_ID="STD-Chyu-1997" TOTAL_1="36" TOTAL_2="37" VAR="1.9451951951951953" WEIGHT="66.62950161667968"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="580" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="33.37049838332033"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-021.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal complication</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="581" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.673007565344359" CI_START="0.10992472329414438" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6354166666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-021.26" LOG_CI_END="0.5650218228685513" LOG_CI_START="-0.9589046189261543" LOG_EFFECT_SIZE="-0.19694139802880142" METHOD="MH" NO="26" P_CHI2="1.0" P_Q="0.0" P_Z="0.6124470421703734" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="61" WEIGHT="100.00000000000001" Z="0.5065835680977282">
<NAME>Woman not satisfied</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.673007565344359" CI_START="0.10992472329414438" EFFECT_SIZE="0.6354166666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5650218228685513" LOG_CI_START="-0.9589046189261543" LOG_EFFECT_SIZE="-0.19694139802880142" ORDER="582" O_E="0.0" SE="0.8951619354677579" STUDY_ID="STD-Lyndrup-1991" TOTAL_1="64" TOTAL_2="61" VAR="0.8013148907103824" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" NO="22">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all women favourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.552691664785005" CI_START="0.19523689265096625" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-022.03" LOG_CI_END="1.3531983823737073" LOG_CI_START="-0.7094381130995047" LOG_EFFECT_SIZE="0.32188013463710136" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5407259353630074" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="64" WEIGHT="100.0" Z="0.6117156102029376">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="22.552691664785005" CI_START="0.19523689265096625" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3531983823737073" LOG_CI_START="-0.7094381130995047" LOG_EFFECT_SIZE="0.32188013463710136" ORDER="583" O_E="0.0" SE="1.2116028876562854" STUDY_ID="STD-Keirse-1995" TOTAL_1="61" TOTAL_2="64" VAR="1.4679815573770492" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.762487676168365" CI_START="0.4885346996059904" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-022.11" LOG_CI_END="0.2461260889594437" LOG_CI_START="-0.3111045838137789" LOG_EFFECT_SIZE="-0.032489247427167606" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.8192180773235165" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="140" WEIGHT="100.0" Z="0.2285507885814972">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7624876761683648" CI_START="0.48853469960599044" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24612608895944366" LOG_CI_START="-0.31110458381377887" LOG_EFFECT_SIZE="-0.032489247427167606" ORDER="584" O_E="0.0" SE="0.327320055523307" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.1071384187477808" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" NO="24">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all women, intact, unfavour cervix</NAME>
<DICH_OUTCOME CHI2="11.295555979095306" CI_END="1.325069420941355" CI_START="0.9620245785495986" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.129047984467475" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="149" I2="64.58784315351274" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="0.12223863173847373" LOG_CI_START="-0.016813832128398404" LOG_EFFECT_SIZE="0.05271239980503768" METHOD="MH" NO="1" P_CHI2="0.023435722026157957" P_Q="0.0" P_Z="0.1372851149363693" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="408" TOTAL_2="393" WEIGHT="100.00000000000001" Z="1.4859773395380111">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3069812799665868" CI_START="0.6638886736960186" EFFECT_SIZE="0.9314988290398126" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="42" LOG_CI_END="0.11626936717852775" LOG_CI_START="-0.17790474059133726" LOG_EFFECT_SIZE="-0.03081768670640474" ORDER="585" O_E="0.0" SE="0.17279932708933723" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.02985960744252776" WEIGHT="28.926315606689037"/>
<DICH_DATA CI_END="1.1962022489978994" CI_START="0.789267031588584" EFFECT_SIZE="0.97165991902834" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="38" LOG_CI_END="0.07780461460046488" LOG_CI_START="-0.10277603769658433" LOG_EFFECT_SIZE="-0.012485711548059728" ORDER="586" O_E="0.0" SE="0.10607396904793205" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.011251686909581646" WEIGHT="25.991231685879168"/>
<DICH_DATA CI_END="1.57472062445261" CI_START="0.7244360927471779" EFFECT_SIZE="1.068075117370892" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.19720351557271068" LOG_CI_START="-0.13999992046392368" LOG_EFFECT_SIZE="0.028601797554393477" ORDER="587" O_E="0.0" SE="0.19807496751184767" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.03923369275481951" WEIGHT="23.844139672203735"/>
<DICH_DATA CI_END="4.1033869835640875" CI_START="1.4252699156035287" EFFECT_SIZE="2.4183535762483133" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="13" LOG_CI_END="0.6131424764846473" LOG_CI_START="0.1538971182089092" LOG_EFFECT_SIZE="0.38351979734677827" ORDER="588" O_E="0.0" SE="0.2697629967523553" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.07277207441681127" WEIGHT="8.625408745313882"/>
<DICH_DATA CI_END="1.7094739947338837" CI_START="0.7602338520524323" EFFECT_SIZE="1.14" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.23286249850524962" LOG_CI_START="-0.11905279583230446" LOG_EFFECT_SIZE="0.05690485133647255" ORDER="589" O_E="0.0" SE="0.20671678590268097" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.04273182957393484" WEIGHT="12.612904289914185"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0213852112389894" CI_END="1.9629959579914378" CI_START="0.4364807749817099" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.925640317310167" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="0.292919405344366" LOG_CI_START="-0.3600348802590534" LOG_EFFECT_SIZE="-0.033557737457343695" METHOD="MH" NO="2" P_CHI2="0.5542531100242715" P_Q="0.0" P_Z="0.8403392110965688" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="439" TOTAL_2="467" WEIGHT="100.0" Z="0.20145960680313799">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="590" O_E="0.0" SE="0.0" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.1214686175061974" CI_START="0.03460014351373879" EFFECT_SIZE="0.3286384976525822" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49435897299711784" LOG_CI_START="-1.4609220998460797" LOG_EFFECT_SIZE="-0.4832815634244808" ORDER="591" O_E="0.0" SE="1.1485417809855023" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="1.3191482226693494" WEIGHT="24.145141738021934"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="592" O_E="0.0" SE="0.0" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="28.311269081090536" CI_START="0.11706529015561468" EFFECT_SIZE="1.8205128205128205" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.4519593374880801" LOG_CI_START="-0.931571854102928" LOG_EFFECT_SIZE="0.26019374169257603" ORDER="593" O_E="0.0" SE="1.4000980206102431" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="1.960274467316721" WEIGHT="5.666843124941639"/>
<DICH_DATA CI_END="3.405584464032359" CI_START="0.4711216125718147" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5321916559615373" LOG_CI_START="-0.3268669721672419" LOG_EFFECT_SIZE="0.10266234189714771" ORDER="594" O_E="0.0" SE="0.5046152905716361" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.25463659147869677" WEIGHT="45.97965443840951"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="595" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="3.947708139247265"/>
<DICH_DATA CI_END="3.9074989067326817" CI_START="0.009675918759737532" EFFECT_SIZE="0.19444444444444445" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5918988651813" LOG_CI_START="-2.0143077866873607" LOG_EFFECT_SIZE="-0.7112044607530305" ORDER="596" O_E="0.0" SE="1.5308986882386417" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="2.3436507936507938" WEIGHT="20.260652559379643"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="597" O_E="0.0" SE="0.0" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.379570055322256" CI_END="1.2512808784464742" CI_START="0.8004378504681899" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0007859794559695" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="127" I2="0.0" I2_Q="0.0" ID="CMP-024.03" LOG_CI_END="0.09735480790871012" LOG_CI_START="-0.09667238297834646" LOG_EFFECT_SIZE="3.4121246518181014E-4" METHOD="MH" NO="3" P_CHI2="0.7548096298140455" P_Q="0.0" P_Z="0.9944998187531905" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="798" TOTAL_2="811" WEIGHT="100.00000000000001" Z="0.006893509510445508">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7288008718872945" CI_START="0.32053906950874267" EFFECT_SIZE="0.7444113263785395" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.23774497290326527" LOG_CI_START="-0.4941190281172472" LOG_EFFECT_SIZE="-0.12818702760699097" ORDER="598" O_E="0.0" SE="0.4299005369846816" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.1848144716997176" WEIGHT="9.293192829567307"/>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="599" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="3.226995423679855"/>
<DICH_DATA CI_END="2.331408122561638" CI_START="0.5920088285042477" EFFECT_SIZE="1.1748251748251748" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3676183052073158" LOG_CI_START="-0.22767181668571365" LOG_EFFECT_SIZE="0.06997324426080104" ORDER="600" O_E="0.0" SE="0.34967636433359317" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.12227355977355979" WEIGHT="9.229206911724384"/>
<DICH_DATA CI_END="1.9234385073419273" CI_START="0.8638292084503612" EFFECT_SIZE="1.2890005288207298" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.284078306395904" LOG_CI_START="-0.0635721153448345" LOG_EFFECT_SIZE="0.11025309552553472" ORDER="601" O_E="0.0" SE="0.2042115786278517" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.04170236884567926" WEIGHT="24.705458891411357"/>
<DICH_DATA CI_END="3.021152967753493" CI_START="0.5719843426248314" EFFECT_SIZE="1.3145539906103287" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4801727151340536" LOG_CI_START="-0.2426158593270905" LOG_EFFECT_SIZE="0.11877842790348153" ORDER="602" O_E="0.0" SE="0.4245695864996226" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.18025933378046052" WEIGHT="7.312234311104352"/>
<DICH_DATA CI_END="2.211653210227933" CI_START="0.3341376536453985" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.34471703009577304" LOG_CI_START="-0.4760745813837285" LOG_EFFECT_SIZE="-0.06567877564397773" ORDER="603" O_E="0.0" SE="0.482137055567063" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="0.2324561403508772" WEIGHT="6.5111058106106805"/>
<DICH_DATA CI_END="1.4954350427230212" CI_START="0.27607341539705244" EFFECT_SIZE="0.6425339366515838" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="0.174767553308738" LOG_CI_START="-0.5589754119128463" LOG_EFFECT_SIZE="-0.19210392930205417" ORDER="604" O_E="0.0" SE="0.43100424985741403" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="0.18576466339515219" WEIGHT="9.724990754089744"/>
<DICH_DATA CI_END="2.7485639734791887" CI_START="0.497047299758468" EFFECT_SIZE="1.1688311688311688" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4391058497265867" LOG_CI_START="-0.3036022811929008" LOG_EFFECT_SIZE="0.06775178426684299" ORDER="605" O_E="0.0" SE="0.4362704325666482" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.19033189033189032" WEIGHT="5.9161582767464"/>
<DICH_DATA CI_END="4.652365301456785" CI_START="0.39589254397481366" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6676738079863876" LOG_CI_START="-0.4024226774372058" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="606" O_E="0.0" SE="0.6285799726008515" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.3951127819548872" WEIGHT="3.0943791733916415"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="607" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="0.3985144950929941"/>
<DICH_DATA CI_END="1.6722857022266164" CI_START="0.3777556053060831" EFFECT_SIZE="0.7948051948051948" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2233104766321436" LOG_CI_START="-0.4227890826859849" LOG_EFFECT_SIZE="-0.09973930302692065" ORDER="608" O_E="0.0" SE="0.37952207938786786" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="0.14403700874289108" WEIGHT="9.002849551570609"/>
<DICH_DATA CI_END="3.6075179132023756" CI_START="0.39916641708972667" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5572084962688248" LOG_CI_START="-0.39884600417357535" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="609" O_E="0.0" SE="0.5615911461059686" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.3153846153846154" WEIGHT="4.033744279599818"/>
<DICH_DATA CI_END="1.4227199692045693" CI_START="0.18484655031342975" EFFECT_SIZE="0.5128205128205128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.1531194272823733" LOG_CI_START="-0.7331886500074094" LOG_EFFECT_SIZE="-0.29003461136251807" ORDER="610" O_E="0.0" SE="0.5206217518957583" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.2710470085470086" WEIGHT="7.55116929141086"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="611" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.05" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="173" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="612" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="613" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.755394728377158" CI_END="1.1073918592139997" CI_START="0.7838739754661334" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9316950461824463" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="153" I2="52.96107938822394" I2_Q="0.0" ID="CMP-024.07" LOG_CI_END="0.04430132655226141" LOG_CI_START="-0.10575375384497274" LOG_EFFECT_SIZE="-0.030726213646355662" METHOD="MH" NO="7" P_CHI2="0.047089066491632026" P_Q="0.0" P_Z="0.42216614828055954" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="558" TOTAL_2="540" WEIGHT="100.0" Z="0.8026688862345279">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5642857731829913" CI_START="0.613733129766819" EFFECT_SIZE="0.9798234552332913" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.19431609551360027" LOG_CI_START="-0.2120204325469793" LOG_EFFECT_SIZE="-0.008852168516689544" ORDER="614" O_E="0.0" SE="0.23868408798103774" STUDY_ID="STD-Corrado-2001" TOTAL_1="122" TOTAL_2="111" VAR="0.056970093855339764" WEIGHT="17.57193616822016"/>
<DICH_DATA CI_END="2.331408122561638" CI_START="0.5920088285042477" EFFECT_SIZE="1.1748251748251748" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3676183052073158" LOG_CI_START="-0.22767181668571365" LOG_EFFECT_SIZE="0.06997324426080104" ORDER="615" O_E="0.0" SE="0.34967636433359317" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.12227355977355979" WEIGHT="7.383093835925945"/>
<DICH_DATA CI_END="1.6566925787021856" CI_START="0.5132671348907573" EFFECT_SIZE="0.9221311475409836" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.21924192678994753" LOG_CI_START="-0.28965654324468143" LOG_EFFECT_SIZE="-0.03520730822736695" ORDER="616" O_E="0.0" SE="0.29892948038639505" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.08935883424408014" WEIGHT="12.750735369652125"/>
<DICH_DATA CI_END="1.5424817014185026" CI_START="0.5843573750484679" EFFECT_SIZE="0.9494001043296818" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.18822002066631102" LOG_CI_START="-0.23332147045228657" LOG_EFFECT_SIZE="-0.0225507248929878" ORDER="617" O_E="0.0" SE="0.24761555854709855" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06131346483459159" WEIGHT="17.54871656433819"/>
<DICH_DATA CI_END="1.1296053653640439" CI_START="0.5456946845045478" EFFECT_SIZE="0.7851239669421488" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.05292674651090118" LOG_CI_START="-0.26305027656610575" LOG_EFFECT_SIZE="-0.10506176502760228" ORDER="618" O_E="0.0" SE="0.18560646746692377" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.03444976076555024" WEIGHT="14.874364870913077"/>
<DICH_DATA CI_END="1.3388368861375306" CI_START="0.9939426188468702" EFFECT_SIZE="1.1535714285714285" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" LOG_CI_END="0.12672766904674287" LOG_CI_START="-0.0026386870689756904" LOG_EFFECT_SIZE="0.06204449098888362" ORDER="619" O_E="0.0" SE="0.07599043795616373" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.0057745466607695695" WEIGHT="19.803297960142395"/>
<DICH_DATA CI_END="0.9652635558535889" CI_START="0.19223985931326396" EFFECT_SIZE="0.4307692307692308" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.015354090567863797" LOG_CI_START="-0.7161565600334088" LOG_EFFECT_SIZE="-0.3657553253006363" ORDER="620" O_E="0.0" SE="0.4116548395922328" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.16945970695970694" WEIGHT="10.067855230808107"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5398844020415283" CI_END="1.7179325015994649" CI_START="0.24359933807334827" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6469058820603821" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-024.08" LOG_CI_END="0.23500609618977158" LOG_CI_START="-0.6133238961355615" LOG_EFFECT_SIZE="-0.1891588999728949" METHOD="MH" NO="8" P_CHI2="0.910045565093466" P_Q="0.0" P_Z="0.3820869049161906" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="301" TOTAL_2="291" WEIGHT="100.0" Z="0.874057582912638">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.351608110052847" CI_START="0.05937111711685543" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1569005668674324" LOG_CI_START="-1.2264247793858563" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="621" O_E="0.0" SE="1.3999771060399158" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.9599358974358976" WEIGHT="10.686008124641651"/>
<DICH_DATA CI_END="2.6483015026680636" CI_START="0.09175969562706825" EFFECT_SIZE="0.49295774647887325" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42296742695009537" LOG_CI_START="-1.0373480356876947" LOG_EFFECT_SIZE="-0.3071903043687996" ORDER="622" O_E="0.0" SE="0.8577965314315605" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.7358148893360161" WEIGHT="41.391520831945286"/>
<DICH_DATA CI_END="4.164933703007989" CI_START="0.19842963656176835" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6196080927423374" LOG_CI_START="-0.7023934630587876" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="623" O_E="0.0" SE="0.7765502578908225" STUDY_ID="STD-Perry-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.603030303030303" WEIGHT="32.29288169534565"/>
<DICH_DATA CI_END="7.689287448668567" CI_START="0.013658483466521182" EFFECT_SIZE="0.32407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8858860964400181" LOG_CI_START="-1.864597518713366" LOG_EFFECT_SIZE="-0.4893557111366741" ORDER="624" O_E="0.0" SE="1.6156476906545747" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="2.6103174603174604" WEIGHT="15.62958934806742"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="625" O_E="0.0" SE="0.0" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.09" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Uterine rupture</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="626" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.239982415032324" CI_START="0.906006580607915" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0599208592425098" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-024.10" LOG_CI_END="0.09341552620370377" LOG_CI_START="-0.042868647895674766" LOG_EFFECT_SIZE="0.02527343915401449" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.46726432012176267" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="0.7269373841046556">
<NAME>Epidural analgesia</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.239982415032324" CI_START="0.9060065806079148" EFFECT_SIZE="1.0599208592425098" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="87" LOG_CI_END="0.09341552620370377" LOG_CI_START="-0.04286864789567482" LOG_EFFECT_SIZE="0.02527343915401449" ORDER="627" O_E="0.0" SE="0.08005399848351687" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.006408642673198921" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.144179351864802" CI_END="1.2325403096685956" CI_START="0.6477853085875984" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8935443496801517" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="65" I2="44.01036420011062" I2_Q="0.0" ID="CMP-024.11" LOG_CI_END="0.0908011315844547" LOG_CI_START="-0.18856890577272176" LOG_EFFECT_SIZE="-0.04888388709413355" METHOD="MH" NO="11" P_CHI2="0.12846241087956123" P_Q="0.0" P_Z="0.4927729973169567" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="390" TOTAL_2="386" WEIGHT="100.00000000000001" Z="0.6859050386017564">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2255560435528916" CI_START="0.48182542762847635" EFFECT_SIZE="0.7684426229508197" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="32" LOG_CI_END="0.08833317593020137" LOG_CI_START="-0.3171102844801849" LOG_EFFECT_SIZE="-0.11438855427499177" ORDER="628" O_E="0.0" SE="0.23815949562255806" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.05671994535519125" WEIGHT="48.73037956937028"/>
<DICH_DATA CI_END="1.7624876761683648" CI_START="0.48853469960599044" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24612608895944366" LOG_CI_START="-0.31110458381377887" LOG_EFFECT_SIZE="-0.032489247427167606" ORDER="629" O_E="0.0" SE="0.327320055523307" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.1071384187477808" WEIGHT="26.392169752493878"/>
<DICH_DATA CI_END="8.150609039529751" CI_START="1.0420155332318335" EFFECT_SIZE="2.914285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9111900618227434" LOG_CI_START="0.017874193000540384" LOG_EFFECT_SIZE="0.4645321274116419" ORDER="630" O_E="0.0" SE="0.5247381633310296" STUDY_ID="STD-Wieland-1999" TOTAL_1="35" TOTAL_2="34" VAR="0.2753501400560224" WEIGHT="6.255555526508762"/>
<DICH_DATA CI_END="1.3288565127556677" CI_START="0.1881316738114724" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12347808923266526" LOG_CI_START="-0.7255380805606277" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="631" O_E="0.0" SE="0.498716300834401" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="0.24871794871794875" WEIGHT="15.415476118896592"/>
<DICH_DATA CI_END="4.928287746792142" CI_START="0.04322348093776479" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6926960569477116" LOG_CI_START="-1.364280260794098" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="632" O_E="0.0" SE="1.2082780712385282" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="1.4599358974358976" WEIGHT="3.206419032730491"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.26529923618431384" CI_END="4.457363505835759" CI_START="0.47210633721694467" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.450637638552302" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-024.12" LOG_CI_END="0.6490780530094891" LOG_CI_START="-0.32596016987190607" LOG_EFFECT_SIZE="0.16155894156879147" METHOD="MH" NO="12" P_CHI2="0.6065027062879118" P_Q="0.0" P_Z="0.5160072398127507" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="178" WEIGHT="100.0" Z="0.6495123974104141">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.593206010672255" CI_START="0.36703878250827304" EFFECT_SIZE="1.971830985915493" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0250274182780577" LOG_CI_START="-0.43528804435973234" LOG_EFFECT_SIZE="0.2948696869591627" ORDER="633" O_E="0.0" SE="0.8577965314315605" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.7358148893360161" WEIGHT="41.18231297922212"/>
<DICH_DATA CI_END="5.029145164581975" CI_START="0.23438884176692115" EFFECT_SIZE="1.0857142857142856" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7014941715658538" LOG_CI_START="-0.6300630670327849" LOG_EFFECT_SIZE="0.03571555226653449" ORDER="634" O_E="0.0" SE="0.7821633132674748" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="0.6117794486215539" WEIGHT="58.81768702077788"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.8388324068797015" CI_END="1.8553656656981805" CI_START="0.3663364435296368" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8244319616674675" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-024.13" LOG_CI_END="0.26842951553848954" LOG_CI_START="-0.43611987512048944" LOG_EFFECT_SIZE="-0.08384517979099995" METHOD="MH" NO="13" P_CHI2="0.6984761678948366" P_Q="0.0" P_Z="0.6408629566485295" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="534" TOTAL_2="527" WEIGHT="99.99999999999999" Z="0.4664925833345511">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="635" O_E="0.0" SE="0.0" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.928287746792142" CI_START="0.04322348093776479" EFFECT_SIZE="0.46153846153846156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6926960569477116" LOG_CI_START="-1.364280260794098" LOG_EFFECT_SIZE="-0.3357921019231931" ORDER="636" O_E="0.0" SE="1.2082780712385282" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="1.4599358974358976" WEIGHT="16.51650613805983"/>
<DICH_DATA CI_END="2.0918180543665583" CI_START="0.006193297489086655" EFFECT_SIZE="0.11382113821138211" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3205239070494482" LOG_CI_START="-2.2080780585717683" LOG_EFFECT_SIZE="-0.9437770757611599" ORDER="637" O_E="0.0" SE="1.4853133113875003" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.2061556329849012" WEIGHT="35.302309806209905"/>
<DICH_DATA CI_END="72.0003811846031" CI_START="0.12152730418332627" EFFECT_SIZE="2.958041958041958" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.857334795680317" LOG_CI_START="-0.9153261358603558" LOG_EFFECT_SIZE="0.47100432990998053" ORDER="638" O_E="0.0" SE="1.6286747560799544" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="2.6525814610920992" WEIGHT="3.9982739330690613"/>
<DICH_DATA CI_END="21.060687049972" CI_START="0.18332166760237306" EFFECT_SIZE="1.9649122807017543" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3234725348050522" LOG_CI_START="-0.7367862008096718" LOG_EFFECT_SIZE="0.2933431669976902" ORDER="639" O_E="0.0" SE="1.2102061797453088" STUDY_ID="STD-Legarth-1988" TOTAL_1="57" TOTAL_2="56" VAR="1.4645989974937343" WEIGHT="8.010898994804377"/>
<DICH_DATA CI_END="6.928491935952064" CI_START="0.15163833770929122" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8406387158286682" LOG_CI_START="-0.819190985045122" LOG_EFFECT_SIZE="0.010723865391773066" ORDER="640" O_E="0.0" SE="0.9749921825827943" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="0.9506097560975609" WEIGHT="15.685191014301834"/>
<DICH_DATA CI_END="71.45532212106615" CI_START="0.12595282944426972" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.854034581366758" LOG_CI_START="-0.8997920719274333" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="641" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Yuen-1996" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="3.9703139754951517"/>
<DICH_DATA CI_END="6.298162014230098" CI_START="0.135288835693967" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.799213828256879" LOG_CI_START="-0.8687380407753029" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="642" O_E="0.0" SE="0.9797631843644143" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.9599358974358974" WEIGHT="16.51650613805983"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2160937377711303" CI_END="1.5967163968429898" CI_START="0.61722292407361" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9927386178525084" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="17.76949679612603" I2_Q="0.0" ID="CMP-024.14" LOG_CI_END="0.20322778512798662" LOG_CI_START="-0.2095579523208356" LOG_EFFECT_SIZE="-0.003165083596424547" METHOD="MH" NO="14" P_CHI2="0.27012869304428244" P_Q="0.0" P_Z="0.9760219829719985" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="178" WEIGHT="100.0" Z="0.030056512588784556">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.492157276637085" CI_START="0.5584924037228736" EFFECT_SIZE="0.9128847157016171" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.17381460113650027" LOG_CI_START="-0.25298272952003653" LOG_EFFECT_SIZE="-0.03958406419176816" ORDER="643" O_E="0.0" SE="0.25070286470850933" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06285192637305313" WEIGHT="96.59363869792098"/>
<DICH_DATA CI_END="29.872852890628845" CI_START="0.355137811265585" EFFECT_SIZE="3.257142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4752767001901013" LOG_CI_START="-0.4496030862177075" LOG_EFFECT_SIZE="0.5128368069861969" ORDER="644" O_E="0.0" SE="1.1306839148445602" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="1.2784461152882205" WEIGHT="3.406361302079019"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.13280970863987" CI_END="1.4105540195460833" CI_START="0.7949121970428368" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0588987650974864" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="79" I2="2.58746605034503" I2_Q="0.0" ID="CMP-024.18" LOG_CI_END="0.1493897228498009" LOG_CI_START="-0.09968083919974273" LOG_EFFECT_SIZE="0.024854441825029095" METHOD="MH" NO="18" P_CHI2="0.39988825850851584" P_Q="0.0" P_Z="0.6956754703131863" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="753" TOTAL_2="786" WEIGHT="100.0" Z="0.39116474008046864">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="645" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="4.52159190827592"/>
<DICH_DATA CI_END="6.424963292845577" CI_START="0.1326188130702585" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8078706507955264" LOG_CI_START="-0.8773948633139502" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="646" O_E="0.0" SE="0.9899333051867427" STUDY_ID="STD-Hales-1994" TOTAL_1="104" TOTAL_2="96" VAR="0.9799679487179488" WEIGHT="2.6871174769182615"/>
<DICH_DATA CI_END="1.4765116534173397" CI_START="0.6810569562929598" EFFECT_SIZE="1.0027903732124173" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="47" LOG_CI_END="0.16923687899826878" LOG_CI_START="-0.16681656683993917" LOG_EFFECT_SIZE="0.0012101560791648392" ORDER="647" O_E="0.0" SE="0.19739945757674868" STUDY_ID="STD-Irion-1998" TOTAL_1="488" TOTAL_2="500" VAR="0.038966545851594606" WEIGHT="59.98104800937913"/>
<DICH_DATA CI_END="2.8481801597210152" CI_START="0.2137304774659444" EFFECT_SIZE="0.7802197802197802" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.45456745683913813" LOG_CI_START="-0.6701335440431746" LOG_EFFECT_SIZE="-0.10778304360201832" ORDER="648" O_E="0.0" SE="0.6606549352780141" STUDY_ID="STD-Nuutila-1996" TOTAL_1="39" TOTAL_2="71" VAR="0.436464943507197" WEIGHT="6.412439433554942"/>
<DICH_DATA CI_END="2.3873597788055614" CI_START="0.3233227609657686" EFFECT_SIZE="0.8785714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3779178727879926" LOG_CI_START="-0.4903637212656728" LOG_EFFECT_SIZE="-0.0562229242388401" ORDER="649" O_E="0.0" SE="0.5100329064103319" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="0.26013356562137047" WEIGHT="8.931539571903052"/>
<DICH_DATA CI_END="2.951434255065567" CI_START="0.9839622859680495" EFFECT_SIZE="1.7041420118343196" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.4700331134998702" LOG_CI_START="-0.007021547208755583" LOG_EFFECT_SIZE="0.23150578314555734" ORDER="650" O_E="0.0" SE="0.2802242691589025" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.07852564102564102" WEIGHT="17.4662635999687"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5363232541222724" CI_START="0.5166805102320791" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8909479686386315" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-024.19" LOG_CI_END="0.18648260417936127" LOG_CI_START="-0.28677792021996834" LOG_EFFECT_SIZE="-0.05014765802030352" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.6778757314989756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="0.41536362557842493">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5363232541222727" CI_START="0.5166805102320791" EFFECT_SIZE="0.8909479686386315" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.18648260417936136" LOG_CI_START="-0.28677792021996834" LOG_EFFECT_SIZE="-0.05014765802030352" ORDER="651" O_E="0.0" SE="0.2779955747095443" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.0772815395580898" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.53002242964486" CI_END="2.0642492410602022" CI_START="0.6604198928607602" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.167592078860971" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" I2="20.949317422425352" I2_Q="0.0" ID="CMP-024.20" LOG_CI_END="0.314762133595707" LOG_CI_START="-0.1801798535958873" LOG_EFFECT_SIZE="0.0672911399999098" METHOD="MH" NO="20" P_CHI2="0.28223623571045364" P_Q="0.0" P_Z="0.5940722650657619" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="204" TOTAL_2="203" WEIGHT="100.0" Z="0.532944119882928">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="652" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Ekman-1983" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="18.031979909308212"/>
<DICH_DATA CI_END="6.298162014230098" CI_START="0.135288835693967" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.799213828256879" LOG_CI_START="-0.8687380407753029" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="653" O_E="0.0" SE="0.9797631843644143" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.9599358974358974" WEIGHT="10.716148060388882"/>
<DICH_DATA CI_END="2.7642499987188587" CI_START="0.7750450851286126" EFFECT_SIZE="1.4637002341920375" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.44157731806332656" LOG_CI_START="-0.11067303342522392" LOG_EFFECT_SIZE="0.16545214231905137" ORDER="654" O_E="0.0" SE="0.3243945901477027" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.10523185011709602" WEIGHT="71.2518720303029"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.71353545270564" CI_START="0.12640786289923156" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.21" LOG_CI_END="1.8733992877579861" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" METHOD="MH" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.4904475967996528" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="173" WEIGHT="100.0" Z="0.6895970992341449">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="655" O_E="0.0" SE="0.0" STUDY_ID="STD-Hales-1994" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.71353545270557" CI_START="0.12640786289923156" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8733992877579857" LOG_CI_START="-0.8982259109623312" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="656" O_E="0.0" SE="1.6280663614943174" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="2.6506000774293454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4554001092849402" CI_START="0.18032584258684528" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5122950819672131" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-024.22" LOG_CI_END="0.16298240319629226" LOG_CI_START="-0.7439420298576384" LOG_EFFECT_SIZE="-0.2904798133306731" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.20929080474119843" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="125" WEIGHT="100.0" Z="1.2555179938132324">
<NAME>Other</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4554001092849402" CI_START="0.18032584258684528" EFFECT_SIZE="0.5122950819672131" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.16298240319629226" LOG_CI_START="-0.7439420298576384" LOG_EFFECT_SIZE="-0.2904798133306731" ORDER="657" O_E="0.0" SE="0.5327319013242258" STUDY_ID="STD-Irion-1998" TOTAL_1="122" TOTAL_2="125" VAR="0.2838032786885246" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9024192805761172" CI_END="1.449835629631452" CI_START="0.5397906371163215" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8846511731935388" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-024.23" LOG_CI_END="0.16131876831054429" LOG_CI_START="-0.26777465272500317" LOG_EFFECT_SIZE="-0.053227942207229435" METHOD="MH" NO="23" P_CHI2="0.6368573457915596" P_Q="0.0" P_Z="0.6267849314975094" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="217" TOTAL_2="219" WEIGHT="100.0" Z="0.4862570460557424">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4526455224544084" CI_START="0.5236350501591963" EFFECT_SIZE="0.8721560130010835" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.16215964979437983" LOG_CI_START="-0.28097129111046687" LOG_EFFECT_SIZE="-0.059405820658043514" ORDER="658" O_E="0.0" SE="0.2602973082210413" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06775468866711977" WEIGHT="93.12202061255665"/>
<DICH_DATA CI_END="8.583301772644782" CI_START="0.01519243270503358" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9336543817653437" LOG_CI_START="-1.8183726786862444" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="659" O_E="0.0" SE="1.6165543180629172" STUDY_ID="STD-Ramsey-2003" TOTAL_1="35" TOTAL_2="38" VAR="2.6132478632478633" WEIGHT="5.121206680707882"/>
<DICH_DATA CI_END="73.27799582621054" CI_START="0.12888423379674852" EFFECT_SIZE="3.073170731707317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8649735827460345" LOG_CI_START="-0.8898002059503799" LOG_EFFECT_SIZE="0.4875866883978274" ORDER="660" O_E="0.0" SE="1.618167759830452" STUDY_ID="STD-Thiery-1984" TOTAL_1="40" TOTAL_2="41" VAR="2.6184668989547037" WEIGHT="1.7567727067354684"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-024.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="48" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal complication</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="661" O_E="0.0" SE="0.0" STUDY_ID="STD-Zanini-1989" TOTAL_1="52" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" NO="25">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all women, intact, favourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.552691664785005" CI_START="0.19523689265096625" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-025.03" LOG_CI_END="1.3531983823737073" LOG_CI_START="-0.7094381130995047" LOG_EFFECT_SIZE="0.32188013463710136" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5407259353630074" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="64" WEIGHT="100.0" Z="0.6117156102029376">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="22.552691664785005" CI_START="0.19523689265096625" EFFECT_SIZE="2.098360655737705" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3531983823737073" LOG_CI_START="-0.7094381130995047" LOG_EFFECT_SIZE="0.32188013463710136" ORDER="662" O_E="0.0" SE="1.2116028876562854" STUDY_ID="STD-Keirse-1995" TOTAL_1="61" TOTAL_2="64" VAR="1.4679815573770492" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.762487676168365" CI_START="0.4885346996059904" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-025.11" LOG_CI_END="0.2461260889594437" LOG_CI_START="-0.3111045838137789" LOG_EFFECT_SIZE="-0.032489247427167606" METHOD="MH" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.8192180773235165" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="140" WEIGHT="100.0" Z="0.2285507885814972">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7624876761683648" CI_START="0.48853469960599044" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24612608895944366" LOG_CI_START="-0.31110458381377887" LOG_EFFECT_SIZE="-0.032489247427167606" ORDER="663" O_E="0.0" SE="0.327320055523307" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.1071384187477808" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" NO="26">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all women, intact, variable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.57472062445261" CI_START="0.7244360927471779" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.068075117370892" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="0.19720351557271068" LOG_CI_START="-0.13999992046392368" LOG_EFFECT_SIZE="0.028601797554393477" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7395188069796734" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="140" WEIGHT="100.00000000000001" Z="0.3324906398262604">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.57472062445261" CI_START="0.7244360927471779" EFFECT_SIZE="1.068075117370892" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="36" LOG_CI_END="0.19720351557271068" LOG_CI_START="-0.13999992046392368" LOG_EFFECT_SIZE="0.028601797554393477" ORDER="664" O_E="0.0" SE="0.19807496751184767" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.03923369275481951" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1214686175061974" CI_START="0.03460014351373879" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3286384976525822" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.49435897299711784" LOG_CI_START="-1.4609220998460797" LOG_EFFECT_SIZE="-0.4832815634244808" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3326060495387474" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="140" WEIGHT="100.00000000000001" Z="0.9688780522248259">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1214686175061974" CI_START="0.03460014351373879" EFFECT_SIZE="0.3286384976525822" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.49435897299711784" LOG_CI_START="-1.4609220998460797" LOG_EFFECT_SIZE="-0.4832815634244808" ORDER="665" O_E="0.0" SE="1.1485417809855023" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="1.3191482226693494" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03761463669587135" CI_END="2.586610197019585" CI_START="0.6159907491473657" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2622709507131618" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="0.41273098533086217" LOG_CI_START="-0.21042580995313886" LOG_EFFECT_SIZE="0.10115258768886162" METHOD="MH" NO="3" P_CHI2="0.846219078146926" P_Q="0.0" P_Z="0.5245848942594771" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="171" WEIGHT="100.0" Z="0.6362938840227023">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.021152967753493" CI_START="0.5719843426248314" EFFECT_SIZE="1.3145539906103287" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4801727151340536" LOG_CI_START="-0.2426158593270905" LOG_EFFECT_SIZE="0.11877842790348153" ORDER="666" O_E="0.0" SE="0.4245695864996226" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.18025933378046052" WEIGHT="73.51911070504035"/>
<DICH_DATA CI_END="4.616294603211986" CI_START="0.2703360076906147" EFFECT_SIZE="1.117117117117117" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6642935168865485" LOG_CI_START="-0.5680961041353932" LOG_EFFECT_SIZE="0.0480987063755776" ORDER="667" O_E="0.0" SE="0.723911763815299" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.5240482417901773" WEIGHT="26.480889294959645"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="668" O_E="0.0" SE="0.0" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="669" O_E="0.0" SE="0.0" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0951066687787243" CI_END="1.6582450022282302" CI_START="0.6739948936555163" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0571890388816976" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="8.684694513347122" I2_Q="0.0" ID="CMP-026.07" LOG_CI_END="0.21964869705561085" LOG_CI_START="-0.17134339376977314" LOG_EFFECT_SIZE="0.024152651642918833" METHOD="MH" NO="7" P_CHI2="0.2953429802645283" P_Q="0.0" P_Z="0.8086680587362014" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="171" WEIGHT="99.99999999999999" Z="0.24214467996696257">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5424817014185026" CI_START="0.5843573750484679" EFFECT_SIZE="0.9494001043296818" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.18822002066631102" LOG_CI_START="-0.23332147045228657" LOG_EFFECT_SIZE="-0.0225507248929878" ORDER="670" O_E="0.0" SE="0.24761555854709855" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06131346483459159" WEIGHT="89.28065092769523"/>
<DICH_DATA CI_END="6.930145644165142" CI_START="0.5514817540841652" EFFECT_SIZE="1.954954954954955" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8407423618546033" LOG_CI_START="-0.2584688517308592" LOG_EFFECT_SIZE="0.29113675506187203" ORDER="671" O_E="0.0" SE="0.6456821080433622" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.4169053846473201" WEIGHT="10.719349072304752"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5813702264620655" CI_END="2.4591704594651986" CI_START="0.23541734981570686" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7608754118200767" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-026.08" LOG_CI_END="0.39078863326875074" LOG_CI_START="-0.6281615336269866" LOG_EFFECT_SIZE="-0.11868645017911793" METHOD="MH" NO="8" P_CHI2="0.44577587176217004" P_Q="0.0" P_Z="0.6479658550857207" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="171" WEIGHT="100.00000000000001" Z="0.45658988115712484">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6483015026680636" CI_START="0.09175969562706825" EFFECT_SIZE="0.49295774647887325" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42296742695009537" LOG_CI_START="-1.0373480356876947" LOG_EFFECT_SIZE="-0.3071903043687996" ORDER="672" O_E="0.0" SE="0.8577965314315605" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.7358148893360161" WEIGHT="64.92301485914074"/>
<DICH_DATA CI_END="7.049177464499069" CI_START="0.22405983586143138" EFFECT_SIZE="1.2567567567567568" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8481384441588127" LOG_CI_START="-0.6496359865128948" LOG_EFFECT_SIZE="0.09925122882295893" ORDER="673" O_E="0.0" SE="0.8798001146795659" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.7740482417901773" WEIGHT="35.07698514085928"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.112134899645715" CI_START="0.6180099035734969" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1425061425061425" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-026.10" LOG_CI_END="0.3247216526405573" LOG_CI_START="-0.20900456531108952" LOG_EFFECT_SIZE="0.05785854366473387" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.670880819090465" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="100.0" Z="0.4249394463552102">
<NAME>Epidural analgesia</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.112134899645715" CI_START="0.6180099035734969" EFFECT_SIZE="1.1425061425061425" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.3247216526405573" LOG_CI_START="-0.20900456531108952" LOG_EFFECT_SIZE="0.05785854366473387" ORDER="674" O_E="0.0" SE="0.3135134224121856" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.09829066603260153" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5083325653935054" CI_END="1.7050813973192371" CI_START="0.6646038361482953" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0645203791395732" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-026.11" LOG_CI_END="0.2317451162099198" LOG_CI_START="-0.17743715626641368" LOG_EFFECT_SIZE="0.02715397997175307" METHOD="MH" NO="11" P_CHI2="0.4758616262931382" P_Q="0.0" P_Z="0.7947614977694295" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="171" WEIGHT="99.99999999999999" Z="0.2601325930347395">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7624876761683648" CI_START="0.48853469960599044" EFFECT_SIZE="0.927920463960232" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24612608895944366" LOG_CI_START="-0.31110458381377887" LOG_EFFECT_SIZE="-0.032489247427167606" ORDER="675" O_E="0.0" SE="0.327320055523307" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.1071384187477808" WEIGHT="63.61050616528066"/>
<DICH_DATA CI_END="2.593475870579404" CI_START="0.654950955846688" EFFECT_SIZE="1.3033033033033032" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.4138822117192451" LOG_CI_START="-0.18379121970686346" LOG_EFFECT_SIZE="0.11504549600619081" ORDER="676" O_E="0.0" SE="0.3510763321508963" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.12325459099652647" WEIGHT="36.389493834719325"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.593206010672255" CI_START="0.36703878250827304" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.971830985915493" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-026.12" LOG_CI_END="1.0250274182780577" LOG_CI_START="-0.43528804435973234" LOG_EFFECT_SIZE="0.2948696869591627" METHOD="MH" NO="12" P_CHI2="1.0" P_Q="0.0" P_Z="0.42864100113262005" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="140" WEIGHT="100.0" Z="0.7915193413464624">
<NAME>Meconium stained liquor</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.593206010672255" CI_START="0.36703878250827304" EFFECT_SIZE="1.971830985915493" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0250274182780577" LOG_CI_START="-0.43528804435973234" LOG_EFFECT_SIZE="0.2948696869591627" ORDER="677" O_E="0.0" SE="0.8577965314315605" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.7358148893360161" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.054134887697809" CI_END="6.15117356384297" CI_START="0.1355108881087769" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9129901382531966" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="5.135480129686012" I2_Q="0.0" ID="CMP-026.13" LOG_CI_END="0.7889579814142217" LOG_CI_START="-0.868025808438394" LOG_EFFECT_SIZE="-0.03953391351208619" METHOD="MH" NO="13" P_CHI2="0.3045570710775254" P_Q="0.0" P_Z="0.9254861615128159" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="171" WEIGHT="100.0" Z="0.09352541301385021">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.0003811846031" CI_START="0.12152730418332627" EFFECT_SIZE="2.958041958041958" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.857334795680317" LOG_CI_START="-0.9153261358603558" LOG_EFFECT_SIZE="0.47100432990998053" ORDER="678" O_E="0.0" SE="1.6286747560799544" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="2.6525814610920992" WEIGHT="23.61628839711225"/>
<DICH_DATA CI_END="6.655281347766423" CI_START="0.011839240266198875" EFFECT_SIZE="0.2807017543859649" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8231664197204929" LOG_CI_START="-1.9266761657536262" LOG_EFFECT_SIZE="-0.5517548730165667" ORDER="679" O_E="0.0" SE="1.615271146647826" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="2.6091008771929824" WEIGHT="76.38371160288774"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2105311241651056" CI_END="1.375777802605586" CI_START="0.5532405690106555" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.872431140174251" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-026.14" LOG_CI_END="0.13854829807500432" LOG_CI_START="-0.2570859806750675" LOG_EFFECT_SIZE="-0.05926884130003162" METHOD="MH" NO="14" P_CHI2="0.6463514458414186" P_Q="0.0" P_Z="0.5570470919352766" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="171" WEIGHT="100.0" Z="0.5872332130597063">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.492157276637085" CI_START="0.5584924037228736" EFFECT_SIZE="0.9128847157016171" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.17381460113650027" LOG_CI_START="-0.25298272952003653" LOG_EFFECT_SIZE="-0.03958406419176816" ORDER="680" O_E="0.0" SE="0.25070286470850933" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06285192637305313" WEIGHT="83.325982319213"/>
<DICH_DATA CI_END="2.2819816189823543" CI_START="0.1968737309148568" EFFECT_SIZE="0.6702702702702703" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3583121419197571" LOG_CI_START="-0.7058122284013144" LOG_EFFECT_SIZE="-0.1737500432407787" ORDER="681" O_E="0.0" SE="0.6250719226271837" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.390714908456844" WEIGHT="16.674017680787006"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-026.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="682" O_E="0.0" SE="0.0" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7779932792379125" CI_START="0.024675720470582425" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20945945945945946" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-026.18" LOG_CI_END="0.2499301150169816" LOG_CI_START="-1.6077301581383512" LOG_EFFECT_SIZE="-0.6789000215606847" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.1519790969646242" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="31" WEIGHT="100.0" Z="1.4325758165698206">
<NAME>Maternal side-effects (all)</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7779932792379125" CI_START="0.024675720470582425" EFFECT_SIZE="0.20945945945945946" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2499301150169816" LOG_CI_START="-1.6077301581383512" LOG_EFFECT_SIZE="-0.6789000215606847" ORDER="683" O_E="0.0" SE="1.0911988400180987" STUDY_ID="STD-Seeras-1995" TOTAL_1="37" TOTAL_2="31" VAR="1.190714908456844" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4526455224544084" CI_START="0.5236350501591963" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8721560130010835" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-026.23" LOG_CI_END="0.16215964979437983" LOG_CI_START="-0.28097129111046687" LOG_EFFECT_SIZE="-0.059405820658043514" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.5992337287775997" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="140" WEIGHT="100.0" Z="0.5255027722688969">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4526455224544084" CI_START="0.5236350501591963" EFFECT_SIZE="0.8721560130010835" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.16215964979437983" LOG_CI_START="-0.28097129111046687" LOG_EFFECT_SIZE="-0.059405820658043514" ORDER="684" O_E="0.0" SE="0.2602973082210413" STUDY_ID="STD-Keirse-1995" TOTAL_1="142" TOTAL_2="140" VAR="0.06775468866711977" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" NO="27">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all primiparae</NAME>
<DICH_OUTCOME CHI2="1.581791918301982E-31" CI_END="0.8085477076710452" CI_START="0.27069616496002813" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46783625730994155" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="100.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-0.09229434982435976" LOG_CI_START="-0.5675178969760606" LOG_EFFECT_SIZE="-0.32990612340021025" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0065033005178818945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="2.72126296779326">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8085477076710451" CI_START="0.2706961649600281" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09229434982435981" LOG_CI_START="-0.5675178969760607" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="685" O_E="0.0" SE="0.2791486639914064" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.07792397660818713" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5599647415552997" CI_END="2.0843446508584966" CI_START="0.5825926737659718" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1019636669116875" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="21.873923982839493" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="0.3189695320892884" LOG_CI_START="-0.23463498102489297" LOG_EFFECT_SIZE="0.042167275532197714" METHOD="MH" NO="3" P_CHI2="0.27804231976380156" P_Q="0.0" P_Z="0.765264046618403" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="84" WEIGHT="100.0" Z="0.2985753887892843">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1103133279077895" CI_START="0.41749483550918043" EFFECT_SIZE="1.1395348837209303" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4928041413506582" LOG_CI_START="-0.3793488924528039" LOG_EFFECT_SIZE="0.05672762444892715" ORDER="686" O_E="0.0" SE="0.5123070092832982" STUDY_ID="STD-Keirse-1995" TOTAL_1="43" TOTAL_2="42" VAR="0.2624584717607974" WEIGHT="41.0899926493752"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="687" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="39.57086352339949"/>
<DICH_DATA CI_END="7.652792809458955" CI_START="0.632448848480217" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8838199554662951" LOG_CI_START="-0.19897459382188262" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="688" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Yuen-1996" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="19.339143827225314"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal complication</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.88490151495543" CI_START="0.13613930723311712" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1500000000000004" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.08" LOG_CI_END="1.8626375712827088" LOG_CI_START="-0.8660164637035078" LOG_EFFECT_SIZE="0.49831055378960054" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4740761754003553" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.7158626385178655">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.88490151495549" CI_START="0.13613930723311707" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8626375712827092" LOG_CI_START="-0.8660164637035079" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="689" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.462350366827767" CI_END="1.4036157258738158" CI_START="0.45017390623500053" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7949032483072964" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" I2="55.18056997792899" I2_Q="0.0" ID="CMP-027.11" LOG_CI_END="0.14724822533274015" LOG_CI_START="-0.3466196819400713" LOG_EFFECT_SIZE="-0.09968572830366558" METHOD="MH" NO="11" P_CHI2="0.10740224818225685" P_Q="0.0" P_Z="0.4288124292820362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="84" WEIGHT="100.00000000000001" Z="0.7912254850765265">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5798950576994732" CI_START="0.6580829881338961" EFFECT_SIZE="1.5348837209302326" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5538702957695605" LOG_CI_START="-0.1817193358449962" LOG_EFFECT_SIZE="0.18607547996228216" ORDER="690" O_E="0.0" SE="0.43208899083779206" STUDY_ID="STD-Keirse-1995" TOTAL_1="43" TOTAL_2="42" VAR="0.18670089600322157" WEIGHT="32.941275510817675"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="691" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="27.1914949910404"/>
<DICH_DATA CI_END="1.1671370784818842" CI_START="0.11519164879871585" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.0671218662699943" LOG_CI_START="-0.938579005392869" LOG_EFFECT_SIZE="-0.43572856956143746" ORDER="692" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Yuen-1996" TOTAL_1="20" TOTAL_2="22" VAR="0.34898989898989896" WEIGHT="39.86722949814194"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="693" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" NO="28">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="1.581791918301982E-31" CI_END="0.8085477076710452" CI_START="0.27069616496002813" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46783625730994155" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" I2="100.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="-0.09229434982435976" LOG_CI_START="-0.5675178969760606" LOG_EFFECT_SIZE="-0.32990612340021025" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0065033005178818945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="2.72126296779326">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8085477076710451" CI_START="0.2706961649600281" EFFECT_SIZE="0.4678362573099415" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.09229434982435981" LOG_CI_START="-0.5675178969760607" LOG_EFFECT_SIZE="-0.32990612340021025" ORDER="694" O_E="0.0" SE="0.2791486639914064" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.07792397660818713" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5599647415552997" CI_END="2.0843446508584966" CI_START="0.5825926737659718" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1019636669116875" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="21.873923982839493" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="0.3189695320892884" LOG_CI_START="-0.23463498102489297" LOG_EFFECT_SIZE="0.042167275532197714" METHOD="MH" NO="3" P_CHI2="0.27804231976380156" P_Q="0.0" P_Z="0.765264046618403" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="84" WEIGHT="99.99999999999999" Z="0.2985753887892843">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1103133279077895" CI_START="0.41749483550918043" EFFECT_SIZE="1.1395348837209303" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4928041413506582" LOG_CI_START="-0.3793488924528039" LOG_EFFECT_SIZE="0.05672762444892715" ORDER="695" O_E="0.0" SE="0.5123070092832982" STUDY_ID="STD-Keirse-1995" TOTAL_1="43" TOTAL_2="42" VAR="0.2624584717607974" WEIGHT="41.08999264937519"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="696" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="39.57086352339948"/>
<DICH_DATA CI_END="7.652792809458955" CI_START="0.632448848480217" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8838199554662951" LOG_CI_START="-0.19897459382188262" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="697" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Yuen-1996" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="19.339143827225314"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal complication</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.88490151495543" CI_START="0.13613930723311712" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1500000000000004" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.08" LOG_CI_END="1.8626375712827088" LOG_CI_START="-0.8660164637035078" LOG_EFFECT_SIZE="0.49831055378960054" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4740761754003553" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.7158626385178655">
<NAME>Uterine hyperstimulation without fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.88490151495549" CI_START="0.13613930723311707" EFFECT_SIZE="3.15" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8626375712827092" LOG_CI_START="-0.8660164637035079" LOG_EFFECT_SIZE="0.4983105537896005" ORDER="698" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="2.5690476190476192" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.462350366827768" CI_END="1.4036157258738156" CI_START="0.4501739062350005" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7949032483072963" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" I2="55.180569977929004" I2_Q="0.0" ID="CMP-028.11" LOG_CI_END="0.14724822533274007" LOG_CI_START="-0.34661968194007137" LOG_EFFECT_SIZE="-0.09968572830366564" METHOD="MH" NO="11" P_CHI2="0.10740224818225663" P_Q="0.0" P_Z="0.4288124292820359" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="84" WEIGHT="100.0" Z="0.791225485076527">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5798950576994732" CI_START="0.6580829881338961" EFFECT_SIZE="1.5348837209302326" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5538702957695605" LOG_CI_START="-0.1817193358449962" LOG_EFFECT_SIZE="0.18607547996228216" ORDER="699" O_E="0.0" SE="0.43208899083779206" STUDY_ID="STD-Keirse-1995" TOTAL_1="43" TOTAL_2="42" VAR="0.18670089600322157" WEIGHT="32.94127551081767"/>
<DICH_DATA CI_END="1.8105883556187499" CI_START="0.1529935335051035" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.25781972297870237" LOG_CI_START="-0.8153269248843603" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="700" O_E="0.0" SE="0.6303716531163435" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.3973684210526316" WEIGHT="27.191494991040393"/>
<DICH_DATA CI_END="1.1671370784818842" CI_START="0.11519164879871585" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.0671218662699943" LOG_CI_START="-0.938579005392869" LOG_EFFECT_SIZE="-0.43572856956143746" ORDER="701" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Yuen-1996" TOTAL_1="20" TOTAL_2="22" VAR="0.34898989898989896" WEIGHT="39.86722949814193"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="702" O_E="0.0" SE="0.0" STUDY_ID="STD-Ulmsten-1985" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" NO="29">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all primiparae, intact, unfavourable</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with fetal heart rate changes</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6488176208489637" CI_END="3.2004478663067975" CI_START="0.6834017076982453" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4789156626506026" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="0.5052107571497794" LOG_CI_START="-0.16532394031191497" LOG_EFFECT_SIZE="0.1699434084189322" METHOD="MH" NO="3" P_CHI2="0.42053599639184824" P_Q="0.0" P_Z="0.32047384730464645" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="64" WEIGHT="99.99999999999999" Z="0.993484635983707">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1103133279077895" CI_START="0.41749483550918043" EFFECT_SIZE="1.1395348837209303" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4928041413506582" LOG_CI_START="-0.3793488924528039" LOG_EFFECT_SIZE="0.05672762444892715" ORDER="703" O_E="0.0" SE="0.5123070092832982" STUDY_ID="STD-Keirse-1995" TOTAL_1="43" TOTAL_2="42" VAR="0.2624584717607974" WEIGHT="67.99698795180721"/>
<DICH_DATA CI_END="7.652792809458955" CI_START="0.632448848480217" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8838199554662951" LOG_CI_START="-0.19897459382188262" LOG_EFFECT_SIZE="0.3424226808222063" ORDER="704" O_E="0.0" SE="0.6360388781713383" STUDY_ID="STD-Yuen-1996" TOTAL_1="20" TOTAL_2="22" VAR="0.40454545454545454" WEIGHT="32.00301204819277"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal complication</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.839951450069167" CI_END="1.7066915612514542" CI_START="0.46956559992188124" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8952115095555079" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="73.95800407888002" I2_Q="0.0" ID="CMP-029.11" LOG_CI_END="0.2321550411205926" LOG_CI_START="-0.3283037267334604" LOG_EFFECT_SIZE="-0.04807434280643392" METHOD="MH" NO="11" P_CHI2="0.05004501911598047" P_Q="0.0" P_Z="0.7366908272232611" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="64" WEIGHT="100.0" Z="0.33623875969259254">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.5798950576994732" CI_START="0.6580829881338961" EFFECT_SIZE="1.5348837209302326" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5538702957695605" LOG_CI_START="-0.1817193358449962" LOG_EFFECT_SIZE="0.18607547996228216" ORDER="705" O_E="0.0" SE="0.43208899083779206" STUDY_ID="STD-Keirse-1995" TOTAL_1="43" TOTAL_2="42" VAR="0.18670089600322157" WEIGHT="45.24371913248873"/>
<DICH_DATA CI_END="1.1671370784818842" CI_START="0.11519164879871585" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.0671218662699943" LOG_CI_START="-0.938579005392869" LOG_EFFECT_SIZE="-0.43572856956143746" ORDER="706" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Yuen-1996" TOTAL_1="20" TOTAL_2="22" VAR="0.34898989898989896" WEIGHT="54.75628086751128"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" NO="30">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all mulitiparae</NAME>
<DICH_OUTCOME CHI2="1.3506920340498891" CI_END="2.706906565384825" CI_START="0.17961816061290475" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6972872996300864" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="25.96387816091436" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="0.43247326543504233" LOG_CI_START="-0.745649755334406" LOG_EFFECT_SIZE="-0.15658824494968188" METHOD="MH" NO="3" P_CHI2="0.24515733417255148" P_Q="0.0" P_Z="0.6023593543593432" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="51" WEIGHT="100.0" Z="0.5210106501497053">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.557754324009246" CI_START="0.23833091949998644" EFFECT_SIZE="1.3421052631578947" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8783927704254979" LOG_CI_START="-0.6228196114632454" LOG_EFFECT_SIZE="0.12778657948112618" ORDER="707" O_E="0.0" SE="0.8818195842425857" STUDY_ID="STD-Keirse-1995" TOTAL_1="38" TOTAL_2="34" VAR="0.7776057791537667" WEIGHT="44.512946979038226"/>
<DICH_DATA CI_END="3.5044796881421814" CI_START="0.009245309684524413" EFFECT_SIZE="0.18" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.544623547169233" LOG_CI_START="-2.0340785369626206" LOG_EFFECT_SIZE="-0.744727494896694" ORDER="708" O_E="0.0" SE="1.5147423690002353" STUDY_ID="STD-Yuen-1996" TOTAL_1="19" TOTAL_2="17" VAR="2.2944444444444447" WEIGHT="55.48705302096178"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.041905315670993225" CI_END="13.446669358669164" CI_START="0.3248875330635622" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0901328273244784" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.11" LOG_CI_END="1.1286147261021793" LOG_CI_START="-0.4882669535536997" LOG_EFFECT_SIZE="0.32017388627423987" METHOD="MH" NO="11" P_CHI2="0.8378004769422835" P_Q="0.0" P_Z="0.43761812929773436" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="51" WEIGHT="100.0" Z="0.7762216540437151">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="63.963063612284024" CI_START="0.11332353862842658" EFFECT_SIZE="2.6923076923076925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8059292567947365" LOG_CI_START="-0.9456798727078585" LOG_EFFECT_SIZE="0.4301246920434389" ORDER="709" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Keirse-1995" TOTAL_1="38" TOTAL_2="34" VAR="2.6124542124542125" WEIGHT="33.301707779886144"/>
<DICH_DATA CI_END="18.019872680930362" CI_START="0.17770469987120158" EFFECT_SIZE="1.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2557517181544358" LOG_CI_START="-0.7503010859755834" LOG_EFFECT_SIZE="0.25272531608942617" ORDER="710" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Yuen-1996" TOTAL_1="19" TOTAL_2="17" VAR="1.388544891640867" WEIGHT="66.69829222011386"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" NO="31">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all mulitiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="1.3506920340498891" CI_END="2.706906565384825" CI_START="0.17961816061290475" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6972872996300864" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="25.96387816091436" I2_Q="0.0" ID="CMP-031.03" LOG_CI_END="0.43247326543504233" LOG_CI_START="-0.745649755334406" LOG_EFFECT_SIZE="-0.15658824494968188" METHOD="MH" NO="3" P_CHI2="0.24515733417255148" P_Q="0.0" P_Z="0.6023593543593432" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="51" WEIGHT="100.0" Z="0.5210106501497053">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.557754324009246" CI_START="0.23833091949998644" EFFECT_SIZE="1.3421052631578947" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8783927704254979" LOG_CI_START="-0.6228196114632454" LOG_EFFECT_SIZE="0.12778657948112618" ORDER="711" O_E="0.0" SE="0.8818195842425857" STUDY_ID="STD-Keirse-1995" TOTAL_1="38" TOTAL_2="34" VAR="0.7776057791537667" WEIGHT="44.512946979038226"/>
<DICH_DATA CI_END="3.5044796881421814" CI_START="0.009245309684524413" EFFECT_SIZE="0.18" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.544623547169233" LOG_CI_START="-2.0340785369626206" LOG_EFFECT_SIZE="-0.744727494896694" ORDER="712" O_E="0.0" SE="1.5147423690002353" STUDY_ID="STD-Yuen-1996" TOTAL_1="19" TOTAL_2="17" VAR="2.2944444444444447" WEIGHT="55.48705302096178"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.041905315670993225" CI_END="13.446669358669164" CI_START="0.3248875330635622" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0901328273244784" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-031.11" LOG_CI_END="1.1286147261021793" LOG_CI_START="-0.4882669535536997" LOG_EFFECT_SIZE="0.32017388627423987" METHOD="MH" NO="11" P_CHI2="0.8378004769422835" P_Q="0.0" P_Z="0.43761812929773436" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="51" WEIGHT="100.0" Z="0.7762216540437151">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="63.963063612284024" CI_START="0.11332353862842658" EFFECT_SIZE="2.6923076923076925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8059292567947365" LOG_CI_START="-0.9456798727078585" LOG_EFFECT_SIZE="0.4301246920434389" ORDER="713" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Keirse-1995" TOTAL_1="38" TOTAL_2="34" VAR="2.6124542124542125" WEIGHT="33.301707779886144"/>
<DICH_DATA CI_END="18.019872680930362" CI_START="0.17770469987120158" EFFECT_SIZE="1.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2557517181544358" LOG_CI_START="-0.7503010859755834" LOG_EFFECT_SIZE="0.25272531608942617" ORDER="714" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Yuen-1996" TOTAL_1="19" TOTAL_2="17" VAR="1.388544891640867" WEIGHT="66.69829222011386"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" NO="32">
<NAME>Intracervical prostaglandin (PGE2) vs intravaginal prostaglandin (PGE2): all mulitiparae, intact, unfavourable</NAME>
<DICH_OUTCOME CHI2="1.3506920340498891" CI_END="2.706906565384825" CI_START="0.17961816061290475" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6972872996300864" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="25.96387816091436" I2_Q="0.0" ID="CMP-032.03" LOG_CI_END="0.43247326543504233" LOG_CI_START="-0.745649755334406" LOG_EFFECT_SIZE="-0.15658824494968188" METHOD="MH" NO="3" P_CHI2="0.24515733417255148" P_Q="0.0" P_Z="0.6023593543593432" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="51" WEIGHT="100.0" Z="0.5210106501497053">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.557754324009246" CI_START="0.23833091949998644" EFFECT_SIZE="1.3421052631578947" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8783927704254979" LOG_CI_START="-0.6228196114632454" LOG_EFFECT_SIZE="0.12778657948112618" ORDER="715" O_E="0.0" SE="0.8818195842425857" STUDY_ID="STD-Keirse-1995" TOTAL_1="38" TOTAL_2="34" VAR="0.7776057791537667" WEIGHT="44.512946979038226"/>
<DICH_DATA CI_END="3.5044796881421814" CI_START="0.009245309684524413" EFFECT_SIZE="0.18" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.544623547169233" LOG_CI_START="-2.0340785369626206" LOG_EFFECT_SIZE="-0.744727494896694" ORDER="716" O_E="0.0" SE="1.5147423690002353" STUDY_ID="STD-Yuen-1996" TOTAL_1="19" TOTAL_2="17" VAR="2.2944444444444447" WEIGHT="55.48705302096178"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.041905315670993225" CI_END="13.446669358669164" CI_START="0.3248875330635622" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0901328273244784" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-032.11" LOG_CI_END="1.1286147261021793" LOG_CI_START="-0.4882669535536997" LOG_EFFECT_SIZE="0.32017388627423987" METHOD="MH" NO="11" P_CHI2="0.8378004769422835" P_Q="0.0" P_Z="0.43761812929773436" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="51" WEIGHT="100.0" Z="0.7762216540437151">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Intracervical PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="63.963063612284024" CI_START="0.11332353862842658" EFFECT_SIZE="2.6923076923076925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8059292567947365" LOG_CI_START="-0.9456798727078585" LOG_EFFECT_SIZE="0.4301246920434389" ORDER="717" O_E="0.0" SE="1.616308823354687" STUDY_ID="STD-Keirse-1995" TOTAL_1="38" TOTAL_2="34" VAR="2.6124542124542125" WEIGHT="33.301707779886144"/>
<DICH_DATA CI_END="18.019872680930362" CI_START="0.17770469987120158" EFFECT_SIZE="1.7894736842105263" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2557517181544358" LOG_CI_START="-0.7503010859755834" LOG_EFFECT_SIZE="0.25272531608942617" ORDER="718" O_E="0.0" SE="1.1783653472675046" STUDY_ID="STD-Yuen-1996" TOTAL_1="19" TOTAL_2="17" VAR="1.388544891640867" WEIGHT="66.69829222011386"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-02-04 10:24:12 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-02-04 10:24:12 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-02-04 10:23:35 +0000" MODIFIED_BY="[Empty name]">Methodological quality of trials</TITLE>
<APPENDIX_BODY MODIFIED="2008-02-04 10:24:12 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Methodological item</P>
</TH>
<TH>
<P>Adequate</P>
</TH>
<TH>
<P>Inadequate</P>
</TH>
</TR>
<TR>
<TD>
<P>Generation of random sequence.</P>
</TD>
<TD>
<P>Computer-generated sequence, random-number tables, lot drawing, coin tossing, shuffling cards, throwing dice.</P>
</TD>
<TD>
<P>Case number, date of birth, date of admission, alternation.</P>
</TD>
</TR>
<TR>
<TD>
<P>Concealment of allocation.</P>
</TD>
<TD>
<P>Central randomisation, coded drug boxes, sequentially sealed opaque envelopes.</P>
</TD>
<TD>
<P>Open allocation sequence, any procedure based on inadequate generation.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>